NZ616036B2 - Modulation of signal transducer and activator of transcription 3 (stat3) expression - Google Patents
Modulation of signal transducer and activator of transcription 3 (stat3) expression Download PDFInfo
- Publication number
- NZ616036B2 NZ616036B2 NZ616036A NZ61603612A NZ616036B2 NZ 616036 B2 NZ616036 B2 NZ 616036B2 NZ 616036 A NZ616036 A NZ 616036A NZ 61603612 A NZ61603612 A NZ 61603612A NZ 616036 B2 NZ616036 B2 NZ 616036B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- wing
- certain embodiments
- modified oligonucleotide
- stat3
- single stranded
- Prior art date
Links
- 102000004495 STAT3 Transcription Factor Human genes 0.000 title claims description 489
- 108010017324 STAT3 Transcription Factor Proteins 0.000 title claims description 489
- 230000014509 gene expression Effects 0.000 title claims description 60
- 230000000051 modifying Effects 0.000 title description 7
- 101710035255 stat3.1 Proteins 0.000 title 1
- 229920000272 Oligonucleotide Polymers 0.000 claims abstract description 453
- 239000002777 nucleoside Substances 0.000 claims abstract description 265
- 125000003835 nucleoside group Chemical group 0.000 claims abstract description 123
- 230000000295 complement Effects 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 258
- 108020004999 Messenger RNA Proteins 0.000 claims description 234
- 229920002106 messenger RNA Polymers 0.000 claims description 234
- 235000000346 sugar Nutrition 0.000 claims description 108
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 95
- -1 bicyclic nucleoside Chemical class 0.000 claims description 69
- 125000003729 nucleotide group Chemical group 0.000 claims description 46
- 239000002773 nucleotide Substances 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 35
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 21
- 125000002619 bicyclic group Chemical group 0.000 claims description 19
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 11
- 229940104302 Cytosine Drugs 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 239000000969 carrier Substances 0.000 claims description 2
- 241000764238 Isis Species 0.000 description 481
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 478
- 210000004027 cells Anatomy 0.000 description 354
- 230000000692 anti-sense Effects 0.000 description 260
- 230000002401 inhibitory effect Effects 0.000 description 235
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 214
- 239000000074 antisense oligonucleotide Substances 0.000 description 214
- 241000282414 Homo sapiens Species 0.000 description 205
- 108020004707 nucleic acids Proteins 0.000 description 141
- 150000007523 nucleic acids Chemical class 0.000 description 138
- 206010028980 Neoplasm Diseases 0.000 description 129
- 229920002477 rna polymer Polymers 0.000 description 115
- 230000000694 effects Effects 0.000 description 113
- 239000000523 sample Substances 0.000 description 108
- 239000002953 phosphate buffered saline Substances 0.000 description 89
- 241000699670 Mus sp. Species 0.000 description 87
- 231100000673 dose–response relationship Toxicity 0.000 description 70
- 230000004614 tumor growth Effects 0.000 description 59
- 201000010099 disease Diseases 0.000 description 56
- 238000003753 real-time PCR Methods 0.000 description 54
- 238000004458 analytical method Methods 0.000 description 51
- 230000001603 reducing Effects 0.000 description 40
- 230000037396 body weight Effects 0.000 description 37
- 125000000217 alkyl group Chemical group 0.000 description 36
- 238000006722 reduction reaction Methods 0.000 description 33
- 210000004185 Liver Anatomy 0.000 description 27
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 27
- 238000000338 in vitro Methods 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 241000699660 Mus musculus Species 0.000 description 25
- 231100000730 tolerability Toxicity 0.000 description 25
- 108091006028 chimera Proteins 0.000 description 24
- 230000003463 hyperproliferative Effects 0.000 description 24
- 238000001990 intravenous administration Methods 0.000 description 24
- 230000004048 modification Effects 0.000 description 24
- 238000006011 modification reaction Methods 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 23
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 23
- 239000008177 pharmaceutical agent Substances 0.000 description 23
- 238000005259 measurement Methods 0.000 description 22
- 230000003442 weekly Effects 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 230000002829 reduced Effects 0.000 description 21
- 210000001519 tissues Anatomy 0.000 description 21
- 210000002966 Serum Anatomy 0.000 description 20
- 125000003342 alkenyl group Chemical group 0.000 description 20
- 125000000304 alkynyl group Chemical group 0.000 description 20
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 18
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 18
- 210000000170 Cell Membrane Anatomy 0.000 description 17
- 210000004369 Blood Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 108010082126 Alanine Transaminase Proteins 0.000 description 15
- 102100010966 GPT Human genes 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 238000004520 electroporation Methods 0.000 description 15
- 210000004881 tumor cells Anatomy 0.000 description 15
- 241000282693 Cercopithecidae Species 0.000 description 14
- 230000001747 exhibiting Effects 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 14
- 210000003734 Kidney Anatomy 0.000 description 13
- 241000282567 Macaca fascicularis Species 0.000 description 13
- 230000001965 increased Effects 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000003908 liver function Effects 0.000 description 13
- 239000002609 media Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 108090001123 antibodies Proteins 0.000 description 11
- 102000004965 antibodies Human genes 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 238000001959 radiotherapy Methods 0.000 description 11
- 230000036499 Half live Effects 0.000 description 10
- 206010027476 Metastasis Diseases 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 230000003907 kidney function Effects 0.000 description 10
- 101700033661 ACTB Proteins 0.000 description 9
- 102100011550 ACTB Human genes 0.000 description 9
- 101710032514 ACTI Proteins 0.000 description 9
- 210000002381 Plasma Anatomy 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 210000000056 organs Anatomy 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229940100601 Interleukin-6 Drugs 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 101700080605 NUC1 Proteins 0.000 description 8
- 229920001850 Nucleic acid sequence Polymers 0.000 description 8
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- 101700006494 nucA Proteins 0.000 description 8
- 230000004083 survival Effects 0.000 description 8
- 108010068682 Cyclophilins Proteins 0.000 description 7
- 102000001493 Cyclophilins Human genes 0.000 description 7
- 208000005017 Glioblastoma Diseases 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 206010033128 Ovarian cancer Diseases 0.000 description 7
- 210000000952 Spleen Anatomy 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000000875 corresponding Effects 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 229940109239 Creatinine Drugs 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 102000033147 ERVK-25 Human genes 0.000 description 6
- 229960002743 Glutamine Drugs 0.000 description 6
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 229940049954 Penicillin Drugs 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 229960005322 Streptomycin Drugs 0.000 description 6
- 229940035893 Uracil Drugs 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000003698 anagen phase Effects 0.000 description 6
- 230000000259 anti-tumor Effects 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 229960000626 benzylpenicillin Drugs 0.000 description 6
- 230000004579 body weight change Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000001605 fetal Effects 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 238000004264 monolayer culture Methods 0.000 description 6
- 125000002743 phosphorus functional group Chemical group 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000012096 transfection reagent Substances 0.000 description 6
- 210000001772 Blood Platelets Anatomy 0.000 description 5
- 210000001072 Colon Anatomy 0.000 description 5
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 5
- 206010051635 Gastrointestinal tract adenoma Diseases 0.000 description 5
- 229920002459 Intron Polymers 0.000 description 5
- 206010024324 Leukaemias Diseases 0.000 description 5
- 239000012097 Lipofectamine 2000 Substances 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 125000004103 aminoalkyl group Chemical group 0.000 description 5
- 230000002429 anti-coagulation Effects 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000009030 carcinoma Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000011231 colorectal cancer Diseases 0.000 description 5
- 239000005549 deoxyribonucleoside Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 201000009251 multiple myeloma Diseases 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 150000004713 phosphodiesters Chemical class 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrugs Drugs 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 231100000486 side effect Toxicity 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 229960000643 Adenine Drugs 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 210000000988 Bone and Bones Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 4
- 108090000340 Transaminases Proteins 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 125000004432 carbon atoms Chemical group C* 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000004700 cellular uptake Effects 0.000 description 4
- 230000004059 degradation Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 150000002243 furanoses Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000004450 types of analysis Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 208000003200 Adenoma Diseases 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 3
- 102100013894 BCL2 Human genes 0.000 description 3
- 108060000885 BCL2 Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000016918 Complement C3 Human genes 0.000 description 3
- 108010028780 Complement C3 Proteins 0.000 description 3
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 3
- 206010017758 Gastric cancer Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000003470 Mitochondria Anatomy 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 102100019388 SOAT1 Human genes 0.000 description 3
- 101700025022 SOAT1 Proteins 0.000 description 3
- 229940104230 Thymidine Drugs 0.000 description 3
- 210000002700 Urine Anatomy 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000002730 additional Effects 0.000 description 3
- 238000004164 analytical calibration Methods 0.000 description 3
- 125000004429 atoms Chemical group 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 3
- 210000004748 cultured cells Anatomy 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 230000002489 hematologic Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 description 3
- 229920001239 microRNA Polymers 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 235000020825 overweight Nutrition 0.000 description 3
- 125000004430 oxygen atoms Chemical group O* 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000000865 phosphorylative Effects 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 235000017924 poor diet Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000002342 ribonucleoside Substances 0.000 description 3
- 101710028406 satA Proteins 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 2
- 102100015655 BCL2L1 Human genes 0.000 description 2
- 101710032374 BCL2L1 Proteins 0.000 description 2
- 102100007326 BIRC5 Human genes 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 102000025380 C-Reactive Protein Human genes 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108010072220 Cyclophilin A Proteins 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100010813 EGF Human genes 0.000 description 2
- 101700033006 EGF Proteins 0.000 description 2
- 229940121647 EGFR inhibitors Drugs 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101700025368 ERBB2 Proteins 0.000 description 2
- 102100016662 ERBB2 Human genes 0.000 description 2
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 2
- 210000001652 Frontal Lobe Anatomy 0.000 description 2
- 101710037135 GAPC2 Proteins 0.000 description 2
- 101710037116 GAPC3 Proteins 0.000 description 2
- 101710025049 GAPDG Proteins 0.000 description 2
- 101710008404 GAPDH Proteins 0.000 description 2
- 102100006425 GAPDH Human genes 0.000 description 2
- 101710010461 Gapdh1 Proteins 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- 102100013180 KDR Human genes 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 101710009221 LD Proteins 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 2
- 101710025050 MK0970 Proteins 0.000 description 2
- 102100007359 MT-CO2 Human genes 0.000 description 2
- 101710034449 MT-CO2 Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100012530 PPIA Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 101710037934 QRSL1 Proteins 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 229920000320 RNA (poly(A)) Polymers 0.000 description 2
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- 101710038979 SBXA1 Proteins 0.000 description 2
- 108020004459 Small Interfering RNA Proteins 0.000 description 2
- 229920000978 Start codon Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 229920000401 Three prime untranslated region Polymers 0.000 description 2
- 229940113082 Thymine Drugs 0.000 description 2
- 108091007928 VEGF receptors Proteins 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 101710025091 cbbGC Proteins 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 229920002092 cellular RNA Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000002349 favourable Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 125000003843 furanosyl group Chemical group 0.000 description 2
- 101710025070 gapdh-2 Proteins 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical class 0.000 description 2
- 108091007522 housekeeping proteins Proteins 0.000 description 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 238000000185 intracerebroventricular Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 125000004437 phosphorous atoms Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 101700086982 rnh Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000000087 stabilizing Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000002110 toxicologic Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 206010049460 Abasia Diseases 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N Acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N Anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N Bis-tris methane Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 206010007515 Cardiac arrest Diseases 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 102000031025 DNA-Binding Proteins Human genes 0.000 description 1
- 108091000102 DNA-Binding Proteins Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 101710003775 ERVK-10 Proteins 0.000 description 1
- 101710037030 ERVK-11 Proteins 0.000 description 1
- 101710009283 ERVK-18 Proteins 0.000 description 1
- 101710009286 ERVK-19 Proteins 0.000 description 1
- 101710035700 ERVK-25 Proteins 0.000 description 1
- 101710038044 ERVK-6 Proteins 0.000 description 1
- 101710014468 ERVK-7 Proteins 0.000 description 1
- 101710014482 ERVK-8 Proteins 0.000 description 1
- 101700008821 EXO Proteins 0.000 description 1
- 101700083023 EXRN Proteins 0.000 description 1
- 102000011686 Electron Transport Complex IV Human genes 0.000 description 1
- 108091003147 Electron Transport Complex IV Proteins 0.000 description 1
- 241000083551 Ena Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- HKVAMNSJSFKALM-WDSGEKFTSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-WDSGEKFTSA-N 0.000 description 1
- 229920000665 Exon Polymers 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 229940014144 Folate Drugs 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 101710043924 HERVK_113 Proteins 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 101700011716 IL2RG Proteins 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 206010022095 Injection site reaction Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 101700067074 MAPK Proteins 0.000 description 1
- 101700083887 MAPK1 Proteins 0.000 description 1
- 102100016823 MAPK1 Human genes 0.000 description 1
- 101710041325 MAPKAPK2 Proteins 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 108020004388 MicroRNAs Proteins 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 206010028640 Myopathy Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 108091005503 Nucleic proteins Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 210000004681 Ovum Anatomy 0.000 description 1
- 101710033554 PSMB1 Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- RDOWQLZANAYVLL-UHFFFAOYSA-N Phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical compound C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 230000036823 Plasma Levels Effects 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 101710006375 RNASEH1 Proteins 0.000 description 1
- 101700078434 RT67 Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100019657 STAT1 Human genes 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 101000491354 STAT3 Proteins 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 229920001891 Small hairpin RNA Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N Tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 Tioguanine Drugs 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930013356 epothilones Natural products 0.000 description 1
- 101710024775 erkB Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000002550 fecal Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002414 glycolytic Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 102000024214 human STAT3 protein Human genes 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002318 immunoblotting Methods 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical class CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000002297 mitogenic Effects 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 201000010770 muscular disease Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000000063 preceeding Effects 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 101710024887 rl Proteins 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 101700045897 spk-1 Proteins 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 200000000020 tissue injury Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- HMFHBZSHGGEWLO-NEEWWZBLSA-N α-L-ribose Chemical compound OC[C@@H]1O[C@@H](O)[C@@H](O)[C@H]1O HMFHBZSHGGEWLO-NEEWWZBLSA-N 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N β-D-ribose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Abstract
Disclosed is single stranded modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 12 contiguous nucleobases complementary to an equal length portion ttaaccttgctgacatccaaatagaa, wherein the nucleobase sequence is complementary to ttaaccttgctgacatccaaatagaa. Also disclosed is the use of the above described single stranded modified oligonucleotide in the manufacture of a medicament for treating cancer. y to ttaaccttgctgacatccaaatagaa. Also disclosed is the use of the above described single stranded modified oligonucleotide in the manufacture of a medicament for treating cancer.
Description
BIOL0142WO
MODULATION OF SIGNAL TRANSDUCER AND
ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION
Sequence Listing
The present application is being filed along with a Sequence Listing in electronic format. The
Sequence Listing is provided as a file entitled BIOL0142WOSEQ.txt created March 29, 2012 which is
672 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by
reference in its entirety.
Field
In certain embodiments provided are methods, compounds, and compositions for inhibiting
expression of STAT3 mRNA and protein in an animal. Such methods, compounds, and compositions are
useful to treat, prevent, or ameliorate hyperproliferative diseases.
Background
The STAT (signal transducers and activators of transcription) family of proteins are DNA-
binding proteins that play a dual role in signal transduction and activation of transcription. Presently,
there are six distinct members of the STAT family (STAT1, STAT2, STAT3, STAT4, STAT5, and
STAT6) and several isoforms (STAT1α, STAT1β, STAT3 α and STAT3β). The activities of the STATs
are modulated by various cytokines and mitogenic stimuli. Binding of a cytokine to its receptor results in
the activation of Janus protein tyrosine kinases (JAKs) associated with these receptors. This
phosphorylates STAT, resulting in translocation to the nucleus and transcriptional activation of STAT
responsive genes. Phosphorylation on a specific tyrosine residue on the STATs results in their activation,
resulting in the formation of homodimers and/or heterodimers of STAT which bind to specific gene
promoter sequences. Events mediated by cytokines through STAT activation include cell proliferation
and differentiation and prevention of apoptosis.
The specificity of STAT activation is due to specific cytokines, i.e., each STAT is responsive to a
small number of specific cytokines. Other non-cytokine signaling molecules, such as growth factors,
have also been found to activate STATs. Binding of these factors to a cell surface receptor associated
with protein tyrosine kinase also results in phosphorylation of STAT.
STAT3 (also acute phase response factor (APRF)), in particular, has been found to be responsive
to interleukin-6 (IL-6) as well as epidermal growth factor (EGF) (Darnell, Jr., J.E., et al., Science, 1994,
264, 1415-1421). In addition, STAT3 has been found to have an important role in signal transduction by
interferons (Yang, C.-H., et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 5568-5572). Evidence exists
suggesting that STAT3 may be regulated by the MAPK pathway. ERK2 induces serine phosphorylation
and also associates with STAT3 (Jain, N., et al., Oncogene, 1998, 17, 3157-3167).
BIOL0142WO
STAT3 is expressed in most cell types (Zhong, Z., et al., Proc. Natl. Acad. Sci. USA, 1994, 91,
4806-4810). It induces the expression of genes involved in response to tissue injury and inflammation.
STAT3 has also been shown to prevent apoptosis through the expression of bcl-2 (Fukada, T., et al.,
Immunity, 1996, 5, 449-460).
Recently, STAT3 was detected in the mitochondria of transformed cells, and was shown to
facilitate glycolytic and oxidative phosphorylation activities similar to that of cancer cells (Gough, D.J., et
al., Science, 2009, 324, 1713-1716). The inhibition of STAT3 in the mitochondria impaired malignant
transformation by activated Ras. The data confirms a Ras-mediated transformation function for STAT3 in
the mitochondria in addition to its nuclear roles.
Aberrant expression of or constitutive expression of STAT3 is associated with a number of
disease processes.
Summary
In a first aspect, the invention provides a single stranded modified oligonucleotide consisting of
12 to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 12 contiguous
nucleobases complementary to an equal length portion of nucleobases 3008 to 3033 of SEQ ID NO: 1,
wherein the nucleobase sequence is complementary to SEQ ID NO: 1.
In another aspect, the invention provides a single-stranded modified oligonucleotide consisting
of 12 to 22 linked nucleosides, wherein the modified oligonucleotide comprises:
a 5’-wing consisting of 1 to 5 linked nucleosides;
a 3’-wing consisting of 1 to 5 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides;
wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside or a 2’-
substituted nucleoside;
wherein the nucleobase sequence of the modified oligonucleotide is complementary to an equal length
portion of nucleobases 3016 to 3031 of the nucleobase sequence of SEQ ID NO: 1; and
wherein the compound inhibits expression of STAT3 mRNA expression.
In a further aspect, the invention provides a single stranded modified oligonucleotide consisting
of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 245, or
a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:
a gap segment consisting of ten linked deoxynucleotides; a 5’-wing segment consisting of three
linked nucleosides; and a 3’-wing segment consisting of three linked nucleosides; wherein the gap
segment is positioned between the 5’-wing segment and the 3’-wing segment; wherein each
nucleotide of each wing segment comprises a constrained ethyl nucleoside; wherein each
internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein
each cytosine of the modified oligonucleotide is a 5’-methylcytosine.
BIOL0142WO
In further aspects, the invention provides pharmaceutical compositions comprising the single
stranded modified oligonucleotides of the invention, and the use of the oligonucleotides in the
manufacture of medicaments for treating cancer.
The invention is defined in the claims. However, the description which follows may also refer
to additional compounds, compositions and methods outside the scope of the present claims. This
description is retained for technical information.
Provided herein are methods, compounds, and compositions for modulating expression of
STAT3 mRNA and protein. In certain embodiments, compounds useful for modulating expression of
STAT3 mRNA and protein are antisense compounds. In certain embodiments, the antisense compounds
are antisense oligonucleotides.
In certain embodiments, modulation can occur in a cell or tissue. In certain embodiments, the
cell or tissue is in an animal. In certain embodiments, the animal is a human. In certain embodiments,
STAT3 mRNA levels are reduced. In certain embodiments, STAT3 protein levels are reduced. Such
reduction can occur in a time-dependent manner or in a dose-dependent manner.
Also provided are methods, compounds, and compositions useful for preventing, treating, and
ameliorating diseases, disorders, and conditions. In certain embodiments, such diseases, disorders, and
conditions are hyperproliferative diseases, disorders, and conditions. In certain embodiments such
hyperproliferative diseases, disorders, and conditions include cancer as well as associated malignancies
and metastases. In certain embodiments, such cancers include lung cancer, including non small cell lung
cancer (NSCLC), pancreatic cancer, colorectal cancer, multiple myeloma, hepatocellular carcinoma
(HCC), glioblastoma, ovarian cancer, osteosarcoma, head and neck cancer, breast cancer, epidermoid
carcinomas, intestinal adenomas, prostate cancer, and gastric cancer.
Such diseases, disorders, and conditions can have one or more risk factors, causes, or outcomes
in common. Certain risk factors and causes for development of a hyperproliferative disease include
growing older; tobacco use; exposure to sunlight and ionizing radiation; contact with certain chemicals;
infection with certain viruses and bacteria; certain hormone therapies; family history of cancer; alcohol
use; and certain lifestyle choices including poor diet, lack of physical activity, and/or being overweight.
Certain symptoms and outcomes associated with development of a hyperproliferative disease include a
thickening or lump in the breast or any other part of the body; a new mole or a change in an existing
mole; a sore that does not heal; hoarseness or a cough that does not go away; changes in bowel or bladder
habits; discomfort after eating; difficulty in swallowing; unexplained weight gain or loss; unusual
bleeding or discharge; fatigue; metastasis of one or more tumors throughout the body; cardiovascular
complications, including, cardiac arrest and stroke; and death.
In certain embodiments, methods of treatment include administering a STAT3 antisense
compound to an individual in need thereof. In certain embodiments, methods of treatment include
administering a STAT3 antisense oligonucleotide to an individual in need thereof.
BIOL0142WO
Detailed Description
It is to be understood that both the foregoing general description and the following detailed
description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the
use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including” as well
as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or
“component” encompass both elements and components comprising one unit and elements and
components that comprise more than one subunit, unless specifically stated otherwise.
The section headings used herein are for organizational purposes only and are not to be construed
as limiting the subject matter described. All documents, or portions of documents, cited in this
application, including, but not limited to, patents, patent applications, articles, books, and treatises, are
hereby expressly incorporated by reference for the portions of the document discussed herein, as well as
in their entirety.
Definitions
Unless specific definitions are provided, the nomenclature utilized in connection with, and the
procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and
pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard
techniques may be used for chemical synthesis, and chemical analysis. Where permitted, all patents,
applications, published applications and other publications, GENBANK Accession Numbers and
associated sequence information obtainable through databases such as National Center for Biotechnology
Information (NCBI) and other data referred to throughout in the disclosure herein are incorporated by
reference for the portions of the document discussed herein, as well as in their entirety.
Unless otherwise indicated, the following terms have the following meanings:
“2’-deoxynucleoside” means a nucleoside comprising 2’-H furanosyl sugar moiety, as found
naturally occurring in deoxyribonucleosides (DNA). In certain embodiments, a 2’-deoxynucleoside may
comprise a modified nucleobase or may comprise an RNA nucleobase (e.g., uracil).
“2’-O-methoxyethyl” (also 2’-MOE and 2’-O(CH ) -OCH ) refers to an O-methoxy-ethyl
2 2 3
modification of the 2’ position of a furosyl ring. A 2’-O-methoxyethyl modified sugar is a modified
sugar.
“2’-MOE nucleoside” (also 2’-O-methoxyethyl nucleoside) means a nucleoside comprising a 2’-
MOE modified sugar moiety.
“2’-substituted nucleoside” means a nucleoside comprising a substituent at the 2’-position other
than H or OH. Unless otherwise indicated, a 2’-substituted nucleoside is not a bicyclic nucleoside.
“5’-methylcytosine” means a cytosine modified with a methyl group attached to the 5’ position.
A 5-methylcytosine is a modified nucleobase.
BIOL0142WO
“About” means within ±10% of a value. For example, if it is stated, “the compounds affected at
least about 70% inhibition of STAT3”, it is implied that the STAT3 levels are inhibited within a range of
63% and 77%.
“Active pharmaceutical agent” means the substance or substances in a pharmaceutical
composition that provide a therapeutic benefit when administered to an individual. For example, in
certain embodiments an antisense oligonucleotide targeted to STAT3 is an active pharmaceutical agent.
“Active target region” or “target region” means a region to which one or more active antisense
compounds is targeted. “Active antisense compounds” means antisense compounds that reduce target
nucleic acid levels or protein levels.
“Administered concomitantly” refers to the co-administration of two agents in any manner in
which the pharmacological effects of both are manifest in the patient at the same time. Concomitant
administration does not require that both agents be administered in a single pharmaceutical composition,
in the same dosage form, or by the same route of administration. The effects of both agents need not
manifest themselves at the same time. The effects need only be overlapping for a period of time and need
not be coextensive.
“Administering” means providing a pharmaceutical agent to an individual, and includes, but is
not limited to administering by a medical professional and self-administering.
“Amelioration” refers to a lessening of at least one indicator, sign, or symptom of an associated
disease, disorder, or condition. The severity of indicators may be determined by subjective or objective
measures, which are known to those skilled in the art.
“Animal” refers to a human or non-human animal, including, but not limited to, mice, rats,
rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and
chimpanzees.
“Antibody” refers to a molecule characterized by reacting specifically with an antigen in some
way, where the antibody and the antigen are each defined in terms of the other. Antibody may refer to a
complete antibody molecule or any fragment or region thereof, such as the heavy chain, the light chain,
Fab region, and Fc region.
“Antisense activity” means any detectable or measurable activity attributable to the hybridization
of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity is a
decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic
acid.
“Antisense compound” means an oligomeric compound that is is capable of undergoing
hybridization to a target nucleic acid through hydrogen bonding. Examples of antisense compounds
include single-stranded and double-stranded compounds, such as, antisense oligonucleotides, siRNAs,
shRNAs, snoRNAs, miRNAs, and satellite repeats.
BIOL0142WO
“Antisense inhibition” means reduction of target nucleic acid levels or target protein levels in the
presence of an antisense compound complementary to a target nucleic acid as compared to target nucleic
acid levels or target protein levels in the absence of the antisense compound.
“Antisense oligonucleotide” means a single-stranded oligonucleotide having a nucleobase
sequence that permits hybridization to a corresponding region or segment of a target nucleic acid.
“Bicyclic sugar” means a furosyl ring modified by the bridging of two atoms. A bicyclic sugar is
a modified sugar.
“Bicyclic nucleoside” (also BNA) means a nucleoside having a sugar moiety comprising a bridge
connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain
embodiments, the bridge connects the 4’-carbon and the 2’-carbon of the sugar ring.
“Cap structure” or “terminal cap moiety” means chemical modifications, which have been
incorporated at either terminus of an antisense compound.
“cEt” or “constrained ethyl” means a bicyclic nucleoside having a sugar moiety comprising a
bridge connecting the 4’-carbon and the 2’-carbon, wherein the bridge has the formula: 4’-CH(CH )-O-2’.
“Constrained ethyl nucleoside” (also cEt nucleoside) means a nucleoside comprising a bicyclic
sugar moiety comprising a 4’-CH(CH )-O-2’ bridge.
“Chemically distinct region” refers to a region of an antisense compound that is in some way
chemically different than another region of the same antisense compound. For example, a region having
2’-O-methoxyethyl nucleotides is chemically distinct from a region having nucleotides without 2’-O-
methoxyethyl modifications.
“Chimeric antisense compound” means an antisense compound that has at least two chemically
distinct regions.
“Co-administration” means administration of two or more pharmaceutical agents to an individual.
The two or more pharmaceutical agents may be in a single pharmaceutical composition, or may be in
separate pharmaceutical compositions. Each of the two or more pharmaceutical agents may be
administered through the same or different routes of administration. Co-administration encompasses
parallel or sequential administration.
“Complementarity” means the capacity for pairing between nucleobases of a first nucleic acid
and a second nucleic acid.
“Contiguous nucleobases” means nucleobases immediately adjacent to each other.
“Diluent” means an ingredient in a composition that lacks pharmacological activity, but is
pharmaceutically necessary or desirable. For example, the diluent in an injected composition may be a
liquid, e.g. saline solution.
“Dose” means a specified quantity of a pharmaceutical agent provided in a single administration,
or in a specified time period. In certain embodiments, a dose may be administered in one, two, or more
boluses, tablets, or injections. For example, in certain embodiments where subcutaneous administration is
desired, the desired dose requires a volume not easily accommodated by a single injection, therefore, two
BIOL0142WO
or more injections may be used to achieve the desired dose. In certain embodiments, the pharmaceutical
agent is administered by infusion over an extended period of time or continuously. Doses may be stated
as the amount of pharmaceutical agent per hour, day, week, or month.
“Effective amount” means the amount of active pharmaceutical agent sufficient to effectuate a
desired physiological outcome in an individual in need of the agent. The effective amount may vary
among individuals depending on the health and physical condition of the individual to be treated, the
taxonomic group of the individuals to be treated, the formulation of the composition, assessment of the
individual’s medical condition, and other relevant factors.
“Fully complementary” or “100% complementary” means each nucleobase of a first nucleic acid
has a complementary nucleobase in a second nucleic acid. In certain embodiments, a first nucleic acid is
an antisense compound and a target nucleic acid is a second nucleic acid.
“Gapmer” means a chimeric antisense compound in which an internal region having a plurality of
nucleosides that support RNase H cleavage is positioned between external regions having one or more
nucleosides, wherein the nucleosides comprising the internal region are chemically distinct from the
nucleoside or nucleosides comprising the external regions. The internal region may be referred to as the
“gap” and the external regions may be referred to as the “wings.”
“Gap-widened” means a chimeric antisense compound having a gap segment of 12 or more
contiguous 2’-deoxyribonucleosides positioned between and immediately adjacent to 5’ and 3’ wing
segments having from one to six nucleosides.
“Hybridization” means the annealing of complementary nucleic acid molecules. In certain
embodiments, complementary nucleic acid molecules include an antisense compound and a target nucleic
acid.
“Hyperproliferative disease” means a disease characterized by rapid or excessive growth and
reproduction of cells. Examples of hyperproliferative diseases include cancer, e.g., carcinomas,
sarcomas, lymphomas, and leukemias as well as associated malignancies and metastases.
“Identifying an animal at risk for hyperproliferative disease” means identifying an animal having
been diagnosed with a hyperproliferative disease or identifying an animal predisposed to develop a
hyperproliferative disease. Individuals predisposed to develop a hyperproliferative disease include those
having one or more risk factors for hyperproliferative disease including older age; history of other
hyperproliferative diseases; history of tobacco use; history of exposure to sunlight and/or ionizing
radiation; prior contact with certain chemicals, especially continuous contact; past or current infection
with certain viruses and bacteria; prior or current use of certain hormone therapies; genetic predisposition;
alcohol use; and certain lifestyle choices including poor diet, lack of physical activity, and/or being
overweight. Such identification may be accomplished by any method including evaluating an
individual’s medical history and standard clinical tests or assessments.
“Immediately adjacent” means there are no intervening elements between the immediately
adjacent elements.
BIOL0142WO
“Inhibiting STAT3” means reducing expression of STAT3 mRNA and/or protein levels in the
presence of a STAT3 antisense compound, including a STAT3 antisense oligonucleotide, as compared to
expression of STAT3 mRNA and/or protein levels in the absence of a STAT3 antisense compound, such
as an antisense oligonucleotide.
“Individual” means a human or non-human animal selected for treatment or therapy.
“Internucleoside linkage” refers to the chemical bond between nucleosides.
“Linked nucleosides” means adjacent nucleosides which are bonded together.
“Mismatch” or “non-complementary nucleobase” refers to the case when a nucleobase of a first
nucleic acid is not capable of pairing with the corresponding nucleobase of a second or target nucleic
acid.
“Modified internucleoside linkage” refers to a substitution or any change from a naturally
occurring internucleoside bond (i.e. a phosphodiester internucleoside bond).
“Modified nucleobase” refers to any nucleobase other than adenine, cytosine, guanine, thymidine,
or uracil. An “unmodified nucleobase” means the purine bases adenine (A) and guanine (G), and the
pyrimidine bases thymine (T), cytosine (C), and uracil (U).
“Modified nucleotide” means a nucleotide having, independently, a modified sugar moiety,
modified internucleoside linkage, or modified nucleobase. A “modified nucleoside” means a nucleoside
having, independently, a modified sugar moiety or modified nucleobase.
“Modified oligonucleotide” means an oligonucleotide comprising a modified internucleoside
linkage, a modified sugar, and/or a modified nucleobase.
“Modified sugar” refers to a substitution or change from a natural sugar.
“Motif” means the pattern of chemically distinct regions in an antisense compound.
“Naturally occurring internucleoside linkage” means a 3' to 5' phosphodiester linkage.
“Natural sugar moiety” means a sugar found in DNA (2’-H) or RNA (2’-OH).
“Nucleic acid” refers to molecules composed of monomeric nucleotides. A nucleic acid includes
ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids, double-stranded
nucleic acids, small interfering ribonucleic acids (siRNA), and microRNAs (miRNA).
“Nucleobase” means a heterocyclic moiety capable of pairing with a base of another nucleic acid.
“Nucleobase sequence” means the order of contiguous nucleobases independent of any sugar,
linkage, or nucleobase modification.
“Nucleoside” means a nucleobase linked to a sugar.
"Nucleoside mimetic" includes those structures used to replace the sugar or the sugar and the base
and not necessarily the linkage at one or more positions of an oligomeric compound such as for example
nucleoside mimetics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl, bicyclo or tricyclo
sugar mimetics, e.g., non furanose sugar units. Nucleotide mimetic includes those structures used to
replace the nucleoside and the linkage at one or more positions of an oligomeric compound such as for
example peptide nucleic acids or morpholinos (morpholinos linked by -N(H)-C(=O)-O- or other non-
BIOL0142WO
phosphodiester linkage). Sugar surrogate overlaps with the slightly broader term nucleoside mimetic but
is intended to indicate replacement of the sugar unit (furanose ring) only. The tetrahydropyranyl rings
provided herein are illustrative of an example of a sugar surrogate wherein the furanose sugar group has
been replaced with a tetrahydropyranyl ring system.
“Nucleotide” means a nucleoside having a phosphate group covalently linked to the sugar portion
of the nucleoside.
“Off-target effect” refers to an unwanted or deleterious biological effect associated with
modulation of RNA or protein expression of a gene other than the intended target nucleic acid.
“Oligomeric compound” or “oligomer” means a polymer of linked monomeric subunits which is
capable of hybridizing to at least a region of a nucleic acid molecule.
“Oligonucleotide” means a polymer of linked nucleosides each of which can be modified or
unmodified, independent one from another.
“Parenteral administration” means administration through injection (e.g., bolus injection) or
infusion. Parenteral administration includes subcutaneous administration, intravenous administration,
intramuscular administration, intraarterial administration, intraperitoneal administration, or intracranial
administration, e.g., intrathecal or intracerebroventricular administration.
“Peptide” means a molecule formed by linking at least two amino acids by amide bonds. Peptide
refers to polypeptides and proteins.
“Pharmaceutical composition” means a mixture of substances suitable for administering to an
individual. For example, a pharmaceutical composition may comprise one or more active pharmaceutical
agents and a sterile aqueous solution. In certain embodiments, a pharmaceutical composition shows
activity in free uptake assay in certain cell lines.
“Pharmaceutically acceptable derivative” encompasses pharmaceutically acceptable salts,
conjugates, prodrugs or isomers of the compounds described herein.
“Pharmaceutically acceptable salts” means physiologically and pharmaceutically acceptable salts
of antisense compounds, i.e., salts that retain the desired biological activity of the parent oligonucleotide
and do not impart undesired toxicological effects thereto.
“Phosphorothioate linkage” means a linkage between nucleosides where the phosphodiester bond
is modified by replacing one of the non-bridging oxygen atoms with a sulfur atom. A phosphorothioate
linkage (P=S) is a modified internucleoside linkage.
“Portion” means a defined number of contiguous (i.e., linked) nucleobases of a nucleic acid. In
certain embodiments, a portion is a defined number of contiguous nucleobases of a target nucleic acid. In
certain embodiments, a portion is a defined number of contiguous nucleobases of an antisense compound.
“Prevent” refers to delaying or forestalling the onset or development of a disease, disorder, or
condition for a period of time from minutes to indefinitely. Prevent also means reducing risk of
developing a disease, disorder, or condition.
BIOL0142WO
“Prodrug” means a therapeutic agent that is prepared in an inactive form that is converted to an
active form within the body or cells thereof by the action of endogenous enzymes or other chemicals or
conditions.
“Side effects” means physiological responses attributable to a treatment other than the desired
effects. In certain embodiments, side effects include injection site reactions, liver function test
abnormalities, renal function abnormalities, liver toxicity, renal toxicity, central nervous system
abnormalities, myopathies, and malaise. For example, increased aminotransferase levels in serum may
indicate liver toxicity or liver function abnormality. For example, increased bilirubin may indicate liver
toxicity or liver function abnormality.
“Signal Transducer and Activator of Transcription 3 nucleic acid” or “STAT3 nucleic acid”
means any nucleic acid encoding STAT3. For example, in certain embodiments, a STAT3 nucleic acid
includes a DNA sequence encoding STAT3, an RNA sequence transcribed from DNA encoding STAT3
(including genomic DNA comprising introns and exons), and an mRNA sequence encoding STAT3.
“STAT3 mRNA” means an mRNA encoding a STAT3 protein.
“Single-stranded oligonucleotide” means an oligonucleotide which is not hybridized to a
complementary strand.
“Specifically hybridizable” refers to an antisense compound having a sufficient degree of
complementarity between an antisense oligonucleotide and a target nucleic acid to induce a desired effect,
while exhibiting minimal or no effects on non-target nucleic acids under conditions in which specific
binding is desired, i.e., under physiological conditions in the case of in vivo assays and therapeutic
treatments.
“Targeting” or “targeted” means the process of design and selection of an antisense compound
that will specifically hybridize to a target nucleic acid and induce a desired effect.
“Target nucleic acid,” “target RNA,” “target mRNA,” and “target RNA transcript” all refer to a
nucleic acid capable of being targeted by antisense compounds.
“Target segment” means the sequence of nucleotides of a target nucleic acid to which an
antisense compound is targeted. “5’ target site” refers to the 5’-most nucleotide of a target segment. “3’
target site” refers to the 3’-most nucleotide of a target segment.
“Therapeutically effective amount” means an amount of a pharmaceutical agent that provides a
therapeutic benefit to an individual.
“Treat” refers to administering a pharmaceutical composition to effect an alteration or
improvement of a disease, disorder, or condition.
“Unmodified nucleotide” means a nucleotide composed of naturally occuring nucleobases, sugar
moieties, and internucleoside linkages. In certain embodiments, an unmodified nucleotide is an RNA
nucleotide (i.e. β-D-ribonucleosides) or a DNA nucleotide (i.e. β-D-deoxyribonucleoside).
Certain Embodiments
BIOL0142WO
In certain embodiments provided are methods, compounds, and compositions for inhibiting
STAT3 mRNA or protein expression.
In certain embodiments provided are methods for preventing tumor growth and tumor volume. In
certain embodiments provided are methods for reducing tumor growth and tumor volume.
In certain embodiments provided are methods, compounds, and compositions for the treatment,
prevention, or amelioration of diseases, disorders, and conditions associated with STAT3 in an individual
in need thereof. Also contemplated are methods and compounds for the preparation of a medicament for
the treatment, prevention, or amelioration of a disease, disorder, or condition associated with STAT3.
STAT3 associated diseases, disorders, and conditions include hyperproliferative diseases, e.g., cancer,
carcinomas, sarcomas, lymphomas, and leukemias as well as associated malignancies and metastases.
In certain embodiments provided are STAT3 antisense compounds for use in treating, preventing,
or ameliorating a STAT3 associated disease. In certain embodiments, STAT3 antisense compounds are
STAT3 antisense oligonucleotides, which are capable of inhibiting the expression of STAT3 mRNA
and/or STAT3 protein in a cell, tissue, or animal.
In certain embodiments provided are a STAT3 antisense compound as described herein for use
in treating or preventing lung cancer, including non small cell lung cancer (NSCLC), pancreatic cancer,
colorectal cancer, multiple myeloma, hepatocellular carcinoma (HCC), glioblastoma, ovarian cancer,
osteosarcoma, head and neck cancer, breast cancer, epidermoid carcinomas, intestinal adenomas, prostate
cancer, and gastric cancer.
In certain embodiments provided are a STAT3 antisense compound as described herein for use in
treating or preventing cancer from metastasizing.
In certain embodiments provided are a STAT3 antisense compound, as described herein, for use
in treating, preventing, or ameliorating hyperproliferative diseases, e.g., cancer, carcinomas, sarcomas,
lymphomas, and leukemias as well as associated malignancies and metastases.
In certain embodiments provided are antisense compounds targeted to a STAT3 nucleic acid. In
certain embodiments, the STAT3 nucleic acid is any of the sequences set forth in GENBANK Accession
No. NM_139276.2 (incorporated herein as SEQ ID NO: 1) or the complement of GENBANK Accession
No. NT_010755.14 truncated from nucleotides 4185000 to 4264000 (incorporated herein as SEQ ID NO:
In certain embodiments, the antisense compounds provided herein are targeted to any one of the
following regions of SEQ ID NO 1: 250-286; 250-285; 264-285; 264-282; 728-745; 729-745; 729-744;
787-803; 867-883; 955-978; 1146-1170; 1896-1920; 1899-1920; 1899-1919; 1899-1918; 1899-1916;
1901-1916; 1946-1963; 1947-1963; 2155-2205; 2155-2187; 2156-2179; 2204-2221; 2681-2696; 2699-
2716; 3001-3033; 3008-3033, 3010-3033, 3010-3032, 3015-3033, 3015-3032, 3015-3031, 3016-3033,
3016-3032, 3016-3033; 3452-3499; 3460-3476; 3583-3608; 3591-3616; 3595-3615; 3595-3614; 3595-
3612; 3675-3706; 3713-3790; 3715-3735; 3833-3878; 3889-3932; 3977-4012; 4067-4100; 4225-4256;
4234-4252; 4235-4252; 4235-4251; 4236-4252; 4306-4341; 4431-4456; 4439-4454; 4471-4510; 4488-
BIOL0142WO
4505; 4530-4558; 4539-4572; 4541-4558; 4636-4801; 4782-4796; 4800-4823; 4811-4847; 4813-4859;
4813-4815; 4813-4831; 4827-4859; 4827-4844; 4842-4859.
In certain embodiments, the antisense compounds provided herein are complementary within any
one of the following regions of SEQ ID NO 1: 250-286; 250-285; 264-285; 264-282; 728-745;
729-745; 729-744; 787-803; 867-883; 955-978; 1146-1170; 1896-1920; 1899-1920; 1899-1919;
1899-1918; 1899-1916; 1901-1916; 1946-1963; 1947-1963; 2155-2205; 2155-2187; 2156-2179;
2204-2221; 2681-2696; 2699-2716; 3001-3033; 3008-3033, 3010-3033, 3010-3032, 3015-3033,
3015-3032, 3015-3031, 3016-3033, 3016-3032, 3016-3033; 3452-3499; 3460-3476; 3583-3608;
3591-3616; 3595-3615; 3595-3614; 3595-3612; 3675-3706; 3713-3790; 3715-3735; 3833-3878;
3889-3932; 3977-4012; 4067-4100; 4225-4256; 4234-4252; 4235-4252; 4235-4251; 4236-4252;
4306-4341; 4431-4456; 4439-4454; 4471-4510; 4488-4505; 4530-4558; 4539-4572; 4541-4558;
4636-4801; 4782-4796; 4800-4823; 4811-4847; 4813-4859; 4813-4815; 4813-4831; 4827-4859;
4827-4844; 4842-4859. In certain embodiments, provided are compounds comprising:
a modified antisense oligonucleotide consisting of 12 to 22 linked nucleosides, wherein the modified
antisense oligonucleotide comprises:
a 5’-wing consisting of 1 to 5 linked nucleosides;
a 3’-wing consisting of 1 to 5 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides; and
wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside or 2’-
substituted nucleoside;
wherein the nucleobase sequence of the modified antisense oligonucleotide is complementary to an equal
length portion of any of nucleobases 250-286; 250-285; 264-285; 264-282; 728-745; 729-745;
729-744; 787-803; 867-883; 955-978; 1146-1170; 1896-1920; 1899-1920; 1899-1919; 1899-
1918; 1899-1916; 1901-1916; 1946-1963; 1947-1963; 2155-2205; 2155-2187; 2156-2179; 2204-
2221; 2681-2696; 2699-2716; 3001-3033; 3008-3033, 3010-3033, 3010-3032, 3015-3033, 3015-
3032, 3015-3031, 3016-3033, 3016-3032, 3016-3033; 3452-3499; 3460-3476; 3583-3608; 3591-
3616; 3595-3615; 3595-3614; 3595-3612; 3675-3706; 3713-3790; 3715-3735; 3833-3878; 3889-
3932; 3977-4012; 4067-4100; 4225-4256; 4234-4252; 4235-4252; 4235-4251; 4236-4252; 4306-
4341; 4431-4456; 4439-4454; 4471-4510; 4488-4505; 4530-4558; 4539-4572; 4541-4558; 4636-
4801; 4782-4796; 4800-4823; 4811-4847; 4813-4859; 4813-4815; 4813-4831; 4827-4859; 4827-
4844; 4842-4859 of the nucleobase sequence of SEQ ID NO: 1.
In certain embodiments, the antisense compounds provided herein are targeted to any one of the
following regions of SEQ ID NO 2: 2668-2688; 2703-2720; 5000-5021; 5001-5017; 5697-5722; 5699-
5716; 6475 - 6490; 6475 - 6491; 6476 – 6491; 7682-7705; 8078-8097; 8079-8095; 9862-9811; 9870-
9897; 9875-9893; 9875-9891; 9877-9893; 11699-11719; 12342-12366; 12345-12364;12346-12364;
12347-12364; 12353-12380; 12357-12376; 12358-12376; 12358-12373; 12360-12376; 14128-14148;
16863-16883; 46091-46111; 50692-50709; 50693-50709; 50693-50708; 61325-61349; 66133-66157;
BIOL0142WO
66136-66157; 66136 - 66155; 66136-66153; 66138-66153; 66184-66200; 67067-67083; 4171-74220;
74199-74220; 74202-74220; 74171-74219; 74199-74219; 74202-74219; 74171-74218; 74199-74218;
74202-74218; 74723-74768; 74764-74803; 74782-74802; 74782-74801; 74782-74800; 74782-74799;
74783-74802; 74783-74801; 74783-74800; 74783-74799; 74862-74893; 74900-74977; 74902-74922;
74902-74920; 75070-75119; 75164-75199; 75254-75287; 75412-75443; 75421-75439; 75422-75439;
75422-75438; 75423-75439; 75423-75438; 75493-75528; 75616-75643; 75626-75641; 75658-75699;
75676-75692; 75717-75745; 75726-75759; 75726-75745; 75727-75745; 75728-75745; 75831-75988;
75852-75969; 75969-75984; 75987-76056; 76000-76046; 76000-76032; 76000-76018; 76014-76046;
76014-76032; 76029-76046; and 76031-76046.
In certain embodiments, the antisense compounds provided herein are complementary within
any one of the following regions of SEQ ID NO 2: 2668-2688; 2703-2720; 5000-5021; 5001-5017; 5697-
5722; 5699-5716; 6475 - 6490; 6475 - 6491; 6476 – 6491; 7682-7705; 8078-8097; 8079-8095; 9862-
9811; 9870-9897; 9875-9893; 9875-9891; 9877-9893; 11699-11719; 12342-12366; 12345-12364;12346-
12364; 12347-12364; 12353-12380; 12357-12376; 12358-12376; 12358-12373; 12360-12376; 14128-
14148; 16863-16883; 46091-46111; 50692-50709; 50693-50709; 50693-50708; 61325-61349; 66133-
66157; 66136-66157; 66136 - 66155; 66136-66153; 66138-66153; 66184-66200; 67067-67083; 4171-
74220; 74199-74220; 74202-74220; 74171-74219; 74199-74219; 74202-74219; 74171-74218; 74199-
74218; 74202-74218; 74723-74768; 74764-74803; 74782-74802; 74782-74801; 74782-74800; 74782-
74799; 74783-74802; 74783-74801; 74783-74800; 74783-74799; 74862-74893; 74900-74977; 74902-
74922; 74902-74920; 75070-75119; 75164-75199; 75254-75287; 75412-75443; 75421-75439; 75422-
75439; 75422-75438; 75423-75439; 75423-75438; 75493-75528; 75616-75643; 75626-75641; 75658-
75699; 75676-75692; 75717-75745; 75726-75759; 75726-75745; 75727-75745; 75728-75745; 75831-
75988; 75852-75969; 75969-75984; 75987-76056; 76000-76046; 76000-76032; 76000-76018; 76014-
76046; 76014-76032; 76029-76046; and 76031-76046.
In certain embodiments, provided are compounds comprising:
a modified antisense oligonucleotide consisting of 12 to 22 linked nucleosides, wherein the modified
antisense oligonucleotide comprises:
a 5’-wing consisting of 1 to 5 linked nucleosides;
a 3’-wing consisting of 1 to 5 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides; and
wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside or 2’-
substituted nucleoside;
wherein the nucleobase sequence of the modified antisense oligonucleotide is complementary to an equal
length portion of any of nucleobases 2668-2688; 2703-2720; 5000-5021; 5001-5017; 5697-5722;
5699-5716; 6475 - 6490; 6475 - 6491; 6476 – 6491; 7682-7705; 8078-8097; 8079-8095; 9862-
9811; 9870-9897; 9875-9893; 9875-9891; 9877-9893; 11699-11719; 12342-12366; 12345-
12364;12346-12364; 12347-12364; 12353-12380; 12357-12376; 12358-12376; 12358-12373;
BIOL0142WO
12360-12376; 14128-14148; 16863-16883; 46091-46111; 50692-50709; 50693-50709; 50693-
50708; 61325-61349; 66133-66157; 66136-66157; 66136 - 66155; 66136-66153; 66138-66153;
66184-66200; 67067-67083; 4171-74220; 74199-74220; 74202-74220; 74171-74219; 74199-
74219; 74202-74219; 74171-74218; 74199-74218; 74202-74218; 74723-74768; 74764-74803;
74782-74802; 74782-74801; 74782-74800; 74782-74799; 74783-74802; 74783-74801; 74783-
74800; 74783-74799; 74862-74893; 74900-74977; 74902-74922; 74902-74920; 75070-75119;
75164-75199; 75254-75287; 75412-75443; 75421-75439; 75422-75439; 75422-75438; 75423-
75439; 75423-75438; 75493-75528; 75616-75643; 75626-75641; 75658-75699; 75676-75692;
75717-75745; 75726-75759; 75726-75745; 75727-75745; 75728-75745; 75831-75988; 75852-
75969; 75969-75984; 75987-76056; 76000-76046; 76000-76032; 76000-76018; 76014-76046;
76014-76032; 76029-76046; and 76031-76046 of the nucleobase sequence of SEQ ID NO: 2.
Certain embodiments provide compounds comprising a modified oligonucleotide consisting of 12
to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 12 contiguous
nucleobases complementary to an equal length portion of nucleobases 3008 to 3033 of SEQ ID NO: 1,
wherein the nucleobase sequence is complementary to SEQ ID NO: 1.
Certain embodiments provide compounds comprising a modified oligonucleotide consisting of 12
to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 12 contiguous
nucleobases complementary to an equal length portion of nucleobases 3016 to 3031 of SEQ ID NO: 1,
wherein the nucleobase sequence is complementary to SEQ ID NO: 1.
Certain embodiments provide compounds comprising a modified oligonucleotide consisting of 12
to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 12 contiguous
nucleobases complementary to an equal length portion of nucleobases 6476 to 6491 of SEQ ID NO: 2,
wherein the nucleobase sequence is complementary to SEQ ID NO: 2.
Certain embodiments provide compounds comprising a modified oligonucleotide consisting of 12
to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 12 contiguous
nucleobases complementary to an equal length portion of nucleobases 250-286; 250-285; 264-285; 264-
282; 728-745; 729-745; 729-744; 787-803; 867-883; 955-978; 1146-1170; 1896-1920; 1899-1920; 1899-
1919; 1899-1918; 1899-1916; 1901-1916; 1946-1963; 1947-1963; 2155-2205; 2155-2187; 2156-2179;
2204-2221; 2681-2696; 2699-2716; 3001-3033; 3008-3033, 3010-3033, 3010-3032, 3015-3033, 3015-
3032, 3015-3031, 3016-3033, 3016-3032, 3016-3033; 3452-3499; 3460-3476; 3583-3608; 3591-3616;
3595-3615; 3595-3614; 3595-3612; 3675-3706; 3713-3790; 3715-3735; 3833-3878; 3889-3932; 3977-
4012; 4067-4100; 4225-4256; 4234-4252; 4235-4252; 4235-4251; 4236-4252; 4306-4341; 4431-4456;
4439-4454; 4471-4510; 4488-4505; 4530-4558; 4539-4572; 4541-4558; 4636-4801; 4782-4796; 4800-
4823; 4811-4847; 4813-4859; 4813-4815; 4813-4831; 4827-4859; 4827-4844; or 4842-4859 of SEQ ID
NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is complementary to SEQ ID
NO: 1.
BIOL0142WO
Certain embodiments provide compounds comprising a modified oligonucleotide consisting of
12 to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 12 contiguous
nucleobases complementary to an equal length portion of nucleobases 2668-2688; 2703-2720; 5000-
5021; 5001-5017; 5697-5722; 5699-5716; 6475 - 6490; 6475 - 6491; 6476 – 6491; 7682-7705; 8078-
8097; 8079-8095; 9862-9811; 9870-9897; 9875-9893; 9875-9891; 9877-9893; 11699-11719; 12342-
12366; 12345-12364;12346-12364; 12347-12364; 12353-12380; 12357-12376; 12358-12376; 12358-
12373; 12360-12376; 14128-14148; 16863-16883; 46091-46111; 50692-50709; 50693-50709; 50693-
50708; 61325-61349; 66133-66157; 66136-66157; 66136 - 66155; 66136-66153; 66138-66153; 66184-
66200; 67067-67083; 4171-74220; 74199-74220; 74202-74220; 74171-74219; 74199-74219; 74202-
74219; 74171-74218; 74199-74218; 74202-74218; 74723-74768; 74764-74803; 74782-74802; 74782-
74801; 74782-74800; 74782-74799; 74783-74802; 74783-74801; 74783-74800; 74783-74799; 74862-
74893; 74900-74977; 74902-74922; 74902-74920; 75070-75119; 75164-75199; 75254-75287; 75412-
75443; 75421-75439; 75422-75439; 75422-75438; 75423-75439; 75423-75438; 75493-75528; 75616-
75643; 75626-75641; 75658-75699; 75676-75692; 75717-75745; 75726-75759; 75726-75745; 75727-
75745; 75728-75745; 75831-75988; 75852-75969; 75969-75984; 75987-76056; 76000-76046; 76000-
76032; 76000-76018; 76014-76046; 76014-76032; 76029-76046; or 76031-76046of SEQ ID NO: 2,
wherein the nucleobase sequence of the modified oligonucleotide is complementary to SEQ ID NO: 2.
In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises the
sequence of SEQ ID NO: 245.
In certain embodiments, the nucleobase sequence of the modified oligonucleotide consists of the
sequence of SEQ ID NO: 245.
In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises the
sequence of SEQ ID NO: 413.
In certain embodiments, the nucleobase sequence of the modified oligonucleotide consists of the
sequence of SEQ ID NO: 413.
In certain embodiments, the modified oligonucleotide is 100% complementary to SEQ ID NO: 1
or 2.
In certain embodiments, the modified oligonucleotide consists of a single-stranded modified
oligonucleotide.
In certain embodiments, the modified oligonucleotide has at least one modified internucleoside
linkage.
In certain embodiments, each internucleoside linkage is a phosphorothioate internucleoside
linkage.
In certain embodiments, at least one nucleoside comprises a modified sugar.
In certain embodiments, at least one modified sugar is a bicyclic sugar.
In certain embodiments, the bicyclic sugar comprises a 4’- CH -O-2’ bridge.
In certain embodiments, the bicyclic sugar comprises a 4’-CH(CH )-O-2’ bridge.
BIOL0142WO
In certain embodiments, the modified sugar comprises a 2’-O(CH ) -OCH group.
2 2 3
In certain embodiments, the modified sugar comprises a 2’-O-CH group.
In certain embodiments, at least one nucleoside of the modified oligonucleotide comprises a
modified nucleobase.
In certain embodiments, the modified nucleobase is a 5’-methylcytosine.
In certain embodiments, the modified oligonucleotide comprises:
a 5’-wing consisting of 1 to 5 linked nucleosides;
a 3’-wing consisting of 1 to 5 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides; and
wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside or one 2’-
substituted nucleoside.
In certain embodiments, the modified oligonucleotide comprises:
a 5’-wing consisting of 1 to 5 linked nucleosides;
a 3’-wing consisting of 1 to 5 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides; and
wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside and at least
one 2’-substituted nucleoside.
In certain embodiments, the 2’-substituted nucleoside comprises any of the group consisting of a
2’-O(CH ) -OCH group or a 2’-O-CH group.
2 2 3 3
In certain embodiments, the bicyclic nucleoside comprises any of the group consisting of a 4’-
CH -O-2’ bridge and a 4’-CH(CH )-O-2’ bridge.
In certain embodiments, the modified oligonucleotide comprises:
a 5’-wing consisting of 3 linked nucleosides;
a 3’-wing consisting of 3 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 10 linked 2’-deoxynucleosides;
wherein each nucleoside of each of the 5’-wing and the 3’-wing comprises a constrained ethyl nucleoside;
wherein each internucleoside linkage is a phosphorothioate linkage; and
wherein each cytosine is a 5’-methylcytosine.
Certain embodiments provide compounds, comprising a modified oligonucleotide consisting of
12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 12 contiguous
nucleobases of the nucleobase sequence of SEQ ID NO: 245.
Certain embodiments provide compounds, comprising a modified oligonucleotide consisting of
12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 12 contiguous
nucleobases of the nucleobase sequence of SEQ ID NO: 413.
Certain embodiment provide compounds, comprising a modified oligonucleotide consisting of 12
to 30 linked nucleosides and having a nucleobase sequence comprising at least 12 contiguous nucleobases
BIOL0142WO
of any of the nucleobase sequences of SEQ ID NOs: 9-426, 430-442, 445-464, 471-498, 500-1034, 1036-
1512, and 1541-2757.
In certain embodiments, the modified oligonucleotide consists of a single-stranded modified
oligonucleotide.
In certain embodiments, at least one internucleoside linkage of the modified oligonucleotide is a
modified internucleoside linkage.
In certain embodiments, each internucleoside linkage is a phosphorothioate internucleoside
linkage.
In certain embodiments, at least one nucleoside comprises a modified sugar.
In certain embodiments, at least one modified sugar is a bicyclic sugar.
In certain embodiments, the bicyclic sugar comprises a 4’- CH -O-2’ bridge.
In certain embodiments, the bicyclic sugar comprises a 4’-CH(CH )-O-2’ bridge.
In certain embodiments, the modified sugar comprises a 2’-O(CH ) -OCH group.
2 2 3
In certain embodiments, the modified sugar comprises a 2’-O-CH group.
In certain embodiments, at least one nucleoside of the modified oligonucleotide comprises a
modified nucleobase.
In certain embodiments, the modified nucleobase is a 5’-methylcytosine.
In certain embodiments, the modified oligonucleotide comprises:
a 5’-wing consisting of 1 to 5 linked nucleosides;
a 3’-wing consisting of 1 to 5 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides; and
wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside or 2’-
substituted nucleoside.
In certain embodiments, the modified oligonucleotide comprises:
a 5’-wing consisting of 1 to 5 linked nucleosides;
a 3’-wing consisting of 1 to 5 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides; and
wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside and at least
one 2’-substituted nucleoside.
In certain embodiments, the 2’-substituted nucleoside comprises any of the group consisting of a
2’-O(CH ) -OCH group or a 2’-O-CH group.
2 2 3 3
In certain embodiments, the bicyclic nucleoside comprises any of the group consisting of a 4’-
CH -O-2’ bridge and a 4’-CH(CH )-O-2’ bridge.
In certain embodiments, the modified oligonucleotide comprises:
a 5’-wing consisting of 3 linked nucleosides;
a 3’-wing consisting of 3 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 10 linked 2’-deoxynucleosides;
BIOL0142WO
wherein each nucleoside of each of the 5’-wing and the 3’-wing comprises a constrained ethyl nucleoside;
wherein each internucleoside linkage is a phosphorothioate linkage; and
wherein each cytosine is a 5’-methylcytosine.
Certain embodiments provide compounds comprising:
a modified oligonucleotide consisting of 12 to 22 linked nucleosides, wherein the modified
oligonucleotide comprises:
a 5’-wing consisting of 1 to 5 linked nucleosides;
a 3’-wing consisting of 1 to 5 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides;
wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside or a 2’-
substituted nucleoside;
wherein the nucleobase sequence of the modified oligonucleotide is complementary to an equal length
portion of nucleobases 3016 to 3031 of the nucleobase sequence of SEQ ID NO: 1; and
wherein the compound inhibits expression of STAT3 mRNA expression.
Certain embodiments provide compounds comprising:
a modified oligonucleotide consisting of 12 to 22 linked nucleosides, wherein the modified
oligonucleotide comprises:
a 5’-wing consisting of 1 to 5 linked nucleosides;
a 3’-wing consisting of 1 to 5 linked nucleosides;
a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides;
wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside or a 2’-
substituted nucleoside;
wherein the nucleobase sequence of the modified oligonucleotide is complementary to an equal length
portion of nucleobases 6476 to 6491 of the nucleobase sequence of SEQ ID NO: 2; and
wherein the compound inhibits expression of STAT3 mRNA expression.
In certain embodiments, at least one of the 5’-wing and the 3’-wing comprises at least one 2’-
deoxynucleoside.
In certain embodiments, the modified oligonucleotide consists of a single-stranded modified
oligonucleotide.
In certain embodiments, the modified oligonucleotide comprises at least one bicyclic nucleoside.
In certain embodiments, at least one bicyclic nucleoside comprises a 4’-CH(CH )-O-2’ bridge.
In certain embodiments, each bicyclic nucleoside comprises a 4’-CH(CH )-O-2’ bridge.
In certain embodiments, at least one bicyclic nucleoside comprises a 4’- CH -O-2’ bridge.
In certain embodiments, each bicyclic nucleoside comprises a 4’- CH -O-2’ bridge.
In certain embodiments, the modified oligonucleotide comprises at least one 2’-substituted
nucleoside.
BIOL0142WO
In certain embodiments, at least one 2’-substituted nucleoside comprises a 2’-O(CH ) -OCH
2 2 3
group.
In certain embodiments, each 2’-substituted nucleoside comprises a 2’-O(CH ) -OCH group.
2 2 3
In certain embodiments, at least one 2’-substituted nucleoside comprises a 2’-O-CH group.
In certain embodiments, each 2’-substituted nucleoside comprises a 2’-O-CH group.
In certain embodiments, at least one internucleoside linkage is a modified internucleoside
linkage.
In certain embodiments, each modified internucleoside linkage is a phosphorothioate linkage.
In certain embodiments, at least one nucleoside of the modified oligonucleotide comprises a
modified nucleobase.
In certain embodiments, the modified nucleobase is a 5’-methylcytosine.
In certain embodiments, the modified oligonucleotide has a sugar motif described by Formula A
as follows:
(J) -(B) -(J) -(B) -(A) -(D) -(A) -(B) -(J) -(B) -(J)
m n p r t g v w x y z
wherein:
each A is independently a 2’-substituted nucleoside;
each B is independently a bicyclic nucleoside;
each J is independently either a 2’-substituted nucleoside or a 2’-deoxynucleoside;
each D is a 2’-deoxynucleoside;
m is 0-4; n is 0-2; p is 0-2; r is 0-2; t is 0-2; v is 0-2; w is 0-4; x is 0-2; y is 0-2; z is 0-4; g
is 6-14;
provided that:
at least one of m, n, and r is other than 0;
at least one of w and y is other than 0;
the sum of m, n, p, r, and t is from 2 to 5; and
the sum of v, w, x, y, and z is from 2 to 5.
In certain embodiments, the modified oligonucleotide has a sugar motif of any of the group
consisting of:
k-d(10)-k
e-d(10)-k
k-d(10)-e
k-k-d(10)-k-k
k-k-d(10)-e-e
e-e-d(10)-k-k
k-k-k-d(10)-k-k-k
e-e-e-d(10)-k-k-k
BIOL0142WO
k-k-k-d(10)-e-e-e
k-k-k-d(10)-k-k-k
e-k-k-d(10)-k-k-e
e-e-k-d(10)-k-k-e
e-d-k-d(10)-k-k-e
e-k-d(10)-k-e-k-e
k-d(10)-k-e-k-e-e
e-e-k-d(10)-k-e-k-e
e-d-d-k-d(9)-k-k-e
e-e-e-e-d(9)-k-k-e
wherein, k is a constrained ethyl nucleoside, e is a 2’-MOE substituted nucleoside, and d is a 2’-
deoxynucleoside.
Certain embodiments provide methods of treating a hyperproliferative disease in an animal,
comprising administering to an animal in need thereof a compound comprising a modified
oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising
at least 12 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-426, 430-442,
445-464, 471-498, 500-1034, 1036-1512, and 1541-2757.
Certain embodiments provide methods of treating a hyperproliferative disease in an animal,
comprising administering to an animal in need thereof a compound comprising a modified
oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at
least 12 contiguous nucleobases of SEQ ID NO: 245.
Certain embodiments provide methods of treating a hyperproliferative disease in an animal,
comprising administering to an animal in need thereof a compound comprising a modified
oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at
least 12 contiguous nucleobases of SEQ ID NO: 413.
In certain embodiments, the administering reduces tumor size in the animal.
In certain embodiments, the administering reduces tumor volume in the animal.
In certain embodiments, the administering prevents metastasis in the animal.
In certain embodiments, the administering prolongs survival of the animal.
In certain embodiments, the administering reduces cachaxia in the animal.
Certain embodiments provide methods of reducing expression of STAT3 in an animal,
comprising administering to an animal in need thereof a compound comprising a modified
oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at
least 12 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-426, 430-442,
445-464, 471-498, 500-1034, 1036-1512, and 1541-2757.
Certain embodiments provide methods of reducing expression of STAT3 in an animal,
comprising administering to an animal in need thereof a compound comprising a modified
BIOL0142WO
oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at
least 12 contiguous nucleobases of SEQ ID NO: 245.
Certain embodiments provide methods of reducing expression of STAT3 in an animal,
comprising administering to an animal in need thereof a compound comprising a modified
oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at
least 12 contiguous nucleobases of SEQ ID NO: 413.
In certain embodiments, the compound does not have the wing-gap-wing motif of 22.
Antisense compounds
Oligomeric compounds include, but are not limited to, oligonucleotides, oligonucleosides,
oligonucleotide analogs, oligonucleotide mimetics, antisense compounds, antisense oligonucleotides, and
siRNAs. An oligomeric compound may be “antisense” to a target nucleic acid, meaning that is is capable
of undergoing hybridization to a target nucleic acid through hydrogen bonding.
In certain embodiments, an antisense compound has a nucleobase sequence that, when written
in the 5’ to 3’ direction, comprises the reverse complement of the target segment of a target nucleic acid
to which it is targeted. In certain such embodiments, an antisense oligonucleotide has a nucleobase
sequence that, when written in the 5’ to 3’ direction, comprises the reverse complement of the target
segment of a target nucleic acid to which it is targeted.
In certain embodiments, an antisense compound targeted to a STAT3 nucleic acid is 12 to 30
subunits in length. In certain embodiments, an antisense compound targeted to a STAT3 nucleic acid is
14 to 30 subunits in length. In certain embodiments, an antisense compound targeted to a STAT3 nucleic
acid is 12 to 22 subunits in length. In other words, such antisense compounds are from 12 to 30 linked
subunits, 14 to 30 linked subunits, or 12 to 22 linked subunits, respectively. In other embodiments, the
antisense compound is 8 to 80, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to
, 16 to 50, 17 to 30, 17 to 50, 18 to 22, 18 to 24, 18 to 30, 18 to 50, 19 to 22, 19 to 30, 19 to 50, or 20 to
linked subunits. In certain such embodiments, the antisense compounds are 8, 9, 10, 11, 12, 13, 14,
, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42,
43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 linked subunits in length, or a range defined by any two of the
above values. In some embodiments the antisense compound is an antisense oligonucleotide, and the
linked subunits are nucleotides.
In certain embodiments antisense oligonucleotides targeted to a STAT3 nucleic acid may be
shortened or truncated. For example, a single subunit may be deleted from the 5’ end (5’ truncation), or
alternatively from the 3’ end (3’ truncation). A shortened or truncated antisense compound targeted to a
STAT3 nucleic acid may have two subunits deleted from the 5’ end, or alternatively may have two
subunits deleted from the 3’ end, of the antisense compound. Alternatively, the deleted nucleosides may
BIOL0142WO
be dispersed throughout the antisense compound, for example, in an antisense compound having one
nucleoside deleted from the 5’ end and one nucleoside deleted from the 3’ end.
When a single additional subunit is present in a lengthened antisense compound, the additional
subunit may be located at the 5’ or 3’ end of the antisense compound. When two or more additional
subunits are present, the added subunits may be adjacent to each other, for example, in an antisense
compound having two subunits added to the 5’ end (5’ addition), or alternatively to the 3’ end (3’
addition), of the antisense compound. Alternatively, the added subunits may be dispersed throughout the
antisense compound, for example, in an antisense compound having one subunit added to the 5’ end and
one subunit added to the 3’ end.
It is possible to increase or decrease the length of an antisense compound, such as an antisense
oligonucleotide, and/or introduce mismatch bases without eliminating activity. For example, in Woolf et
al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of antisense oligonucleotides 13-25
nucleobases in length were tested for their ability to induce cleavage of a target RNA in an oocyte
injection model. Antisense oligonucleotides 25 nucleobases in length with 8 or 11 mismatch bases near
the ends of the antisense oligonucleotides were able to direct specific cleavage of the target mRNA, albeit
to a lesser extent than the antisense oligonucleotides that contained no mismatches. Similarly, target
specific cleavage was achieved using 13 nucleobase antisense oligonucleotides, including those with 1 or
3 mismatches.
Gautschi et al. (J. Natl. Cancer Inst. 93:463-471, March 2001) demonstrated the ability of an
oligonucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-
xL mRNA to reduce the expression of both bcl-2 and bcl-xL in vitro and in vivo. Furthermore, this
oligonucleotide demonstrated potent anti-tumor activity in vivo.
Maher and Dolnick (Nuc. Acid. Res. 16:3341-3358,1988) tested a series of tandem 14
nucleobase antisense oligonucleotides, and a 28 and 42 nucleobase antisense oligonucleotides comprised
of the sequence of two or three of the tandem antisense oligonucleotides, respectively, for their ability to
arrest translation of human DHFR in a rabbit reticulocyte assay. Each of the three 14 nucleobase
antisense oligonucleotides alone was able to inhibit translation, albeit at a more modest level than the 28
or 42 nucleobase antisense oligonucleotides.
In certain embodiments, the compounds as described herein are efficacious by virtue of having
at least one of an in vitro IC of less than 20uM, less than 19uM, less than 18uM, less than 17uM, less
than 16uM, less than 15uM, less than 14uM, less than 13uM, less than 12uM, less than 11uM, less than
10uM, less than 9uM, less than 8uM, less than 7uM, less than 6uM, less than 5uM, less than 4uM, less
than 3uM, less than 2uM, less than 1uM when delivered to HuVEC cells as described herein.
In certain embodiments, the compounds as described herein are efficacious by virtue of having
at least one of an in vitro IC of less than 1.0uM, less than 0.9uM, less than 0.8uM, less than 0.7uM, less
than 0.6uM, less than 0.5uM, less than 0.4uM, less than 0.3uM, less than 0.2uM, less than 0.1uM when
delivered to HuVEC cells as described herein.
BIOL0142WO
In certain embodiments, the compounds as described herein are efficacious by virtue of having
at least one of an in vitro IC of less than 0.95uM, less than 0.90uM, less than 0.85uM, less than 0.80uM,
less than 0.75uM, less than 0.70uM, less than 0.65uM, less than 0.60uM, less than 0.55uM, less than
0.50uM, less than 0.45uM, less than 0.40uM, less than 0.35uM, less than 0.30uM, less than 0.25uM, less
than 0.20uM, less than 0.15uM, less than 0.10uM, less than 0.05uM, less than 0.04uM, less than 0.03uM,
less than 0.02uM, less than 0.01uM when delivered to HuVEC cells as described herein.
In certain embodiments, the compound as described herein are efficacious by virtue of having at
least one of an in vitro IC of less of less than 20uM, less than 15uM, less than 10uM, less than 5uM, less
than 2 uM when delivered by free uptake methods to cancer cell lines as described herein.
In certain embodiments, the compounds as described herein are highly tolerable as
demonstrated by having at least one of an increase an ALT or AST value of no more than 4 fold, 3 fold,
or 2 fold over saline treated animals or an increase in liver, spleen, or kidney weight of no more than
%, 20%, 15%, 12%, 10%, 5%, or 2%. In certain embodiments, the compounds as described herein are
highly tolerable as demonstrated by having no increase of ALT or AST over saline treated animals. In
certain embodiments, the compounds as described herein are highly tolerable as demonstrated by having
no increase in liver, spleen, or kidney weight over saline treated animals. In certain embodiments, these
compounds include ISIS 455265, ISIS 455269, ISIS 455271, ISIS 455272, ISIS 455291, ISIS 455371,
ISIS 455394, ISIS 455703, ISIS 455429, ISIS 455471, ISIS 455527, ISIS 455530, ISIS 455536, ISIS
455548, ISIS 455611, ISIS 465236, ISIS 465237, ISIS 465588, ISIS 465740, ISIS 465754, ISIS 465830,
ISIS 466670, ISIS 466720; ISIS 481374, ISIS 481390, ISIS 481420, ISIS 481431, ISIS 481453, ISIS
481464, ISIS 481475, ISIS 481495, ISIS 481500, ISIS 481501, ISIS 481525, ISIS 481548, ISIS 481549,
ISIS 481597, ISIS 481695, ISIS 481700, ISIS 481702, ISIS 481710, ISIS 481725, ISIS 481750, and ISIS
481763. In certain embodiments, such compounds include compounds comprising the sequence of any
one of SEQ ID NOs 57, 90, 90, 175, 223, 245, 267, 307, 317, 318, 366, 411, 413, 54, 258, 268, 272, 288,
464, 367, 393, 1564, 1568, 1571, 1572, 1590, 1670, 1693, 1728, 1770, 1826, 1829, 1835, 1847, 1910,
1997, 2168, 2198, 2325, 2339, 2720, 2731, 2732, and 2756.
Antisense Compound Motifs
In certain embodiments, antisense compounds targeted to a STAT3 nucleic acid have
chemically modified subunits arranged in patterns, or motifs, to confer to the antisense compounds
properties such as enhanced inhibitory activity, increased binding affinity for a target nucleic acid, or
resistance to degradation by in vivo nucleases.
Chimeric antisense compounds typically contain at least one region modified so as to confer
increased resistance to nuclease degradation, increased cellular uptake, increased binding affinity for the
target nucleic acid, and/or increased inhibitory activity. A second region of a chimeric antisense
BIOL0142WO
compound may optionally serve as a substrate for the cellular endonuclease RNase H, which cleaves the
RNA strand of an RNA:DNA duplex.
Antisense compounds having a gapmer motif are considered chimeric antisense compounds. In
a gapmer an internal region having a plurality of nucleotides that supports RNaseH cleavage is positioned
between external regions having a plurality of nucleotides that are chemically distinct from the
nucleosides of the internal region. In the case of an antisense oligonucleotide having a gapmer motif, the
gap segment generally serves as the substrate for endonuclease cleavage, while the wing segments
comprise modified nucleosides. In certain embodiments, the regions of a gapmer are differentiated by the
types of sugar moieties comprising each distinct region. The types of sugar moieties that are used to
differentiate the regions of a gapmer may in some embodiments include β-D-ribonucleosides, β-D-
deoxyribonucleosides, 2'-modified nucleosides (such 2’-modified nucleosides may include 2’-MOE and
2’-O-CH , among others), and bicyclic sugar modified nucleosides (such bicyclic sugar modified
nucleosides may include those having a constrained ethyl). In certain embodiments, wings may include
several modified sugar moieties, including, for example 2’-MOE and constrained ethyl. In certain
embodiments, wings may include several modified and unmodified sugar moieties. In certain
embodiments, wings may include various combinations of 2’-MOE nucleosides, constrained ethyl
nucleosides, and 2’-deoxynucleosides.
Each distinct region may comprise uniform sugar moieties, variant, or alternating sugar
moieties. The wing-gap-wing motif is frequently described as “X-Y-Z”, where “X” represents the length
of the 5’-wing, “Y” represents the length of the gap, and “Z” represents the length of the 3’-wing. “X”
and “Z” may comprise uniform, variant, or alternating sugar moieties. In certain embodiments, “X” and
“Y” may include one or more 2’-deoxynucleosides.
“Y” may comprise 2’-deoxynucleosides. As used herein, a gapmer described as “X-Y-Z” has a
configuration such that the gap is positioned immediately adjacent to each of the 5’-wing and the 3’ wing.
Thus, no intervening nucleotides exist between the 5’-wing and gap, or the gap and the 3’-wing. Any of
the antisense compounds described herein can have a gapmer motif. In certain embodiments, “X” and
“Z” are the same, in other embodiments they are different. In certain embodiments, “Y” is between 8 and
nucleosides. X, Y, or Z can be any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
, 30 or more nucleosides.
In certain embodiments, gapmers provided herein include, for example, 11-mers having a motif
of 11.
In certain embodiments, gapmers provided herein include, for example, 12-mers having a motif
of 12, 21, or 11.
In certain embodiments, gapmers provided herein include, for example, 13-mers having a motif
of 13, 22, 31, 12, or 21.
In certain embodiments, gapmers provided herein include, for example, 14-mers having a motif
of 14, 23, 32, 41, 13, 22, or 31.
BIOL0142WO
In certain embodiments, gapmers provided herein include, for example, 15-mers having a motif
of 15, 24, 33, 42, 51, 14, 23, 32, or 41.
In certain embodiments, gapmers provided herein include, for example, 16-mers having a motif
of 25, 34, 43, 52, 15, 24, 33, 42, or 51.
In certain embodiments, gapmers provided herein include, for example, 17-mers having a motif
of 35, 44, 53, 25, 34, 43, or 52.
In certain embodiments, gapmers provided herein include, for example, 18-mers having a motif
of 45, 54, 35, 44, or 53.
In certain embodiments, gapmers provided herein include, for example, 19-mers having a motif
of 55, 45, or 54.
In certain embodiments, gapmers provided herein include, for example, 20-mers having a motif
of 55.
In certain embodiments, the antisense compound has a “wingmer” motif, having a wing-gap or
gap-wing configuration, i.e. an X-Y or Y-Z configuration as described above for the gapmer
configuration. Thus, wingmer configurations provided herein include, but are not limited to, for example
-10, 8-4, 4-12, 12-4, 3-14, 16-2, 18-1, 10-3, 2-10, 1-10, 8-2, 2-13, 5-13, 5-8, or 6-8.
In certain embodiments, antisense compound targeted to a STAT3 nucleic acid has a 22
gapmer motif.
In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 33
gapmer motif.
In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 55
gapmer motif.
In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 15
gapmer motif.
In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 34
gapmer motif.
In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 24
gapmer motif.
In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 43
gapmer motif.
In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a gap-
widened motif.
In certain embodiments, the antisense compounds targeted to a STAT3 nucleic acid has
any of the following sugar motifs:
k-d(10)-k
e-d(10)-k
k-d(10)-e
BIOL0142WO
k-k-d(10)-k-k
k-k-d(10)-e-e
e-e-d(10)-k-k
k-k-k-d(10)-k-k-k
e-e-e-d(10)-k-k-k
k-k-k-d(10)-e-e-e
k-k-k-d(10)-k-k-k
e-k-k-d(10)-k-k-e
e-e-k-d(10)-k-k-e
e-d-k-d(10)-k-k-e
e-k-d(10)-k-e-k-e
k-d(10)-k-e-k-e-e
e-e-k-d(10)-k-e-k-e
e-d-d-k-d(9)-k-k-e
e-e-e-e-d(9)-k-k-e
wherein, k is a constrained ethyl nucleoside, e is a 2’-MOE substituted nucleoside, and d is a 2’-
deoxynucleoside.
In certain embodiments, the antisense oligonucleotide has a sugar motif described by Formula A
as follows: (J) -(B) -(J) -(B) -(A) -(D) -(A) -(B) -(J) -(B) -(J)
m n p r t g v w x y z
wherein:
each A is independently a 2’-substituted nucleoside;
each B is independently a bicyclic nucleoside;
each J is independently either a 2’-substituted nucleoside or a 2’-deoxynucleoside;
each D is a 2’-deoxynucleoside;
m is 0-4; n is 0-2; p is 0-2; r is 0-2; t is 0-2; v is 0-2; w is 0-4; x is 0-2; y is 0-2; z is 0-4; g
is 6-14;
provided that:
at least one of m, n, and r is other than 0;
at least one of w and y is other than 0;
the sum of m, n, p, r, and t is from 2 to 5; and
the sum of v, w, x, y, and z is from 2 to 5.
Target Nucleic Acids, Target Regions and Nucleotide Sequences
Nucleotide sequences that encode STAT3 include, without limitation, the following: GENBANK
Accession No. NM_139276.2 (incorporated herein as SEQ ID NO: 1) and the complement of GENBANK
BIOL0142WO
Accession No. NT_010755.14 truncated from nucleotides 4185000 to 4264000 (incorporated herein as
SEQ ID NO: 2).
It is understood that the sequence set forth in each SEQ ID NO in the Examples contained herein
is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As
such, antisense compounds defined by a SEQ ID NO may comprise, independently, one or more
modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Antisense compounds
described by Isis Number (Isis No) indicate a combination of nucleobase sequence and motif.
In certain embodiments, a target region is a structurally defined region of the target nucleic acid.
For example, a target region may encompass a 3’ UTR, a 5’ UTR, an exon, an intron, an exon/intron
junction, a coding region, a translation initiation region, translation termination region, or other defined
nucleic acid region. The structurally defined regions for STAT3 can be obtained by accession number
from sequence databases such as NCBI and such information is incorporated herein by reference. In
certain embodiments, a target region may encompass the sequence from a 5’ target site of one target
segment within the target region to a 3’ target site of another target segment within the same target region.
Targeting includes determination of at least one target segment to which an antisense compound
hybridizes, such that a desired effect occurs. In certain embodiments, the desired effect is a reduction in
mRNA target nucleic acid levels. In certain embodiments, the desired effect is reduction of levels of
protein encoded by the target nucleic acid or a phenotypic change associated with the target nucleic acid.
A target region may contain one or more target segments. Multiple target segments within a
target region may be overlapping. Alternatively, they may be non-overlapping. In certain embodiments,
target segments within a target region are separated by no more than about 300 nucleotides. In certain
emodiments, target segments within a target region are separated by a number of nucleotides that is, is
about, is no more than, is no more than about, 250, 200, 150, 100, 90, 80, 70, 60, 50, 40, 30, 20, or 10
nucleotides on the target nucleic acid, or is a range defined by any two of the preceeding values. In
certain embodiments, target segments within a target region are separated by no more than, or no more
than about, 5 nucleotides on the target nucleic acid. In certain embodiments, target segments are
contiguous. Contemplated are target regions defined by a range having a starting nucleic acid that is any
of the 5’ target sites or 3’ target sites listed herein.
Suitable target segments may be found within a 5’ UTR, a coding region, a 3’ UTR, an intron, an
exon, or an exon/intron junction. Target segments containing a start codon or a stop codon are also
suitable target segments. A suitable target segment may specifcally exclude a certain structurally defined
region such as the start codon or stop codon.
The determination of suitable target segments may include a comparison of the sequence of a
target nucleic acid to other sequences throughout the genome. For example, the BLAST algorithm may
be used to identify regions of similarity amongst different nucleic acids. This comparison can prevent the
selection of antisense compound sequences that may hybridize in a non-specific manner to sequences
other than a selected target nucleic acid (i.e., non-target or off-target sequences).
BIOL0142WO
There may be variation in activity (e.g., as defined by percent reduction of target nucleic acid
levels) of the antisense compounds within an active target region. In certain embodiments, reductions in
STAT3 mRNA levels are indicative of inhibition of STAT3 expression. Reductions in levels of a STAT3
protein are also indicative of inhibition of target mRNA expression. Further, phenotypic changes are
indicative of inhibition of STAT3 expression. In certain embodiments, reduced cellular growth, reduced
tumor growth, and reduced tumor volume can be indicative of inhibition of STAT3 expression. In certain
embodiments, amelioration of symptoms associated with cancer can be indicative of inhibition of STAT3
expression. In certain embodiments, reduction of cachexia is indicative of inhibition of STAT3
expression. In certain embodiments, reduction of cancer markers can be indicative of inhibition of
STAT3 expression.
Hybridization
In some embodiments, hybridization occurs between an antisense compound disclosed herein and
a STAT3 nucleic acid. The most common mechanism of hybridization involves hydrogen bonding (e.g.,
Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary
nucleobases of the nucleic acid molecules.
Hybridization can occur under varying conditions. Stringent conditions are sequence-dependent
and are determined by the nature and composition of the nucleic acid molecules to be hybridized.
Methods of determining whether a sequence is specifically hybridizable to a target nucleic acid
are well known in the art. In certain embodiments, the antisense compounds provided herein are
specifically hybridizable with a STAT3 nucleic acid.
Complementarity
An antisense compound and a target nucleic acid are complementary to each other when a
sufficient number of nucleobases of the antisense compound can hydrogen bond with the corresponding
nucleobases of the target nucleic acid, such that a desired effect will occur (e.g., antisense inhibition of a
target nucleic acid, such as a STAT3 nucleic acid).
Non-complementary nucleobases between an antisense compound and a STAT3 nucleic acid
may be tolerated provided that the antisense compound remains able to specifically hybridize to a target
nucleic acid. Moreover, an antisense compound may hybridize over one or more segments of a STAT3
nucleic acid such that intervening or adjacent segments are not involved in the hybridization event (e.g., a
loop structure, mismatch or hairpin structure).
In certain embodiments, the antisense compounds provided herein, or a specified portion
thereof, are, or are at least, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99%, or 100% complementary to a STAT3 nucleic acid, a target region, target segment,
or specified portion thereof. Percent complementarity of an antisense compound with a target nucleic
acid can be determined using routine methods.
BIOL0142WO
For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound
are complementary to a target region, and would therefore specifically hybridize, would represent 90
percent complementarity. In this example, the remaining noncomplementary nucleobases may be
clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to
complementary nucleobases. As such, an antisense compound which is 18 nucleobases in length having
four noncomplementary nucleobases which are flanked by two regions of complete complementarity with
the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would
thus fall within the scope of the present invention. Percent complementarity of an antisense compound
with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local
alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990,
215, 403 410; Zhang and Madden, Genome Res., 1997, 7, 649 656). Percent homology, sequence
identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence
Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison
Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981,
2, 482 489).
In certain embodiments, the antisense compounds provided herein, or specified portions thereof,
are fully complementary (i.e. 100% complementary) to a target nucleic acid, or specified portion thereof.
For example, an antisense compound may be fully complementary to a STAT3 nucleic acid, or a target
region, or a target segment or target sequence thereof. As used herein, “fully complementary” means
each nucleobase of an antisense compound is capable of precise base pairing with the corresponding
nucleobases of a target nucleic acid. For example, a 20 nucleobase antisense compound is fully
complementary to a target sequence that is 400 nucleobases long, so long as there is a corresponding 20
nucleobase portion of the target nucleic acid that is fully complementary to the antisense compound.
Fully complementary can also be used in reference to a specified portion of the first and /or the second
nucleic acid. For example, a 20 nucleobase portion of a 30 nucleobase antisense compound can be “fully
complementary” to a target sequence that is 400 nucleobases long. The 20 nucleobase portion of the 30
nucleobase oligonucleotide is fully complementary to the target sequence if the target sequence has a
corresponding 20 nucleobase portion wherein each nucleobase is complementary to the 20 nucleobase
portion of the antisense compound. At the same time, the entire 30 nucleobase antisense compound may
or may not be fully complementary to the target sequence, depending on whether the remaining 10
nucleobases of the antisense compound are also complementary to the target sequence.
The location of a non-complementary nucleobase may be at the 5’ end or 3’ end of the antisense
compound. Alternatively, the non-complementary nucleobase or nucleobases may be at an internal
position of the antisense compound. When two or more non-complementary nucleobases are present,
they may be contiguous (i.e. linked) or non-contiguous. In one embodiment, a non-complementary
nucleobase is located in the wing segment of a gapmer antisense oligonucleotide.
BIOL0142WO
In certain embodiments, antisense compounds that are, or are up to 11, 12, 13, 14, 15, 16, 17,
18, 19, or 20 nucleobases in length comprise no more than 4, no more than 3, no more than 2, or no more
than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a STAT3 nucleic acid,
or specified portion thereof.
In certain embodiments, antisense compounds that are, or are up to 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length comprise no more than 6, no
more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary
nucleobase(s) relative to a target nucleic acid, such as a STAT3 nucleic acid, or specified portion thereof.
The antisense compounds provided herein also include those which are complementary to a
portion of a target nucleic acid. As used herein, “portion” refers to a defined number of contiguous (i.e.
linked) nucleobases within a region or segment of a target nucleic acid. A “portion” can also refer to a
defined number of contiguous nucleobases of an antisense compound. In certain embodiments, the
antisense compounds, are complementary to at least an 8 nucleobase portion of a target segment. In
certain embodiments, the antisense compounds are complementary to at least a 9 nucleobase portion of a
target segment. In certain embodiments, the antisense compounds are complementary to at least a 10
nucleobase portion of a target segment. In certain embodiments, the antisense compounds are
complementary to at least an 11 nucleobase portion of a target segment. In certain embodiments, the
antisense compounds are complementary to at least a 12 nucleobase portion of a target segment. In
certain embodiments, the antisense compounds are complementary to at least a 13 nucleobase portion of a
target segment. In certain embodiments, the antisense compounds are complementary to at least a 14
nucleobase portion of a target segment. In certain embodiments, the antisense compounds are
complementary to at least a 15 nucleobase portion of a target segment. Also contemplated are antisense
compounds that are complementary to at least a 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more
nucleobase portion of a target segment, or a range defined by any two of these values.
Identity
The antisense compounds provided herein may also have a defined percent identity to a particular
nucleotide sequence, SEQ ID NO, or compound represented by a specific Isis number, or portion thereof.
As used herein, an antisense compound is identical to the sequence disclosed herein if it has the same
nucleobase pairing ability. For example, a RNA which contains uracil in place of thymidine in a
disclosed DNA sequence would be considered identical to the DNA sequence since both uracil and
thymidine pair with adenine. Shortened and lengthened versions of the antisense compounds described
herein as well as compounds having non-identical bases relative to the antisense compounds provided
herein also are contemplated. The non-identical bases may be adjacent to each other or dispersed
throughout the antisense compound. Percent identity of an antisense compound is calculated according to
the number of bases that have identical base pairing relative to the sequence to which it is being
compared.
BIOL0142WO
In certain embodiments, the antisense compounds, or portions thereof, are at least 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to one or more of the antisense
compounds or SEQ ID NOs, or a portion thereof, disclosed herein.
In certain embodiments, a portion of the antisense compound is compared to an equal length
portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic
acid.
In certain embodiments, a portion of the antisense oligonucleotide is compared to an equal length
portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic
acid.
Modifications
A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the
nucleoside is normally a heterocyclic base moiety. Nucleotides are nucleosides that further include a
phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that
include a pentofuranosyl sugar, the phosphate group can be linked to the 2', 3' or 5' hydroxyl moiety of
the sugar. Oligonucleotides are formed through the covalent linkage of adjacent nucleosides to one
another, to form a linear polymeric oligonucleotide. Within the oligonucleotide structure, the phosphate
groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.
Modifications to antisense compounds encompass substitutions or changes to internucleoside
linkages, sugar moieties, or nucleobases. Modified antisense compounds are often preferred over native
forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity
for nucleic acid target, increased stability in the presence of nucleases, or increased inhibitory activity.
Chemically modified nucleosides may also be employed to increase the binding affinity of a
shortened or truncated antisense oligonucleotide for its target nucleic acid. Consequently, comparable
results can often be obtained with shorter antisense compounds that have such chemically modified
nucleosides.
Modified Internucleoside Linkages
The naturally occuring internucleoside linkage of RNA and DNA is a 3' to 5' phosphodiester
linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, internucleoside
linkages are often selected over antisense compounds having naturally occurring internucleoside linkages
because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for
target nucleic acids, and increased stability in the presence of nucleases.
Oligonucleotides having modified internucleoside linkages include internucleoside linkages that
retain a phosphorus atom as well as internucleoside linkages that do not have a phosphorus atom.
BIOL0142WO
Representative phosphorus containing internucleoside linkages include, but are not limited to,
phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates.
Methods of preparation of phosphorous-containing and non-phosphorous-containing linkages are well
known.
In certain embodiments, antisense compounds targeted to a STAT3 nucleic acid comprise one
or more modified internucleoside linkages. In certain embodiments, the modified internucleoside
linkages are phosphorothioate linkages. In certain embodiments, each internucleoside linkage of an
antisense compound is a phosphorothioate internucleoside linkage.
Modified Sugar Moieties
Antisense compounds provided herein can optionally contain one or more nucleosides wherein
the sugar group has been modified. Such sugar modified nucleosides may impart enhanced nuclease
stability, increased binding affinity, or some other beneficial biological property to the antisense
compounds. In certain embodiments, nucleosides comprise a chemically modified ribofuranose ring
moiety. Examples of chemically modified ribofuranose rings include, without limitation, addition of
substitutent groups (including 5' and 2' substituent groups); bridging of non-geminal ring atoms to form
bicyclic nucleic acids (BNA); replacement of the ribosyl ring oxygen atom with S, N(R), or C(R1)(R)2 (R
= H, C -C alkyl or a protecting group); and combinations thereof. Examples of chemically modified
1 12
sugars include, 2'-F-5'-methyl substituted nucleoside (see, PCT International Application WO
2008/101157, published on 8/21/08 for other disclosed 5', 2'-bis substituted nucleosides), replacement of
the ribosyl ring oxygen atom with S with further substitution at the 2'-position (see, published U.S. Patent
Application US2005/0130923, published on June 16, 2005), or, alternatively, 5'-substitution of a BNA
(see, PCT International Application , published on 11/22/07, wherein LNA is
substituted with, for example, a 5'-methyl or a 5'-vinyl group).
Examples of nucleosides having modified sugar moieties include, without limitation,
nucleosides comprising 5'-vinyl, 5'-methyl (R or S), 4'-S, 2'-F, 2'-OCH , and 2'-O(CH )2OCH substituent
3 2 3
groups. The substituent at the 2’ position can also be selected from allyl, amino, azido, thio, O-allyl, O-
C -C alkyl, OCF , O(CH )2SCH , O(CH )2-O-N(Rm)(Rn), and O-CH -C(=O)-N(Rm)(Rn), where each
1 10 3 2 3 2 2
Rm and Rn is, independently, H or substituted or unsubstituted C -C alkyl.
1 10
As used herein, “bicyclic nucleosides” refer to modified nucleosides comprising a bicyclic sugar
moiety. Examples of bicyclic nucleosides include, without limitation, nucleosides comprising a bridge
between the 4' and the 2' ribosyl ring atoms. In certain embodiments, antisense compounds provided
herein include one or more bicyclic nucleosides wherein the bridge comprises a 4’ to 2’ bicyclic
nucleoside. Examples of such 4’ to 2’ bicyclic nucleosides, include, but are not limited to, one of the
formulae: 4'-(CH )-O-2' (LNA); 4'-(CH )-S-2'; 4'-(CH ) -O-2' (ENA); 4'-CH(CH )-O-2' and 4'-C-
2 2 2 2 3
H(CH OCH )-O-2', and analogs thereof (see, U.S. Patent 7,399,845, issued on July 15, 2008); 4'-
C(CH )(CH )-O-2', and analogs thereof (see, published PCT International Application WO2009/006478,
BIOL0142WO
published January 8, 2009); 4'-CH -N(OCH )-2', and analogs thereof (see, published PCT International
Application WO2008/150729, published December 11, 2008); 4'-CH -O-N(CH )-2' (see, published U.S.
Patent Application US2004/0171570, published September 2, 2004); 4'-CH -N(R)-O-2', wherein R is H,
C -C alkyl, or a protecting group (see, U.S. Patent 7,427,672, issued on September 23, 2008); 4'-CH -C-
1 12 2
(H)(CH )-2' (see, Chattopadhyaya, et al., J. Org. Chem.,2009, 74, 118-134); and 4'-CH -C(=CH )-2', and
3 2 2
analogs thereof (see, published PCT International Application , published on December
8, 2008). Also see, for example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al.,
Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5633-
5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63,
10035-10039; Srivastava et al., J. Am. Chem. Soc., 129(26) 8362-8379 (Jul. 4, 2007); Elayadi et al., Curr.
Opinion Invens. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; Orum et al., Curr.
Opinion Mol. Ther., 2001, 3, 239-243; U.S. Patent Nos U.S. 6,670,461, 7,053,207, 6,268,490, 6,770,748,
6,794,499, 7,034,133, 6,525,191, 7,399,845; published PCT International applications ,
WO 94/14226, , and ; U.S. Patent Publication Nos. US2004/0171570,
US2007/0287831, and US2008/0039618; and U.S. Patent Serial Nos. 12/129,154, 60/989,574,
61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787, and 61/099,844; and PCT International
Application Nos. , , and . Each of the
foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations
including for example α-L-ribofuranose and β-D-ribofuranose (see PCT international application
PCT/DK98/00393, published on March 25, 1999 as WO 99/14226).
In certain embodiments, bicyclic sugar moieties of BNA nucleosides include, but are not limited
to, compounds having at least one bridge between the 4' and the 2’ position of the pentofuranosyl sugar
moiety wherein such bridges independently comprises 1 or from 2 to 4 linked groups independently
selected from -[C(R )(R )] -, -C(R )=C(R )-, -C(R )=N-, -C(=NR )-, -C(=O)-, -C(=S)-, -O-, -Si(R ) -, -
a b n a b a a a 2
S(=O) -, and -N(R )-;
wherein:
x is 0, 1, or 2;
n is 1, 2, 3, or 4;
each R and R is, independently, H, a protecting group, hydroxyl, C -C alkyl, substituted C -
a b 1 12 1
C alkyl, C -C alkenyl, substituted C -C alkenyl, C -C alkynyl, substituted C -C alkynyl, C -C
12 2 12 2 12 2 12 2 12 5 20
aryl, substituted C -C aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted
20
heteroaryl, C -C alicyclic radical, substituted C -C alicyclic radical, halogen, OJ , NJ J , SJ , N , COOJ ,
7 5 7 1 1 2 1 3 1
acyl (C(=O)-H), substituted acyl, CN, sulfonyl (S(=O) -J ), or sulfoxyl (S(=O)-J ); and
2 1 1
each J and J is, independently, H, C -C alkyl, substituted C -C alkyl, C -C alkenyl,
1 2 1 12 1 12 2 12
substituted C -C alkenyl, C -C alkynyl, substituted C -C alkynyl, C -C aryl, substituted C -C aryl,
2 12 2 12 2 12 5 20 5 20
acyl (C(=O)-H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C -C
1 12
aminoalkyl, substituted C -C aminoalkyl, or a protecting group.
1 12
BIOL0142WO
In certain embodiments, the bridge of a bicyclic sugar moiety is, -[C(R )(R )] -, -[C(R )(R )] -O-,
a b n a b n
-C(R R )-N(R)-O- or, –C(R R )-O-N(R)-. In certain embodiments, the bridge is 4'-CH -2', 4'-(CH ) -2',
a b a b 2 2 2
4'-(CH ) -2', 4'-CH -O-2', 4'-(CH ) -O-2', 4'-CH -O-N(R)-2', and 4'-CH -N(R)-O-2'-, wherein each R is,
2 3 2 2 2 2 2
independently, H, a protecting group, or C -C alkyl.
1 12
In certain embodiments, bicyclic nucleosides are further defined by isomeric configuration. For
example, a nucleoside comprising a 4’-2’ methylene-oxy bridge, may be in the α-L configuration or in the
-O-2’) BNA's have been incorporated into
β-D configuration. Previously, α-L-methyleneoxy (4’-CH
antisense oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research, 2003,
21, 6365-6372).
In certain embodiments, bicyclic nucleosides include, but are not limited to, (A) α-L-
Methyleneoxy (4’-CH -O-2’) BNA , (B) β-D-Methyleneoxy (4’-CH -O-2’) BNA , (C) Ethyleneoxy (4’-
(CH ) -O-2’) BNA , (D) Aminooxy (4’-CH -O-N(R)-2’) BNA, (E) Oxyamino (4’-CH -N(R)-O-2’) BNA,
2 2 2 2
(F) Methyl(methyleneoxy) (4’-CH(CH )-O-2’) BNA, (G) methylene-thio (4’-CH -S-2’) BNA, (H)
methylene-amino (4’-CH2-N(R)-2’) BNA, (I) methyl carbocyclic (4’-CH -CH(CH )-2’) BNA, and (J)
propylene carbocyclic (4’-(CH ) -2’) BNA as depicted below.
Bx Bx
O Bx Bx
O N 3
(D) (E)
Bx Bx
Bx O O
wherein Bx is the base moiety and R is, independently, H, a protecting group or C -C alkyl.
1 12
In certain embodiments, bicyclic nucleoside having Formula I:
BIOL0142WO
wherein:
Bx is a heterocyclic base moiety;
-Q -Q -Q - is -CH -N(R )-CH -, -C(=O)-N(R )-CH -, -CH -O-N(R )-, -CH -N(R )-O-, or -N(R )-
a b c 2 c 2 c 2 2 c 2 c c
O-CH ;
R is C -C alkyl or an amino protecting group; and
c 1 12
T and T are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive
phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium.
In certain embodiments, bicyclic nucleoside having Formula II:
wherein:
Bx is a heterocyclic base moiety;
T and T are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive
phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;
Z is C -C alkyl, C -C alkenyl, C -C alkynyl, substituted C -C alkyl, substituted C -C alkenyl,
a 1 6 2 6 2 6 1 6 2 6
substituted C -C alkynyl, acyl, substituted acyl, substituted amide, thiol, or substituted thio.
In one embodiment, each of the substituted groups is, independently, mono or poly substituted
with substituent groups independently selected from halogen, oxo, hydroxyl, OJ , NJ J , SJ , N ,
c c d c 3
OC(=X)J , and NJ C(=X)NJ J , wherein each J , J , and J is, independently, H, C -C alkyl, or substituted
c e c d c d e 1 6
C -C alkyl and X is O or NJ .
1 6 c
In certain embodiments, bicyclic nucleoside having Formula III:
BIOL0142WO
wherein:
Bx is a heterocyclic base moiety;
T and T are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive
phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;
Z is C -C alkyl, C -C alkenyl, C -C alkynyl, substituted C -C alkyl, substituted C -C alkenyl,
b 1 6 2 6 2 6 1 6 2 6
substituted C -C alkynyl, or substituted acyl (C(=O)-).
In certain embodiments, bicyclic nucleoside having Formula IV:
wherein:
Bx is a heterocyclic base moiety;
T and T are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive
phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;
R is C -C alkyl, substituted C -C alkyl, C -C alkenyl, substituted C -C alkenyl, C -C alkynyl,
d 1 6 1 6 2 6 2 6 2 6
or substituted C -C alkynyl;
each q , q , q and q is, independently, H, halogen, C -C alkyl, substituted C -C alkyl, C -C
a b c d 1 6 1 6 2 6
alkenyl, substituted C -C alkenyl, C -C alkynyl, or substituted C -C alkynyl, C -C alkoxyl, substituted
2 6 2 6 2 6 1 6
C -C alkoxyl, acyl, substituted acyl, C -C aminoalkyl, or substituted C -C aminoalkyl;
1 6 1 6 1 6
In certain embodiments, bicyclic nucleoside having Formula V:
wherein:
Bx is a heterocyclic base moiety;
T and T are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive
phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;
q , q q and q are each, independently, hydrogen, halogen, C -C alkyl, substituted C -C alkyl,
a b, e f 1 12 1 12
C -C alkenyl, substituted C -C alkenyl, C -C alkynyl, substituted C -C alkynyl, C -C alkoxy,
2 12 2 12 2 12 2 12 1 12
substituted C -C alkoxy, OJ , SJ , SOJ , SO J , NJ J , N , CN, C(=O)OJ , C(=O)NJ J , C(=O)J , O-C(=O)-
1 12 j j j 2 j j k 3 j j k j
NJ J , N(H)C(=NH)NJ J , N(H)C(=O)NJ J or N(H)C(=S)NJ J ;
j k j k j k j k
BIOL0142WO
or q and q together are =C(q )(q );
e f g h
q and q are each, independently, H, halogen, C -C alkyl, or substituted C -C alkyl.
g h 1 12 1 12
The synthesis and preparation of the methyleneoxy (4’-CH -O-2’) BNA monomers adenine,
cytosine, guanine, 5-methyl-cytosine, thymine, and uracil, along with their oligomerization, and nucleic
acid recognition properties have been described (see, e.g., Koshkin et al., Tetrahedron, 1998, 54, 3607-
3630). BNAs and preparation thereof are also described in WO 98/39352 and WO 99/14226.
-O-2’) BNA, methyleneoxy (4’-CH -O-2’) BNA, and 2'-thio-
Analogs of methyleneoxy (4’-CH
BNAs, have also been prepared (see, e.g., Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222).
Preparation of locked nucleoside analogs comprising oligodeoxyribonucleotide duplexes as substrates for
nucleic acid polymerases has also been described (see, e.g., Wengel et al., WO 99/14226). Furthermore,
synthesis of 2'-amino-BNA, a novel comformationally restricted high-affinity oligonucleotide analog, has
been described in the art (see, e.g., Singh et al., J. Org. Chem., 1998, 63, 10035-10039). In addition, 2'-
amino- and 2'-methylamino-BNA's have been prepared and the thermal stability of their duplexes with
complementary RNA and DNA strands has been previously reported.
In certain embodiments, bicyclic nucleoside having Formula VI:
wherein:
Bx is a heterocyclic base moiety;
T and T are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive
phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;
each q , q , q and q is, independently, H, halogen, C -C alkyl, substituted C -C alkyl, C -C
i j k l 1 12 1 12 2 12
alkenyl, substituted C -C alkenyl, C -C alkynyl, substituted C -C alkynyl, C -C alkoxyl, substituted
2 12 2 12 2 12 1 12
C -C alkoxyl, OJ , SJ , SOJ , SO J , NJ J , N , CN, C(=O)OJ , C(=O)NJ J , C(=O)J , O-C(=O)NJ J ,
1 12 j j j 2 j j k 3 j j k j j k
N(H)C(=NH)NJ J , N(H)C(=O)NJ J , or N(H)C(=S)NJ J ; and
j k j k j k
q and q or q and q together are =C(q )(q ), wherein q and q are each, independently, H,
i j l k g h g h
halogen, C -C alkyl, or substituted C -C alkyl.
1 12 1 12
One carbocyclic bicyclic nucleoside having a 4'-(CH ) -2' bridge and the alkenyl analog, bridge
4'-CH=CH-CH -2', have been described (see, e.g., Freier et al., Nucleic Acids Research, 1997, 25(22),
4429-4443 and Albaek et al., J. Org. Chem., 2006, 71, 7731-7740). The synthesis and preparation of
carbocyclic bicyclic nucleosides along with their oligomerization and biochemical studies have also been
described (see, e.g., Srivastava et al., J. Am. Chem. Soc. 2007, 129(26), 8362-8379).
As used herein, “4’-2’ bicyclic nucleoside” or “4’ to 2’ bicyclic nucleoside” refers to a bicyclic
nucleoside comprising a furanose ring comprising a bridge connecting the 2’ carbon atom and the 4’
BIOL0142WO
carbon atom.
As used herein, “monocylic nucleosides” refer to nucleosides comprising modified sugar moieties
that are not bicyclic sugar moieties. In certain embodiments, the sugar moiety, or sugar moiety analogue,
of a nucleoside may be modified or substituted at any position.
As used herein, “2’-modified sugar” means a furanosyl sugar modified at the 2’ position. In
certain embodiments, such modifications include substituents selected from: a halide, including, but not
limited to substituted and unsubstituted alkoxy, substituted and unsubstituted thioalkyl, substituted and
unsubstituted amino alkyl, substituted and unsubstituted alkyl, substituted and unsubstituted allyl, and
substituted and unsubstituted alkynyl. In certain embodiments, 2’ modifications are selected from
substituents including, but not limited to: O[(CH ) O] CH , O(CH ) NH , O(CH ) CH , O(CH ) ONH ,
2 n m 3 2 n 2 2 n 3 2 n 2
OCH C(=O)N(H)CH , and O(CH ) ON[(CH ) CH ] , where n and m are from 1 to about 10. Other 2'-
2 3 2 n 2 n 3 2
substituent groups can also be selected from: C -C alkyl; substituted alkyl; alkenyl; alkynyl; alkaryl;
1 12
aralkyl; O-alkaryl or O-aralkyl; SH; SCH ; OCN; Cl; Br; CN; CF ; OCF ; SOCH ; SO CH ; ONO ; NO ;
3 3 3 3 2 3 2 2
N ; NH ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an
RNA cleaving group; a reporter group; an intercalator; a group for improving pharmacokinetic properties;
and a group for improving the pharmacodynamic properties of an antisense compound, and other
substituents having similar properties. In certain embodiments, modifed nucleosides comprise a 2’-MOE
side chain (see, e.g., Baker et al., J. Biol. Chem., 1997, 272, 11944-12000). Such 2'-MOE substitution
have been described as having improved binding affinity compared to unmodified nucleosides and to
other modified nucleosides, such as 2’- O-methyl, O-propyl, and O-aminopropyl. Oligonucleotides
having the 2'-MOE substituent also have been shown to be antisense inhibitors of gene expression with
promising features for in vivo use (see, e.g., Martin, P., Helv. Chim. Acta, 1995, 78, 486-504; Altmann et
al., Chimia, 1996, 50, 168-176; Altmann et al., Biochem. Soc. Trans., 1996, 24, 630-637; and Altmann et
al., Nucleosides Nucleotides, 1997, 16, 917-926).
As used herein, a “modified tetrahydropyran nucleoside” or “modified THP nucleoside” means a
nucleoside having a six-membered tetrahydropyran “sugar” substituted in for the pentofuranosyl residue
in normal nucleosides (a sugar surrogate). Modified THP nucleosides include, but are not limited to,
what is referred to in the art as hexitol nucleic acid (HNA), anitol nucleic acid (ANA), manitol nucleic
acid (MNA) (see Leumann, CJ. Bioorg. & Med. Chem. (2002) 10:841-854), fluoro HNA (F-HNA), or
those compounds having Formula X:
Formula X:
BIOL0142WO
wherein independently for each of said at least one tetrahydropyran nucleoside analog of Formula X:
Bx is a heterocyclic base moiety;
T and T are each, independently, an internucleoside linking group linking the tetrahydropyran
nucleoside analog to the antisense compound or one of T and T is an internucleoside linking group
linking the tetrahydropyran nucleoside analog to the antisense compound and the other of T and T is H,
a hydroxyl protecting group, a linked conjugate group, or a 5' or 3'-terminal group;
q , q , q , q , q , q and q are each, independently, H, C -C alkyl, substituted C -C alkyl, C -C
1 2 3 4 5 6 7 1 6 1 6 2 6
alkenyl, substituted C -C alkenyl, C -C alkynyl, or substituted C -C alkynyl; and
2 6 2 6 2 6
one of R and R is hydrogen and the other is selected from halogen, substituted or unsubstituted
alkoxy, NJ J , SJ , N , OC(=X)J , OC(=X)NJ J , NJ C(=X)NJ J , and CN, wherein X is O, S, or NJ , and
1 2 1 3 1 1 2 3 1 2 1
each J , J , and J is, independently, H or C -C alkyl.
1 2 3 1 6
In certain embodiments, the modified THP nucleosides of Formula X are provided wherein q ,
q , q , q , q , q and q are each H. In certain embodiments, at least one of q , q , q , q , q , q and q is
n p r s t, u m n p r s t, u
other than H. In certain embodiments, at least one of q , q , q , q , q , q and q is methyl. In certain
m n p r s t u
embodiments, THP nucleosides of Formula X are provided wherein one of R and R is F. In certain
embodiments, R is fluoro and R is H, R is methoxy and R is H, and R is methoxyethoxy and R is H.
1 2 1 2 1 2
As used herein, “2’-modified” or “2’-substituted” refers to a nucleoside comprising a sugar
comprising a substituent at the 2’ position other than H or OH. 2’-modified nucleosides, include, but are
not limited to, bicyclic nucleosides wherein the bridge connecting two carbon atoms of the sugar ring
connects the 2’ carbon and another carbon of the sugar ring and nucleosides with non-bridging
2’substituents, such as allyl, amino, azido, thio, O-allyl, O-C -C alkyl, -OCF , O-(CH ) -O-CH , 2'-
1 10 3 2 2 3
O(CH ) SCH , O-(CH ) -O-N(R )(R ), or O-CH -C(=O)-N(R )(R ), where each R and R is,
2 2 3 2 2 m n 2 m n m n
independently, H or substituted or unsubstituted C -C alkyl. 2’-modifed nucleosides may further
1 10
comprise other modifications, for example, at other positions of the sugar and/or at the nucleobase.
As used herein, “2’-F” refers to a sugar comprising a fluoro group at the 2’ position.
As used herein, “2’-OMe” or “2’-OCH ” or “2’-O-methyl” each refers to a nucleoside comprising
a sugar comprising an -OCH group at the 2’ position of the sugar ring.
As used herein, "oligonucleotide" refers to a compound comprising a plurality of linked
nucleosides. In certain embodiments, one or more of the plurality of nucleosides is modified. In certain
embodiments, an oligonucleotide comprises one or more ribonucleosides (RNA) and/or
deoxyribonucleosides (DNA).
Many other bicyclo and tricyclo sugar surrogate ring systems are also known in the art that can be
used to modify nucleosides for incorporation into antisense compounds (see, e.g., review article:
Leumann, J. C, Bioorganic & Medicinal Chemistry, 2002, 10, 841-854).
Such ring systems can undergo various additional substitutions to enhance activity.
Methods for the preparations of modified sugars are well known to those skilled in the art.
BIOL0142WO
In nucleotides having modified sugar moieties, the nucleobase moieties (natural, modified, or a
combination thereof) are maintained for hybridization with an appropriate nucleic acid target.
In certain embodiments, antisense compounds comprise one or more nucleotides having
modified sugar moieties. In certain embodiments, the modified sugar moiety is 2’-MOE. In certain
embodiments, the 2’-MOE modified nucleotides are arranged in a gapmer motif. In certain embodiments,
the modified sugar moiety is a cEt. In certain embodiments, the cEt modified nucleotides are arranged
throughout the wings of a gapmer motif.
Compositions and Methods for Formulating Pharmaceutical Compositions
Antisense oligonucleotides may be admixed with pharmaceutically acceptable active or inert
substances for the preparation of pharmaceutical compositions or formulations. Compositions and
methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria,
including, but not limited to, route of administration, extent of disease, or dose to be administered.
An antisense compound targeted to a STAT3 nucleic acid can be utilized in pharmaceutical
compositions by combining the antisense compound with a suitable pharmaceutically acceptable diluent
or carrier. A pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS). PBS is a
diluent suitable for use in compositions to be delivered parenterally. Accordingly, in one embodiment,
employed in the methods described herein is a pharmaceutical composition comprising an antisense
compound targeted to a STAT3 nucleic acid and a pharmaceutically acceptable diluent. In certain
embodiments, the pharmaceutically acceptable diluent is PBS. In certain embodiments, the antisense
compound is an antisense oligonucleotide.
Pharmaceutical compositions comprising antisense compounds encompass any
pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon
administration to an animal, including a human, is capable of providing (directly or indirectly) the
biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn
to pharmaceutically acceptable salts of antisense compounds, prodrugs, pharmaceutically acceptable salts
of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are
not limited to, sodium and potassium salts.
A prodrug can include the incorporation of additional nucleosides at one or both ends of an
antisense compound which are cleaved by endogenous nucleases within the body, to form the active
antisense compound.
Conjugated Antisense compounds
Antisense compounds may be covalently linked to one or more moieties or conjugates which
enhance the activity, cellular distribution or cellular uptake of the resulting antisense oligonucleotides.
Typical conjugate groups include cholesterol moieties and lipid moieties. Additional conjugate groups
BIOL0142WO
include carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine,
fluoresceins, rhodamines, coumarins, and dyes.
Antisense compounds can also be modified to have one or more stabilizing groups that are
generally attached to one or both termini of antisense compounds to enhance properties such as, for
example, nuclease stability. Included in stabilizing groups are cap structures. These terminal
modifications protect the antisense compound having terminal nucleic acid from exonuclease
degradation, and can help in delivery and/or localization within a cell. The cap can be present at the 5'-
terminus (5'-cap), or at the 3'-terminus (3'-cap), or can be present on both termini. Cap structures are well
known in the art and include, for example, inverted deoxy abasic caps. Further 3' and 5'-stabilizing
groups that can be used to cap one or both ends of an antisense compound to impart nuclease stability
include those disclosed in WO 03/004602 published on January 16, 2003.
Cell culture and antisense compounds treatment
The effects of antisense compounds on the level, activity or expression of STAT3 nucleic acids
can be tested in vitro in a variety of cell types. Cell types used for such analyses are available from
commerical vendors (e.g. American Type Culture Collection, Manassus, VA; Zen-Bio, Inc., Research
Triangle Park, NC; Clonetics Corporation, Walkersville, MD) and are cultured according to the vendor’s
instructions using commercially available reagents (e.g. Invitrogen Life Technologies, Carlsbad, CA).
Illustrative cell types include, but are not limited to, HuVEC cells, b.END cells, HepG2 cells, Hep3B
cells, and primary hepatocytes.
In vitro testing of antisense oligonucleotides
Described herein are methods for treatment of cells with antisense oligonucleotides, which can
be modified appropriately for treatment with other antisense compounds.
Cells may be treated with antisense oligonucleotides when the cells reach approximately 60-
80% confluency in culture.
One reagent commonly used to introduce antisense oligonucleotides into cultured cells includes
the cationic lipid transfection reagent LIPOFECTIN (Invitrogen, Carlsbad, CA). Antisense
oligonucleotides may be mixed with LIPOFECTIN in OPTI-MEM 1 (Invitrogen, Carlsbad, CA) to
achieve the desired final concentration of antisense oligonucleotide and a LIPOFECTIN concentration
that may range from 2 to 12 ug/mL per 100 nM antisense oligonucleotide.
Another reagent used to introduce antisense oligonucleotides into cultured cells includes
LIPOFECTAMINE (Invitrogen, Carlsbad, CA). Antisense oligonucleotide is mixed with
LIPOFECTAMINE in OPTI-MEM 1 reduced serum medium (Invitrogen, Carlsbad, CA) to achieve the
desired concentration of antisense oligonucleotide and a LIPOFECTAMINE concentration that may range
from 2 to 12 ug/mL per 100 nM antisense oligonucleotide.
BIOL0142WO
Another technique used to introduce antisense oligonucleotides into cultured cells includes
electroporation.
Cells are treated with antisense oligonucleotides by routine methods. Cells may be harvested 16-
24 hours after antisense oligonucleotide treatment, at which time RNA or protein levels of target nucleic
acids are measured by methods known in the art and described herein. In general, when treatments are
performed in multiple replicates, the data are presented as the average of the replicate treatments.
The concentration of antisense oligonucleotide used varies from cell line to cell line. Methods
to determine the optimal antisense oligonucleotide concentration for a particular cell line are well known
in the art. Antisense oligonucleotides are typically used at concentrations ranging from 1 nM to 300 nM
when transfected with LIPOFECTAMINE. Antisense oligonucleotides are used at higher concentrations
ranging from 625 to 20,000 nM when transfected using electroporation.
Free Uptake Assays
In certain embodiments, transfection-independent activity (i.e., free uptake) of antisense
oligonucleotides in cancer cell lines is a measure of potency. Free uptake may be measured in cancer cell
lines such as, for example, SK-BR-3 cells, U251-MG cells, MDA-MB-231 cells, H460 cells, A431 cells,
colo205 cells, SNB-19 cells, SK-OV3 cells, H1993 lung cancer cells, H358 lung cancer cells, PC-9 lung
cancer cells, KHM-35 lung cancer cells, Capan-1 pancreatic cancer cells, HPAF-11 pancreatic cancer
cells, and Colo 201colorectal cancer cells.
In free uptake assays, antisense oligonucleotides are administered to cells lines without the aid
of a transfection agent or electroporation. Antisense oligonucleotides are administered to cell lines at one
or more doses and percent inhbition of target mRNA or protein expression is meausred. Where multiple
doses are administered, IC50 may be measured. In certain embodiments, antisense oligonucleotides
exhibiting a high degree of potency, as measured by percent inhbition after single dose or multiple doses,
are preferred over antisense oligonucleotides exhibiting a lower degree of potency. Those antisense
oligonucleotides exhibiting a high degree of in vitro potency are more likely to exhibit in vivo potency.
RNA Isolation
RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA
isolation are well known in the art. RNA is prepared using methods well known in the art, for example,
using the TRIZOL Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended
protocols.
Analysis of inhibition of target levels or expression
Inhibition of levels or expression of a STAT3 nucleic acid can be assayed in a variety of ways
known in the art. For example, target nucleic acid levels can be quantitated by, e.g., Northern blot
analysis, competitive polymerase chain reaction (PCR), or quantitaive real-time PCR. RNA analysis can
BIOL0142WO
be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are well known in
the art. Northern blot analysis is also routine in the art. Quantitative real-time PCR can be conveniently
accomplished using the commercially available ABI PRISM 7600, 7700, or 7900 Sequence Detection
System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer’s
instructions.
Quantitative Real-Time PCR Analysis of Target RNA Levels
Quantitation of target RNA levels may be accomplished by quantitative real-time PCR using the
ABI PRISM 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, CA)
according to manufacturer’s instructions. Methods of quantitative real-time PCR are well known in the
art.
Prior to real-time PCR, the isolated RNA is subjected to a reverse transcriptase (RT) reaction,
which produces complementary DNA (cDNA) that is then used as the substrate for the real-time PCR
amplification. The RT and real-time PCR reactions are performed sequentially in the same sample well.
RT and real-time PCR reagents may be obtained from Invitrogen (Carlsbad, CA). RT real-time-PCR
reactions are carried out by methods well known to those skilled in the art.
Gene (or RNA) target quantities obtained by real time PCR are normalized using either the
expression level of a gene whose expression is constant, such as cyclophilin A, or by quantifying total
RNA using RIBOGREEN (Invitrogen, Inc. Carlsbad, CA). Cyclophilin A expression is quantified by real
time PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is
quantified using RIBOGREEN RNA quantification reagent (Invetrogen, Inc. Eugene, OR). Methods of
RNA quantification by RIBOGREEN are taught in Jones, L.J., et al, (Analytical Biochemistry, 1998, 265,
368-374). A CYTOFLUOR 4000 instrument (PE Applied Biosystems) is used to measure RIBOGREEN
fluorescence.
Probes and primers are designed to hybridize to a STAT3 nucleic acid. Methods for designing
real-time PCR probes and primers are well known in the art, and may include the use of software such as
PRIMER EXPRESS Software (Applied Biosystems, Foster City, CA).
Analysis of Protein Levels
Antisense inhibition of STAT3 nucleic acids can be assessed by measuring STAT3 protein
levels. Protein levels of STAT3 can be evaluated or quantitated in a variety of ways well known in the
art, such as immunoprecipitation, Western blot analysis (immunoblotting), enzyme-linked
immunosorbent assay (ELISA), quantitative protein assays, protein activity assays (for example, caspase
activity assays), immunohistochemistry, immunocytochemistry or fluorescence-activated cell sorting
(FACS). Antibodies directed to a target can be identified and obtained from a variety of sources, such as
the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via
BIOL0142WO
conventional monoclonal or polyclonal antibody generation methods well known in the art. Antibodies
useful for the detection of mouse, rat, monkey, and human STAT3 are commercially available.
In vivo testing of antisense compounds
Antisense compounds, for example, antisense oligonucleotides, are tested in animals to assess
their ability to inhibit expression of STAT3 and produce phenotypic changes, such as, reduced cellular
growth, amelioration of symptoms associated with cancer, reduction of cachexia, and reduction of cancer
markers. Testing may be performed in normal animals, or in experimental disease models. For
administration to animals, antisense oligonucleotides are formulated in a pharmaceutically acceptable
diluent, such as phosphate-buffered saline. Administration includes parenteral routes of administration,
such as intraperitoneal, intravenous, subcutaneous, intrathecal, and intracerebroventricular. Calculation
of antisense oligonucleotide dosage and dosing frequency is within the abilities of those skilled in the art,
and depends upon factors such as route of administration and animal body weight. Following a period of
treatment with antisense oligonucleotides, RNA is isolated from liver tissue and changes in STAT3
nucleic acid expression are measured. Changes in STAT3 protein levels are also measured.
In certain embodiments, xenograft tumor models are used to measure the effect of antisense
oligonucleotides on tumor growth and metastasis. In xenograft tumor model described herein, cells from
a cancerous cell line are inoculated into an animal. Such cell lines may include, for example, human
breast cancer cells, MDA-MB-231, A431 human epidermoid carcinoma, U251 human glioma tumor cells,
and human NCI-H460 non-small cell lung carcinoma cells. Certain compounds described herein and
used in xenograft models described herein may target human STAT3, mouse STAT3, rat STAT3, and/or
monkey STAT3. Certain compounds described herein and used in xenograft models described herein
may cross-react with one or more species STAT3. In certain embodiments, compounds described herein
and used in xenograft models described herein may be more potent inhibitors of tumor growth and tumor
volume than the data suggests wherein endogenous STAT3 is not reduced (due to lack of cross-
reactivity).
Certain Indications
In certain embodiments, provided are methods, compounds, and compositions of treating an
individual comprising administering one or more pharmaceutical compositions provided herein. In
certain embodiments, the individual has a hyperproliferative disease. In certain embodiments, the
hyperproliferative disease is cancer, e.g., carcinomas, sarcomas, lymphomas, and leukemias as well as
associated malignancies and metastases. In certain embodiments, the type of cancer is lung cancer,
including non small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, multiple myeloma,
hepatocellular carcinoma (HCC), glioblastoma, ovarian cancer, osteosarcoma, head and neck cancer,
breast cancer, epidermoid carcinomas, intestinal adenomas, prostate cancer, and gastric cancer. In certain
embodiments, the individual is at risk for a hyperproliferative disease, including, cancer, e.g., carcinomas,
BIOL0142WO
sarcomas, lymphomas, and leukemias as well as associated malignancies and metastases. This includes
individuals having one or more risk factors for developing a hyperproliferative disease, including,
growing older; tobacco use; exposure to sunlight and ionizing radiation; contact with certain chemicals;
infection with certain viruses and bacteria; certain hormone therapies; genetic predisposition; alcohol use;
and certain lifestyle choices including poor diet, lack of physical activity, and/or being overweight. In
certain embodiments, the individual has been identified as in need of treatment for a hyperproliferative
disease. In certain embodiments, are provided methods for prophylactically reducing STAT3 expression
in an individual. Certain embodiments include treating an individual in need thereof by administering to
an individual a therapeutically effective amount of an antisense compound targeted to a STAT3 nucleic
acid.
In certain embodiments, treatment with the methods, compounds, and compositions
described herein is useful for preventing metastasis of a cancer associated with the upregulation of certain
genes, such as STAT3, at the tumor bone interface to bone. In certain embodiments, treatment with the
methods, compounds, and compositions described herein is useful for preventing cancer from
metastasizing to bone. In certain embodiments, treatment with the methods, compounds, and
compositions described herein is useful for preventing renal cell carcinoma, breast cancer, non small cell
lung carcinoma, and prostate cancer from metastasizing to bone.
In one embodiment, administration of a therapeutically effective amount of an antisense
compound targeted to a STAT3 nucleic acid is accompanied by monitoring of STAT3 levels in the serum
of an individual to determine an individual’s response to administration of the antisense compound. An
individual’s response to administration of the antisense compound is used by a physician to determine the
amount and duration of therapeutic intervention.
In certain embodiments, administration of an antisense compound targeted to a STAT3 nucleic
acid results in reduction of STAT3 expression by at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75,
80, 85, 90, 95 or 99%, or a range defined by any two of these values. In certain embodiments,
administration of an antisense compound targeted to a STAT3 nucleic acid results in reduced cellular
growth, reduced tumor growth, reduced tumor volume, amelioration of symptoms associated with cancer,
and reduction of cancer markers. In certain embodiments, administration of a STAT3 antisense
compound decreases cellular growth, tumor growth, and tumor volume by at least 15, 20, 25, 30, 35, 40,
45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined by any two of these values.
In certain embodiments, pharmaceutical compositions comprising an antisense compound
targeted to STAT3 are used for the preparation of a medicament for treating a patient suffering or
susceptible to a hyperproliferative disease.
Certain Combination Therapies
In certain embodiments, one or more pharmaceutical compositions provided herein are co-
administered with one or more other pharmaceutical agents. In certain embodiments, such one or more
BIOL0142WO
other pharmaceutical agents are designed to treat the same disease, disorder, or condition as the one or
more pharmaceutical compositions provided herein. In certain embodiments, such one or more other
pharmaceutical agents are designed to treat a different disease, disorder, or condition as the one or more
pharmaceutical compositions provided herein. In certain embodiments, such one or more other
pharmaceutical agents are designed to treat an undesired side effect of one or more pharmaceutical
compositions provided herein. In certain embodiments, one or more pharmaceutical compositions
provided herein are co-administered with another pharmaceutical agent to treat an undesired effect of that
other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions provided
herein are co-administered with another pharmaceutical agent to produce a combinational effect. In
certain embodiments, one or more pharmaceutical compositions provided herein are co-administered with
another pharmaceutical agent to produce a synergistic effect.
In certain embodiments, one or more pharmaceutical compositions provided herein and one or
more other pharmaceutical agents are administered at the same time. In certain embodiments, one or
more pharmaceutical compositions provided herein and one or more other pharmaceutical agents are
administered at different times. In certain embodiments, one or more pharmaceutical compositions
provided herein and one or more other pharmaceutical agents are prepared together in a single
formulation. In certain embodiments, one or more pharmaceutical compositions provided herein and one
or more other pharmaceutical agents are prepared separately. In certain embodiments, one or more other
pharmaceutical agents include all-trans retinoic acid, azacitidine, azathioprine, bleomycin, carboplatin,
capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, docetaxel,
doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea,
idarubicin, imatinib, mechlorethamine, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin,
paclitaxel, pemetrexed, teniposide, tioguanine, valrubicin, vinblastine, vincristine, vindesine, or
vinorelbine. In certain embodiments, one or more other pharmaceutical agents include another antisense
oligonucleotide. In certain embodiments, another antisense oligonucleotide is a second STAT3 antisense
oligonucleotide.
In certain embodiments, one or more other pharmaceutical agents include molecular targeted
therapies. In certain embodiments, the molecular targeted therapy is an EGFR inhibitor, a mTOR
inhibitor, a HER2 inhibitor, or a VEGF/VEGFR inhibitor. In certain embodiments, EGFR inhibitors
include gefitinib, erlotinib, lapatinib, cetuximab, panitumumbo. In certain embodiments, mTOR
inhibitors include everolimus and temsirolimus. In certain embodiments, HER2 inhibitors include
trastuzumab and lapatinib. In certain embodiments, VEGF/VEGFR inhibitors include pazopanib,
bevacizumab, sunitinib, and sorafenib.
In certain embodiments, one more pharmaceutical compositions provided herein are
administered with radiation therapy. In certain embodiments, one or more pharmaceutical compositions
are administered at the same time as radiation therapy. In certain embodiments, one or more
pharmaceutical compositions are administered before radiation therapy. In certain embodiments, one or
BIOL0142WO
more pharmaceutical compositions are administered after radiation therapy. In certain embodiments, one
or more pharmaceutical compositions are administered at various time points throughout a radiation
therapy regimen.
In certain embodiments, radiation therapy is useful for inhibiting tumor growth. In certain
embodiments, radiation therapy is useful for increasing overall survival. In certain embodiments,
radiation therapy used in conjunction with administration of one or more pharmaceuticals provided herein
is advantageous over using either therapy alone because both radiation therapy and administration with
one or more pharmaceuticals can be limited to achieve effective antiproliferative response with limited
toxicity.
In certain embodiments, a physician designs a therapy regimen including both radiation therapy
and administration of one more pharmaceutical compositions provided herein. In certain embodiments, a
physician designs a therapy regimen including radiation therapy, administration of one or more
pharmaceutical compositions provided herein, and administration of one or more other chemotherapeutic
agents.
Tolerability
In certain embodiments, the compounds provided herein display minimal side effects.
Side effects include responses to the administration of the antisense compound that are typically
unrelated to the targeting of STAT3, such as an inflammatory response in the animal. In certain
embodiments compounds are well tolerated by the animal. Increased tolerability can depend on
a number of factors, including, but not limited to, the nucleotide sequence of the antisense
compound, chemical modifications to the nucleotides, the particular motif of unmodified and
modified nucleosides in the antisense compound, or combinations thereof. Tolerability may be
determined by a number of factors. Such factors include body weight, organ weight, liver
function, kidney function, platelet count, white blood cell count.
In certain embodiments, the compounds provided herein demonstrate minimal effect on
organ weight. In certain embodiments, the compounds demonstrate less than a 7-fold, 6-fold, 5-
fold, 4-fold, 3-fold, 2-fold or no significant increase in spleen and/or liver weight.
In certain embodiments, the compounds provided herein demonstrate minimal effect on
liver function. Factors for the evaluation of liver function include ALT levels, AST levels,
plasma bilirubin levels and plasma albumin levels. In certain embodiments the compounds
provided herein demonstrate less than a 7-fold, less than a 6-fold, less than a 5-fold, less than a
4-fold, less than a 3-fold or less than a 2-fold or no significant increase in ALT or AST. In
certain embodiments the compounds provided herein demonstrate less than a 3-fold, less than a
2-fold or no significant increase in plasma bilirubin levels.
BIOL0142WO
In certain embodiments, the compounds provided herein demonstrate minimal effect on
kidney function. In certain embodiments, the compounds provided herein demonstrate less than
a 3-fold, less than a 2-fold, or no significant increase in plasma concentrations of blood urea
nitrogen (BUN). In certain embodiments, the compounds provided herein demonstrate less than
a 6-fold, 5-fold, 4-fold, 3-fold, 2-fold, or no significant increase in the ratio of urine protein to
creatinine.
In certain embodiments, the compounds provided herein demonstrate minimal effect on
hematological factors. In certain embodiments, the compounds provided herein demonstrate less
than a 60%, 50%, 40%, 30%, 20%, 10% or 5% decrease in platelet count. In certain
embodiments, the compounds provided herein demonstrate less than a 4-fold, less than a 3-fold,
less than a 2-fold or no significant increase in monocyte count.
In certain embodiments compounds further display favorable pharmacokinetics. In
certain embodiments, antisense compounds exhibit relatively high half-lives in relevant
biological fluids or tissues.
In certain embodiments, compounds or compositions further display favorable viscosity.
In certain embodiments, the viscosity of the compound or composition is no more than 40cP at a
concentration of 165-185 mg/mL.
In other embodiments, the compounds display combinations of the characteristics above
and reduce STAT3 mRNA expression in an animal model with high efficiency.
EXAMPLES
Non-limiting disclosure and incorporation by reference
While certain compounds, compositions and methods described herein have been described with
specificity in accordance with certain embodiments, the following examples serve only to illustrate the
compounds described herein and are not intended to limit the same. Each of the references recited in the
present application is incorporated herein by reference in its entirety.
Example 1: Antisense inhibition of human STAT3 in HuVEC cells
Antisense oligonucleotides were designed targeting a human STAT3 nucleic acid and were
tested for their effect on human STAT3 mRNA expression in vitro. The chimeric antisense
oligonucleotides presented in Tables 1 and 2 were designed as either 22 cEt gapmers or 33 cEt
gapmers. The 22 cEt gapmers are 14 nucleotides in length, wherein the central gap segment
comprises ten 2’-deoxynucleosides and is flanked on both sides (in the 5’ and 3’ directions) by wings
BIOL0142WO
comprising two nucleosides each. The 33 cEt gapmers are 16 nucleosides in length, wherein the
central gap segment comprises ten 2’-deoxynucleosides and is flanked on both sides (in the 5’ and 3’
directions) by wings comprising three nucleosides each. Each nucleoside in the 5’ wing segment and
each nucleoside in the 3’ wing segment has an cEt sugar modification. The internucleoside linkages
throughout each gapmer are phosphorothioate (P=S) linkages. All cytosine residues throughout each
gapmer are 5’-methylcytosines.
Potency of cEt gapmers was compared to ISIS 337332, ISIS 337333, and ISIS 345785, which are
55 MOE gapmers targeting human STAT3 and are further described in USPN 7,307,069,
incorporated herein by reference.
Cultured HuVEC cells at a density of 20,000 cells per well were transfected using electroporation
with 1,000 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was
isolated from the cells and STAT3 mRNA levels were measured by quantitative real-time PCR. Human
primer probe set RTS199 (forward sequence ACATGCCACTTTGGTGTTTCATAA, designated herein
as SEQ ID NO: 6; reverse sequence TCTTCGTAGATTGTGCTGATAGAGAAC, designated herein as
SEQ ID NO: 7; probe sequence CAGTATAGCCGCTTCCTGCAAGAGTCGAA, designated herein as
SEQ ID NO: 8) was used to measure mRNA levels. STAT3 mRNA levels were adjusted according to
total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of
STAT3, relative to untreated control cells. All cEt gapmers and MOE gapmers were tested under the
same conditions.
“Human Target start site” indicates the 5’-most nucleoside to which the gapmer is targeted in the
human gene sequence. “Human Target stop site” indicates the 3’-most nucleoside to which the gapmer is
targeted human gene sequence. Each gapmer listed in Table 1 is targeted to human STAT3 mRNA,
designated herein as SEQ ID NO: 1 (GENBANK Accession No. NM_139276.2). Each gapmer listed in
Table 2 is targeted to the human STAT3 genomic sequence, designated herein as SEQ ID NO: 2 (the
complement of GENBANK Accession No. NT_010755.14 truncated from nucleotides 4185000 to
4264000).
Table 1
Inhibition of human STAT3 mRNA levels by cEt and MOE chimeric antisense oligonucleotides targeted
to SEQ ID NO: 1
Wing
Human Human SEQ
ISIS %
Chem
Start Stop Sequence Motif ID
NO inhibition
Site Site NO
481350 76 91 TCCAGGATCCGGTTGG 33 52
481575 77 90 CCAGGATCCGGTTG 22 41
481351 132 147 GGCCGAAGGGCCTCTC 33 14
481576 133 146 GCCGAAGGGCCTCT 22 8
481352 225 240 CCTGCTAAAATCAGGG 33 15
BIOL0142WO
481577 226 239 CTGCTAAAATCAGG 22 12
481353 240 255 ATTCCATTGGGCCATC 33 78
481578 241 254 TTCCATTGGGCCAT 22 51
481354 264 279 CCGTGTGTCAAGCTGC 33 98
481579 265 278 CGTGTGTCAAGCTG 22 91
481355 322 337 ACTGCCGCAGCTCCAT 33 95
481580 323 336 CTGCCGCAGCTCCA 22 76
481356 346 361 GACTCTCAATCCAAGG 33 83
481581 347 360 ACTCTCAATCCAAG 22 31
481357 375 390 TTCTTTGCTGGCCGCA 33 97
481582 376 389 TCTTTGCTGGCCGC 22 87
481358 403 418 GATTATGAAACACCAA 33 85
481583 404 417 ATTATGAAACACCA 22 20
481359 429 444 ATACTGCTGGTCAATC 33 90
481584 430 443 TACTGCTGGTCAAT 22 42
481360 459 474 GAGAACATTCGACTCT 33 75
481585 460 473 AGAACATTCGACTC 22 77
481361 474 489 TAGATTGTGCTGATAG 33 90
481586 475 488 AGATTGTGCTGATA 22 81
481362 490 505 ACTGCTTGATTCTTCG 33 59
481587 491 504 CTGCTTGATTCTTC 22 23
481363 511 526 CAAGATACCTGCTCTG 33 84
481588 512 525 AAGATACCTGCTCT 22 58
481364 542 557 GCCACAATCCGGGCAA 33 36
481589 543 556 CCACAATCCGGGCA 22 69
481365 589 604 CAGTGGCTGCAGTCTG 33 36
481590 590 603 AGTGGCTGCAGTCT 22 30
481366 607 622 GGCCCCCTTGCTGGGC 33 1
481591 608 621 GCCCCCTTGCTGGG 22 0
481367 638 653 GTCACCACGGCTGCTG 33 70
481592 639 652 TCACCACGGCTGCT 22 48
481368 659 674 TCCAGCATCTGCTGCT 33 81
481593 660 673 CCAGCATCTGCTGC 22 46
481369 675 690 ATCCTGAAGGTGCTGC 33 29
481594 676 689 TCCTGAAGGTGCTG 22 16
481370 701 716 TCTAGATCCTGCACTC 33 79
481595 702 715 CTAGATCCTGCACT 22 47
481371 709 724 TTTTCTGTTCTAGATC 33 83
481596 710 723 TTTCTGTTCTAGAT 22 48
481372 730 745 GGAGATTCTCTACCAC 33 85
481597 731 744 GAGATTCTCTACCA 22 80
481373 751 766 AGTTGAAATCAAAGTC 33 87
481598 752 765 GTTGAAATCAAAGT 22 6
481374 788 803 AGATCTTGCATGTCTC 33 92
481599 789 802 GATCTTGCATGTCT 22 51
BIOL0142WO
481375 799 814 TGTTTCCATTCAGATC 33 65
481600 800 813 GTTTCCATTCAGAT 22 42
481376 868 883 TCCGCATCTGGTCCAG 33 82
481601 869 882 CCGCATCTGGTCCA 22 70
481785 872 885 TCTCCGCATCTGGT 22 28
481377 884 899 TCACTCACGATGCTTC 33 85
481602 885 898 CACTCACGATGCTT 22 55
481378 892 907 CCGCCAGCTCACTCAC 33 89
481603 893 906 CGCCAGCTCACTCA 22 60
481379 955 970 TCCAGTCAGCCAGCTC 33 91
481604 956 969 CCAGTCAGCCAGCT 22 70
481380 963 978 CCGCCTCTTCCAGTCA 33 73
481605 964 977 CGCCTCTTCCAGTC 22 55
481381 1010 1025 CGATCTAGGCAGATGT 33 26
481606 1011 1024 GATCTAGGCAGATG 22 35
481382 1045 1060 GAGATTCTGCTAATGA 33 81
481607 1046 1059 AGATTCTGCTAATG 22 51
481383 1053 1068 CTGAAGTTGAGATTCT 33 84
481608 1054 1067 TGAAGTTGAGATTC 22 26
481384 1098 1113 AACTTTTTGCTGCAAC 33 76
481609 1099 1112 ACTTTTTGCTGCAA 22 34
481385 1113 1128 GTCCCCTTTGTAGGAA 33 41
481610 1114 1127 TCCCCTTTGTAGGA 22 37
481386 1186 1201 AGGCACTTTTCATTAA 33 45
481611 1187 1200 GGCACTTTTCATTA 22 32
481387 1225 1240 CAGGATGCATGGGCAT 33 92
481612 1226 1239 AGGATGCATGGGCA 22 86
481388 1269 1284 TTTAGTAGTGAACTGG 33 74
481613 1270 1283 TTAGTAGTGAACTG 22 22
481389 1282 1297 CCAGCAACCTGACTTT 33 66
481614 1283 1296 CAGCAACCTGACTT 22 34
481390 1305 1320 ATAATTCAACTCAGGG 33 92
481615 1306 1319 TAATTCAACTCAGG 22 48
481391 1314 1329 TTTAAGCTGATAATTC 33 44
481616 1315 1328 TTAAGCTGATAATT 22 0
481392 1326 1341 GCACACTTTAATTTTA 33 49
481617 1327 1340 CACACTTTAATTTT 22 1
481393 1347 1362 GTCCCCAGAGTCTTTG 33 39
481618 1348 1361 TCCCCAGAGTCTTT 22 41
481394 1437 1452 GAGGCTGCCGTTGTTG 33 62
481619 1438 1451 AGGCTGCCGTTGTT 22 29
481395 1468 1483 CCCTCAGGGTCAAGTG 33 72
481620 1469 1482 CCTCAGGGTCAAGT 22 37
481396 1480 1495 CACATCTCTGCTCCCT 33 92
481621 1481 1494 ACATCTCTGCTCCC 22 74
BIOL0142WO
481397 1517 1532 ATCAGGGAAGCATCAC 33 59
481622 1518 1531 TCAGGGAAGCATCA 22 49
481398 1542 1557 GATCAGGTGCAGCTCC 33 73
481623 1543 1556 ATCAGGTGCAGCTC 22 40
481399 1563 1578 ATACACCTCGGTCTCA 33 73
481624 1564 1577 TACACCTCGGTCTC 22 43
481400 1579 1594 TCTTGAGGCCTTGGTG 33 47
481625 1580 1593 CTTGAGGCCTTGGT 22 16
481401 1589 1604 TCTAGGTCAATCTTGA 33 74
481626 1590 1603 CTAGGTCAATCTTG 22 54
481402 1599 1614 GGAGTGGGTCTCTAGG 33 52
481627 1600 1613 GAGTGGGTCTCTAG 22 13
481789 1604 1617 CAAGGAGTGGGTCT 22 10
481403 1607 1622 ACTGGCAAGGAGTGGG 33 58
481628 1608 1621 CTGGCAAGGAGTGG 22 38
481404 1633 1648 TCTGACAGATGTTGGA 33 50
481629 1634 1647 CTGACAGATGTTGG 22 64
481405 1641 1656 ATTTGGCATCTGACAG 33 75
481630 1642 1655 TTTGGCATCTGACA 22 39
481406 1691 1706 TTCTTGGGATTGTTGG 33 72
481631 1692 1705 TCTTGGGATTGTTG 22 33
481407 1729 1744 CCCAGGTTCCAATTGG 33 50
481632 1730 1743 CCAGGTTCCAATTG 22 32
481408 1780 1795 CTCGCTTGGTGGTGGA 33 53
481633 1781 1794 TCGCTTGGTGGTGG 22 35
481409 1795 1810 GCTCGATGCTCAGTCC 33 86
481634 1796 1809 CTCGATGCTCAGTC 22 43
481410 1825 1840 CCAAGAGTTTCTCTGC 33 91
481635 1826 1839 CAAGAGTTTCTCTG 22 43
481411 1840 1855 AATTCACACCAGGTCC 33 72
481636 1841 1854 ATTCACACCAGGTC 22 42
481412 1858 1873 TGATCTGACACCCTGA 33 90
481637 1859 1872 GATCTGACACCCTG 22 79
481413 1866 1881 AGCCCATGTGATCTGA 33 80
481638 1867 1880 GCCCATGTGATCTG 22 64
481414 1888 1903 CCATGTTTTCTTTGCA 33 69
481639 1889 1902 CATGTTTTCTTTGC 22 16
481415 1896 1911 CTTGCCAGCCATGTTT 33 88
481640 1897 1910 TTGCCAGCCATGTT 22 57
337332 1898 1917 GAAGCCCTTGCCAGCCATGT 55 63
481416 1901 1916 AAGCCCTTGCCAGCCA 33 87
481641 1902 1915 AGCCCTTGCCAGCC 22 68
337333 1903 1922 AAGGAGAAGCCCTTGCCAGC 55 49
481417 1903 1918 AGAAGCCCTTGCCAGC 33 97
481418 1904 1919 GAGAAGCCCTTGCCAG 33 92
BIOL0142WO
481642 1904 1917 GAAGCCCTTGCCAG 22 67
481419 1905 1920 GGAGAAGCCCTTGCCA 33 83
481643 1905 1918 AGAAGCCCTTGCCA 22 58
481644 1906 1919 GAGAAGCCCTTGCC 22 45
481420 1948 1963 ACTTTTTCACAAGGTC 33 94
481645 1949 1962 CTTTTTCACAAGGT 22 50
481421 2021 2036 CTCAAGATGGCCCGCT 33 86
481646 2022 2035 TCAAGATGGCCCGC 22 41
481422 2036 2051 CCTGGAGGCTTAGTGC 33 80
481647 2037 2050 CTGGAGGCTTAGTG 22 0
481423 2077 2092 CTCCTTCTTTGCTGCT 33 69
481648 2078 2091 TCCTTCTTTGCTGC 22 51
481424 2093 2108 CAAGTGAAAGTGACGC 33 70
481649 2094 2107 AAGTGAAAGTGACG 22 25
481425 2115 2130 ACCGCTGATGTCCTTC 33 78
481650 2116 2129 CCGCTGATGTCCTT 22 79
481426 2131 2146 ACTGGATCTGGGTCTT 33 80
481651 2132 2145 CTGGATCTGGGTCT 22 64
481427 2155 2170 GCTGCTTTGTGTATGG 33 75
481652 2156 2169 CTGCTTTGTGTATG 22 82
481428 2164 2179 TGTTCAGCTGCTGCTT 33 77
481653 2165 2178 GTTCAGCTGCTGCT 22 79
481429 2172 2187 TGACATGTTGTTCAGC 33 84
481654 2173 2186 GACATGTTGTTCAG 22 70
481430 2190 2205 CATGATGATTTCAGCA 33 67
481655 2191 2204 ATGATGATTTCAGC 22 31
481431 2206 2221 CCATGATCTTATAGCC 33 91
481656 2207 2220 CATGATCTTATAGC 22 0
481432 2233 2248 GTGGAGACACCAGGAT 33 55
481657 2234 2247 TGGAGACACCAGGA 22 58
481433 2256 2271 AATGTCAGGATAGAGA 33 73
481658 2257 2270 ATGTCAGGATAGAG 22 62
481434 2266 2281 CCTCCTTGGGAATGTC 33 73
345785 2267 2286 TGCCTCCTCCTTGGGAATGT 55 50
481659 2267 2280 CTCCTTGGGAATGT 22 51
481435 2269 2284 CCTCCTCCTTGGGAAT 33 49
481660 2270 2283 CTCCTCCTTGGGAA 22 54
481436 2275 2290 CGAATGCCTCCTCCTT 33 82
481661 2276 2289 GAATGCCTCCTCCT 22 76
481437 2296 2311 TCTCTGGCCGACAATA 33 49
481662 2297 2310 CTCTGGCCGACAAT 22 43
481438 2353 2368 ACTTGGTCTTCAGGTA 33 51
481663 2354 2367 CTTGGTCTTCAGGT 22 52
481439 2371 2386 TTGGTGTCACACAGAT 33 82
481664 2372 2385 TGGTGTCACACAGA 22 89
BIOL0142WO
481440 2387 2402 GTATTGCTGCAGGTCG 33 79
481665 2388 2401 TATTGCTGCAGGTC 22 43
481441 2395 2410 GGTCAATGGTATTGCT 33 55
481666 2396 2409 GTCAATGGTATTGC 22 36
481442 2403 2418 CATCGGCAGGTCAATG 33 44
481667 2404 2417 ATCGGCAGGTCAAT 22 31
481443 2423 2438 GAATCTAAAGTGCGGG 33 78
481668 2424 2437 AATCTAAAGTGCGG 22 41
481444 2431 2446 GCATCAATGAATCTAA 33 66
481669 2432 2445 CATCAATGAATCTA 22 0
481445 2439 2454 TCCAAACTGCATCAAT 33 70
481670 2440 2453 CCAAACTGCATCAA 22 60
481446 2460 2475 TTCAGCACCTTCACCA 33 44
481671 2461 2474 TCAGCACCTTCACC 22 41
481447 2476 2491 GCCCTCCTGCTGAGGG 33 10
481672 2477 2490 CCCTCCTGCTGAGG 22 15
481448 2484 2499 CTCAAACTGCCCTCCT 33 29
481797 2484 2497 CAAACTGCCCTCCT 22 11
481673 2485 2498 TCAAACTGCCCTCC 22 33
481449 2503 2518 CCATGTCAAAGGTGAG 33 77
481674 2504 2517 CATGTCAAAGGTGA 22 31
481450 2530 2545 GGGAGGTAGCGCACTC 33 53
481675 2531 2544 GGAGGTAGCGCACT 22 41
481451 2592 2607 GAATGCAGGTAGGCGC 33 55
481676 2593 2606 AATGCAGGTAGGCG 22 39
481452 2631 2646 TTTCAGATGATCTGGG 33 71
481677 2632 2645 TTCAGATGATCTGG 22 38
481574 2650 2665 GGAACCACAAAGTTAG 33 69
481799 2651 2664 GAACCACAAAGTTA 22 50
481453 2681 2696 GATAGCAGAAGTAGGA 33 92
481678 2682 2695 ATAGCAGAAGTAGG 22 78
481454 2702 2717 AAAGTGCCCAGATTGC 33 85
481679 2703 2716 AAGTGCCCAGATTG 22 69
481455 2722 2737 CACTCATTTCTCTATT 33 74
481680 2723 2736 ACTCATTTCTCTAT 22 39
481456 2767 2782 AACACATCCTTATTTG 33 48
481681 2768 2781 ACACATCCTTATTT 22 47
481457 2779 2794 TGGGTCTCAGAGAACA 33 88
481682 2780 2793 GGGTCTCAGAGAAC 22 77
481458 2832 2847 CAAGACATTTCCTTTT 33 54
481683 2833 2846 AAGACATTTCCTTT 22 29
481459 2908 2923 GGAGGCACTTGTCTAA 33 76
481684 2909 2922 GAGGCACTTGTCTA 22 89
481460 2943 2958 TTACAGAAACAGGCAG 33 83
481685 2944 2957 TACAGAAACAGGCA 22 36
BIOL0142WO
481461 2969 2984 AGCTATAGGTGGCCTG 33 75
481686 2970 2983 GCTATAGGTGGCCT 22 70
481462 2984 2999 ATGCCAGGAGTATGTA 33 89
481687 2985 2998 TGCCAGGAGTATGT 22 80
481463 3001 3016 CAAGGTTAAAAAGTGC 33 88
481688 3002 3015 AAGGTTAAAAAGTG 22 13
481464 3016 3031 CTATTTGGATGTCAGC 33 97
481689 3017 3030 TATTTGGATGTCAG 22 40
481465 3032 3047 TAGATAGTCCTATCTT 33 51
481690 3033 3046 AGATAGTCCTATCT 22 64
481466 3047 3062 AAGAAACCTAGGGCTT 33 74
481691 3048 3061 AGAAACCTAGGGCT 22 77
481467 3097 3112 GCTGATACAGTGTTTT 33 74
481692 3098 3111 CTGATACAGTGTTT 22 74
481468 3112 3127 ATACAGAAAGGCTATG 33 71
481693 3113 3126 TACAGAAAGGCTAT 22 25
481469 3127 3142 GCTTAAGTTTCTTAAA 33 61
481694 3128 3141 CTTAAGTTTCTTAA 22 0
481470 3461 3476 AGCACCAAGGAGGCTG 33 49
481695 3462 3475 GCACCAAGGAGGCT 22 83
481471 3476 3491 AAGCTGAATGCTTAAA 33 36
481696 3477 3490 AGCTGAATGCTTAA 22 33
481472 3491 3506 TTACCAGCCTGAAGGA 33 76
481697 3492 3505 TACCAGCCTGAAGG 22 63
481473 3506 3521 CAGGGATTATATAAAT 33 53
481698 3507 3520 AGGGATTATATAAA 22 15
481474 3521 3536 ACCTGAAGCCCGTTTC 33 80
481699 3522 3535 CCTGAAGCCCGTTT 22 57
481475 3536 3551 TGTCTTAAGGGTTTGA 33 93
481700 3537 3550 GTCTTAAGGGTTTG 22 89
481476 3551 3566 GGTTGCAGCTTCAGAT 33 92
481701 3552 3565 GTTGCAGCTTCAGA 22 60
481477 3567 3582 TCAACACCAAAGGCCA 33 95
481702 3568 3581 CAACACCAAAGGCC 22 89
481478 3585 3600 TCCTTAAACCTTCCTA 33 84
481703 3586 3599 CCTTAAACCTTCCT 22 57
481479 3600 3615 AAAATGCTTAGATTCT 33 80
481704 3601 3614 AAATGCTTAGATTC 22 32
481480 3628 3643 AAATAAGTCTATTTAT 33 5
481705 3629 3642 AATAAGTCTATTTA 22 25
481481 3648 3663 GGCCAATACATTACAA 33 63
481706 3649 3662 GCCAATACATTACA 22 56
481482 3670 3685 TGCCCAGCCTTACTCA 33 55
481707 3671 3684 GCCCAGCCTTACTC 22 43
481483 3685 3700 GTTGTAAGCACCCTCT 33 1
BIOL0142WO
481708 3686 3699 TTGTAAGCACCCTC 22 56
481484 3700 3715 AGAAAGGGAGTCAAGG 33 60
481709 3701 3714 GAAAGGGAGTCAAG 22 27
481485 3717 3732 GCAGATCAAGTCCAGG 33 90
481710 3718 3731 CAGATCAAGTCCAG 22 88
481486 3730 3745 AGCCTCTGAAACAGCA 33 75
481711 3731 3744 GCCTCTGAAACAGC 22 74
481487 3746 3761 CCCACAGAAACAACCT 33 66
481712 3747 3760 CCACAGAAACAACC 22 45
481488 3761 3776 AGCCCTGATAAGGCAC 33 23
481713 3762 3775 GCCCTGATAAGGCA 22 18
481489 3776 3791 AATCAGAAGTATCCCA 33 60
481714 3777 3790 ATCAGAAGTATCCC 22 43
481490 3833 3848 GCCTCTAGCAGGATCA 33 78
481715 3834 3847 CCTCTAGCAGGATC 22 79
481491 3848 3863 CACGCAAGGAGACATG 33 70
481716 3849 3862 ACGCAAGGAGACAT 22 68
481492 3863 3878 TGAGGGACCTTTAGAC 33 61
481717 3864 3877 GAGGGACCTTTAGA 22 44
481493 3886 3901 CAGGATTCCTAAAACA 33 43
481718 3887 3900 AGGATTCCTAAAAC 22 7
481494 3901 3916 ATGAGGTCCTGAGACC 33 60
481719 3902 3915 TGAGGTCCTGAGAC 22 29
481495 3940 3955 CATCATGTCCAACCTG 33 92
481720 3941 3954 ATCATGTCCAACCT 22 63
481496 3955 3970 GGGCCCCATAGTGTGC 33 29
481721 3956 3969 GGCCCCATAGTGTG 22 19
481497 3977 3992 AGCTCAACCAGACACG 33 67
481722 3978 3991 GCTCAACCAGACAC 22 69
481498 3992 4007 GAACCATATTCCCTGA 33 90
481723 3993 4006 AACCATATTCCCTG 22 49
481499 4007 4022 CAAGAAACTGGCTAAG 33 43
481724 4008 4021 AAGAAACTGGCTAA 22 17
481500 4022 4037 GCCACTGGATATCACC 33 92
481501 4048 4063 AACTGAATGAAGACGC 33 91
481726 4049 4062 ACTGAATGAAGACG 22 56
481502 4063 4078 CCTTTGCCCTGCATGA 33 85
481727 4064 4077 CTTTGCCCTGCATG 22 70
481503 4078 4093 AAGTTTATCAGTAAGC 33 57
481728 4079 4092 AGTTTATCAGTAAG 22 22
481504 4093 4108 TACGAGGGCAGACTCA 33 60
481729 4094 4107 ACGAGGGCAGACTC 22 22
481505 4108 4123 AGGTATACACCCTCAT 33 45
481730 4109 4122 GGTATACACCCTCA 22 47
481506 4123 4138 CCTCAGAGGGAGGCCA 33 32
BIOL0142WO
481731 4124 4137 CTCAGAGGGAGGCC 22 0
481507 4138 4153 GGGAGGAGTCACCAGC 33 64
481732 4139 4152 GGAGGAGTCACCAG 22 59
481508 4205 4220 TAGCCAGCCAAGGCGG 33 33
481733 4206 4219 AGCCAGCCAAGGCG 22 50
481509 4220 4235 ACAGGAGAGGCGAGCT 33 46
481734 4221 4234 CAGGAGAGGCGAGC 22 28
481510 4237 4252 TAGGTGTTCCCATACG 33 95
481735 4238 4251 AGGTGTTCCCATAC 22 22
481511 4258 4273 GGCAGCCCATCCAGCA 33 43
481736 4259 4272 GCAGCCCATCCAGC 22 54
481512 4275 4290 CATGCCTCTGAGTCAG 33 30
481737 4276 4289 ATGCCTCTGAGTCA 22 31
481513 4290 4305 GTTGCCAAATCCGGCC 33 85
481738 4291 4304 TTGCCAAATCCGGC 22 70
481514 4305 4320 GCAAGGTGGTTTTGAG 33 85
481739 4306 4319 CAAGGTGGTTTTGA 22 60
481515 4325 4340 AGAAACTCTGATCAGC 33 88
481740 4326 4339 GAAACTCTGATCAG 22 71
481516 4364 4379 CAGAGACCAGCTAATT 33 78
481741 4365 4378 AGAGACCAGCTAAT 22 80
481517 4394 4409 ATCTTAGAGAAGGTCG 33 87
481742 4395 4408 TCTTAGAGAAGGTC 22 64
481518 4425 4440 CCAGGCAGGAGGACTG 33 67
481743 4426 4439 CAGGCAGGAGGACT 22 75
481519 4437 4452 CATCAACTGTCTCCAG 33 29
481744 4438 4451 ATCAACTGTCTCCA 22 69
481520 4439 4454 CACATCAACTGTCTCC 33 73
481745 4440 4453 ACATCAACTGTCTC 22 74
481521 4459 4474 GAAGTAAGAGCTCTGC 33 86
481746 4460 4473 AAGTAAGAGCTCTG 22 67
481522 4474 4489 AAGAGTGTTGCTGGAG 33 92
481747 4475 4488 AGAGTGTTGCTGGA 22 95
481523 4489 4504 GCTTATTATGTACTGA 33 95
481748 4490 4503 CTTATTATGTACTG 22 15
481524 4530 4545 GCCCAAGTCTCACCTT 33 70
481749 4531 4544 CCCAAGTCTCACCT 22 70
481525 4541 4556 CCCAATGGTAAGCCCA 33 93
481750 4542 4555 CCAATGGTAAGCCC 22 94
481526 4543 4558 AACCCAATGGTAAGCC 33 82
481751 4544 4557 ACCCAATGGTAAGC 22 54
481527 4560 4575 TAGGTCCCTATGATTT 33 55
481752 4561 4574 AGGTCCCTATGATT 22 62
481528 4579 4594 AAGCCCTGAACCCTCG 33 77
481753 4580 4593 AGCCCTGAACCCTC 22 71
BIOL0142WO
481529 4615 4630 CCTAAGGCCATGAACT 33 64
481754 4616 4629 CTAAGGCCATGAAC 22 53
481530 4630 4645 ACCAGATACATGCTAC 33 87
481755 4631 4644 CCAGATACATGCTA 22 84
481531 4646 4661 TACAATCAGAGTTAAG 33 66
481756 4647 4660 ACAATCAGAGTTAA 22 5
481532 4664 4679 TCCTCTCAGAACTTTT 33 65
481757 4665 4678 CCTCTCAGAACTTT 22 81
481533 4666 4681 GCTCCTCTCAGAACTT 33 80
481758 4667 4680 CTCCTCTCAGAACT 22 62
481534 4693 4708 TTCTTTAATGGGCCAC 33 79
481759 4694 4707 TCTTTAATGGGCCA 22 74
481535 4767 4782 ACGGGATTCCCTCGGC 33 78
481760 4768 4781 CGGGATTCCCTCGG 22 78
481536 4782 4797 GTAGGTAAGCAACCCA 33 91
481761 4783 4796 TAGGTAAGCAACCC 22 78
481537 4830 4845 GAATTTGAATGCAGTG 33 84
481762 4831 4844 AATTTGAATGCAGT 22 2
481538 4844 4859 TGAAGTACACATTGGA 33 92
481763 4845 4858 GAAGTACACATTGG 22 96
481539 4860 4875 ATAAATTTTTACACTA 33 19
481764 4861 4874 TAAATTTTTACACT 22 1
481765 4869 4882 CAATAATATAAATT 22 0
481541 4934 4949 CTGGAAGTTAAAGTAG 33 71
481766 4935 4948 TGGAAGTTAAAGTA 22 10
Table 2
Inhibition of human STAT3 mRNA levels by cEt and MOE chimeric antisense oligonucleotides targeted
to SEQ ID NO: 2
Wing
Human Human SEQ
ISIS %
Chem
Start Stop Sequence Motif ID
NO inhibition
Site Site NO
481350 1065 1080 TCCAGGATCCGGTTGG 33 52 9
481575 1066 1079 CCAGGATCCGGTTG 22 41 10
481351 1121 1136 GGCCGAAGGGCCTCTC 33 14 11
481576 1122 1135 GCCGAAGGGCCTCT 22 8 12
481542 1988 2003 GGCTCAATTATTTATC 33 64 399
481767 1989 2002 GCTCAATTATTTAT 22 0 400
481543 1996 2011 AATGCAATGGCTCAAT 33 84 401
481768 1997 2010 ATGCAATGGCTCAA 22 95 402
481544 2004 2019 ATCCAGTAAATGCAAT 33 58 403
481769 2005 2018 TCCAGTAAATGCAA 22 55 404
481545 2061 2076 AGAAAACTCCCACTCT 33 36 405
481770 2062 2075 GAAAACTCCCACTC 22 42 406
481546 2113 2128 CTGTCTTTGTTTCCCT 33 70 407
481771 2114 2127 TGTCTTTGTTTCCC 22 75 408
BIOL0142WO
481547 2121 2136 AGGCCAGCCTGTCTTT 33 87 409
481772 2122 2135 GGCCAGCCTGTCTT 22 53 410
481548 2705 2720 CTAATGGTTCTTTGTG 33 78 411
481773 2706 2719 TAATGGTTCTTTGT 22 9 412
481549 6476 6491 GAAATTCATTCTTCCA 33 96 413
481774 6477 6490 AAATTCATTCTTCC 22 56 414
481550 10001 10016 ACACACACAGATGTGA 33 48 415
481775 10002 10015 CACACACAGATGTG 22 35 416
481551 10337 10352 CTACCCAAACATCCCC 33 69 417
481776 10338 10351 TACCCAAACATCCC 22 62 418
481552 10345 10360 TACAAAAACTACCCAA 33 30 419
481777 10346 10359 ACAAAAACTACCCA 22 1 420
481553 10364 10379 AGTTTTCAGAAATGGC 33 96
481778 10365 10378 GTTTTCAGAAATGG 22 47
481554 15469 15484 CAAGCTTTTCTATGAA 33 86
481779 15470 15483 AAGCTTTTCTATGA 22 60
481555 24588 24603 TTATTCAGGTCACTTT 33 73
481780 24589 24602 TATTCAGGTCACTT 22 60
481352 40953 40968 CCTGCTAAAATCAGGG 33 15 13
481577 40954 40967 CTGCTAAAATCAGG 22 12 14
481353 40968 40983 ATTCCATTGGGCCATC 33 78 15
481578 40969 40982 TTCCATTGGGCCAT 22 51 16
481354 40992 41007 CCGTGTGTCAAGCTGC 33 98 17
481579 40993 41006 CGTGTGTCAAGCTG 22 91 18
481355 41050 41065 ACTGCCGCAGCTCCAT 33 95 19
481580 41051 41064 CTGCCGCAGCTCCA 22 76 20
481356 41074 41089 GACTCTCAATCCAAGG 33 83 21
481581 41075 41088 ACTCTCAATCCAAG 22 31 22
481556 42765 42780 GCATATGCCCTAGGAA 33 23 430
481781 42766 42779 CATATGCCCTAGGA 22 15 431
481357 42778 42793 TTCTTTGCTGGCCGCA 33 97 23
481582 42779 42792 TCTTTGCTGGCCGC 22 87 24
481358 42806 42821 GATTATGAAACACCAA 33 85 25
481583 42807 42820 ATTATGAAACACCA 22 20 26
481359 42832 42847 ATACTGCTGGTCAATC 33 90 27
481584 42833 42846 TACTGCTGGTCAAT 22 42 28
481360 42862 42877 GAGAACATTCGACTCT 33 75 29
481585 42863 42876 AGAACATTCGACTC 22 77 30
481361 42877 42892 TAGATTGTGCTGATAG 33 90 31
481586 42878 42891 AGATTGTGCTGATA 22 81 32
481362 42893 42908 ACTGCTTGATTCTTCG 33 59 33
481587 42894 42907 CTGCTTGATTCTTC 22 23 34
481557 43043 43058 GCTAATTACTTCTCCT 33 57 432
481782 43044 43057 CTAATTACTTCTCC 22 25 433
481588 43826 43839 AAGATACCTGCTCT 22 58 36
BIOL0142WO
481364 43856 43871 GCCACAATCCGGGCAA 33 36 37
481589 43857 43870 CCACAATCCGGGCA 22 69 38
481365 43903 43918 CAGTGGCTGCAGTCTG 33 36 39
481590 43904 43917 AGTGGCTGCAGTCT 22 30 40
481558 50069 50084 GCCCCCTTGCTGCCAA 33 0 434
481783 50070 50083 CCCCCTTGCTGCCA 22 39 435
481367 50101 50116 GTCACCACGGCTGCTG 33 70 43
481592 50102 50115 TCACCACGGCTGCT 22 48 44
481368 50122 50137 TCCAGCATCTGCTGCT 33 81 45
481593 50123 50136 CCAGCATCTGCTGC 22 46 46
481369 50138 50153 ATCCTGAAGGTGCTGC 33 29 47
481594 50139 50152 TCCTGAAGGTGCTG 22 16 48
481559 50668 50683 TGTTCTAGATCCTGTT 33 72 436
481784 50669 50682 GTTCTAGATCCTGT 22 79 437
481371 50673 50688 TTTTCTGTTCTAGATC 33 83 51
481596 50674 50687 TTTCTGTTCTAGAT 22 48 52
481372 50694 50709 GGAGATTCTCTACCAC 33 85 53
481597 50695 50708 GAGATTCTCTACCA 22 80 54
481373 50715 50730 AGTTGAAATCAAAGTC 33 87 55
481598 50716 50729 GTTGAAATCAAAGT 22 6 56
481599 51626 51639 GATCTTGCATGTCT 22 51 58
481375 51636 51651 TGTTTCCATTCAGATC 33 65 59
481600 51637 51650 GTTTCCATTCAGAT 22 42 60
481376 51705 51720 TCCGCATCTGGTCCAG 33 82 61
481601 51706 51719 CCGCATCTGGTCCA 22 70 62
481560 51708 51723 CTCTCCGCATCTGGTC 33 63 438
481785 51709 51722 TCTCCGCATCTGGT 22 28 63
481378 51905 51920 CCGCCAGCTCACTCAC 33 89 66
481603 51906 51919 CGCCAGCTCACTCA 22 60 67
481379 51968 51983 TCCAGTCAGCCAGCTC 33 91 68
481604 51969 51982 CCAGTCAGCCAGCT 22 70 69
481380 51976 51991 CCGCCTCTTCCAGTCA 33 73 70
481605 51977 51990 CGCCTCTTCCAGTC 22 55 71
481381 52023 52038 CGATCTAGGCAGATGT 33 26 72
481606 52024 52037 GATCTAGGCAGATG 22 35 73
481382 55443 55458 GAGATTCTGCTAATGA 33 81 74
481607 55444 55457 AGATTCTGCTAATG 22 51
481383 55451 55466 CTGAAGTTGAGATTCT 33 84
481608 55452 55465 TGAAGTTGAGATTC 22 26
481384 55496 55511 AACTTTTTGCTGCAAC 33 76
481609 55497 55510 ACTTTTTGCTGCAA 22 34
481385 55511 55526 GTCCCCTTTGTAGGAA 33 41
481610 55512 55525 TCCCCTTTGTAGGA 22 37
481387 55748 55763 CAGGATGCATGGGCAT 33 92 84
481612 55749 55762 AGGATGCATGGGCA 22 86
BIOL0142WO
481388 55792 55807 TTTAGTAGTGAACTGG 33 74
481613 55793 55806 TTAGTAGTGAACTG 22 22
481561 57949 57964 TGACCAGCAACCTATT 33 43
481786 57950 57963 GACCAGCAACCTAT 22 59
481390 57969 57984 ATAATTCAACTCAGGG 33 92
481615 57970 57983 TAATTCAACTCAGG 22 48
481391 57978 57993 TTTAAGCTGATAATTC 33 44
481616 57979 57992 TTAAGCTGATAATT 22 0
481392 57990 58005 GCACACTTTAATTTTA 33 49
481617 57991 58004 CACACTTTAATTTT 22 1
481562 59703 59718 CCCAGAGTCTCTGTAA 33 36 441
481787 59704 59717 CCAGAGTCTCTGTA 22 22 442
481394 59895 59910 GAGGCTGCCGTTGTTG 33 62
481619 59896 59909 AGGCTGCCGTTGTT 22 29
481396 60034 60049 CACATCTCTGCTCCCT 33 92 102
481621 60035 60048 ACATCTCTGCTCCC 22 74 103
481563 60064 60079 TTACATCACAATTGGC 33 24 445
481788 60065 60078 TACATCACAATTGG 22 3 446
481398 63306 63321 GATCAGGTGCAGCTCC 33 73 106
481623 63307 63320 ATCAGGTGCAGCTC 22 40 107
481399 63327 63342 ATACACCTCGGTCTCA 33 73 108
481624 63328 63341 TACACCTCGGTCTC 22 43 109
481400 63343 63358 TCTTGAGGCCTTGGTG 33 47 110
481625 63344 63357 CTTGAGGCCTTGGT 22 16 111
481401 63353 63368 TCTAGGTCAATCTTGA 33 74 112
481626 63354 63367 CTAGGTCAATCTTG 22 54 113
481564 64421 64436 GCAAGGAGTGGGTCTG 33 33 446
481789 64422 64435 CAAGGAGTGGGTCT 22 10 116
481403 64425 64440 ACTGGCAAGGAGTGGG 33 58 117
481628 64426 64439 CTGGCAAGGAGTGG 22 38 118
481404 64451 64466 TCTGACAGATGTTGGA 33 50 119
481629 64452 64465 CTGACAGATGTTGG 22 64 120
481405 64459 64474 ATTTGGCATCTGACAG 33 75 121
481630 64460 64473 TTTGGCATCTGACA 22 39 122
481407 64663 64678 CCCAGGTTCCAATTGG 33 50 125
481632 64664 64677 CCAGGTTCCAATTG 22 32 126
481408 64714 64729 CTCGCTTGGTGGTGGA 33 53 127
481633 64715 64728 TCGCTTGGTGGTGG 22 35 128
481409 64729 64744 GCTCGATGCTCAGTCC 33 86 129
481634 64730 64743 CTCGATGCTCAGTC 22 43 130
481410 64759 64774 CCAAGAGTTTCTCTGC 33 91 131
481635 64760 64773 CAAGAGTTTCTCTG 22 43 132
481411 65859 65874 AATTCACACCAGGTCC 33 72 133
481636 65860 65873 ATTCACACCAGGTC 22 42 134
481412 65877 65892 TGATCTGACACCCTGA 33 90 135
BIOL0142WO
481637 65878 65891 GATCTGACACCCTG 22 79 136
481413 65885 65900 AGCCCATGTGATCTGA 33 80 137
481638 65886 65899 GCCCATGTGATCTG 22 64 138
481565 66119 66134 TTTCCTGGAGAAAAGA 33 4 447
481790 66120 66133 TTCCTGGAGAAAAG 22 3 448
481566 66127 66142 AGCCATGTTTTCCTGG 33 62 449
481791 66128 66141 GCCATGTTTTCCTG 22 73 450
481415 66133 66148 CTTGCCAGCCATGTTT 33 88 141
481640 66134 66147 TTGCCAGCCATGTT 22 57 142
337332 66135 66154 GAAGCCCTTGCCAGCCATGT 55 63 143
481416 66138 66153 AAGCCCTTGCCAGCCA 33 87 144
481641 66139 66152 AGCCCTTGCCAGCC 22 68 145
337333 66140 66159 AAGGAGAAGCCCTTGCCAGC 55 49 146
481417 66140 66155 AGAAGCCCTTGCCAGC 33 97
481418 66141 66156 GAGAAGCCCTTGCCAG 33 92
481642 66141 66154 GAAGCCCTTGCCAG 22 67
481419 66142 66157 GGAGAAGCCCTTGCCA 33 83
481643 66142 66155 AGAAGCCCTTGCCA 22 58
481644 66143 66156 GAGAAGCCCTTGCC 22 45
481420 66185 66200 ACTTTTTCACAAGGTC 33 94
481645 66186 66199 CTTTTTCACAAGGT 22 50
481421 66374 66389 CTCAAGATGGCCCGCT 33 86
481646 66375 66388 TCAAGATGGCCCGC 22 41
481422 66389 66404 CCTGGAGGCTTAGTGC 33 80
481647 66390 66403 CTGGAGGCTTAGTG 22 0
481423 66430 66445 CTCCTTCTTTGCTGCT 33 69
481648 66431 66444 TCCTTCTTTGCTGC 22 51
481424 66446 66461 CAAGTGAAAGTGACGC 33 70
481649 66447 66460 AAGTGAAAGTGACG 22 25
481425 66468 66483 ACCGCTGATGTCCTTC 33 78
481650 66469 66482 CCGCTGATGTCCTT 22 79
481426 66993 67008 ACTGGATCTGGGTCTT 33 80
481651 66994 67007 CTGGATCTGGGTCT 22 64
481427 67017 67032 GCTGCTTTGTGTATGG 33 75
481652 67018 67031 CTGCTTTGTGTATG 22 82
481428 67026 67041 TGTTCAGCTGCTGCTT 33 77
481653 67027 67040 GTTCAGCTGCTGCT 22 79
481429 67034 67049 TGACATGTTGTTCAGC 33 84
481654 67035 67048 GACATGTTGTTCAG 22 70
481430 67052 67067 CATGATGATTTCAGCA 33 67
481655 67053 67066 ATGATGATTTCAGC 22 31
481431 67068 67083 CCATGATCTTATAGCC 33 91
481656 67069 67082 CATGATCTTATAGC 22 0
481432 67095 67110 GTGGAGACACCAGGAT 33 55
481657 67096 67109 TGGAGACACCAGGA 22 58
BIOL0142WO
481433 67118 67133 AATGTCAGGATAGAGA 33 73
481658 67119 67132 ATGTCAGGATAGAG 22 62
481434 67128 67143 CCTCCTTGGGAATGTC 33 73
345785 67129 67148 TGCCTCCTCCTTGGGAATGT 55 50
481659 67129 67142 CTCCTTGGGAATGT 22 51
481435 67131 67146 CCTCCTCCTTGGGAAT 33 49
481660 67132 67145 CTCCTCCTTGGGAA 22 54
481436 67137 67152 CGAATGCCTCCTCCTT 33 82
481661 67138 67151 GAATGCCTCCTCCT 22 76
481437 67158 67173 TCTCTGGCCGACAATA 33 49
481662 67159 67172 CTCTGGCCGACAAT 22 43 189
481567 67194 67209 AACAACTACCTGGGTC 33 20 451
481792 67195 67208 ACAACTACCTGGGT 22 0 452
481438 72272 72287 ACTTGGTCTTCAGGTA 33 51 190
481663 72273 72286 CTTGGTCTTCAGGT 22 52 191
481568 72290 72305 ACGGTGTCACACAGAT 33 85 453
481793 72291 72304 CGGTGTCACACAGA 22 93 454
481569 72430 72445 AACACACAAGGTCACT 33 62 455
481794 72431 72444 ACACACAAGGTCAC 22 81 456
481570 72438 72453 GCTTTTTAAACACACA 33 79 457
481795 72439 72452 CTTTTTAAACACAC 22 0 458
481571 72528 72543 TGACAAGACACAATGG 33 12 459
481796 72529 72542 GACAAGACACAATG 22 36 460
481440 72586 72601 GTATTGCTGCAGGTCG 33 79
481665 72587 72600 TATTGCTGCAGGTC 22 43
481441 72594 72609 GGTCAATGGTATTGCT 33 55
481666 72595 72608 GTCAATGGTATTGC 22 36
481442 72602 72617 CATCGGCAGGTCAATG 33 44
481667 72603 72616 ATCGGCAGGTCAAT 22 31
481443 72622 72637 GAATCTAAAGTGCGGG 33 78
481668 72623 72636 AATCTAAAGTGCGG 22 41
481444 72630 72645 GCATCAATGAATCTAA 33 66
481669 72631 72644 CATCAATGAATCTA 22 0
481445 72638 72653 TCCAAACTGCATCAAT 33 70
481670 72639 72652 CCAAACTGCATCAA 22 60
481446 72659 72674 TTCAGCACCTTCACCA 33 44
481671 72660 72673 TCAGCACCTTCACC 22 41
481447 72675 72690 GCCCTCCTGCTGAGGG 33 10
481672 72676 72689 CCCTCCTGCTGAGG 22 15 209
481572 72682 72697 CCAAACTGCCCTCCTG 33 51 461
481797 72683 72696 CAAACTGCCCTCCT 22 11 211
481573 73535 73550 GGTCAGAAAAGCCAGA 33 55 462
481798 73536 73549 GTCAGAAAAGCCAG 22 59 463
481449 73690 73705 CCATGTCAAAGGTGAG 33 77
481674 73691 73704 CATGTCAAAGGTGA 22 31
BIOL0142WO
481450 73717 73732 GGGAGGTAGCGCACTC 33 53
481675 73718 73731 GGAGGTAGCGCACT 22 41
481451 73779 73794 GAATGCAGGTAGGCGC 33 55
481676 73780 73793 AATGCAGGTAGGCG 22 39
481452 73818 73833 TTTCAGATGATCTGGG 33 71
481677 73819 73832 TTCAGATGATCTGG 22 38
481574 73837 73852 GGAACCACAAAGTTAG 33 69
481799 73838 73851 GAACCACAAAGTTA 22 50
481453 73868 73883 GATAGCAGAAGTAGGA 33 92
481678 73869 73882 ATAGCAGAAGTAGG 22 78
481454 73889 73904 AAAGTGCCCAGATTGC 33 85
481679 73890 73903 AAGTGCCCAGATTG 22 69
481455 73909 73924 CACTCATTTCTCTATT 33 74
481680 73910 73923 ACTCATTTCTCTAT 22 39
481456 73954 73969 AACACATCCTTATTTG 33 48
481681 73955 73968 ACACATCCTTATTT 22 47
481457 73966 73981 TGGGTCTCAGAGAACA 33 88
481682 73967 73980 GGGTCTCAGAGAAC 22 77
481458 74019 74034 CAAGACATTTCCTTTT 33 54
481683 74020 74033 AAGACATTTCCTTT 22 29
481459 74095 74110 GGAGGCACTTGTCTAA 33 76
481684 74096 74109 GAGGCACTTGTCTA 22 89
481460 74130 74145 TTACAGAAACAGGCAG 33 83
481685 74131 74144 TACAGAAACAGGCA 22 36
481461 74156 74171 AGCTATAGGTGGCCTG 33 75
481686 74157 74170 GCTATAGGTGGCCT 22 70
481462 74171 74186 ATGCCAGGAGTATGTA 33 89
481687 74172 74185 TGCCAGGAGTATGT 22 80
481463 74188 74203 CAAGGTTAAAAAGTGC 33 88
481688 74189 74202 AAGGTTAAAAAGTG 22 13
481464 74203 74218 CTATTTGGATGTCAGC 33 97
481689 74204 74217 TATTTGGATGTCAG 22 40
481465 74219 74234 TAGATAGTCCTATCTT 33 51
481690 74220 74233 AGATAGTCCTATCT 22 64
481466 74234 74249 AAGAAACCTAGGGCTT 33 74
481691 74235 74248 AGAAACCTAGGGCT 22 77
481467 74284 74299 GCTGATACAGTGTTTT 33 74
481692 74285 74298 CTGATACAGTGTTT 22 74
481468 74299 74314 ATACAGAAAGGCTATG 33 71
481693 74300 74313 TACAGAAAGGCTAT 22 25
481469 74314 74329 GCTTAAGTTTCTTAAA 33 61
481694 74315 74328 CTTAAGTTTCTTAA 22 0
481470 74648 74663 AGCACCAAGGAGGCTG 33 49
481695 74649 74662 GCACCAAGGAGGCT 22 83
481471 74663 74678 AAGCTGAATGCTTAAA 33 36
BIOL0142WO
481696 74664 74677 AGCTGAATGCTTAA 22 33
481472 74678 74693 TTACCAGCCTGAAGGA 33 76
481697 74679 74692 TACCAGCCTGAAGG 22 63
481473 74693 74708 CAGGGATTATATAAAT 33 53
481698 74694 74707 AGGGATTATATAAA 22 15
481474 74708 74723 ACCTGAAGCCCGTTTC 33 80
481699 74709 74722 CCTGAAGCCCGTTT 22 57
481475 74723 74738 TGTCTTAAGGGTTTGA 33 93
481700 74724 74737 GTCTTAAGGGTTTG 22 89
481476 74738 74753 GGTTGCAGCTTCAGAT 33 92
481701 74739 74752 GTTGCAGCTTCAGA 22 60
481477 74754 74769 TCAACACCAAAGGCCA 33 95
481702 74755 74768 CAACACCAAAGGCC 22 89
481478 74772 74787 TCCTTAAACCTTCCTA 33 84
481703 74773 74786 CCTTAAACCTTCCT 22 57
481479 74787 74802 AAAATGCTTAGATTCT 33 80
481704 74788 74801 AAATGCTTAGATTC 22 32
481480 74815 74830 AAATAAGTCTATTTAT 33 5
481705 74816 74829 AATAAGTCTATTTA 22 25
481481 74835 74850 GGCCAATACATTACAA 33 63
481706 74836 74849 GCCAATACATTACA 22 56
481482 74857 74872 TGCCCAGCCTTACTCA 33 55
481707 74858 74871 GCCCAGCCTTACTC 22 43
481483 74872 74887 GTTGTAAGCACCCTCT 33 1
481708 74873 74886 TTGTAAGCACCCTC 22 56
481484 74887 74902 AGAAAGGGAGTCAAGG 33 60
481709 74888 74901 GAAAGGGAGTCAAG 22 27
481485 74904 74919 GCAGATCAAGTCCAGG 33 90
481710 74905 74918 CAGATCAAGTCCAG 22 88
481486 74917 74932 AGCCTCTGAAACAGCA 33 75
481711 74918 74931 GCCTCTGAAACAGC 22 74
481487 74933 74948 CCCACAGAAACAACCT 33 66
481712 74934 74947 CCACAGAAACAACC 22 45
481488 74948 74963 AGCCCTGATAAGGCAC 33 23
481713 74949 74962 GCCCTGATAAGGCA 22 18
481489 74963 74978 AATCAGAAGTATCCCA 33 60
481714 74964 74977 ATCAGAAGTATCCC 22 43
481490 75020 75035 GCCTCTAGCAGGATCA 33 78
481715 75021 75034 CCTCTAGCAGGATC 22 79
481491 75035 75050 CACGCAAGGAGACATG 33 70
481716 75036 75049 ACGCAAGGAGACAT 22 68
481492 75050 75065 TGAGGGACCTTTAGAC 33 61
481717 75051 75064 GAGGGACCTTTAGA 22 44
481493 75073 75088 CAGGATTCCTAAAACA 33 43
481718 75074 75087 AGGATTCCTAAAAC 22 7
BIOL0142WO
481494 75088 75103 ATGAGGTCCTGAGACC 33 60
481719 75089 75102 TGAGGTCCTGAGAC 22 29
481495 75127 75142 CATCATGTCCAACCTG 33 92
481720 75128 75141 ATCATGTCCAACCT 22 63
481496 75142 75157 GGGCCCCATAGTGTGC 33 29
481721 75143 75156 GGCCCCATAGTGTG 22 19
481497 75164 75179 AGCTCAACCAGACACG 33 67
481722 75165 75178 GCTCAACCAGACAC 22 69
481498 75179 75194 GAACCATATTCCCTGA 33 90
481723 75180 75193 AACCATATTCCCTG 22 49
481499 75194 75209 CAAGAAACTGGCTAAG 33 43
481724 75195 75208 AAGAAACTGGCTAA 22 17
481500 75209 75224 GCCACTGGATATCACC 33 92
481725 75210 75223 CCACTGGATATCAC 22 88 464
481501 75235 75250 AACTGAATGAAGACGC 33 91
481726 75236 75249 ACTGAATGAAGACG 22 56
481502 75250 75265 CCTTTGCCCTGCATGA 33 85
481727 75251 75264 CTTTGCCCTGCATG 22 70
481503 75265 75280 AAGTTTATCAGTAAGC 33 57
481728 75266 75279 AGTTTATCAGTAAG 22 22
481504 75280 75295 TACGAGGGCAGACTCA 33 60
481729 75281 75294 ACGAGGGCAGACTC 22 22
481505 75295 75310 AGGTATACACCCTCAT 33 45
481730 75296 75309 GGTATACACCCTCA 22 47
481506 75310 75325 CCTCAGAGGGAGGCCA 33 32
481731 75311 75324 CTCAGAGGGAGGCC 22 0
481507 75325 75340 GGGAGGAGTCACCAGC 33 64
481732 75326 75339 GGAGGAGTCACCAG 22 59
481508 75392 75407 TAGCCAGCCAAGGCGG 33 33
481733 75393 75406 AGCCAGCCAAGGCG 22 50
481509 75407 75422 ACAGGAGAGGCGAGCT 33 46
481734 75408 75421 CAGGAGAGGCGAGC 22 28
481510 75424 75439 TAGGTGTTCCCATACG 33 95
481735 75425 75438 AGGTGTTCCCATAC 22 22
481511 75445 75460 GGCAGCCCATCCAGCA 33 43
481736 75446 75459 GCAGCCCATCCAGC 22 54
481512 75462 75477 CATGCCTCTGAGTCAG 33 30
481737 75463 75476 ATGCCTCTGAGTCA 22 31
481513 75477 75492 GTTGCCAAATCCGGCC 33 85
481738 75478 75491 TTGCCAAATCCGGC 22 70
481514 75492 75507 GCAAGGTGGTTTTGAG 33 85
481739 75493 75506 CAAGGTGGTTTTGA 22 60
481515 75512 75527 AGAAACTCTGATCAGC 33 88
481740 75513 75526 GAAACTCTGATCAG 22 71
481516 75551 75566 CAGAGACCAGCTAATT 33 78
BIOL0142WO
481741 75552 75565 AGAGACCAGCTAAT 22 80
481517 75581 75596 ATCTTAGAGAAGGTCG 33 87
481742 75582 75595 TCTTAGAGAAGGTC 22 64
481518 75612 75627 CCAGGCAGGAGGACTG 33 67
481743 75613 75626 CAGGCAGGAGGACT 22 75
481519 75624 75639 CATCAACTGTCTCCAG 33 29
481744 75625 75638 ATCAACTGTCTCCA 22 69
481520 75626 75641 CACATCAACTGTCTCC 33 73
481745 75627 75640 ACATCAACTGTCTC 22 74
481521 75646 75661 GAAGTAAGAGCTCTGC 33 86
481746 75647 75660 AAGTAAGAGCTCTG 22 67
481522 75661 75676 AAGAGTGTTGCTGGAG 33 92
481747 75662 75675 AGAGTGTTGCTGGA 22 95
481523 75676 75691 GCTTATTATGTACTGA 33 95
481748 75677 75690 CTTATTATGTACTG 22 15
481524 75717 75732 GCCCAAGTCTCACCTT 33 70
481749 75718 75731 CCCAAGTCTCACCT 22 70
481525 75728 75743 CCCAATGGTAAGCCCA 33 93
481750 75729 75742 CCAATGGTAAGCCC 22 94
481526 75730 75745 AACCCAATGGTAAGCC 33 82
481751 75731 75744 ACCCAATGGTAAGC 22 54
481527 75747 75762 TAGGTCCCTATGATTT 33 55
481752 75748 75761 AGGTCCCTATGATT 22 62
481528 75766 75781 AAGCCCTGAACCCTCG 33 77
481753 75767 75780 AGCCCTGAACCCTC 22 71
481529 75802 75817 CCTAAGGCCATGAACT 33 64
481754 75803 75816 CTAAGGCCATGAAC 22 53
481530 75817 75832 ACCAGATACATGCTAC 33 87
481755 75818 75831 CCAGATACATGCTA 22 84
481531 75833 75848 TACAATCAGAGTTAAG 33 66
481756 75834 75847 ACAATCAGAGTTAA 22 5
481532 75851 75866 TCCTCTCAGAACTTTT 33 65
481757 75852 75865 CCTCTCAGAACTTT 22 81
481533 75853 75868 GCTCCTCTCAGAACTT 33 80
481758 75854 75867 CTCCTCTCAGAACT 22 62
481534 75880 75895 TTCTTTAATGGGCCAC 33 79
481759 75881 75894 TCTTTAATGGGCCA 22 74
481535 75954 75969 ACGGGATTCCCTCGGC 33 78
481760 75955 75968 CGGGATTCCCTCGG 22 78
481536 75969 75984 GTAGGTAAGCAACCCA 33 91
481761 75970 75983 TAGGTAAGCAACCC 22 78
481537 76017 76032 GAATTTGAATGCAGTG 33 84
481762 76018 76031 AATTTGAATGCAGT 22 2
481538 76031 76046 TGAAGTACACATTGGA 33 92
481763 76032 76045 GAAGTACACATTGG 22 96
BIOL0142WO
481539 76047 76062 ATAAATTTTTACACTA 33 19
481764 76048 76061 TAAATTTTTACACT 22 1
481765 76056 76069 CAATAATATAAATT 22 0
481541 76121 76136 CTGGAAGTTAAAGTAG 33 71
481766 76122 76135 TGGAAGTTAAAGTA 22 10
Example 2: Antisense inhibition of murine STAT3 in b.END cells
Antisense oligonucleotides tested in the study described in Example 1 were also tested for their
effects on STAT3 mRNA in b.END cells. Cultured b.END cells at a density of 20,000 cells per well were
transfected using electroporation with 7,000 nM antisense oligonucleotide. After a treatment period of
approximately 24 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Murine primer probe set RTS2381 (forward sequence
GCCACGTTGGTGTTTCATAATCT, designated herein as SEQ ID NO: 465; reverse sequence
GATAGAGGACATTGGACTCTTGCA, designated herein as SEQ ID NO: 466; probe sequence
TTGGGTGAAATTGACCAGCAATATAGCCG, designated herein as SEQ ID NO: 467) was used to
measure RNA. STAT3 mRNA levels were adjusted according to total RNA content, as measured by
RIBOGREEN®.
Certain sequences complementary to the STAT3 mouse gene sequence showed good inhibition in
b. END cells. Results are presented in Table 3 as percent inhibition of STAT3, relative to untreated
control cells. The human oligonucleotides in Table 3 were compared to the mouse STAT-3 genomic
sequence, designated herein as SEQ ID NO: 3 (the complement of GENBANK Accession No.
NT_165773.2 truncated from nucleotides 12286001 to 12344000). “Mouse Target start site” indicates the
’-most nucleotide to which the gapmer is targeted in the murine sequence. “Mouse Target stop site”
indicates the 3’-most nucleotide to which the gapmer is targeted murine sequence.
Table 3
Inhibition of human STAT3 mRNA levels by certain cEt chimeric antisense oligonucleotides
complementary to SEQ ID NO: 1 and SEQ ID NO: 3
Mouse Mouse
ISIS % SEQ ID
Start Stop
NO inhibition NO
Site Site
481549 5283 5298 96 413
481553 9913 9928 94 421
481768 3189 3202 91 402
481356 30356 30371 83 21
481548 4045 4060 82 411
481554 14662 14677 82 423
481426 48328 48343 82 165
481580 30333 30346 81 20
481412 47413 47428 81 135
481417 47636 47651 81 147
BIOL0142WO
481418 47637 47652 80 148
481355 30332 30347 79 19
481396 43120 43135 79 443
481416 47634 47649 79 144
481420 47681 47696 79 153
481358 32842 32857 78 25
481363 33520 33535 78 35
481570 51870 51885 78 457
481382 37857 37872 77 74
481378 36560 36575 76 66
481431 48403 48418 76 175
481453 53034 53049 76 223
481621 43121 43134 75 444
481641 47635 47648 75 145
481637 47414 47427 74 136
481380 36631 36646 73 70
481574 53000 53015 73 221
481601 36392 36405 71 62
481419 47638 47653 71 150
481371 35938 35953 70 51
481642 47637 47650 70 149
481542 3180 3195 69 399
481547 3313 3328 69 409
481772 3314 3327 69 410
481362 32929 32944 69 33
481653 48362 48375 69 170
481786 38812 38825 68 440
481415 47629 47644 68 141
481543 3188 3203 67 401
481793 51714 51727 67 454
481443 52060 52075 67 200
481684 53229 53242 67 236
481398 45226 45241 66 106
481560 36394 36409 65 438
481643 47638 47651 65 151
481430 48387 48402 65 173
481440 52024 52039 65 194
Example 3: Tolerability of antisense oligonucleotides targeting STAT3 in BALB/c mice
Forty antisense oligonucleotides exhibiting a high level of potency, selected from among the 452
compounds evaluated in Example 1, were further tested for in vivo tolerability.
Groups of 2-4 male BALB/c mice were injected subcutaneously twice a week for 3 weeks with
mg/kg of ISIS antisense oligonucleotides. One group of 4 male BALB/c mice was injected
BIOL0142WO
subcutaneously twice a week for 3 weeks with PBS. This group of mice was utilized as a control group to
which the treatment groups were compared. One day after the last dose, body weights were taken, mice
were euthanized, and organs and plasma were harvested for further analysis.
The body weights of the mice were measured pre-dose and at the end of the treatment period.
Percent increase over the initial body weight was calculated. Liver, spleen, and kidney weights were
measured at the end of the study and were compared to PBS treated mice.
To evaluate the effect of ISIS oligonucleotides on metabolic function, plasma concentrations of
transaminases and BUN were measured using an automated clinical chemistry analyzer (Hitachi Olympus
AU400e, Melville, NY). Plasma concentrations of ALT (alanine transaminase), AST (aspartate
transaminase), and BUN were measured.
Among the forty antisense oligonucleotides tested, certain antisense oligonucleotides, including
ISIS 481374, ISIS 481390, ISIS 481420, ISIS 481431, ISIS 481453, ISIS 481464, ISIS 481475, ISIS
481495, ISIS 481500, ISIS 481501, ISIS 481525, ISIS 481548, ISIS 481549, ISIS 481597, ISIS 481695,
ISIS 481700, ISIS 481702, ISIS 481710, ISIS 481725, ISIS 481750, and ISIS 481763 met tolerability
thresholds for body weight, organ weight, ALT, AST, and BUN parameters.
Example 4: Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
Gapmers from Examples 1 and 2 exhibiting significant in vitro inhibition of STAT3 were tested
at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per well and transfected
using electroporation with 31.25 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, and 1,0000 nM
concentrations of antisense oligonucleotide, as specified in Table 4. After a treatment period of
approximately 16 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199 (forward sequence
ACATGCCACTTTGGTGTTTCATAA, designated herein as SEQ ID NO: 6; reverse sequence
TCTTCGTAGATTGTGCTGATAGAGAAC, designated herein as SEQ ID NO: 7; probe sequence
CAGTATAGCCGCTTCCTGCAAGAGTCGAA, designated herein as SEQ ID NO: 8) was used to
measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as measured
by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated control
cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 4 and was calculated by plotting the concentrations of oligonucleotides used versus the percent
inhibition of STAT3 mRNA expression achieved at each concentration and noting the concentration of
oligonucleotide at which 50% inhibition of STAT3 mRNA expression was achieved compared to the
control. As illustrated in Table 4, STAT3 mRNA levels were significantly reduced in a dose-dependent
manner in antisense oligonucleotide treated cells.
BIOL0142WO
Table 4
Dose-dependent antisense inhibition of human STAT3 in HuVEC cells using electroporation
31.25 62.5 125.0 250.0 500.0 1000.0
ISIS No
nM nM nM nM nM nM
(μM)
481355 19 15 36 61 75 89 0.18
481374 25 42 52 72 82 88 0.10
481390 17 37 44 60 73 86 0.15
481420 23 20 40 60 81 92 0.16
481453 21 37 52 69 79 88 0.12
481464 57 73 81 90 94 94 <0.03
481475 22 46 54 78 83 92 0.10
481500 25 37 42 75 83 90 0.12
481501 32 57 69 82 94 94 0.05
481523 35 60 74 85 90 93 0.04
481525 36 53 60 79 89 92 0.06
481549 0 16 60 81 90 96 0.15
481554 0 15 28 49 70 86 0.25
481597 8 18 39 48 64 83 0.24
481695 15 27 39 50 64 80 0.22
481700 0 17 44 58 80 88 0.20
481710 12 39 65 79 86 90 0.11
481715 11 26 32 44 53 69 0.36
481725 27 40 56 77 89 93 0.09
481750 7 24 46 63 83 89 0.16
481755 17 28 30 54 68 80 0.20
481768 7 21 27 44 67 85 0.26
Example 5: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in SK-BR-3 cells
Gapmers from Example 4 were tested at various doses in SK-BR-3 cells. Cells were plated at a
density of 4,000 cells per well. Cells were incubated with 0.02 μM, 0.1 μM, 0.5 μM, 1 μΜ. 2.5 μΜ, and
μM concentrations of antisense oligonucleotide, as specified in Table 5. After approximately 24
hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by quantitative real-
time PCR. Human STAT3 primer probe set RTS199, described hereinabove, was used to measure
mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as measured by
RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 5. As illustrated in Table 5, most of the ISIS oligonucleotides were able to penetrate the cell
membrane and STAT3 mRNA levels were significantly reduced in a dose-dependent manner in antisense
oligonucleotide treated cells.
BIOL0142WO
Table 5
Dose-dependent antisense inhibition of human STAT3 by free-uptake of ISIS oligonucleotide by SK-BR-
3 cells
ISIS No
0.02 μM 0.1 μM 0.5 μM 1 μM 2.5 μM 10 μM IC (μM)
481374 10 18 18 16 8 25 15.9
481390 0 10 11 12 40 72 3.2
481453 14 13 27 45 58 79 1.3
481464 23 32 57 70 85 93 0.5
481475 0 0 35 49 72 88 1.0
481500 7 9 26 45 49 75 1.7
481501 0 0 4 5 53 65 2.7
481523 9 24 56 67 83 92 0.5
481525 0 17 13 15 32 68 4.4
481549 0 0 0 16 33 54 8.2
481597 1 0 11 14 22 44 10.6
481710 5 0 10 13 27 66 6.0
481725 29 45 47 39 39 63 2.6
481750 19 24 36 42 71 80 1.1
481763 30 38 51 63 81 89 0.6
481768 12 5 34 25 32 35 12.4
Example 6: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in U251-MG cells
Gapmers from Example 5 were further tested at various doses in U251-MG cells. Cells were
plated at a density of 4,000 cells per well. Cells were incubated with 0.02 μM, 0.1 μM, 0.5 μM, 1
μΜ. 2.5 μΜ, and 10 μM concentrations of antisense oligonucleotide, as specified in Table 6. After
approximately 24 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199, described hereinabove, was used
to measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
measured by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 6. As illustrated in Table 6, most of the ISIS oligonucleotides were able to penetrate the cell
membrane and STAT3 mRNA levels were significantly reduced in a dose-dependent manner in antisense
oligonucleotide treated cells.
Table 6
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
U251-MG cells
ISIS No 0.02 μM 0.1 μM 0.5 μM 1 μM 2.5 μM 10 μM IC (μM)
481374 0 0 10 0 12 25 15.7
481390 0 4 10 8 16 31 13.9
BIOL0142WO
481453 4 3 15 16 20 42 11.0
481464 13 11 41 42 54 79 1.3
481475 3 13 26 37 41 67 2.6
481500 2 12 14 12 25 38 11.7
481501 0 0 2 1 14 47 10.3
481523 22 27 39 45 63 83 1.1
481525 1 1 17 17 35 60 6.3
481549 0 0 0 0 9 29 14.5
481597 3 3 12 18 18 47 10.1
481695 0 14 12 22 25 33 12.9
481710 0 0 0 0 6 23 16.8
481725 0 0 5 7 20 38 11.8
481750 4 15 18 18 17 33 13.2
481763 15 16 25 36 36 64 3.2
481768 22 16 18 22 21 37 12.2
Example 7: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in U251-MG cells
ISIS 481464 and ISIS 481549, from the studies described above, were further tested at different
doses in U251-MG cells. Cells were plated at a density of 4,000 cells per well. Cells were incubated
with 0.1 μM, 1 μM, 5 μM, 10 μΜ, and 20 μM concentrations of antisense oligonucleotide, as specified in
Table 7. After approximately 24 hours, RNA was isolated from the cells and STAT3 mRNA levels were
measured by quantitative real-time PCR. Human STAT3 primer probe set RTS199, described
hereinabove, was used to measure mRNA levels. STAT3 mRNA levels were adjusted according to total
RNA content, as measured by RIBOGREEN . Results are presented as percent inhibition of STAT3,
relative to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 7. As illustrated in Table 7, both the ISIS oligonucleotides were able to penetrate the cell
membrane.
Table 7
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
U251-MG cells
ISIS No
0.1 μM 1 μM 5 μM 10 μM 20 μM IC (μM)
481464 0 30 69 80 79 2.3
481549 0 0 26 35 38 >20
Example 8: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in MDA-MB-231 cells
BIOL0142WO
ISIS 481464 and ISIS 481549 were further tested at different doses in MDA-MB-231 cells. Cells
were plated at a density of 4,000 cells per well. Cells were incubated with 0.02 μM, 0.2 μM, 1.0 μM, 5.0
μΜ, and 10.0 μM concentrations of antisense oligonucleotide, as specified in Table 8. After
approximately 24 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199, described hereinabove, was used
to measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
measured by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 8. As illustrated in Table 8, both the ISIS oligonucleotides were able to penetrate the cell membrane
and significantly reduce STAT3 mRNA levels in a dose-dependent manner.
Table 8
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
MDA-MB-231 cells
ISIS No
0.02 μM 0.2 μM 1.0 μM 5.0 μM 10.0 μM IC (μM)
481464 0 25 71 85 87 0.6
481549 0 2 33 49 66 4.4
Example 9: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in A431 cells
ISIS 481464 and ISIS 481549 were further tested at different doses in A431 cells. Cells were
plated at a density of 4,000 cells per well. Cells were incubated with 0.02 μM, 0.2 μM, 1.0 μM, 5.0
μΜ, and 10.0 μM concentrations of antisense oligonucleotide, as specified in Table 9. After
approximately 24 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199, described hereinabove, was used
to measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
measured by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 9. As illustrated in Table 9, both the ISIS oligonucleotides were able to penetrate the cell membrane
and significantly reduce STAT3 mRNA levels in a dose-dependent manner.
Table 9
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
A431 cells
ISIS No
0.02 μM 0.2 μM 1.0 μM 5.0 μM 10.0 μM IC (μM)
481464 79 93 98 98 98 <0.02
481549 0 38 68 82 84 0.6
BIOL0142WO
Example 10: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in H460 cells
ISIS 481464 and ISIS 481549 were further tested at different doses in H460 cells. Cells were
plated at a density of 4,000 cells per well. Cells were incubated with 0.02 μM, 0.2 μM, 1.0 μM, 5.0
μΜ, and 10.0 μM concentrations of antisense oligonucleotide, as specified in Table 10. After
approximately 24 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199, described hereinabove, was used
to measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
measured by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 10. As illustrated in Table 10, both the ISIS oligonucleotides were able to penetrate the cell
membrane and significantly reduce STAT3 mRNA levels in a dose-dependent manner.
Table 10
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
H460 cells
ISIS No
0.02 μM 0.2 μM 1.0 μM 5.0 μM 10.0 μM IC (μM)
481464 46 89 96 97 98 0.01
481549 8 53 78 96 98 0.23
Example 11: Antisense inhibition of human STAT3 in HuVEC cells
Antisense oligonucleotides were designed targeting a human STAT3 nucleic acid and were
tested for their effect on human STAT3 mRNA expression in vitro. Cultured HuVEC cells at a density of
,000 cells per well were transfected using electroporation with 1,000 nM antisense oligonucleotide.
After a treatment period of approximately 24 hours, RNA was isolated from the cells and STAT3 mRNA
levels were measured by quantitative real-time PCR. Human primer probe set RTS199 (forward
sequence ACATGCCACTTTGGTGTTTCATAA, designated herein as SEQ ID NO: 6; reverse sequence
TCTTCGTAGATTGTGCTGATAGAGAAC, designated herein as SEQ ID NO: 7; probe sequence
CAGTATAGCCGCTTCCTGCAAGAGTCGAA, designated herein as SEQ ID NO: 8) was used to
measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
measured by RIBOGREEN®. Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
The chimeric antisense oligonucleotides in Table 11 were designed as 33 MOE, deoxy, and
cEt gapmers. The gapmers are 16 nucleotides in length, wherein the central gap segment comprises of ten
2’-deoxynucleosides and is flanked on both sides (in the 5’ and 3’ directions) by wings comprising three
nucleosides each. Each nucleoside in the 5’-wing segment has a 2’-MOE sugar modification. Each
nucleoside in the 3’-wing segment has a cEt sugar modification. The internucleoside linkages throughout
BIOL0142WO
each gapmer are phosphorothioate (P=S) linkages. All cytosine residues throughout each gapmer are 5’-
methylcytosines. The chemistry column of Table 11 presents the sugar motif of each gapmer, wherein ‘e’
indicates a 2’-MOE nucleoside, ‘k’ indicates a constrained ethyl (cEt) nucleoside, and ‘d’ indicates a 2’-
deoxynucleoside.
“Human Target start site” indicates the 5’-most nucleoside to which the gapmer is targeted in the
human gene sequence. “Human Target stop site” indicates the 3’-most nucleoside to which the gapmer is
targeted in the human gene sequence. Each gapmer listed in Table 11 is targeted to human STAT3
mRNA, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NM_139276.2).
Table 11
Inhibition of human STAT3 mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID
NO: 1
Human Human
ISIS % SEQ
Start Stop Sequence Chemistry
No inhibition ID NO
Site Site
1 16 528170 CGCAGCTCCGGAAACC e-e-e-d -k-k-k 12 471
(10)
2 17 528171 CCGCAGCTCCGGAAAC e-e-e-d -k-k-k 11 472
(10)
4 19 528172 CGCCGCAGCTCCGGAA e-e-e-d -k-k-k 10 473
(10)
20 528173 CCGCCGCAGCTCCGGA e-e-e-d -k-k-k 22
(10)
32 47 528174 ACCCCCGGCTCCCCCT e-e-e-d -k-k-k 18
(10) 475
34 49 528175 GAACCCCCGGCTCCCC e-e-e-d -k-k-k 17
(10)
50 528176 GGAACCCCCGGCTCCC e-e-e-d -k-k-k 23
(10) 477
36 51 528177 CGGAACCCCCGGCTCC e-e-e-d -k-k-k 15
(10)
38 53 528178 GTCGGAACCCCCGGCT e-e-e-d -k-k-k 21
(10) 479
39 54 528179 CGTCGGAACCCCCGGC e-e-e-d -k-k-k 19
(10)
57 72 528180 TTGTTCCCTCGGCTGC e-e-e-d -k-k-k 40
(10) 481
58 73 528181 CTTGTTCCCTCGGCTG e-e-e-d -k-k-k 28
(10)
60 75 528182 GGCTTGTTCCCTCGGC e-e-e-d -k-k-k 25
(10) 483
61 76 528183 GGGCTTGTTCCCTCGG e-e-e-d -k-k-k 34
(10)
75 90 528184 CCAGGATCCGGTTGGG e-e-e-d -k-k-k 34
(10) 485
76 91 528185 TCCAGGATCCGGTTGG e-e-e-d -k-k-k 15 9
(10)
77 92 528186 GTCCAGGATCCGGTTG e-e-e-d -k-k-k 28
(10) 486
78 93 528187 TGTCCAGGATCCGGTT e-e-e-d -k-k-k 27
(10)
79 94 528188 CTGTCCAGGATCCGGT e-e-e-d -k-k-k 33
(10) 488
81 96 528189 GCCTGTCCAGGATCCG e-e-e-d -k-k-k 63
(10)
83 98 528190 GTGCCTGTCCAGGATC e-e-e-d -k-k-k 36
(10) 490
189 204 528191 AGAGGCCGAGAGGCCG e-e-e-d -k-k-k 2
(10)
210 225 528192 GGTCCCAACTGTTTCT e-e-e-d -k-k-k 11
(10) 492
232 247 528193 GGGCCATCCTGCTAAA e-e-e-d -k-k-k 14
(10)
233 248 528194 TGGGCCATCCTGCTAA e-e-e-d -k-k-k 16
(10) 494
234 249 528195 TTGGGCCATCCTGCTA e-e-e-d -k-k-k 9
(10)
236 251 528196 CATTGGGCCATCCTGC e-e-e-d -k-k-k 39
(10) 496
237 252 528197 CCATTGGGCCATCCTG e-e-e-d -k-k-k 38
(10)
239 254 528198 TTCCATTGGGCCATCC e-e-e-d -k-k-k 19
(10) 498
BIOL0142WO
240 255 528199 ATTCCATTGGGCCATC e-e-e-d -k-k-k 27
(10)
244 259 528200 GCTGATTCCATTGGGC e-e-e-d -k-k-k 18
(10) 500
245 260 528201 AGCTGATTCCATTGGG e-e-e-d -k-k-k 20
(10)
246 261 528202 TAGCTGATTCCATTGG e-e-e-d -k-k-k 41
(10) 502
247 262 528203 GTAGCTGATTCCATTG e-e-e-d -k-k-k 37
(10) 503
250 265 528204 GCTGTAGCTGATTCCA e-e-e-d -k-k-k 83
(10) 504
251 266 528205 TGCTGTAGCTGATTCC e-e-e-d -k-k-k 72
(10)
252 267 528206 CTGCTGTAGCTGATTC e-e-e-d -k-k-k 44 506
(10)
253 268 528207 GCTGCTGTAGCTGATT e-e-e-d -k-k-k 49 507
(10)
263 278 528208 CGTGTGTCAAGCTGCT e-e-e-d -k-k-k 73 508
(10)
264 279 528209 CCGTGTGTCAAGCTGC e-e-e-d -k-k-k 81 17
(10)
265 280 528210 ACCGTGTGTCAAGCTG e-e-e-d -k-k-k 78
(10) 509
266 281 528211 TACCGTGTGTCAAGCT e-e-e-d -k-k-k 72
(10)
267 282 528212 GTACCGTGTGTCAAGC e-e-e-d -k-k-k 81
(10) 511
268 283 528213 GGTACCGTGTGTCAAG e-e-e-d -k-k-k 46
(10)
270 285 528214 CAGGTACCGTGTGTCA e-e-e-d -k-k-k 80
(10) 513
271 286 528215 CCAGGTACCGTGTGTC e-e-e-d -k-k-k 69
(10) 514
272 287 528216 TCCAGGTACCGTGTGT e-e-e-d -k-k-k 41
(10) 515
273 288 528217 CTCCAGGTACCGTGTG e-e-e-d -k-k-k 44
(10)
274 289 528218 GCTCCAGGTACCGTGT e-e-e-d -k-k-k 32
(10) 517
275 290 528219 TGCTCCAGGTACCGTG e-e-e-d -k-k-k 50
(10)
291 306 528220 GTAGAGCTGATGGAGC e-e-e-d -k-k-k 12
(10) 519
292 307 528221 TGTAGAGCTGATGGAG e-e-e-d -k-k-k 0
(10) 520
295 310 528222 CACTGTAGAGCTGATG e-e-e-d -k-k-k 0
(10) 521
297 312 528223 GTCACTGTAGAGCTGA e-e-e-d -k-k-k 44
(10)
302 317 528224 AAGCTGTCACTGTAGA e-e-e-d -k-k-k 20
(10) 523
303 318 528225 GAAGCTGTCACTGTAG e-e-e-d -k-k-k 24
(10)
307 322 528226 TTGGGAAGCTGTCACT e-e-e-d -k-k-k 35
(10) 525
308 323 528227 ATTGGGAAGCTGTCAC e-e-e-d -k-k-k 29
(10) 526
310 325 528228 CCATTGGGAAGCTGTC e-e-e-d -k-k-k 33 527
(10)
322 337 519639 ACTGCCGCAGCTCCAT e-e-e-d -k-k-k 37 19
(10)
329 344 528229 GCCAGAAACTGCCGCA e-e-e-d -k-k-k 20
(10) 528
330 345 528230 GGCCAGAAACTGCCGC e-e-e-d -k-k-k 1
(10)
331 346 528231 GGGCCAGAAACTGCCG e-e-e-d -k-k-k 1
(10) 530
345 360 528232 ACTCTCAATCCAAGGG e-e-e-d -k-k-k 14
(10) 531
346 361 528233 GACTCTCAATCCAAGG e-e-e-d -k-k-k 10 21
(10)
347 362 528234 TGACTCTCAATCCAAG e-e-e-d -k-k-k 6
(10)
351 366 528235 ATCTTGACTCTCAATC e-e-e-d -k-k-k 38
(10) 533
353 368 528236 CAATCTTGACTCTCAA e-e-e-d -k-k-k 29
(10)
354 369 528237 CCAATCTTGACTCTCA e-e-e-d -k-k-k 60
(10) 535
355 370 528238 CCCAATCTTGACTCTC e-e-e-d -k-k-k 37
(10) 536
356 371 528239 GCCCAATCTTGACTCT e-e-e-d -k-k-k 48
(10) 537
357 372 528240 TGCCCAATCTTGACTC e-e-e-d -k-k-k 40
(10)
358 373 528241 ATGCCCAATCTTGACT e-e-e-d -k-k-k 21
(10) 539
359 374 528242 TATGCCCAATCTTGAC e-e-e-d -k-k-k 27
(10)
BIOL0142WO
362 377 528243 GCATATGCCCAATCTT e-e-e-d -k-k-k 16
(10)
363 378 528244 CGCATATGCCCAATCT e-e-e-d -k-k-k 50
(10) 542
367 382 528245 TGGCCGCATATGCCCA e-e-e-d -k-k-k 67
(10)
368 383 528246 CTGGCCGCATATGCCC e-e-e-d -k-k-k 47
(10) 544
369 384 528247 GCTGGCCGCATATGCC e-e-e-d -k-k-k 54
(10) 545
370 385 528248 TGCTGGCCGCATATGC e-e-e-d -k-k-k 35
(10) 546
371 386 528249 TTGCTGGCCGCATATG e-e-e-d -k-k-k 22
(10)
372 387 528250 TTTGCTGGCCGCATAT e-e-e-d -k-k-k 19
(10) 548
373 388 528251 CTTTGCTGGCCGCATA e-e-e-d -k-k-k 27
(10)
374 389 528252 TCTTTGCTGGCCGCAT e-e-e-d -k-k-k 34
(10) 550
375 390 528253 TTCTTTGCTGGCCGCA e-e-e-d -k-k-k 59
(10) 23
376 391 528254 ATTCTTTGCTGGCCGC e-e-e-d -k-k-k 63
(10) 551
378 393 528255 TGATTCTTTGCTGGCC e-e-e-d -k-k-k 30
(10)
379 394 528256 GTGATTCTTTGCTGGC e-e-e-d -k-k-k 47
(10) 553
383 398 528257 GCATGTGATTCTTTGC e-e-e-d -k-k-k 43
(10)
384 399 528258 GGCATGTGATTCTTTG e-e-e-d -k-k-k 47
(10) 555
388 403 528259 AAGTGGCATGTGATTC e-e-e-d -k-k-k 43
(10) 556
391 406 528260 CCAAAGTGGCATGTGA e-e-e-d -k-k-k 46
(10) 557
393 408 528261 CACCAAAGTGGCATGT e-e-e-d -k-k-k 32
(10)
395 410 528262 AACACCAAAGTGGCAT e-e-e-d -k-k-k 41
(10) 559
397 412 528263 GAAACACCAAAGTGGC e-e-e-d -k-k-k 69
(10)
427 442 528264 ACTGCTGGTCAATCTC e-e-e-d -k-k-k 27
(10) 561
428 443 528265 TACTGCTGGTCAATCT e-e-e-d -k-k-k 32
(10) 562
430 445 528266 TATACTGCTGGTCAAT e-e-e-d -k-k-k 27
(10) 563
431 446 528267 CTATACTGCTGGTCAA e-e-e-d -k-k-k 38
(10)
432 447 528268 GCTATACTGCTGGTCA e-e-e-d -k-k-k 58
(10) 565
433 448 528269 GGCTATACTGCTGGTC e-e-e-d -k-k-k 69
(10)
434 449 528270 CGGCTATACTGCTGGT e-e-e-d -k-k-k 73
(10) 567
435 450 528271 GCGGCTATACTGCTGG e-e-e-d -k-k-k 71
(10) 568
436 451 528272 AGCGGCTATACTGCTG e-e-e-d -k-k-k 54
(10) 569
437 452 528273 AAGCGGCTATACTGCT e-e-e-d -k-k-k 36
(10)
439 454 528274 GGAAGCGGCTATACTG e-e-e-d -k-k-k 27
(10) 571
440 455 528275 AGGAAGCGGCTATACT e-e-e-d -k-k-k 21
(10)
441 456 528276 CAGGAAGCGGCTATAC e-e-e-d -k-k-k 12
(10) 573
442 457 528277 GCAGGAAGCGGCTATA e-e-e-d -k-k-k 14
(10) 574
443 458 528278 TGCAGGAAGCGGCTAT e-e-e-d -k-k-k 21
(10) 575
444 459 528279 TTGCAGGAAGCGGCTA e-e-e-d -k-k-k 31
(10)
445 460 528280 CTTGCAGGAAGCGGCT e-e-e-d -k-k-k 44
(10) 577
463 478 528281 GATAGAGAACATTCGA e-e-e-d -k-k-k 25
(10)
464 479 528282 TGATAGAGAACATTCG e-e-e-d -k-k-k 39
(10) 579
469 484 528283 TGTGCTGATAGAGAAC e-e-e-d -k-k-k 41
(10) 580
471 486 528284 ATTGTGCTGATAGAGA e-e-e-d -k-k-k 38
(10) 581
472 487 528285 GATTGTGCTGATAGAG e-e-e-d -k-k-k 50
(10)
473 488 528286 AGATTGTGCTGATAGA e-e-e-d -k-k-k 49
(10) 583
475 490 528287 GTAGATTGTGCTGATA e-e-e-d -k-k-k 14
(10)
BIOL0142WO
476 491 528288 CGTAGATTGTGCTGAT e-e-e-d -k-k-k 8
(10)
490 505 528289 ACTGCTTGATTCTTCG e-e-e-d -k-k-k 9
(10) 33
511 526 528290 CAAGATACCTGCTCTG e-e-e-d -k-k-k 48
(10)
512 527 528291 TCAAGATACCTGCTCT e-e-e-d -k-k-k 34
(10) 586
513 528 528292 CTCAAGATACCTGCTC e-e-e-d -k-k-k 19
(10) 587
514 529 528293 TCTCAAGATACCTGCT e-e-e-d -k-k-k 31
(10) 588
517 532 528294 GCTTCTCAAGATACCT e-e-e-d -k-k-k 42
(10)
519 534 528295 TGGCTTCTCAAGATAC e-e-e-d -k-k-k 37
(10) 590
522 537 528296 CATTGGCTTCTCAAGA e-e-e-d -k-k-k 11
(10)
523 538 528297 CCATTGGCTTCTCAAG e-e-e-d -k-k-k 23
(10) 592
530 545 528298 GCAATCTCCATTGGCT e-e-e-d -k-k-k 46
(10) 593
531 546 528299 GGCAATCTCCATTGGC e-e-e-d -k-k-k 37
(10) 594
532 547 528300 GGGCAATCTCCATTGG e-e-e-d -k-k-k 24
(10)
533 548 528301 CGGGCAATCTCCATTG e-e-e-d -k-k-k 15
(10) 596
534 549 528302 CCGGGCAATCTCCATT e-e-e-d -k-k-k 30
(10)
535 550 528303 TCCGGGCAATCTCCAT e-e-e-d -k-k-k 29
(10) 598
536 551 528304 ATCCGGGCAATCTCCA e-e-e-d -k-k-k 32
(10) 599
537 552 528305 AATCCGGGCAATCTCC e-e-e-d -k-k-k 32
(10) 600
538 553 528306 CAATCCGGGCAATCTC e-e-e-d -k-k-k 24
(10)
539 554 528307 ACAATCCGGGCAATCT e-e-e-d -k-k-k 21
(10) 602
540 555 528308 CACAATCCGGGCAATC e-e-e-d -k-k-k 14
(10)
541 556 528309 CCACAATCCGGGCAAT e-e-e-d -k-k-k 13
(10) 604
543 558 528310 GGCCACAATCCGGGCA e-e-e-d -k-k-k 27
(10) 605
546 561 528311 CCGGGCCACAATCCGG e-e-e-d -k-k-k 27
(10) 606
547 562 528312 ACCGGGCCACAATCCG e-e-e-d -k-k-k 58
(10)
548 563 528313 CACCGGGCCACAATCC e-e-e-d -k-k-k 25
(10) 608
549 564 528314 GCACCGGGCCACAATC e-e-e-d -k-k-k 18
(10)
550 565 528315 GGCACCGGGCCACAAT e-e-e-d -k-k-k 33
(10) 610
551 566 528316 AGGCACCGGGCCACAA e-e-e-d -k-k-k 42
(10) 611
558 573 528317 TTCCCACAGGCACCGG e-e-e-d -k-k-k 47
(10) 612
586 601 528318 TGGCTGCAGTCTGTAG e-e-e-d -k-k-k 12
(10)
592 607 528319 CCGCAGTGGCTGCAGT e-e-e-d -k-k-k 10
(10) 614
599 614 528320 TGCTGGGCCGCAGTGG e-e-e-d -k-k-k 14
(10)
601 616 528321 CTTGCTGGGCCGCAGT e-e-e-d -k-k-k 0
(10) 616
603 618 528322 CCCTTGCTGGGCCGCA e-e-e-d -k-k-k 6
(10) 617
604 619 528323 CCCCTTGCTGGGCCGC e-e-e-d -k-k-k 21
(10) 618
605 620 528324 CCCCCTTGCTGGGCCG e-e-e-d -k-k-k 8
(10)
608 623 528325 TGGCCCCCTTGCTGGG e-e-e-d -k-k-k 0
(10) 620
615 630 528326 GTTGGCCTGGCCCCCT e-e-e-d -k-k-k 31
(10)
616 631 528327 GGTTGGCCTGGCCCCC e-e-e-d -k-k-k 47
(10) 622
617 632 528328 TGGTTGGCCTGGCCCC e-e-e-d -k-k-k 36
(10) 623
646 661 528329 GCTTCTCCGTCACCAC e-e-e-d -k-k-k 28
(10) 624
647 662 528330 TGCTTCTCCGTCACCA e-e-e-d -k-k-k 22
(10)
649 664 528331 GCTGCTTCTCCGTCAC e-e-e-d -k-k-k 35
(10) 626
667 682 528332 GGTGCTGCTCCAGCAT e-e-e-d -k-k-k 21
(10)
BIOL0142WO
678 693 528333 GACATCCTGAAGGTGC e-e-e-d -k-k-k 0
(10)
682 697 528334 TCCGGACATCCTGAAG e-e-e-d -k-k-k 1
(10) 629
683 698 528335 TTCCGGACATCCTGAA e-e-e-d -k-k-k 0
(10)
684 699 528336 CTTCCGGACATCCTGA e-e-e-d -k-k-k 0
(10) 631
685 700 528337 TCTTCCGGACATCCTG e-e-e-d -k-k-k 0
(10) 632
686 701 528338 CTCTTCCGGACATCCT e-e-e-d -k-k-k 19
(10) 633
687 702 528339 TCTCTTCCGGACATCC e-e-e-d -k-k-k 21
(10)
688 703 528340 CTCTCTTCCGGACATC e-e-e-d -k-k-k 17
(10) 635
689 704 528341 ACTCTCTTCCGGACAT e-e-e-d -k-k-k 37
(10)
727 742 528342 GATTCTCTACCACTTT e-e-e-d -k-k-k 33
(10) 637
730 745 528343 GGAGATTCTCTACCAC e-e-e-d -k-k-k 40
(10) 53
731 746 528344 TGGAGATTCTCTACCA e-e-e-d -k-k-k 32
(10) 638
732 747 528345 CTGGAGATTCTCTACC e-e-e-d -k-k-k 18
(10)
733 748 528346 CCTGGAGATTCTCTAC e-e-e-d -k-k-k 12
(10) 640
738 753 528347 GTCATCCTGGAGATTC e-e-e-d -k-k-k 54
(10)
764 779 528348 TTGAGGGTTTTATAGT e-e-e-d -k-k-k 0
(10) 642
775 790 528349 CTCCTTGACTCTTGAG e-e-e-d -k-k-k 21
(10) 643
781 796 528350 GCATGTCTCCTTGACT e-e-e-d -k-k-k 29
(10) 644
782 797 528351 TGCATGTCTCCTTGAC e-e-e-d -k-k-k 30
(10)
783 798 528352 TTGCATGTCTCCTTGA e-e-e-d -k-k-k 17
(10) 646
787 802 528353 GATCTTGCATGTCTCC e-e-e-d -k-k-k 61
(10)
788 803 518346 AGATCTTGCATGTCTC e-e-e-d -k-k-k 36
(10) 57
790 805 528354 TCAGATCTTGCATGTC e-e-e-d -k-k-k 43
(10) 648
792 807 528355 ATTCAGATCTTGCATG e-e-e-d -k-k-k 9
(10) 649
794 809 528356 CCATTCAGATCTTGCA e-e-e-d -k-k-k 37
(10)
795 810 528357 TCCATTCAGATCTTGC e-e-e-d -k-k-k 55
(10) 651
796 811 528358 TTCCATTCAGATCTTG e-e-e-d -k-k-k 17
(10)
803 818 528359 TGGTTGTTTCCATTCA e-e-e-d -k-k-k 33
(10) 653
804 819 528360 CTGGTTGTTTCCATTC e-e-e-d -k-k-k 18
(10) 654
806 821 528361 GACTGGTTGTTTCCAT e-e-e-d -k-k-k 23
(10) 655
807 822 528362 TGACTGGTTGTTTCCA e-e-e-d -k-k-k 33
(10)
813 828 528363 GGTCACTGACTGGTTG e-e-e-d -k-k-k 43
(10) 657
814 829 528364 TGGTCACTGACTGGTT e-e-e-d -k-k-k 62
(10)
848 863 528365 GTGAGCATCTGTTCCA e-e-e-d -k-k-k 41
(10) 659
852 867 528366 CGCAGTGAGCATCTGT e-e-e-d -k-k-k 0
(10) 660
853 868 528367 GCGCAGTGAGCATCTG e-e-e-d -k-k-k 0
(10) 661
854 869 528368 AGCGCAGTGAGCATCT e-e-e-d -k-k-k 7
(10)
855 870 528369 CAGCGCAGTGAGCATC e-e-e-d -k-k-k 6
(10) 663
857 872 528370 TCCAGCGCAGTGAGCA e-e-e-d -k-k-k 12
(10)
858 873 528371 GTCCAGCGCAGTGAGC e-e-e-d -k-k-k 11
(10) 665
859 874 528372 GGTCCAGCGCAGTGAG e-e-e-d -k-k-k 8
(10) 666
860 875 528373 TGGTCCAGCGCAGTGA e-e-e-d -k-k-k 12
(10) 667
862 877 528374 TCTGGTCCAGCGCAGT e-e-e-d -k-k-k 9
(10)
863 878 528375 ATCTGGTCCAGCGCAG e-e-e-d -k-k-k 8
(10) 669
864 879 528376 CATCTGGTCCAGCGCA e-e-e-d -k-k-k 0
(10)
BIOL0142WO
865 880 528377 GCATCTGGTCCAGCGC e-e-e-d -k-k-k 28
(10)
867 882 528378 CCGCATCTGGTCCAGC e-e-e-d -k-k-k 72
(10) 672
868 883 528379 TCCGCATCTGGTCCAG e-e-e-d -k-k-k 43
(10)
869 884 528380 CTCCGCATCTGGTCCA e-e-e-d -k-k-k 34
(10) 673
870 885 528381 TCTCCGCATCTGGTCC e-e-e-d -k-k-k 42
(10) 674
871 886 528382 TTCTCCGCATCTGGTC e-e-e-d -k-k-k 37
(10) 675
872 887 528383 CTTCTCCGCATCTGGT e-e-e-d -k-k-k 23
(10)
873 888 528384 GCTTCTCCGCATCTGG e-e-e-d -k-k-k 36
(10) 677
875 890 528385 ATGCTTCTCCGCATCT e-e-e-d -k-k-k 45
(10)
876 891 528386 GATGCTTCTCCGCATC e-e-e-d -k-k-k 14
(10) 679
877 892 528387 CGATGCTTCTCCGCAT e-e-e-d -k-k-k 25
(10) 680
878 893 528388 ACGATGCTTCTCCGCA e-e-e-d -k-k-k 39
(10) 681
879 894 528389 CACGATGCTTCTCCGC e-e-e-d -k-k-k 46
(10)
880 895 528390 TCACGATGCTTCTCCG e-e-e-d -k-k-k 17
(10) 683
881 896 528391 CTCACGATGCTTCTCC e-e-e-d -k-k-k 20
(10)
882 897 528392 ACTCACGATGCTTCTC e-e-e-d -k-k-k 16
(10) 685
883 898 528393 CACTCACGATGCTTCT e-e-e-d -k-k-k 39
(10) 686
885 900 528394 CTCACTCACGATGCTT e-e-e-d -k-k-k 45
(10) 687
886 901 528395 GCTCACTCACGATGCT e-e-e-d -k-k-k 37
(10)
888 903 528396 CAGCTCACTCACGATG e-e-e-d -k-k-k 24
(10) 689
889 904 528397 CCAGCTCACTCACGAT e-e-e-d -k-k-k 25
(10)
890 905 528398 GCCAGCTCACTCACGA e-e-e-d -k-k-k 18
(10) 691
891 906 528399 CGCCAGCTCACTCACG e-e-e-d -k-k-k 4
(10) 692
1068 1083 528477 AATTTGTTGACGGGTC e-e-e-d -k-k-k 37
(10) 693
1069 1084 528478 TAATTTGTTGACGGGT e-e-e-d -k-k-k 35
(10)
1070 1085 528479 TTAATTTGTTGACGGG e-e-e-d -k-k-k 40
(10) 695
1072 1087 528480 TCTTAATTTGTTGACG e-e-e-d -k-k-k 6
(10)
1087 1102 528481 GCAACTCCTCCAGTTT e-e-e-d -k-k-k 42
(10) 697
1088 1103 528482 TGCAACTCCTCCAGTT e-e-e-d -k-k-k 28
(10) 698
1094 1109 528483 TTTTGCTGCAACTCCT e-e-e-d -k-k-k 49
(10) 699
1095 1110 528484 TTTTTGCTGCAACTCC e-e-e-d -k-k-k 58
(10)
1114 1129 528485 GGTCCCCTTTGTAGGA e-e-e-d -k-k-k 35
(10) 701
1115 1130 528486 GGGTCCCCTTTGTAGG e-e-e-d -k-k-k 31
(10)
1129 1144 528487 GGTGCTGTACAATGGG e-e-e-d -k-k-k 61
(10) 703
1130 1145 528488 CGGTGCTGTACAATGG e-e-e-d -k-k-k 61
(10) 704
1131 1146 528489 CCGGTGCTGTACAATG e-e-e-d -k-k-k 37
(10) 705
1132 1147 528490 GCCGGTGCTGTACAAT e-e-e-d -k-k-k 33
(10)
1133 1148 528491 GGCCGGTGCTGTACAA e-e-e-d -k-k-k 39
(10) 707
1134 1149 528492 CGGCCGGTGCTGTACA e-e-e-d -k-k-k 38
(10)
1136 1151 528493 ATCGGCCGGTGCTGTA e-e-e-d -k-k-k 29
(10) 709
1137 1152 528494 CATCGGCCGGTGCTGT e-e-e-d -k-k-k 43
(10) 710
1138 1153 528495 GCATCGGCCGGTGCTG e-e-e-d -k-k-k 41
(10) 711
1139 1154 528496 AGCATCGGCCGGTGCT e-e-e-d -k-k-k 18
(10)
1140 1155 528497 CAGCATCGGCCGGTGC e-e-e-d -k-k-k 15
(10) 713
1141 1156 528498 CCAGCATCGGCCGGTG e-e-e-d -k-k-k 39
(10)
BIOL0142WO
1142 1157 528499 TCCAGCATCGGCCGGT e-e-e-d -k-k-k 50
(10)
1144 1159 528500 CCTCCAGCATCGGCCG e-e-e-d -k-k-k 58
(10) 716
1146 1161 528501 CTCCTCCAGCATCGGC e-e-e-d -k-k-k 67
(10)
1147 1162 528502 TCTCCTCCAGCATCGG e-e-e-d -k-k-k 76
(10) 718
1153 1168 528503 CGATTCTCTCCTCCAG e-e-e-d -k-k-k 68
(10) 719
1154 1169 528504 ACGATTCTCTCCTCCA e-e-e-d -k-k-k 69
(10) 720
1155 1170 528505 CACGATTCTCTCCTCC e-e-e-d -k-k-k 68
(10)
1156 1171 528506 CCACGATTCTCTCCTC e-e-e-d -k-k-k 45
(10) 722
1157 1172 528507 TCCACGATTCTCTCCT e-e-e-d -k-k-k 42
(10)
1158 1173 528508 CTCCACGATTCTCTCC e-e-e-d -k-k-k 41
(10) 724
1159 1174 528509 GCTCCACGATTCTCTC e-e-e-d -k-k-k 32
(10) 725
1160 1175 528510 AGCTCCACGATTCTCT e-e-e-d -k-k-k 7
(10) 726
1161 1176 528511 CAGCTCCACGATTCTC e-e-e-d -k-k-k 5
(10)
1162 1177 528512 ACAGCTCCACGATTCT e-e-e-d -k-k-k 0
(10) 728
1163 1178 528513 AACAGCTCCACGATTC e-e-e-d -k-k-k 8
(10)
1184 1199 528514 GCACTTTTCATTAAGT e-e-e-d -k-k-k 14
(10) 730
1185 1200 528515 GGCACTTTTCATTAAG e-e-e-d -k-k-k 15
(10) 731
1199 1214 528516 CGCTCCACCACAAAGG e-e-e-d -k-k-k 46
(10) 732
1205 1220 528517 GGCTGCCGCTCCACCA e-e-e-d -k-k-k 55
(10)
1206 1221 528518 GGGCTGCCGCTCCACC e-e-e-d -k-k-k 80
(10) 734
1207 1222 528519 AGGGCTGCCGCTCCAC e-e-e-d -k-k-k 61
(10)
1208 1223 528520 CAGGGCTGCCGCTCCA e-e-e-d -k-k-k 63
(10) 736
1211 1226 528521 ATGCAGGGCTGCCGCT e-e-e-d -k-k-k 37
(10) 737
1212 1227 528522 CATGCAGGGCTGCCGC e-e-e-d -k-k-k 38
(10) 738
1221 1236 528523 ATGCATGGGCATGCAG e-e-e-d -k-k-k 26
(10)
1222 1237 528524 GATGCATGGGCATGCA e-e-e-d -k-k-k 42
(10) 740
1223 1238 528525 GGATGCATGGGCATGC e-e-e-d -k-k-k 43
(10)
1252 1267 528526 CGCCGGTCTTGATGAC e-e-e-d -k-k-k 11
(10) 742
1253 1268 528527 ACGCCGGTCTTGATGA e-e-e-d -k-k-k 0
(10) 743
1265 1280 528528 GTAGTGAACTGGACGC e-e-e-d -k-k-k 10
(10) 744
1284 1299 528529 GACCAGCAACCTGACT e-e-e-d -k-k-k 22
(10)
1285 1300 528530 TGACCAGCAACCTGAC e-e-e-d -k-k-k 31
(10) 746
1288 1303 528531 ATTTGACCAGCAACCT e-e-e-d -k-k-k 48
(10)
1289 1304 528532 AATTTGACCAGCAACC e-e-e-d -k-k-k 22
(10) 748
1290 1305 528533 GAATTTGACCAGCAAC e-e-e-d -k-k-k 11
(10) 749
1293 1308 528534 AGGGAATTTGACCAGC e-e-e-d -k-k-k 67
(10) 750
1294 1309 528535 CAGGGAATTTGACCAG e-e-e-d -k-k-k 50
(10)
1295 1310 528536 TCAGGGAATTTGACCA e-e-e-d -k-k-k 38
(10) 752
1296 1311 528537 CTCAGGGAATTTGACC e-e-e-d -k-k-k 17
(10)
1336 1351 528539 CTTTGTCAATGCACAC e-e-e-d -k-k-k 67
(10) 754
1338 1353 528540 GTCTTTGTCAATGCAC e-e-e-d -k-k-k 61
(10) 755
1339 1354 528541 AGTCTTTGTCAATGCA e-e-e-d -k-k-k 65
(10) 756
1343 1358 528542 CCAGAGTCTTTGTCAA e-e-e-d -k-k-k 10
(10)
1345 1360 528543 CCCCAGAGTCTTTGTC e-e-e-d -k-k-k 7
(10) 758
1371 1386 528544 CCGGGATCCTCTGAGA e-e-e-d -k-k-k 12
(10)
BIOL0142WO
1372 1387 528545 TCCGGGATCCTCTGAG e-e-e-d -k-k-k 11
(10)
1373 1388 528546 TTCCGGGATCCTCTGA e-e-e-d -k-k-k 7
(10) 761
1374 1389 528547 TTTCCGGGATCCTCTG e-e-e-d -k-k-k 14
(10)
1375 1390 528548 ATTTCCGGGATCCTCT e-e-e-d -k-k-k 14
(10) 763
1376 1391 528549 AATTTCCGGGATCCTC e-e-e-d -k-k-k 19
(10) 764
1377 1392 528550 AAATTTCCGGGATCCT e-e-e-d -k-k-k 14
(10) 765
1379 1394 528551 TTAAATTTCCGGGATC e-e-e-d -k-k-k 1
(10)
1380 1395 528552 GTTAAATTTCCGGGAT e-e-e-d -k-k-k 9
(10) 767
1381 1396 528553 TGTTAAATTTCCGGGA e-e-e-d -k-k-k 0
(10)
1382 1397 528554 ATGTTAAATTTCCGGG e-e-e-d -k-k-k 12
(10) 769
1384 1399 528555 GAATGTTAAATTTCCG e-e-e-d -k-k-k 13
(10) 770
1392 1407 528556 TGTGCCCAGAATGTTA e-e-e-d -k-k-k 18
(10) 771
1435 1450 528557 GGCTGCCGTTGTTGGA e-e-e-d -k-k-k 48
(10)
1436 1451 528558 AGGCTGCCGTTGTTGG e-e-e-d -k-k-k 38
(10) 773
1437 1452 528559 GAGGCTGCCGTTGTTG e-e-e-d -k-k-k 24 98
(10)
1438 1453 528560 AGAGGCTGCCGTTGTT e-e-e-d -k-k-k 27
(10) 774
1439 1454 528561 GAGAGGCTGCCGTTGT e-e-e-d -k-k-k 10
(10) 775
1440 1455 528562 AGAGAGGCTGCCGTTG e-e-e-d -k-k-k 17
(10) 776
1441 1456 528563 CAGAGAGGCTGCCGTT e-e-e-d -k-k-k 27
(10)
1461 1476 528564 GGTCAAGTGTTTGAAT e-e-e-d -k-k-k 7
(10) 778
1471 1486 528565 GCTCCCTCAGGGTCAA e-e-e-d -k-k-k 48
(10)
1496 1511 528566 GCTCGGCCCCCATTCC e-e-e-d -k-k-k 42
(10) 780
1497 1512 528567 GGCTCGGCCCCCATTC e-e-e-d -k-k-k 45
(10) 781
1498 1513 528568 TGGCTCGGCCCCCATT e-e-e-d -k-k-k 34
(10) 782
1499 1514 528569 TTGGCTCGGCCCCCAT e-e-e-d -k-k-k 49
(10)
1517 1532 528570 ATCAGGGAAGCATCAC e-e-e-d -k-k-k 22
(10) 104
1519 1534 528571 CAATCAGGGAAGCATC e-e-e-d -k-k-k 13
(10)
1523 1538 528572 GTCACAATCAGGGAAG e-e-e-d -k-k-k 30
(10) 785
1525 1540 528573 CAGTCACAATCAGGGA e-e-e-d -k-k-k 27
(10) 786
1526 1541 528574 TCAGTCACAATCAGGG e-e-e-d -k-k-k 51
(10) 787
1529 1544 528575 TCCTCAGTCACAATCA e-e-e-d -k-k-k 14
(10)
1537 1552 528576 GGTGCAGCTCCTCAGT e-e-e-d -k-k-k 28
(10) 789
1543 1558 528577 TGATCAGGTGCAGCTC e-e-e-d -k-k-k 30
(10)
1544 1559 528578 GTGATCAGGTGCAGCT e-e-e-d -k-k-k 36
(10) 791
1545 1560 528579 GGTGATCAGGTGCAGC e-e-e-d -k-k-k 39
(10) 792
1576 1591 528580 TGAGGCCTTGGTGATA e-e-e-d -k-k-k 10
(10) 793
1578 1593 528581 CTTGAGGCCTTGGTGA e-e-e-d -k-k-k 5
(10)
1579 1594 528582 TCTTGAGGCCTTGGTG e-e-e-d -k-k-k 15
(10) 110
1580 1595 528583 ATCTTGAGGCCTTGGT e-e-e-d -k-k-k 5
(10)
1581 1596 528584 AATCTTGAGGCCTTGG e-e-e-d -k-k-k 15
(10) 796
1582 1597 528585 CAATCTTGAGGCCTTG e-e-e-d -k-k-k 7
(10) 797
1583 1598 528586 TCAATCTTGAGGCCTT e-e-e-d -k-k-k 9
(10) 798
1584 1599 528587 GTCAATCTTGAGGCCT e-e-e-d -k-k-k 25
(10)
1585 1600 528588 GGTCAATCTTGAGGCC e-e-e-d -k-k-k 26
(10) 800
1586 1601 528589 AGGTCAATCTTGAGGC e-e-e-d -k-k-k 31
(10)
BIOL0142WO
1587 1602 528590 TAGGTCAATCTTGAGG e-e-e-d -k-k-k 27
(10)
1588 1603 528591 CTAGGTCAATCTTGAG e-e-e-d -k-k-k 24
(10) 803
1590 1605 528592 CTCTAGGTCAATCTTG e-e-e-d -k-k-k 33
(10)
1592 1607 528593 GTCTCTAGGTCAATCT e-e-e-d -k-k-k 30
(10) 805
1594 1609 528594 GGGTCTCTAGGTCAAT e-e-e-d -k-k-k 25
(10) 806
1595 1610 528595 TGGGTCTCTAGGTCAA e-e-e-d -k-k-k 28
(10) 807
1596 1611 528596 GTGGGTCTCTAGGTCA e-e-e-d -k-k-k 34
(10)
1597 1612 528597 AGTGGGTCTCTAGGTC e-e-e-d -k-k-k 19
(10) 809
1599 1614 528598 GGAGTGGGTCTCTAGG e-e-e-d -k-k-k 31
(10)
1600 1615 528599 AGGAGTGGGTCTCTAG e-e-e-d -k-k-k 10
(10) 810
1601 1616 528600 AAGGAGTGGGTCTCTA e-e-e-d -k-k-k 14
(10) 811
1602 1617 528601 CAAGGAGTGGGTCTCT e-e-e-d -k-k-k 11
(10) 812
1609 1624 528602 CAACTGGCAAGGAGTG e-e-e-d -k-k-k 17
(10)
1629 1644 528603 ACAGATGTTGGAGATC e-e-e-d -k-k-k 8
(10) 814
1632 1647 528604 CTGACAGATGTTGGAG e-e-e-d -k-k-k 11
(10)
1633 1648 528605 TCTGACAGATGTTGGA e-e-e-d -k-k-k 25 119
(10)
1650 1665 528606 CGCCCAGGCATTTGGC e-e-e-d -k-k-k 18
(10) 816
1651 1666 528607 ACGCCCAGGCATTTGG e-e-e-d -k-k-k 36
(10) 817
1677 1692 528608 GGTCAGCATGTTGTAC e-e-e-d -k-k-k 11
(10)
1678 1693 528609 TGGTCAGCATGTTGTA e-e-e-d -k-k-k 9
(10) 819
1680 1695 528610 GTTGGTCAGCATGTTG e-e-e-d -k-k-k 19
(10)
1682 1697 528611 TTGTTGGTCAGCATGT e-e-e-d -k-k-k 27
(10) 821
1711 1726 528612 GCTTGGTAAAAAAGTT e-e-e-d -k-k-k 0
(10) 822
1712 1727 528613 GGCTTGGTAAAAAAGT e-e-e-d -k-k-k 0
(10) 823
1713 1728 528614 GGGCTTGGTAAAAAAG e-e-e-d -k-k-k 0
(10)
1736 1751 528615 ACTTGATCCCAGGTTC e-e-e-d -k-k-k 26
(10) 825
1741 1756 528616 CGGCCACTTGATCCCA e-e-e-d -k-k-k 41
(10)
1742 1757 528617 TCGGCCACTTGATCCC e-e-e-d -k-k-k 40
(10) 827
1743 1758 528618 CTCGGCCACTTGATCC e-e-e-d -k-k-k 27
(10) 828
1744 1759 528619 CCTCGGCCACTTGATC e-e-e-d -k-k-k 10
(10) 829
1745 1760 528620 ACCTCGGCCACTTGAT e-e-e-d -k-k-k 16
(10)
1746 1761 528621 GACCTCGGCCACTTGA e-e-e-d -k-k-k 31
(10) 831
1747 1762 528622 GGACCTCGGCCACTTG e-e-e-d -k-k-k 59
(10)
1748 1763 528623 AGGACCTCGGCCACTT e-e-e-d -k-k-k 49
(10) 833
1749 1764 528624 CAGGACCTCGGCCACT e-e-e-d -k-k-k 32
(10) 834
1753 1768 528625 AGCTCAGGACCTCGGC e-e-e-d -k-k-k 28
(10) 835
1754 1769 528626 CAGCTCAGGACCTCGG e-e-e-d -k-k-k 58
(10)
1755 1770 528627 CCAGCTCAGGACCTCG e-e-e-d -k-k-k 56
(10) 837
1778 1793 528628 CGCTTGGTGGTGGAGG e-e-e-d -k-k-k 15
(10)
1779 1794 528629 TCGCTTGGTGGTGGAG e-e-e-d -k-k-k 9
(10) 839
1780 1795 528630 CTCGCTTGGTGGTGGA e-e-e-d -k-k-k 14
(10) 127
1781 1796 528631 CCTCGCTTGGTGGTGG e-e-e-d -k-k-k 26
(10) 840
1782 1797 528632 TCCTCGCTTGGTGGTG e-e-e-d -k-k-k 24
(10)
1783 1798 528633 GTCCTCGCTTGGTGGT e-e-e-d -k-k-k 40
(10) 842
1784 1799 528634 AGTCCTCGCTTGGTGG e-e-e-d -k-k-k 38
(10)
BIOL0142WO
1785 1800 528635 CAGTCCTCGCTTGGTG e-e-e-d -k-k-k 20
(10)
1786 1801 528636 TCAGTCCTCGCTTGGT e-e-e-d -k-k-k 23
(10) 845
1787 1802 528637 CTCAGTCCTCGCTTGG e-e-e-d -k-k-k 33
(10)
1788 1803 528638 GCTCAGTCCTCGCTTG e-e-e-d -k-k-k 15
(10) 847
1789 1804 528639 TGCTCAGTCCTCGCTT e-e-e-d -k-k-k 15
(10) 848
1791 1806 528640 GATGCTCAGTCCTCGC e-e-e-d -k-k-k 43
(10) 849
1792 1807 528641 CGATGCTCAGTCCTCG e-e-e-d -k-k-k 46
(10)
1793 1808 528642 TCGATGCTCAGTCCTC e-e-e-d -k-k-k 39
(10) 851
1794 1809 528643 CTCGATGCTCAGTCCT e-e-e-d -k-k-k 32
(10)
1795 1810 528644 GCTCGATGCTCAGTCC e-e-e-d -k-k-k 43
(10) 129
1796 1811 528645 TGCTCGATGCTCAGTC e-e-e-d -k-k-k 22
(10) 853
1797 1812 528646 CTGCTCGATGCTCAGT e-e-e-d -k-k-k 38
(10) 854
1799 1814 528647 AGCTGCTCGATGCTCA e-e-e-d -k-k-k 40
(10)
1800 1815 528648 CAGCTGCTCGATGCTC e-e-e-d -k-k-k 39
(10) 856
1802 1817 528649 GTCAGCTGCTCGATGC e-e-e-d -k-k-k 32
(10)
1803 1818 528650 AGTCAGCTGCTCGATG e-e-e-d -k-k-k 10
(10) 858
1804 1819 528651 TAGTCAGCTGCTCGAT e-e-e-d -k-k-k 4
(10) 859
1805 1820 528652 GTAGTCAGCTGCTCGA e-e-e-d -k-k-k 17
(10) 860
1806 1821 528653 TGTAGTCAGCTGCTCG e-e-e-d -k-k-k 28
(10)
1807 1822 528654 GTGTAGTCAGCTGCTC e-e-e-d -k-k-k 31
(10) 862
1808 1823 528655 AGTGTAGTCAGCTGCT e-e-e-d -k-k-k 30
(10)
1809 1824 528656 CAGTGTAGTCAGCTGC e-e-e-d -k-k-k 30
(10) 864
1810 1825 528657 CCAGTGTAGTCAGCTG e-e-e-d -k-k-k 23
(10) 865
1811 1826 528658 GCCAGTGTAGTCAGCT e-e-e-d -k-k-k 30
(10) 866
1832 1847 528659 CCAGGTCCCAAGAGTT e-e-e-d -k-k-k 12
(10)
1852 1867 528660 GACACCCTGAATAATT e-e-e-d -k-k-k 10
(10) 868
1853 1868 528661 TGACACCCTGAATAAT e-e-e-d -k-k-k 10
(10)
1856 1871 528662 ATCTGACACCCTGAAT e-e-e-d -k-k-k 12
(10) 870
1857 1872 528663 GATCTGACACCCTGAA e-e-e-d -k-k-k 22
(10) 871
1859 1874 528664 GTGATCTGACACCCTG e-e-e-d -k-k-k 61
(10) 872
1861 1876 528665 ATGTGATCTGACACCC e-e-e-d -k-k-k 36
(10)
1865 1880 528666 GCCCATGTGATCTGAC e-e-e-d -k-k-k 46
(10) 874
1866 1881 528667 AGCCCATGTGATCTGA e-e-e-d -k-k-k 36
(10)
1867 1882 528668 TAGCCCATGTGATCTG e-e-e-d -k-k-k 44
(10) 875
1869 1884 528669 TTTAGCCCATGTGATC e-e-e-d -k-k-k 12
(10) 876
1907 1922 528670 AAGGAGAAGCCCTTGC e-e-e-d -k-k-k 35
(10) 877
1925 1940 528671 TTGTCCAGCCAGACCC e-e-e-d -k-k-k 40
(10)
1926 1941 528672 ATTGTCCAGCCAGACC e-e-e-d -k-k-k 36
(10) 879
1927 1942 528673 TATTGTCCAGCCAGAC e-e-e-d -k-k-k 23
(10)
1928 1943 528674 ATATTGTCCAGCCAGA e-e-e-d -k-k-k 24
(10) 881
1929 1944 528675 GATATTGTCCAGCCAG e-e-e-d -k-k-k 52
(10) 882
1931 1946 528676 ATGATATTGTCCAGCC e-e-e-d -k-k-k 41
(10) 883
1933 1948 528677 CAATGATATTGTCCAG e-e-e-d -k-k-k 23
(10)
1935 1950 528678 GTCAATGATATTGTCC e-e-e-d -k-k-k 32
(10) 885
1936 1951 528679 GGTCAATGATATTGTC e-e-e-d -k-k-k 26
(10)
BIOL0142WO
1941 1956 528680 CACAAGGTCAATGATA e-e-e-d -k-k-k 5
(10)
1942 1957 528681 TCACAAGGTCAATGAT e-e-e-d -k-k-k 9
(10) 888
1948 1963 518340 ACTTTTTCACAAGGTC e-e-e-d -k-k-k 52
(10)
1950 1965 528682 GTACTTTTTCACAAGG e-e-e-d -k-k-k 21
(10) 889
1954 1969 528683 GGATGTACTTTTTCAC e-e-e-d -k-k-k 0
(10) 890
1958 1973 528684 GCCAGGATGTACTTTT e-e-e-d -k-k-k 0
(10) 891
1962 1977 528685 AAGGGCCAGGATGTAC e-e-e-d -k-k-k 0
(10)
1963 1978 528686 AAAGGGCCAGGATGTA e-e-e-d -k-k-k 0
(10) 893
2004 2019 528687 CCGCTCCTTACTGATA e-e-e-d -k-k-k 21
(10)
2010 2025 528688 CCGCTCCCGCTCCTTA e-e-e-d -k-k-k 32
(10) 895
2014 2029 528689 TGGCCCGCTCCCGCTC e-e-e-d -k-k-k 52
(10) 896
2015 2030 528690 ATGGCCCGCTCCCGCT e-e-e-d -k-k-k 41
(10) 897
2017 2032 528691 AGATGGCCCGCTCCCG e-e-e-d -k-k-k 51
(10)
2018 2033 528692 AAGATGGCCCGCTCCC e-e-e-d -k-k-k 45
(10) 899
2019 2034 528693 CAAGATGGCCCGCTCC e-e-e-d -k-k-k 46
(10)
2020 2035 528694 TCAAGATGGCCCGCTC e-e-e-d -k-k-k 27
(10) 901
2022 2037 528695 GCTCAAGATGGCCCGC e-e-e-d -k-k-k 54
(10) 902
2023 2038 528696 TGCTCAAGATGGCCCG e-e-e-d -k-k-k 46
(10) 903
2024 2039 528697 GTGCTCAAGATGGCCC e-e-e-d -k-k-k 60
(10)
2041 2056 528698 AGGTGCCTGGAGGCTT e-e-e-d -k-k-k 17
(10) 905
2093 2108 528699 CAAGTGAAAGTGACGC e-e-e-d -k-k-k 2
(10)
2094 2109 528700 CCAAGTGAAAGTGACG e-e-e-d -k-k-k 13
(10) 906
2095 2110 528701 CCCAAGTGAAAGTGAC e-e-e-d -k-k-k 14
(10) 907
2128 2143 528702 GGATCTGGGTCTTACC e-e-e-d -k-k-k 22
(10) 908
2129 2144 528703 TGGATCTGGGTCTTAC e-e-e-d -k-k-k 22
(10)
2131 2146 528704 ACTGGATCTGGGTCTT e-e-e-d -k-k-k 21 165
(10)
2133 2148 528705 GGACTGGATCTGGGTC e-e-e-d -k-k-k 38
(10)
2138 2153 528706 TCCACGGACTGGATCT e-e-e-d -k-k-k 13
(10) 911
2139 2154 528707 TTCCACGGACTGGATC e-e-e-d -k-k-k 19
(10) 912
2140 2155 528708 GTTCCACGGACTGGAT e-e-e-d -k-k-k 2
(10) 913
2141 2156 528709 GGTTCCACGGACTGGA e-e-e-d -k-k-k 42
(10)
2142 2157 528710 TGGTTCCACGGACTGG e-e-e-d -k-k-k 63
(10) 915
2143 2158 528711 ATGGTTCCACGGACTG e-e-e-d -k-k-k 62
(10)
2144 2159 528712 TATGGTTCCACGGACT e-e-e-d -k-k-k 35
(10) 917
2146 2161 528713 TGTATGGTTCCACGGA e-e-e-d -k-k-k 40
(10) 918
2147 2162 528714 GTGTATGGTTCCACGG e-e-e-d -k-k-k 48
(10) 919
2193 2208 528715 GCCCATGATGATTTCA e-e-e-d -k-k-k 36
(10)
2194 2209 528716 AGCCCATGATGATTTC e-e-e-d -k-k-k 25
(10) 921
2195 2210 528717 TAGCCCATGATGATTT e-e-e-d -k-k-k 27
(10)
2196 2211 528718 ATAGCCCATGATGATT e-e-e-d -k-k-k 19
(10) 923
2197 2212 528719 TATAGCCCATGATGAT e-e-e-d -k-k-k 14
(10) 924
2198 2213 528720 TTATAGCCCATGATGA e-e-e-d -k-k-k 14
(10) 925
2199 2214 528721 CTTATAGCCCATGATG e-e-e-d -k-k-k 21
(10)
2200 2215 528722 TCTTATAGCCCATGAT e-e-e-d -k-k-k 0
(10) 927
2201 2216 528723 ATCTTATAGCCCATGA e-e-e-d -k-k-k 17
(10)
BIOL0142WO
2202 2217 528724 GATCTTATAGCCCATG e-e-e-d -k-k-k 35
(10)
2203 2218 528725 TGATCTTATAGCCCAT e-e-e-d -k-k-k 45
(10) 930
2204 2219 528726 ATGATCTTATAGCCCA e-e-e-d -k-k-k 67
(10)
2205 2220 528727 CATGATCTTATAGCCC e-e-e-d -k-k-k 45
(10) 932
2206 2221 528728 CCATGATCTTATAGCC e-e-e-d -k-k-k 38 175
(10)
2207 2222 528729 TCCATGATCTTATAGC e-e-e-d -k-k-k 0
(10) 933
2208 2223 528730 ATCCATGATCTTATAG e-e-e-d -k-k-k 12
(10)
2213 2228 528731 GTAGCATCCATGATCT e-e-e-d -k-k-k 14
(10) 935
2214 2229 528732 GGTAGCATCCATGATC e-e-e-d -k-k-k 25
(10)
2217 2232 528733 ATTGGTAGCATCCATG e-e-e-d -k-k-k 22
(10) 937
2218 2233 528734 TATTGGTAGCATCCAT e-e-e-d -k-k-k 15
(10) 938
2219 2234 528735 ATATTGGTAGCATCCA e-e-e-d -k-k-k 28
(10) 939
2264 2279 528736 TCCTTGGGAATGTCAG e-e-e-d -k-k-k 30
(10)
2266 2281 528737 CCTCCTTGGGAATGTC e-e-e-d -k-k-k 30 181
(10)
2275 2290 528738 CGAATGCCTCCTCCTT e-e-e-d -k-k-k 29 186
(10)
2277 2292 528739 TCCGAATGCCTCCTCC e-e-e-d -k-k-k 33
(10) 941
2278 2293 528740 TTCCGAATGCCTCCTC e-e-e-d -k-k-k 27
(10) 942
2279 2294 528741 TTTCCGAATGCCTCCT e-e-e-d -k-k-k 20
(10) 943
2280 2295 528742 CTTTCCGAATGCCTCC e-e-e-d -k-k-k 25
(10)
2281 2296 528743 ACTTTCCGAATGCCTC e-e-e-d -k-k-k 39
(10) 945
2283 2298 528744 ATACTTTCCGAATGCC e-e-e-d -k-k-k 44
(10)
2285 2300 528745 CAATACTTTCCGAATG e-e-e-d -k-k-k 0
(10) 947
2286 2301 528746 ACAATACTTTCCGAAT e-e-e-d -k-k-k 0
(10) 948
2288 2303 528747 CGACAATACTTTCCGA e-e-e-d -k-k-k 11
(10) 949
2289 2304 528748 CCGACAATACTTTCCG e-e-e-d -k-k-k 31
(10)
2290 2305 528749 GCCGACAATACTTTCC e-e-e-d -k-k-k 18
(10) 951
2291 2306 528750 GGCCGACAATACTTTC e-e-e-d -k-k-k 16
(10)
2293 2308 528751 CTGGCCGACAATACTT e-e-e-d -k-k-k 18
(10) 953
2294 2309 528752 TCTGGCCGACAATACT e-e-e-d -k-k-k 8
(10) 954
2295 2310 528753 CTCTGGCCGACAATAC e-e-e-d -k-k-k 0
(10) 955
2296 2311 528754 TCTCTGGCCGACAATA e-e-e-d -k-k-k 6 188
(10)
2297 2312 528755 CTCTCTGGCCGACAAT e-e-e-d -k-k-k 18
(10) 956
2298 2313 528756 GCTCTCTGGCCGACAA e-e-e-d -k-k-k 35
(10)
2299 2314 528757 GGCTCTCTGGCCGACA e-e-e-d -k-k-k 57
(10) 958
2300 2315 528758 TGGCTCTCTGGCCGAC e-e-e-d -k-k-k 64
(10) 959
2301 2316 528759 CTGGCTCTCTGGCCGA e-e-e-d -k-k-k 12
(10) 960
2326 2341 528760 TACCTGGGTCAGCTTC e-e-e-d -k-k-k 21
(10)
2328 2343 528761 GCTACCTGGGTCAGCT e-e-e-d -k-k-k 18
(10) 962
2329 2344 528762 CGCTACCTGGGTCAGC e-e-e-d -k-k-k 28
(10)
2330 2345 528763 GCGCTACCTGGGTCAG e-e-e-d -k-k-k 26
(10) 964
2349 2364 528764 GGTCTTCAGGTATGGG e-e-e-d -k-k-k 38
(10) 965
2350 2365 528765 TGGTCTTCAGGTATGG e-e-e-d -k-k-k 12
(10) 966
2352 2367 528766 CTTGGTCTTCAGGTAT e-e-e-d -k-k-k 0
(10)
2353 2368 528767 ACTTGGTCTTCAGGTA e-e-e-d -k-k-k 10 190
(10)
2358 2373 528768 GATAAACTTGGTCTTC e-e-e-d -k-k-k 9
(10)
BIOL0142WO
2360 2375 528769 CAGATAAACTTGGTCT e-e-e-d -k-k-k 15
(10)
2361 2376 528770 ACAGATAAACTTGGTC e-e-e-d -k-k-k 7
(10) 970
2369 2384 528771 GGTGTCACACAGATAA e-e-e-d -k-k-k 35
(10)
2373 2388 528772 CGTTGGTGTCACACAG e-e-e-d -k-k-k 52
(10) 972
2387 2402 528773 GTATTGCTGCAGGTCG e-e-e-d -k-k-k 49 194
(10)
2388 2403 528774 GGTATTGCTGCAGGTC e-e-e-d -k-k-k 48
(10) 973
2389 2404 528775 TGGTATTGCTGCAGGT e-e-e-d -k-k-k 35
(10)
2390 2405 528776 ATGGTATTGCTGCAGG e-e-e-d -k-k-k 20
(10) 975
2392 2407 528777 CAATGGTATTGCTGCA e-e-e-d -k-k-k 24
(10)
2393 2408 528778 TCAATGGTATTGCTGC e-e-e-d -k-k-k 15
(10) 977
2394 2409 528779 GTCAATGGTATTGCTG e-e-e-d -k-k-k 16
(10) 978
2395 2410 528780 GGTCAATGGTATTGCT e-e-e-d -k-k-k 34 196
(10)
2396 2411 528781 AGGTCAATGGTATTGC e-e-e-d -k-k-k 26
(10)
2397 2412 528782 CAGGTCAATGGTATTG e-e-e-d -k-k-k 16
(10) 980
2398 2413 528783 GCAGGTCAATGGTATT e-e-e-d -k-k-k 10
(10)
2399 2414 528784 GGCAGGTCAATGGTAT e-e-e-d -k-k-k 32
(10) 982
2400 2415 528785 CGGCAGGTCAATGGTA e-e-e-d -k-k-k 39
(10) 983
2401 2416 528786 TCGGCAGGTCAATGGT e-e-e-d -k-k-k 51
(10) 984
2403 2418 528787 CATCGGCAGGTCAATG e-e-e-d -k-k-k 26 198
(10)
2404 2419 528788 ACATCGGCAGGTCAAT e-e-e-d -k-k-k 20
(10) 985
2405 2420 528789 GACATCGGCAGGTCAA e-e-e-d -k-k-k 42
(10)
2406 2421 528790 GGACATCGGCAGGTCA e-e-e-d -k-k-k 58
(10) 987
2407 2422 528791 GGGACATCGGCAGGTC e-e-e-d -k-k-k 68
(10) 988
2423 2438 528792 GAATCTAAAGTGCGGG e-e-e-d -k-k-k 46 200
(10)
2424 2439 528793 TGAATCTAAAGTGCGG e-e-e-d -k-k-k 43
(10)
2427 2442 528794 CAATGAATCTAAAGTG e-e-e-d -k-k-k 20
(10) 990
2462 2477 528795 GGTTCAGCACCTTCAC e-e-e-d -k-k-k 13
(10)
2463 2478 528796 GGGTTCAGCACCTTCA e-e-e-d -k-k-k 24
(10) 992
2464 2479 528797 AGGGTTCAGCACCTTC e-e-e-d -k-k-k 23
(10) 993
2465 2480 528798 GAGGGTTCAGCACCTT e-e-e-d -k-k-k 18
(10) 994
2466 2481 528799 TGAGGGTTCAGCACCT e-e-e-d -k-k-k 24
(10)
2490 2505 528800 GAGGGACTCAAACTGC e-e-e-d -k-k-k 28
(10) 996
2492 2507 528801 GTGAGGGACTCAAACT e-e-e-d -k-k-k 22
(10)
2493 2508 528802 GGTGAGGGACTCAAAC e-e-e-d -k-k-k 20
(10) 998
2494 2509 528803 AGGTGAGGGACTCAAA e-e-e-d -k-k-k 13
(10) 999
2495 2510 528804 AAGGTGAGGGACTCAA e-e-e-d -k-k-k 20
(10) 1000
2497 2512 528805 CAAAGGTGAGGGACTC e-e-e-d -k-k-k 20
1001
(10)
2498 2513 528806 TCAAAGGTGAGGGACT e-e-e-d -k-k-k 18
(10) 1002
2506 2521 528807 ACTCCATGTCAAAGGT e-e-e-d -k-k-k 54
1003
(10)
2510 2525 528808 GTCAACTCCATGTCAA e-e-e-d -k-k-k 39
(10) 1004
2511 2526 528809 GGTCAACTCCATGTCA e-e-e-d -k-k-k 56
(10) 1005
2513 2528 528810 GAGGTCAACTCCATGT e-e-e-d -k-k-k 41
(10) 1006
2514 2529 528811 CGAGGTCAACTCCATG e-e-e-d -k-k-k 45
1007
(10)
2515 2530 528812 CCGAGGTCAACTCCAT e-e-e-d -k-k-k 45
(10) 1008
2517 2532 528813 CTCCGAGGTCAACTCC e-e-e-d -k-k-k 58
1009
(10)
BIOL0142WO
2518 2533 528814 ACTCCGAGGTCAACTC e-e-e-d -k-k-k 40
1010
(10)
2519 2534 528815 CACTCCGAGGTCAACT e-e-e-d -k-k-k 30
(10) 1011
2551 2566 528816 CGTTCTCAGCTCCTCA e-e-e-d -k-k-k 54
1012
(10)
2554 2569 528817 TTCCGTTCTCAGCTCC e-e-e-d -k-k-k 53
(10) 1013
2555 2570 528818 CTTCCGTTCTCAGCTC e-e-e-d -k-k-k 27
(10) 1014
2556 2571 528819 GCTTCCGTTCTCAGCT e-e-e-d -k-k-k 35
(10) 1015
2557 2572 528820 AGCTTCCGTTCTCAGC e-e-e-d -k-k-k 38
1016
(10)
2558 2573 528821 CAGCTTCCGTTCTCAG e-e-e-d -k-k-k 53
(10) 1017
2559 2574 528822 GCAGCTTCCGTTCTCA e-e-e-d -k-k-k 66
1018
(10)
2614 2629 528823 TTTGGCTGTGTGAGGG e-e-e-d -k-k-k 62
(10) 1019
2615 2630 528824 GTTTGGCTGTGTGAGG e-e-e-d -k-k-k 50
(10) 1020
2616 2631 528825 GGTTTGGCTGTGTGAG e-e-e-d -k-k-k 15
(10) 1021
2641 2656 528826 AAGTTAGTAGTTTCAG e-e-e-d -k-k-k 20
1022
(10)
2677 2692 528827 GCAGAAGTAGGAGATT e-e-e-d -k-k-k 28
(10) 1023
2690 2705 528828 TTGCTCAAAGATAGCA e-e-e-d -k-k-k 39
1024
(10)
2691 2706 528829 ATTGCTCAAAGATAGC e-e-e-d -k-k-k 37
(10) 1025
2692 2707 528830 GATTGCTCAAAGATAG e-e-e-d -k-k-k 22
(10) 1026
2694 2709 528831 CAGATTGCTCAAAGAT e-e-e-d -k-k-k 26
(10) 1027
2695 2710 528832 CCAGATTGCTCAAAGA e-e-e-d -k-k-k 41
1028
(10)
2699 2714 528833 GTGCCCAGATTGCTCA e-e-e-d -k-k-k 77
(10) 1029
2738 2753 528834 GCAGATCACCCACATT e-e-e-d -k-k-k 49
1030
(10)
2743 2758 528835 TAAAAGCAGATCACCC e-e-e-d -k-k-k 40
(10) 1031
2809 2824 528836 CTAGCCACCCCCCGCC e-e-e-d -k-k-k 19
(10) 1032
2810 2825 528837 TCTAGCCACCCCCCGC e-e-e-d -k-k-k 9
(10) 1033
2811 2826 528838 CTCTAGCCACCCCCCG e-e-e-d -k-k-k 16
1034
(10)
2908 2923 528839 GGAGGCACTTGTCTAA e-e-e-d -k-k-k 56 235
(10)
2909 2924 528840 AGGAGGCACTTGTCTA e-e-e-d -k-k-k 62
1036
(10)
2910 2925 528841 CAGGAGGCACTTGTCT e-e-e-d -k-k-k 52
(10) 1037
2911 2926 528842 CCAGGAGGCACTTGTC e-e-e-d -k-k-k 59
(10) 1038
2932 2947 528843 GGCAGAAGGATGCCGC e-e-e-d -k-k-k 35
(10) 1039
2945 2960 528844 GCTTACAGAAACAGGC e-e-e-d -k-k-k 62
1040
(10)
2980 2995 528845 CAGGAGTATGTAGCTA e-e-e-d -k-k-k 65
(10) 1041
2981 2996 528846 CCAGGAGTATGTAGCT e-e-e-d -k-k-k 80
1042
(10)
2982 2997 528847 GCCAGGAGTATGTAGC e-e-e-d -k-k-k 72
(10) 1043
2983 2998 528848 TGCCAGGAGTATGTAG e-e-e-d -k-k-k 46
(10) 1044
2984 2999 528849 ATGCCAGGAGTATGTA e-e-e-d -k-k-k 59 241
(10)
3001 3016 528850 CAAGGTTAAAAAGTGC e-e-e-d -k-k-k 10 243
(10)
3008 3023 528851 ATGTCAGCAAGGTTAA e-e-e-d -k-k-k 61
(10) 1045
3010 3025 528852 GGATGTCAGCAAGGTT e-e-e-d -k-k-k 88
1046
(10)
3012 3027 528853 TTGGATGTCAGCAAGG e-e-e-d -k-k-k 91
(10) 1047
3016 3031 518349 CTATTTGGATGTCAGC e-e-e-d -k-k-k 85 245
(10)
3030 3045 528854 GATAGTCCTATCTTCT e-e-e-d -k-k-k 42
(10) 1048
3091 3106 528855 ACAGTGTTTTTTGCCC e-e-e-d -k-k-k 59
1049
(10)
3108 3123 528856 AGAAAGGCTATGCTGA e-e-e-d -k-k-k 56
(10) 1050
3452 3467 528857 GAGGCTGTTAACTGAA e-e-e-d -k-k-k 40
1051
(10)
BIOL0142WO
3458 3473 528858 ACCAAGGAGGCTGTTA e-e-e-d -k-k-k 26
1052
(10)
3474 3489 528859 GCTGAATGCTTAAAGC e-e-e-d -k-k-k 36
(10) 1053
4022 4037 518344 GCCACTGGATATCACC e-e-e-d -k-k-k 55 317
(10)
Example 12: Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
Gapmers from the study described in Example 11, above, exhibiting significant in vitro inhibition
of STAT3 were tested at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per
well and transfected using electroporation with 23.4375 nM, 93.75 nM, 375.0 nM, and 1,500.0 nM
concentrations of antisense oligonucleotide, as specified in Table 12. After a treatment period of
approximately 16 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199, described hereinabove, was used
to measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
measured by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 12 and was calculated by plotting the concentrations of oligonucleotides used versus the percent
inhibition of STAT3 mRNA expression achieved at each concentration, and noting the concentration of
oligonucleotide at which 50% inhibition of STAT3 mRNA expression was achieved compared to the
control. As illustrated in Table 12, STAT3 mRNA levels were significantly reduced in a dose-dependent
manner in antisense oligonucleotide treated cells.
Table 12
Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
23.4375 93.75 375.0 1500.0 IC
ISIS No
nM nM nM nM (μM)
518340 0 8 28 63 1.0
518349
13 30 68 90 0.2
528189 8 13 43 71 0.5
528204 4 24 53 79 0.3
528205 0 9 59 80 0.4
528208 0 19 56 84 0.3
528209 0 28 58 90 0.3
528210 0 16 49 87 0.3
528211 0 10 47 86 0.4
528212 0 16 42 83 0.4
528214 0 25 55 88 0.3
528215 3 16 53 82 0.3
528237 13 19 33 73 0.6
528245 3 16 53 78 0.4
528263 0 3 32 76 0.6
528264 9 0 19 50 >1.5
BIOL0142WO
528268 0 7 25 63 1.0
528269 0 11 39 77 0.5
528270 5 9 48 79 0.4
528271 0 14 37 81 0.5
528327 0 0 26 72 0.8
528347 0 2 25 69 0.9
528357 0 17 36 69 0.6
528389 0 3 19 82 0.7
528501 0 17 40 69 0.6
528502 0 10 35 76 0.6
528503 3 1 38 70 0.7
528504 0 19 45 72 0.5
528505 0 7 41 73 0.6
528518 0 24 51 81 0.3
528534 0 8 32 72 0.7
528539 0 7 39 73 0.6
528557 0 9 26 53 >1.5
528565 4 12 31 57 1.3
528567 8 13 25 54 >1.5
528569 9 19 37 60 0.8
528574 5 17 32 62 0.9
528622 10 4 29 68 0.9
528623 0 13 24 62 1.1
528626 1 0 34 68 0.8
528627 22 19 30 64 1.0
528664 0 14 37 74 0.5
528675 0 10 28 62 1.0
528689 0 16 33 65 0.7
528691 0 3 34 61 0.9
528695 1 4 36 66 0.8
528697 3 15 39 72 0.5
528710 13 16 28 63 1.0
528711 8 13 14 62 >1.5
528726 0 8 36 72 0.6
528757 4 10 29 76 0.6
528758 1 5 28 62 1.1
528772 0 2 21 63 1.2
528773 9 8 28 70 0.8
528791 4 9 41 69 0.6
528822 0 0 40 46 >1.5
528833 0 23 47 82 0.4
528846 10 19 49 85 0.3
528847 0 19 45 75 0.4
528852 5 33 66 93 0.2
528853 19 46 77 95 0.1
BIOL0142WO
Example 13: Antisense inhibition of human STAT3 in HuVEC cells
Antisense oligonucleotides were designed targeting a human STAT3 nucleic acid and were
tested for their effect on human STAT3 mRNA expression in vitro. The chimeric antisense
oligonucleotides in Tables 13 and 14 are gapmers16 or 17 nucleotides in length having various chemical
modifications. Each gapmer comprises a central gap segment consisting of nine or ten 2’-
deoxynucleosides and is flanked on both sides (in the 5’ and 3’ directions) by wings comprising 1, 2, 3, 4,
or 5 nucleotides each. Each of the nucleotides in the wings comprise a 2’-MOE sugar modification or a
cEt sugar modification. Gapmer motifs include 33, 43, 24, 15, and 34. The chemistry
column of Tables 13 and 14 provides the sugar motif of each gapmer, wherein ‘e’ indicates a 2’-MOE
nucleoside, ‘k’ indicates a constrained ethyl (cEt) nucleoside, and ‘d’ indicates a 2’- deoxynucleoside.
The internucleoside linkages throughout each gapmer are phosphorothioate (P=S) linkages. All cytosine
residues throughout each gapmer are 5’-methylcytosines.
Potency of the chimeric antisense oligonucleotides was compared to ISIS 481464, ISIS 518344,
and ISIS 518349 (described previously herein).
Cultured HuVEC cells at a density of 20,000 cells per well were transfected using electroporation
with 1,000 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was
isolated from the cells and STAT3 mRNA levels were measured by quantitative real-time PCR. Human
primer probe set RTS199, described hereinabove, was used to measure mRNA levels. STAT3 mRNA
levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are
presented as percent inhibition of STAT3, relative to untreated control cells.
“Human Target start site” indicates the 5’-most nucleoside to which the gapmer is targeted in the
human gene sequence. “Human Target stop site” indicates the 3’-most nucleoside to which the gapmer is
targeted in the human gene sequence. Each gapmer listed in Table 13 is targeted to human STAT3
mRNA, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NM_139276.2). Each gapmer
listed in Table 14 is targeted to human STAT3 genomic sequence, designated herein as SEQ ID NO: 2
(the complement of GENBANK Accession No. NT_010755.14 truncated from nucleotides 4185000 to
4264000).
Table 13
Inhibition of human STAT3 mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID
NO: 1
Human Human
ISIS % SEQ
Start Stop Sequence Chemistry
No inhibition ID NO
Site Site
728 743 530423 AGATTCTCTACCACTT k-d(10)-k-e-k-e-e 70 1054
729 745 530053 GGAGATTCTCTACCACT e-e-k-d(10)-k-e-k-e 84 1055
729 744 530373 GAGATTCTCTACCACT e-k-d(10)-k-e-k-e 85 1056
730 745 530121 GGAGATTCTCTACCAC e-k-k-d(10)-k-k-e 77 53
BIOL0142WO
730 745 530168 GGAGATTCTCTACCAC e-e-k-d(10)-k-k-e 75 53
730 745 530218 GGAGATTCTCTACCAC e-d-k-d(10)-k-k-e 61 53
730 745 530268 GGAGATTCTCTACCAC e-d-d-k-d(9)-k-k-e 76 53
730 745 530318 GGAGATTCTCTACCAC e-e-e-e-d(9)-k-k-e 27 53
786 801 530424 ATCTTGCATGTCTCCT k-d(10)-k-e-k-e-e 42 1057
787 803 530058 AGATCTTGCATGTCTCC e-e-k-d(10)-k-e-k-e 73 1058
787 802 530374 GATCTTGCATGTCTCC e-k-d(10)-k-e-k-e 71 647
788 803 530122 AGATCTTGCATGTCTC e-k-k-d(10)-k-k-e 80 57
788 803 530169 AGATCTTGCATGTCTC e-e-k-d(10)-k-k-e 72 57
788 803 530219 AGATCTTGCATGTCTC e-d-k-d(10)-k-k-e 55 57
788 803 530269 AGATCTTGCATGTCTC e-d-d-k-d(9)-k-k-e 76 57
788 803 530319 AGATCTTGCATGTCTC e-e-e-e-d(9)-k-k-e 30 57
892 907 528400 CCGCCAGCTCACTCAC e-e-e-d(10)-k-k-k 57 66
893 908 528401 CCCGCCAGCTCACTCA e-e-e-d(10)-k-k-k 57 1059
894 909 528402 CCCCGCCAGCTCACTC e-e-e-d(10)-k-k-k 42 1060
897 912 528403 AAGCCCCGCCAGCTCA e-e-e-d(10)-k-k-k 72
1061
898 913 528404 AAAGCCCCGCCAGCTC e-e-e-d(10)-k-k-k 52
1062
899 914 528405 AAAAGCCCCGCCAGCT e-e-e-d(10)-k-k-k 27
1063
900 915 528406 CAAAAGCCCCGCCAGC e-e-e-d(10)-k-k-k 29
1064
901 916 528407 ACAAAAGCCCCGCCAG e-e-e-d(10)-k-k-k 9
1065
903 918 528408 TGACAAAAGCCCCGCC e-e-e-d(10)-k-k-k 10
1066
904 919 528409 CTGACAAAAGCCCCGC e-e-e-d(10)-k-k-k 31
1067
905 920 528410 GCTGACAAAAGCCCCG e-e-e-d(10)-k-k-k 39
1068
906 921 528411 CGCTGACAAAAGCCCC e-e-e-d(10)-k-k-k 49
1069
907 922 528412 TCGCTGACAAAAGCCC e-e-e-d(10)-k-k-k 39
1070
908 923 528413 ATCGCTGACAAAAGCC e-e-e-d(10)-k-k-k 20
1071
909 924 528414 CATCGCTGACAAAAGC e-e-e-d(10)-k-k-k 10
1072
911 926 528415 TCCATCGCTGACAAAA e-e-e-d(10)-k-k-k 11
1073
912 927 528416 CTCCATCGCTGACAAA e-e-e-d(10)-k-k-k 15
1074
913 928 528417 ACTCCATCGCTGACAA e-e-e-d(10)-k-k-k 22
1075
914 929 528418 TACTCCATCGCTGACA e-e-e-d(10)-k-k-k 19
1076
915 930 528419 GTACTCCATCGCTGAC e-e-e-d(10)-k-k-k 37
1077
916 931 528420 CGTACTCCATCGCTGA e-e-e-d(10)-k-k-k 35
1078
930 945 528421 GAGAGTTTTCTGCACG e-e-e-d(10)-k-k-k 36
1079
932 947 528422 GTGAGAGTTTTCTGCA e-e-e-d(10)-k-k-k 22
1080
951 966 528423 GTCAGCCAGCTCCTCG e-e-e-d(10)-k-k-k 49
1081
962 977 528424 CGCCTCTTCCAGTCAG e-e-e-d(10)-k-k-k 42
1082
964 979 528425 GCCGCCTCTTCCAGTC e-e-e-d(10)-k-k-k 44
1083
965 980 528426 TGCCGCCTCTTCCAGT e-e-e-d(10)-k-k-k 15
1084
970 985 528427 TCTGTTGCCGCCTCTT e-e-e-d(10)-k-k-k 9
1085
971 986 528428 ATCTGTTGCCGCCTCT e-e-e-d(10)-k-k-k 30
1086
972 987 528429 AATCTGTTGCCGCCTC e-e-e-d(10)-k-k-k 23
1087
973 988 528430 CAATCTGTTGCCGCCT e-e-e-d(10)-k-k-k 12
1088
974 989 528431 GCAATCTGTTGCCGCC e-e-e-d(10)-k-k-k 48
1089
975 990 528432 GGCAATCTGTTGCCGC e-e-e-d(10)-k-k-k 18
1090
BIOL0142WO
976 991 528433 AGGCAATCTGTTGCCG e-e-e-d(10)-k-k-k 0
1091
977 992 528434 CAGGCAATCTGTTGCC e-e-e-d(10)-k-k-k 8
1092
978 993 528435 GCAGGCAATCTGTTGC e-e-e-d(10)-k-k-k 13
1093
982 997 528436 CAATGCAGGCAATCTG e-e-e-d(10)-k-k-k 9
1094
983 998 528437 CCAATGCAGGCAATCT e-e-e-d(10)-k-k-k 26
1095
984 999 528438 TCCAATGCAGGCAATC e-e-e-d(10)-k-k-k 10
1096
985 1000 528439 CTCCAATGCAGGCAAT e-e-e-d(10)-k-k-k 2
1097
986 1001 528440 CCTCCAATGCAGGCAA e-e-e-d(10)-k-k-k 28
1098
1003 1018 528441 GGCAGATGTTGGGCGG e-e-e-d(10)-k-k-k 8
1099
1004 1019 528442 AGGCAGATGTTGGGCG e-e-e-d(10)-k-k-k 0
1100
1005 1020 528443 TAGGCAGATGTTGGGC e-e-e-d(10)-k-k-k 1
1101
1006 1021 528444 CTAGGCAGATGTTGGG e-e-e-d(10)-k-k-k 0
1102
1007 1022 528445 TCTAGGCAGATGTTGG e-e-e-d(10)-k-k-k 7 1103
1008 1023 528446 ATCTAGGCAGATGTTG e-e-e-d(10)-k-k-k 3 1104
1010 1025 528447 CGATCTAGGCAGATGT e-e-e-d(10)-k-k-k 9 72
1011 1026 528448 CCGATCTAGGCAGATG e-e-e-d(10)-k-k-k 13
1105
1013 1028 528449 AGCCGATCTAGGCAGA e-e-e-d(10)-k-k-k 4
1106
1014 1029 528450 TAGCCGATCTAGGCAG e-e-e-d(10)-k-k-k 11
1107
1015 1030 528451 CTAGCCGATCTAGGCA e-e-e-d(10)-k-k-k 5
1108
1016 1031 528452 TCTAGCCGATCTAGGC e-e-e-d(10)-k-k-k 5
1109
1017 1032 528453 TTCTAGCCGATCTAGG e-e-e-d(10)-k-k-k 24
1110
1018 1033 528454 TTTCTAGCCGATCTAG e-e-e-d(10)-k-k-k 29
1111
1019 1034 528455 TTTTCTAGCCGATCTA e-e-e-d(10)-k-k-k 28
1112
1020 1035 528456 GTTTTCTAGCCGATCT e-e-e-d(10)-k-k-k 42
1113
1022 1037 528457 CAGTTTTCTAGCCGAT e-e-e-d(10)-k-k-k 50
1114
1023 1038 528458 CCAGTTTTCTAGCCGA e-e-e-d(10)-k-k-k 70
1115
1024 1039 528459 TCCAGTTTTCTAGCCG e-e-e-d(10)-k-k-k 56
1116
1025 1040 528460 ATCCAGTTTTCTAGCC e-e-e-d(10)-k-k-k 42
1117
1029 1044 528461 CGTTATCCAGTTTTCT e-e-e-d(10)-k-k-k 47
1118
1043 1058 528462 GATTCTGCTAATGACG e-e-e-d(10)-k-k-k 42
1119
1044 1059 528463 AGATTCTGCTAATGAC e-e-e-d(10)-k-k-k 38
1120
1048 1063 528464 GTTGAGATTCTGCTAA e-e-e-d(10)-k-k-k 30
1121
1049 1064 528465 AGTTGAGATTCTGCTA e-e-e-d(10)-k-k-k 48
1122
1056 1071 528466 GGTCTGAAGTTGAGAT e-e-e-d(10)-k-k-k 27
1123
1058 1073 528467 CGGGTCTGAAGTTGAG e-e-e-d(10)-k-k-k 44
1124
1059 1074 528468 ACGGGTCTGAAGTTGA e-e-e-d(10)-k-k-k 41
1125
1060 1075 528469 GACGGGTCTGAAGTTG e-e-e-d(10)-k-k-k 45
1126
1061 1076 528470 TGACGGGTCTGAAGTT e-e-e-d(10)-k-k-k 34
1127
1062 1077 528471 TTGACGGGTCTGAAGT e-e-e-d(10)-k-k-k 19
1128
1063 1078 528472 GTTGACGGGTCTGAAG e-e-e-d(10)-k-k-k 21
1129
1064 1079 528473 TGTTGACGGGTCTGAA e-e-e-d(10)-k-k-k 37
1130
1065 1080 528474 TTGTTGACGGGTCTGA e-e-e-d(10)-k-k-k 55
1131
1066 1081 528475 TTTGTTGACGGGTCTG e-e-e-d(10)-k-k-k 63
1132
1067 1082 528476 ATTTGTTGACGGGTCT e-e-e-d(10)-k-k-k 65
1133
1899 1914 530425 GCCCTTGCCAGCCATG k-d(10)-k-e-k-e-e 73
1134
BIOL0142WO
1900 1916 530054 AAGCCCTTGCCAGCCAT e-e-k-d(10)-k-e-k-e 75
1135
1900 1915 530375 AGCCCTTGCCAGCCAT e-k-d(10)-k-e-k-e 77 1136
1901 1916 530123 AAGCCCTTGCCAGCCA e-k-k-d(10)-k-k-e 86 144
1901 1916 530170 AAGCCCTTGCCAGCCA e-e-k-d(10)-k-k-e 87 144
1901 1916 530220 AAGCCCTTGCCAGCCA e-d-k-d(10)-k-k-e 74 144
1901 1916 530270 AAGCCCTTGCCAGCCA e-d-d-k-d(9)-k-k-e 87 144
1901 1916 530320 AAGCCCTTGCCAGCCA e-e-e-e-d(9)-k-k-e 17 144
1946 1961 530426 TTTTTCACAAGGTCAA k-d(10)-k-e-k-e-e 55 1137
1947 1963 530059 ACTTTTTCACAAGGTCA e-e-k-d(10)-k-e-k-e 73 1138
1947 1962 530376 CTTTTTCACAAGGTCA e-k-d(10)-k-e-k-e 77 1139
1948 1963 530124 ACTTTTTCACAAGGTC e-k-k-d(10)-k-k-e 79 153
1948 1963 530171 ACTTTTTCACAAGGTC e-e-k-d(10)-k-k-e 69 153
1948 1963 530221 ACTTTTTCACAAGGTC e-d-k-d(10)-k-k-e 64 153
1948 1963 530271 ACTTTTTCACAAGGTC e-d-d-k-d(9)-k-k-e 73 153
1948 1963 530321 ACTTTTTCACAAGGTC e-e-e-e-d(9)-k-k-e 44 153
2204 2219 530427 ATGATCTTATAGCCCA k-d(10)-k-e-k-e-e 43 931
2205 2221 530060 CCATGATCTTATAGCCC e-e-k-d(10)-k-e-k-e 77 1140
2205 2220 530377 CATGATCTTATAGCCC e-k-d(10)-k-e-k-e 66 932
2206 2221 530125 CCATGATCTTATAGCC e-k-k-d(10)-k-k-e 65 175
2206 2221 530172 CCATGATCTTATAGCC e-e-k-d(10)-k-k-e 59 175
2206 2221 530222 CCATGATCTTATAGCC e-d-k-d(10)-k-k-e 48 175
2206 2221 530272 CCATGATCTTATAGCC e-d-d-k-d(9)-k-k-e 63 175
2206 2221 530322 CCATGATCTTATAGCC e-e-e-e-d(9)-k-k-e 55 175
2679 2694 530428 TAGCAGAAGTAGGAGA k-d(10)-k-e-k-e-e 49 1141
2680 2696 530061 GATAGCAGAAGTAGGAG e-e-k-d(10)-k-e-k-e 49 1142
2680 2695 530378 ATAGCAGAAGTAGGAG e-k-d(10)-k-e-k-e 48 1143
2681 2696 530126 GATAGCAGAAGTAGGA e-k-k-d(10)-k-k-e 70 223
2681 2696 530173 GATAGCAGAAGTAGGA e-e-k-d(10)-k-k-e 62 223
2681 2696 530223 GATAGCAGAAGTAGGA e-d-k-d(10)-k-k-e 44 223
2681 2696 530273 GATAGCAGAAGTAGGA e-d-d-k-d(9)-k-k-e 63 223
2681 2696 530323 GATAGCAGAAGTAGGA e-e-e-e-d(9)-k-k-e 63 223
3012 3027 530513 TTGGATGTCAGCAAGG k-d(10)-k-e-k-e-e 88 1047
3013 3028 530507 TTTGGATGTCAGCAAG e-k-d(10)-k-e-k-e 86 1144
3013 3028 530514 TTTGGATGTCAGCAAG k-d(10)-k-e-k-e-e 80 1144
3014 3029 530430 ATTTGGATGTCAGCAA k-d(10)-k-e-k-e-e 87 1145
3014 3029 530468 ATTTGGATGTCAGCAA e-k-k-d(10)-k-k-e 81 1145
3014 3029 530476 ATTTGGATGTCAGCAA e-e-k-d(10)-k-k-e 82 1145
3014 3029 530484 ATTTGGATGTCAGCAA e-d-k-d(10)-k-k-e 74 1145
3014 3029 530492 ATTTGGATGTCAGCAA e-d-d-k-d(9)-k-k-e 83 1145
3014 3029 530500 ATTTGGATGTCAGCAA e-e-e-e-d(9)-k-k-e 56 1145
3014 3029 530508 ATTTGGATGTCAGCAA e-k-d(10)-k-e-k-e 83 1145
3015 3031 530062 CTATTTGGATGTCAGCA e-e-k-d(10)-k-e-k-e 94 1146
3015 3030 530380 TATTTGGATGTCAGCA e-k-d(10)-k-e-k-e 94 1147
3015 3030 530469 TATTTGGATGTCAGCA e-k-k-d(10)-k-k-e 91 1147
3015 3030 530477 TATTTGGATGTCAGCA e-e-k-d(10)-k-k-e 87 1147
BIOL0142WO
3015 3030 530485 TATTTGGATGTCAGCA e-d-k-d(10)-k-k-e 87 1147
3015 3030 530493 TATTTGGATGTCAGCA e-d-d-k-d(9)-k-k-e 81 1147
3015 3030 530501 TATTTGGATGTCAGCA e-e-e-e-d(9)-k-k-e 74 1147
3015 3030 530515 TATTTGGATGTCAGCA k-d(10)-k-e-k-e-e 87 1147
3016 3031 481464 CTATTTGGATGTCAGC k-k-k-d(10)-k-k-k 93 245
3016 3031 518349 CTATTTGGATGTCAGC e-e-e-d(10)-k-k-k 58 245
3016 3031 519637 CTATTTGGATGTCAGC e-k-k-d(10)-k-k-e 96 245
3016 3031 530175 CTATTTGGATGTCAGC e-e-k-d(10)-k-k-e 93 245
3016 3031 530225 CTATTTGGATGTCAGC e-d-k-d(10)-k-k-e 85 245
3016 3031 530275 CTATTTGGATGTCAGC e-d-d-k-d(9)-k-k-e 91 245
3016 3031 530325 CTATTTGGATGTCAGC e-e-e-e-d(9)-k-k-e 91 245
3017 3032 530470 TCTATTTGGATGTCAG e-k-k-d(10)-k-k-e 91 1148
3017 3032 530478 TCTATTTGGATGTCAG e-e-k-d(10)-k-k-e 87 1148
3017 3032 530486 TCTATTTGGATGTCAG e-d-k-d(10)-k-k-e 84 1148
3017 3032 530494 TCTATTTGGATGTCAG e-d-d-k-d(9)-k-k-e 60 1148
3017 3032 530502 TCTATTTGGATGTCAG e-e-e-e-d(9)-k-k-e 64 1148
3017 3032 530509 TCTATTTGGATGTCAG e-k-d(10)-k-e-k-e 80 1148
3018 3033 530471 TTCTATTTGGATGTCA e-k-k-d(10)-k-k-e 83 1149
3018 3033 530479 TTCTATTTGGATGTCA e-e-k-d(10)-k-k-e 74 1149
3018 3033 530487 TTCTATTTGGATGTCA e-d-k-d(10)-k-k-e 71 1149
3018 3033 530495 TTCTATTTGGATGTCA e-d-d-k-d(9)-k-k-e 68 1149
3018 3033 530503 TTCTATTTGGATGTCA e-e-e-e-d(9)-k-k-e 53 1149
3459 3474 530431 CACCAAGGAGGCTGTT k-d(10)-k-e-k-e-e 44 1150
3460 3476 530055 AGCACCAAGGAGGCTGT e-e-k-d(10)-k-e-k-e 45 1151
3460 3475 530381 GCACCAAGGAGGCTGT e-k-d(10)-k-e-k-e 74 1152
3461 3476 530128 AGCACCAAGGAGGCTG e-k-k-d(10)-k-k-e 52 257
3461 3476 530176 AGCACCAAGGAGGCTG e-e-k-d(10)-k-k-e 66 257
3461 3476 530226 AGCACCAAGGAGGCTG e-d-k-d(10)-k-k-e 51 257
3461 3476 530276 AGCACCAAGGAGGCTG e-d-d-k-d(9)-k-k-e 70 257
3461 3476 530326 AGCACCAAGGAGGCTG e-e-e-e-d(9)-k-k-e 52 257
3527 3542 528860 GGTTTGACCTGAAGCC e-e-e-d(10)-k-k-k 58 1153
3528 3543 528861 GGGTTTGACCTGAAGC e-e-e-d(10)-k-k-k 42 1154
3529 3544 528862 AGGGTTTGACCTGAAG e-e-e-d(10)-k-k-k 57
1155
3530 3545 528863 AAGGGTTTGACCTGAA e-e-e-d(10)-k-k-k 43
1156
3531 3546 528864 TAAGGGTTTGACCTGA e-e-e-d(10)-k-k-k 50
1157
3532 3547 528865 TTAAGGGTTTGACCTG e-e-e-d(10)-k-k-k 32
1158
3547 3562 528866 GCAGCTTCAGATGTCT e-e-e-d(10)-k-k-k 60
1159
3548 3563 528867 TGCAGCTTCAGATGTC e-e-e-d(10)-k-k-k 47
1160
3583 3598 530388 CTTAAACCTTCCTATT k-d(10)-k-e-k-e-e 14
1161
3584 3599 530338 CCTTAAACCTTCCTAT e-k-d(10)-k-e-k-e 47
1162
3585 3600 530086 TCCTTAAACCTTCCTA e-k-k-d(10)-k-k-e 58 273
3585 3600 530133 TCCTTAAACCTTCCTA e-e-k-d(10)-k-k-e 53 273
3585 3600 530183 TCCTTAAACCTTCCTA e-d-k-d(10)-k-k-e 52 273
3585 3600 530233 TCCTTAAACCTTCCTA e-d-d-k-d(9)-k-k-e 29 273
3585 3600 530283 TCCTTAAACCTTCCTA e-e-e-e-d(9)-k-k-e 32 273
BIOL0142WO
3590 3605 528868 GATTCTCCTTAAACCT e-e-e-d(10)-k-k-k 45 1163
3591 3606 530389 AGATTCTCCTTAAACC k-d(10)-k-e-k-e-e 44 1164
3592 3607 530339 TAGATTCTCCTTAAAC e-k-d(10)-k-e-k-e 41 1165
3593 3608 530087 TTAGATTCTCCTTAAA e-k-k-d(10)-k-k-e 43 1166
3593 3608 530134 TTAGATTCTCCTTAAA e-e-k-d(10)-k-k-e 28 1166
3593 3608 530184 TTAGATTCTCCTTAAA e-d-k-d(10)-k-k-e 13 1166
3593 3608 530234 TTAGATTCTCCTTAAA e-d-d-k-d(9)-k-k-e 15 1166
3593 3608 530284 TTAGATTCTCCTTAAA e-e-e-e-d(9)-k-k-e 14 1166
3595 3610 530390 GCTTAGATTCTCCTTA k-d(10)-k-e-k-e-e 83 1167
3596 3611 530340 TGCTTAGATTCTCCTT e-k-d(10)-k-e-k-e 89 1168
3597 3612 528869 ATGCTTAGATTCTCCT e-e-e-d(10)-k-k-k 83 1169
3597 3612 530088 ATGCTTAGATTCTCCT e-k-k-d(10)-k-k-e 90 1169
3597 3612 530135 ATGCTTAGATTCTCCT e-e-k-d(10)-k-k-e 91 1169
3597 3612 530185 ATGCTTAGATTCTCCT e-d-k-d(10)-k-k-e 85 1169
3597 3612 530235 ATGCTTAGATTCTCCT e-d-d-k-d(9)-k-k-e 28 1169
3597 3612 530285 ATGCTTAGATTCTCCT e-e-e-e-d(9)-k-k-e 86 1169
3597 3612 530391 ATGCTTAGATTCTCCT k-d(10)-k-e-k-e-e 79 1169
3598 3614 530021 AAATGCTTAGATTCTCC e-e-k-d(10)-k-e-k-e 87 1170
3598 3613 530341 AATGCTTAGATTCTCC e-k-d(10)-k-e-k-e 88 1171
3599 3614 530089 AAATGCTTAGATTCTC e-k-k-d(10)-k-k-e 71 1172
3599 3614 530136 AAATGCTTAGATTCTC e-e-k-d(10)-k-k-e 66 1172
3599 3614 530186 AAATGCTTAGATTCTC e-d-k-d(10)-k-k-e 51 1172
3599 3614 530236 AAATGCTTAGATTCTC e-d-d-k-d(9)-k-k-e 74 1172
3599 3614 530286 AAATGCTTAGATTCTC e-e-e-e-d(9)-k-k-e 56 1172
3682 3697 528870 GTAAGCACCCTCTGCC e-e-e-d(10)-k-k-k 26 1173
3684 3699 528871 TTGTAAGCACCCTCTG e-e-e-d(10)-k-k-k 14 1174
3686 3701 528872 GGTTGTAAGCACCCTC e-e-e-d(10)-k-k-k 47 1175
3687 3702 528873 AGGTTGTAAGCACCCT e-e-e-d(10)-k-k-k 40 1176
3688 3703 528874 AAGGTTGTAAGCACCC e-e-e-d(10)-k-k-k 54 1177
3690 3705 528875 TCAAGGTTGTAAGCAC e-e-e-d(10)-k-k-k 15 1178
3691 3706 528876 GTCAAGGTTGTAAGCA e-e-e-d(10)-k-k-k 28 1179
3692 3707 528877 AGTCAAGGTTGTAAGC e-e-e-d(10)-k-k-k 28 1180
3694 3709 528878 GGAGTCAAGGTTGTAA e-e-e-d(10)-k-k-k 6 1181
3695 3710 528879 GGGAGTCAAGGTTGTA e-e-e-d(10)-k-k-k 22 1182
3714 3729 530392 GATCAAGTCCAGGGAG k-d(10)-k-e-k-e-e 47 1183
3715 3731 530022 CAGATCAAGTCCAGGGA e-e-k-d(10)-k-e-k-e 80 1184
3715 3730 530342 AGATCAAGTCCAGGGA e-k-d(10)-k-e-k-e 70 1185
3715 3730 530393 AGATCAAGTCCAGGGA k-d(10)-k-e-k-e-e 46 1185
3716 3732 530023 GCAGATCAAGTCCAGGG e-e-k-d(10)-k-e-k-e 74 1186
3716 3731 530090 CAGATCAAGTCCAGGG e-k-k-d(10)-k-k-e 78 1187
3716 3731 530137 CAGATCAAGTCCAGGG e-e-k-d(10)-k-k-e 76 1187
3716 3731 530187 CAGATCAAGTCCAGGG e-d-k-d(10)-k-k-e 68 1187
3716 3731 530237 CAGATCAAGTCCAGGG e-d-d-k-d(9)-k-k-e 36 1187
3716 3731 530287 CAGATCAAGTCCAGGG e-e-e-e-d(9)-k-k-e 56 1187
3716 3731 530343 CAGATCAAGTCCAGGG e-k-d(10)-k-e-k-e 68 1187
BIOL0142WO
3716 3731 530394 CAGATCAAGTCCAGGG k-d(10)-k-e-k-e-e 49 1187
3717 3732 518343 GCAGATCAAGTCCAGG e-e-e-d(10)-k-k-k 5 1188
3717 3733 530024 AGCAGATCAAGTCCAGG e-e-k-d(10)-k-e-k-e 79 1189
3717 3732 530091 GCAGATCAAGTCCAGG e-k-k-d(10)-k-k-e 81 1188
3717 3732 530138 GCAGATCAAGTCCAGG e-e-k-d(10)-k-k-e 81 1188
3717 3732 530188 GCAGATCAAGTCCAGG e-d-k-d(10)-k-k-e 78 1188
3717 3732 530238 GCAGATCAAGTCCAGG e-d-d-k-d(9)-k-k-e 29 1188
3717 3732 530288 GCAGATCAAGTCCAGG e-e-e-e-d(9)-k-k-e 69 1188
3717 3732 530344 GCAGATCAAGTCCAGG e-k-d(10)-k-e-k-e 85 1188
3718 3733 530092 AGCAGATCAAGTCCAG e-k-k-d(10)-k-k-e 85 1190
3718 3733 530139 AGCAGATCAAGTCCAG e-e-k-d(10)-k-k-e 79 1190
3718 3733 530189 AGCAGATCAAGTCCAG e-d-k-d(10)-k-k-e 77 1190
3718 3733 530239 AGCAGATCAAGTCCAG e-d-d-k-d(9)-k-k-e 61 1190
3718 3733 530289 AGCAGATCAAGTCCAG e-e-e-e-d(9)-k-k-e 75 1190
3720 3735 528880 ACAGCAGATCAAGTCC e-e-e-d(10)-k-k-k 65 1191
3721 3736 528881 AACAGCAGATCAAGTC e-e-e-d(10)-k-k-k 44 1192
3737 3752 528882 ACAACCTAGCCTCTGA e-e-e-d(10)-k-k-k 39 1193
3738 3753 528883 AACAACCTAGCCTCTG e-e-e-d(10)-k-k-k 46 1194
3740 3755 528884 GAAACAACCTAGCCTC e-e-e-d(10)-k-k-k 37 1195
3741 3756 528885 AGAAACAACCTAGCCT e-e-e-d(10)-k-k-k 20 1196
3742 3757 528886 CAGAAACAACCTAGCC e-e-e-d(10)-k-k-k 21 1197
3755 3770 528887 GATAAGGCACCCACAG e-e-e-d(10)-k-k-k 25 1198
3756 3771 528888 TGATAAGGCACCCACA e-e-e-d(10)-k-k-k 12 1199
3757 3772 528889 CTGATAAGGCACCCAC e-e-e-d(10)-k-k-k 25 1200
3759 3774 528890 CCCTGATAAGGCACCC e-e-e-d(10)-k-k-k 42 1201
3760 3775 528891 GCCCTGATAAGGCACC e-e-e-d(10)-k-k-k 49 1202
3765 3780 528892 TCCCAGCCCTGATAAG e-e-e-d(10)-k-k-k 0 1203
3767 3782 528893 TATCCCAGCCCTGATA e-e-e-d(10)-k-k-k 0 1204
3770 3785 528894 AAGTATCCCAGCCCTG e-e-e-d(10)-k-k-k 25
1205
3771 3786 528895 GAAGTATCCCAGCCCT e-e-e-d(10)-k-k-k 39
1206
3772 3787 528896 AGAAGTATCCCAGCCC e-e-e-d(10)-k-k-k 22
1207
3773 3788 528897 CAGAAGTATCCCAGCC e-e-e-d(10)-k-k-k 36
1208
3892 3907 528898 TGAGACCAGGATTCCT e-e-e-d(10)-k-k-k 41
1209
3896 3911 528899 GTCCTGAGACCAGGAT e-e-e-d(10)-k-k-k 19
1210
3977 3992 528900 AGCTCAACCAGACACG e-e-e-d(10)-k-k-k 54
3979 3994 528901 TGAGCTCAACCAGACA e-e-e-d(10)-k-k-k 40 1211
3984 3999 528902 TTCCCTGAGCTCAACC e-e-e-d(10)-k-k-k 32 1212
3992 4007 528903 GAACCATATTCCCTGA e-e-e-d(10)-k-k-k 30 313
3995 4010 528904 TAAGAACCATATTCCC e-e-e-d(10)-k-k-k 27 1213
4022 4037 518344 GCCACTGGATATCACC e-e-e-d(10)-k-k-k 89 317
4067 4082 528905 TAAGCCTTTGCCCTGC e-e-e-d(10)-k-k-k 64 1214
4068 4083 528906 GTAAGCCTTTGCCCTG e-e-e-d(10)-k-k-k 53 1215
4069 4084 528907 AGTAAGCCTTTGCCCT e-e-e-d(10)-k-k-k 45 1216
4070 4085 528908 CAGTAAGCCTTTGCCC e-e-e-d(10)-k-k-k 40 1217
4072 4087 528909 ATCAGTAAGCCTTTGC e-e-e-d(10)-k-k-k 53
1218
BIOL0142WO
4073 4088 528910 TATCAGTAAGCCTTTG e-e-e-d(10)-k-k-k 47
1219
4077 4092 528911 AGTTTATCAGTAAGCC e-e-e-d(10)-k-k-k 58
1220
4083 4098 528912 GACTCAAGTTTATCAG e-e-e-d(10)-k-k-k 37
1221
4085 4100 528913 CAGACTCAAGTTTATC e-e-e-d(10)-k-k-k 39
1222
4086 4101 528914 GCAGACTCAAGTTTAT e-e-e-d(10)-k-k-k 0
1223
4087 4102 528915 GGCAGACTCAAGTTTA e-e-e-d(10)-k-k-k 1
1224
4088 4103 528916 GGGCAGACTCAAGTTT e-e-e-d(10)-k-k-k 0
1225
4089 4104 528917 AGGGCAGACTCAAGTT e-e-e-d(10)-k-k-k 9
1226
4091 4106 528918 CGAGGGCAGACTCAAG e-e-e-d(10)-k-k-k 2
1227
4093 4108 528919 TACGAGGGCAGACTCA e-e-e-d(10)-k-k-k 20 324
4094 4109 528920 ATACGAGGGCAGACTC e-e-e-d(10)-k-k-k 14 1228
4095 4110 528921 CATACGAGGGCAGACT e-e-e-d(10)-k-k-k 0 1229
4096 4111 528922 TCATACGAGGGCAGAC e-e-e-d(10)-k-k-k 8 1230
4098 4113 528923 CCTCATACGAGGGCAG e-e-e-d(10)-k-k-k 2 1231
4099 4114 528924 CCCTCATACGAGGGCA e-e-e-d(10)-k-k-k 2 1232
4100 4115 528925 ACCCTCATACGAGGGC e-e-e-d(10)-k-k-k 0 1233
4225 4240 528926 TACGCACAGGAGAGGC e-e-e-d(10)-k-k-k 20
1233
4226 4241 528927 ATACGCACAGGAGAGG e-e-e-d(10)-k-k-k 0
1234
4227 4242 528928 CATACGCACAGGAGAG e-e-e-d(10)-k-k-k 6
1235
4228 4243 528929 CCATACGCACAGGAGA e-e-e-d(10)-k-k-k 4
1236
4229 4244 528930 CCCATACGCACAGGAG e-e-e-d(10)-k-k-k 36
1237
4230 4245 528931 TCCCATACGCACAGGA e-e-e-d(10)-k-k-k 22 1238
4231 4246 528932 TTCCCATACGCACAGG e-e-e-d(10)-k-k-k 32 1239
4232 4247 528933 GTTCCCATACGCACAG e-e-e-d(10)-k-k-k 45 1240
4233 4248 528934 TGTTCCCATACGCACA e-e-e-d(10)-k-k-k 36 1241
4234 4249 528935 GTGTTCCCATACGCAC e-e-e-d(10)-k-k-k 20 1242
4234 4249 530395 GTGTTCCCATACGCAC k-d(10)-k-e-k-e-e 71 1242
4235 4250 528936 GGTGTTCCCATACGCA e-e-e-d(10)-k-k-k 71 1243
4235 4251 530025 AGGTGTTCCCATACGCA e-e-k-d(10)-k-e-k-e 90 1244
4235 4250 530345 GGTGTTCCCATACGCA e-k-d(10)-k-e-k-e 93 1243
4235 4250 530396 GGTGTTCCCATACGCA k-d(10)-k-e-k-e-e 71 1243
4236 4251 528937 AGGTGTTCCCATACGC e-e-e-d(10)-k-k-k 73 1245
4236 4252 530026 TAGGTGTTCCCATACGC e-e-k-d(10)-k-e-k-e 87 1246
4236 4251 530093 AGGTGTTCCCATACGC e-k-k-d(10)-k-k-e 95 1245
4236 4251 530140 AGGTGTTCCCATACGC e-e-k-d(10)-k-k-e 89 1245
4236 4251 530190 AGGTGTTCCCATACGC e-d-k-d(10)-k-k-e 82 1245
4236 4251 530240 AGGTGTTCCCATACGC e-d-d-k-d(9)-k-k-e 50 1245
4236 4251 530290 AGGTGTTCCCATACGC e-e-e-e-d(9)-k-k-e 69 1245
4236 4251 530346 AGGTGTTCCCATACGC e-k-d(10)-k-e-k-e 89 1245
4237 4252 528938 TAGGTGTTCCCATACG e-e-e-d(10)-k-k-k 72 336
4237 4252 530094 TAGGTGTTCCCATACG e-k-k-d(10)-k-k-e 88 336
4237 4252 530141 TAGGTGTTCCCATACG e-e-k-d(10)-k-k-e 80 336
4237 4252 530191 TAGGTGTTCCCATACG e-d-k-d(10)-k-k-e 74 336
4237 4252 530241 TAGGTGTTCCCATACG e-d-d-k-d(9)-k-k-e 53 336
4237 4252 530291 TAGGTGTTCCCATACG e-e-e-e-d(9)-k-k-e 68 336
BIOL0142WO
4238 4253 528939 CTAGGTGTTCCCATAC e-e-e-d(10)-k-k-k 39 1247
4239 4254 528940 GCTAGGTGTTCCCATA e-e-e-d(10)-k-k-k 62 1248
4240 4255 528941 TGCTAGGTGTTCCCAT e-e-e-d(10)-k-k-k 49 1249
4242 4257 528942 CGTGCTAGGTGTTCCC e-e-e-d(10)-k-k-k 77 1250
4304 4319 528943 CAAGGTGGTTTTGAGT e-e-e-d(10)-k-k-k 25 1251
4305 4320 528944 GCAAGGTGGTTTTGAG e-e-e-d(10)-k-k-k 28 344
4320 4335 528945 CTCTGATCAGCTGAGG e-e-e-d(10)-k-k-k 74 1252
4321 4336 528946 ACTCTGATCAGCTGAG e-e-e-d(10)-k-k-k 56 1253
4362 4377 528947 GAGACCAGCTAATTTG e-e-e-d(10)-k-k-k 36 1254
4395 4410 528948 CATCTTAGAGAAGGTC e-e-e-d(10)-k-k-k 59 1255
4435 4450 528949 TCAACTGTCTCCAGGC e-e-e-d(10)-k-k-k 67 1256
4435 4450 530397 TCAACTGTCTCCAGGC k-d(10)-k-e-k-e-e 60 1256
4436 4451 528950 ATCAACTGTCTCCAGG e-e-e-d(10)-k-k-k 57 1257
4436 4452 530027 CATCAACTGTCTCCAGG e-e-k-d(10)-k-e-k-e 56 1258
4436 4451 530347 ATCAACTGTCTCCAGG e-k-d(10)-k-e-k-e 49 1257
4437 4452 530095 CATCAACTGTCTCCAG e-k-k-d(10)-k-k-e 40 354
4437 4452 530142 CATCAACTGTCTCCAG e-e-k-d(10)-k-k-e 43 354
4437 4452 530192 CATCAACTGTCTCCAG e-d-k-d(10)-k-k-e 42 354
4437 4452 530242 CATCAACTGTCTCCAG e-d-d-k-d(9)-k-k-e 0 354
4437 4452 530292 CATCAACTGTCTCCAG e-e-e-e-d(9)-k-k-e 36 354
4437 4452 530398 CATCAACTGTCTCCAG k-d(10)-k-e-k-e-e 28 354
4438 4454 530028 CACATCAACTGTCTCCA e-e-k-d(10)-k-e-k-e 57 1259
4438 4453 530348 ACATCAACTGTCTCCA e-k-d(10)-k-e-k-e 58 1260
4439 4454 530096 CACATCAACTGTCTCC e-k-k-d(10)-k-k-e 72 356
4439 4454 530143 CACATCAACTGTCTCC e-e-k-d(10)-k-k-e 74 356
4439 4454 530193 CACATCAACTGTCTCC e-d-k-d(10)-k-k-e 62 356
4439 4454 530243 CACATCAACTGTCTCC e-d-d-k-d(9)-k-k-e 34 356
4439 4454 530293 CACATCAACTGTCTCC e-e-e-e-d(9)-k-k-e 59 356
4441 4456 528951 GACACATCAACTGTCT e-e-e-d(10)-k-k-k 16 1261
4475 4490 528952 GAAGAGTGTTGCTGGA e-e-e-d(10)-k-k-k 57 1262
4477 4492 528953 CTGAAGAGTGTTGCTG e-e-e-d(10)-k-k-k 46 1263
4479 4494 528954 TACTGAAGAGTGTTGC e-e-e-d(10)-k-k-k 42 1264
4485 4500 530510 ATTATGTACTGAAGAG k-d(10)-k-e-k-e-e 53 1265
4486 4501 530504 TATTATGTACTGAAGA e-k-d(10)-k-e-k-e 25 1266
4486 4501 530511 TATTATGTACTGAAGA k-d(10)-k-e-k-e-e 31 1266
4487 4502 530432 TTATTATGTACTGAAG k-d(10)-k-e-k-e-e 15 1267
4487 4502 530463 TTATTATGTACTGAAG e-k-k-d(10)-k-k-e 20 1267
4487 4502 530472 TTATTATGTACTGAAG e-e-k-d(10)-k-k-e 17 1267
4487 4502 530480 TTATTATGTACTGAAG e-d-k-d(10)-k-k-e 4 1267
4487 4502 530488 TTATTATGTACTGAAG e-d-d-k-d(9)-k-k-e 13 1267
4487 4502 530496 TTATTATGTACTGAAG e-e-e-e-d(9)-k-k-e 0 1267
4487 4502 530505 TTATTATGTACTGAAG e-k-d(10)-k-e-k-e 37 1267
4488 4504 530063 GCTTATTATGTACTGAA e-e-k-d(10)-k-e-k-e 74 1268
4488 4503 530382 CTTATTATGTACTGAA e-k-d(10)-k-e-k-e 17 1269
4488 4503 530465 CTTATTATGTACTGAA e-k-k-d(10)-k-k-e 63 1269
BIOL0142WO
4488 4503 530473 CTTATTATGTACTGAA e-e-k-d(10)-k-k-e 45 1269
4488 4503 530481 CTTATTATGTACTGAA e-d-k-d(10)-k-k-e 14 1269
4488 4503 530489 CTTATTATGTACTGAA e-d-d-k-d(9)-k-k-e 13 1269
4488 4503 530497 CTTATTATGTACTGAA e-e-e-e-d(9)-k-k-e 7 1269
4488 4503 530512 CTTATTATGTACTGAA k-d(10)-k-e-k-e-e 21 1269
4489 4504 519638 GCTTATTATGTACTGA e-k-k-d(10)-k-k-e 86 362
4489 4504 530177 GCTTATTATGTACTGA e-e-k-d(10)-k-k-e 71 362
4489 4504 530227 GCTTATTATGTACTGA e-d-k-d(10)-k-k-e 51 362
4489 4504 530277 GCTTATTATGTACTGA e-d-d-k-d(9)-k-k-e 70 362
4489 4504 530327 GCTTATTATGTACTGA e-e-e-e-d(9)-k-k-e 61 362
4490 4505 530466 AGCTTATTATGTACTG e-k-k-d(10)-k-k-e 82 1270
4490 4505 530474 AGCTTATTATGTACTG e-e-k-d(10)-k-k-e 62 1270
4490 4505 530482 AGCTTATTATGTACTG e-d-k-d(10)-k-k-e 53 1270
4490 4505 530490 AGCTTATTATGTACTG e-d-d-k-d(9)-k-k-e 42 1270
4490 4505 530498 AGCTTATTATGTACTG e-e-e-e-d(9)-k-k-e 45 1270
4490 4505 530506 AGCTTATTATGTACTG e-k-d(10)-k-e-k-e 70 1270
4491 4506 530467 AAGCTTATTATGTACT e-k-k-d(10)-k-k-e 50 1271
4491 4506 530475 AAGCTTATTATGTACT e-e-k-d(10)-k-k-e 26 1271
4491 4506 530483 AAGCTTATTATGTACT e-d-k-d(10)-k-k-e 19 1271
4491 4506 530491 AAGCTTATTATGTACT e-d-d-k-d(9)-k-k-e 13 1271
4491 4506 530499 AAGCTTATTATGTACT e-e-e-e-d(9)-k-k-e 15 1271
4492 4507 528955 TAAGCTTATTATGTAC e-e-e-d(10)-k-k-k 0 1272
4499 4514 528956 TATCAGTTAAGCTTAT e-e-e-d(10)-k-k-k 0 1273
4502 4517 528957 GTTTATCAGTTAAGCT e-e-e-d(10)-k-k-k 31 1274
4539 4554 530433 CAATGGTAAGCCCAAG k-d(10)-k-e-k-e-e 62 1275
4540 4555 528958 CCAATGGTAAGCCCAA e-e-e-d(10)-k-k-k 66 1276
4540 4556 530056 CCCAATGGTAAGCCCAA e-e-k-d(10)-k-e-k-e 73 1277
4540 4555 530383 CCAATGGTAAGCCCAA e-k-d(10)-k-e-k-e 64 1276
4541 4556 518345 CCCAATGGTAAGCCCA e-e-e-d(10)-k-k-k 80 366
4541 4556 519636 CCCAATGGTAAGCCCA e-k-k-d(10)-k-k-e 90 366
4541 4556 530178 CCCAATGGTAAGCCCA e-e-k-d(10)-k-k-e 86 366
4541 4556 530228 CCCAATGGTAAGCCCA e-d-k-d(10)-k-k-e 77 366
4541 4556 530278 CCCAATGGTAAGCCCA e-d-d-k-d(9)-k-k-e 86 366
4541 4556 530328 CCCAATGGTAAGCCCA e-e-e-e-d(9)-k-k-e 80 366
4542 4557 528959 ACCCAATGGTAAGCCC e-e-e-d(10)-k-k-k 73 1277
4544 4559 528960 AAACCCAATGGTAAGC e-e-e-d(10)-k-k-k 43 1278
4545 4560 528961 TAAACCCAATGGTAAG e-e-e-d(10)-k-k-k 18 1279
4546 4561 528962 TTAAACCCAATGGTAA e-e-e-d(10)-k-k-k 13 1280
4547 4562 528963 TTTAAACCCAATGGTA e-e-e-d(10)-k-k-k 2 1281
4554 4569 528964 CCTATGATTTAAACCC e-e-e-d(10)-k-k-k 17 1282
4558 4573 528965 GGTCCCTATGATTTAA e-e-e-d(10)-k-k-k 31 1283
4559 4574 528966 AGGTCCCTATGATTTA e-e-e-d(10)-k-k-k 22 1284
4615 4630 528967 CCTAAGGCCATGAACT e-e-e-d(10)-k-k-k 19 374
4616 4631 528968 ACCTAAGGCCATGAAC e-e-e-d(10)-k-k-k 25 1285
4617 4632 528969 TACCTAAGGCCATGAA e-e-e-d(10)-k-k-k 41 1286
BIOL0142WO
4618 4633 528970 CTACCTAAGGCCATGA e-e-e-d(10)-k-k-k 55 1287
4619 4634 528971 GCTACCTAAGGCCATG e-e-e-d(10)-k-k-k 66 1288
4620 4635 528972 TGCTACCTAAGGCCAT e-e-e-d(10)-k-k-k 56 1289
4621 4636 528973 ATGCTACCTAAGGCCA e-e-e-d(10)-k-k-k 71 1290
4622 4637 528974 CATGCTACCTAAGGCC e-e-e-d(10)-k-k-k 58 1291
4623 4638 528975 ACATGCTACCTAAGGC e-e-e-d(10)-k-k-k 34 1292
4636 4651 528976 GTTAAGACCAGATACA e-e-e-d(10)-k-k-k 45 1293
4637 4652 528977 AGTTAAGACCAGATAC e-e-e-d(10)-k-k-k 40 1294
4638 4653 528978 GAGTTAAGACCAGATA e-e-e-d(10)-k-k-k 40 1295
4639 4654 528979 AGAGTTAAGACCAGAT e-e-e-d(10)-k-k-k 62 1296
4644 4659 530399 CAATCAGAGTTAAGAC k-d(10)-k-e-k-e-e 36 1297
4645 4661 530029 TACAATCAGAGTTAAGA e-e-k-d(10)-k-e-k-e 29 1298
4645 4660 530349 ACAATCAGAGTTAAGA e-k-d(10)-k-e-k-e 33 1299
4646 4661 528980 TACAATCAGAGTTAAG e-e-e-d(10)-k-k-k 0 378
4646 4661 530097 TACAATCAGAGTTAAG e-k-k-d(10)-k-k-e 41 378
4646 4661 530144 TACAATCAGAGTTAAG e-e-k-d(10)-k-k-e 16 378
4646 4661 530194 TACAATCAGAGTTAAG e-d-k-d(10)-k-k-e 28 378
4646 4661 530244 TACAATCAGAGTTAAG e-d-d-k-d(9)-k-k-e 0 378
4646 4661 530294 TACAATCAGAGTTAAG e-e-e-e-d(9)-k-k-e 7 378
4648 4663 528981 GCTACAATCAGAGTTA e-e-e-d(10)-k-k-k 52 1300
4649 4664 528982 TGCTACAATCAGAGTT e-e-e-d(10)-k-k-k 47 1301
4650 4665 528983 TTGCTACAATCAGAGT e-e-e-d(10)-k-k-k 44 1302
4662 4677 530400 CTCTCAGAACTTTTGC k-d(10)-k-e-k-e-e 65 1303
4663 4679 530030 TCCTCTCAGAACTTTTG e-e-k-d(10)-k-e-k-e 47 1304
4663 4678 530350 CCTCTCAGAACTTTTG e-k-d(10)-k-e-k-e 54 1305
4664 4679 530098 TCCTCTCAGAACTTTT e-k-k-d(10)-k-k-e 42 380
4664 4679 530145 TCCTCTCAGAACTTTT e-e-k-d(10)-k-k-e 38 380
4664 4679 530195 TCCTCTCAGAACTTTT e-d-k-d(10)-k-k-e 43 380
4664 4679 530245 TCCTCTCAGAACTTTT e-d-d-k-d(9)-k-k-e 28 380
4664 4679 530295 TCCTCTCAGAACTTTT e-e-e-e-d(9)-k-k-e 39 380
4770 4785 528984 CCCACGGGATTCCCTC e-e-e-d(10)-k-k-k 39 1306
4771 4786 528985 ACCCACGGGATTCCCT e-e-e-d(10)-k-k-k 36 1307
4772 4787 528986 AACCCACGGGATTCCC e-e-e-d(10)-k-k-k 47 1308
4773 4788 528987 CAACCCACGGGATTCC e-e-e-d(10)-k-k-k 39 1309
4774 4789 528988 GCAACCCACGGGATTC e-e-e-d(10)-k-k-k 48 1310
4775 4790 528989 AGCAACCCACGGGATT e-e-e-d(10)-k-k-k 40 1311
4777 4792 528990 TAAGCAACCCACGGGA e-e-e-d(10)-k-k-k 27 1312
4778 4793 528991 GTAAGCAACCCACGGG e-e-e-d(10)-k-k-k 47 1313
4779 4794 528992 GGTAAGCAACCCACGG e-e-e-d(10)-k-k-k 42 1314
4780 4795 528993 AGGTAAGCAACCCACG e-e-e-d(10)-k-k-k 54 1315
4780 4795 530434 AGGTAAGCAACCCACG k-d(10)-k-e-k-e-e 51 1315
4781 4796 528994 TAGGTAAGCAACCCAC e-e-e-d(10)-k-k-k 53 1316
4781 4797 530064 GTAGGTAAGCAACCCAC e-e-k-d(10)-k-e-k-e 53 1317
4781 4796 530384 TAGGTAAGCAACCCAC e-k-d(10)-k-e-k-e 48 1316
4782 4797 528995 GTAGGTAAGCAACCCA e-e-e-d(10)-k-k-k 64 388
BIOL0142WO
4782 4797 530129 GTAGGTAAGCAACCCA e-k-k-d(10)-k-k-e 79 388
4782 4797 530179 GTAGGTAAGCAACCCA e-e-k-d(10)-k-k-e 74 388
4782 4797 530229 GTAGGTAAGCAACCCA e-d-k-d(10)-k-k-e 64 388
4782 4797 530279 GTAGGTAAGCAACCCA e-d-d-k-d(9)-k-k-e 55 388
4782 4797 530329 GTAGGTAAGCAACCCA e-e-e-e-d(9)-k-k-e 61 388
4784 4799 528996 AGGTAGGTAAGCAACC e-e-e-d(10)-k-k-k 21 1318
4788 4803 528997 TTATAGGTAGGTAAGC e-e-e-d(10)-k-k-k 10 1319
4792 4807 528998 CACCTTATAGGTAGGT e-e-e-d(10)-k-k-k 22 1320
4794 4809 528999 ACCACCTTATAGGTAG e-e-e-d(10)-k-k-k 15 1321
4797 4812 529000 TAAACCACCTTATAGG e-e-e-d(10)-k-k-k 0 1322
4798 4813 529001 ATAAACCACCTTATAG e-e-e-d(10)-k-k-k 7 1323
4810 4825 529002 GGACAGCAGCTTATAA e-e-e-d(10)-k-k-k 12 1324
4811 4826 529003 AGGACAGCAGCTTATA e-e-e-d(10)-k-k-k 40 1325
4811 4826 530401 AGGACAGCAGCTTATA k-d(10)-k-e-k-e-e 41 1325
4812 4827 529004 CAGGACAGCAGCTTAT e-e-e-d(10)-k-k-k 38 1326
4812 4828 530031 CCAGGACAGCAGCTTAT e-e-k-d(10)-k-e-k-e 58 1327
4812 4827 530351 CAGGACAGCAGCTTAT e-k-d(10)-k-e-k-e 58 1326
4812 4827 530402 CAGGACAGCAGCTTAT k-d(10)-k-e-k-e-e 60 1326
4813 4829 530032 GCCAGGACAGCAGCTTA e-e-k-d(10)-k-e-k-e 74 1328
4813 4828 530099 CCAGGACAGCAGCTTA e-k-k-d(10)-k-k-e 73 1329
4813 4828 530146 CCAGGACAGCAGCTTA e-e-k-d(10)-k-k-e 70 1329
4813 4828 530196 CCAGGACAGCAGCTTA e-d-k-d(10)-k-k-e 67 1329
4813 4828 530246 CCAGGACAGCAGCTTA e-d-d-k-d(9)-k-k-e 39 1329
4813 4828 530296 CCAGGACAGCAGCTTA e-e-e-e-d(9)-k-k-e 67 1329
4813 4828 530352 CCAGGACAGCAGCTTA e-k-d(10)-k-e-k-e 67 1329
4814 4829 530100 GCCAGGACAGCAGCTT e-k-k-d(10)-k-k-e 77 1330
4814 4829 530147 GCCAGGACAGCAGCTT e-e-k-d(10)-k-k-e 84 1330
4814 4829 530197 GCCAGGACAGCAGCTT e-d-k-d(10)-k-k-e 71 1330
4814 4829 530247 GCCAGGACAGCAGCTT e-d-d-k-d(9)-k-k-e 53 1330
4814 4829 530297 GCCAGGACAGCAGCTT e-e-e-e-d(9)-k-k-e 75 1330
4814 4829 530403 GCCAGGACAGCAGCTT k-d(10)-k-e-k-e-e 77 1330
4815 4831 530033 TGGCCAGGACAGCAGCT e-e-k-d(10)-k-e-k-e 65 1331
4815 4830 530353 GGCCAGGACAGCAGCT e-k-d(10)-k-e-k-e 83 1332
4816 4831 530101 TGGCCAGGACAGCAGC e-k-k-d(10)-k-k-e 59 1333
4816 4831 530148 TGGCCAGGACAGCAGC e-e-k-d(10)-k-k-e 79 1333
4816 4831 530198 TGGCCAGGACAGCAGC e-d-k-d(10)-k-k-e 54 1333
4816 4831 530248 TGGCCAGGACAGCAGC e-d-d-k-d(9)-k-k-e 32 1333
4816 4831 530298 TGGCCAGGACAGCAGC e-e-e-e-d(9)-k-k-e 73 1333
4827 4842 530404 TTTGAATGCAGTGGCC k-d(10)-k-e-k-e-e 67 1334
4828 4844 530034 AATTTGAATGCAGTGGC e-e-k-d(10)-k-e-k-e 69 1335
4828 4843 530354 ATTTGAATGCAGTGGC e-k-d(10)-k-e-k-e 85 1336
4828 4843 530405 ATTTGAATGCAGTGGC k-d(10)-k-e-k-e-e 55 1336
4829 4845 530035 GAATTTGAATGCAGTGG e-e-k-d(10)-k-e-k-e 69 1337
4829 4844 530102 AATTTGAATGCAGTGG e-k-k-d(10)-k-k-e 71 1338
4829 4844 530149 AATTTGAATGCAGTGG e-e-k-d(10)-k-k-e 70 1338
BIOL0142WO
4829 4844 530199 AATTTGAATGCAGTGG e-d-k-d(10)-k-k-e 58 1338
4829 4844 530249 AATTTGAATGCAGTGG e-d-d-k-d(9)-k-k-e 47 1338
4829 4844 530299 AATTTGAATGCAGTGG e-e-e-e-d(9)-k-k-e 47 1338
4829 4844 530355 AATTTGAATGCAGTGG e-k-d(10)-k-e-k-e 72 1338
4830 4845 530103 GAATTTGAATGCAGTG e-k-k-d(10)-k-k-e 77 390
4830 4845 530150 GAATTTGAATGCAGTG e-e-k-d(10)-k-k-e 73 390
4830 4845 530200 GAATTTGAATGCAGTG e-d-k-d(10)-k-k-e 63 390
4830 4845 530250 GAATTTGAATGCAGTG e-d-d-k-d(9)-k-k-e 59 390
4830 4845 530300 GAATTTGAATGCAGTG e-e-e-e-d(9)-k-k-e 65 390
4842 4857 530435 AAGTACACATTGGAAT k-d(10)-k-e-k-e-e 62 1339
4843 4859 530057 TGAAGTACACATTGGAA e-e-k-d(10)-k-e-k-e 69 1340
4843 4858 530385 GAAGTACACATTGGAA e-k-d(10)-k-e-k-e 70 1341
4844 4859 529005 TGAAGTACACATTGGA e-e-e-d(10)-k-k-k 64 392
4844 4859 530130 TGAAGTACACATTGGA e-k-k-d(10)-k-k-e 85 392
4844 4859 530180 TGAAGTACACATTGGA e-e-k-d(10)-k-k-e 82 392
4844 4859 530230 TGAAGTACACATTGGA e-d-k-d(10)-k-k-e 65 392
4844 4859 530280 TGAAGTACACATTGGA e-d-d-k-d(9)-k-k-e 75 392
4844 4859 530330 TGAAGTACACATTGGA e-e-e-e-d(9)-k-k-e 52 392
4852 4867 529006 TTACACTATGAAGTAC e-e-e-d(10)-k-k-k 16 1342
4929 4944 529007 AGTTAAAGTAGATACA e-e-e-d(10)-k-k-k 0 1343
4934 4949 529008 CTGGAAGTTAAAGTAG e-e-e-d(10)-k-k-k 30 397
4943 4958 529009 CGTTTATTTCTGGAAG e-e-e-d(10)-k-k-k 52 1344
4957 4972 529010 CGGTTCCTATATAACG e-e-e-d(10)-k-k-k 21 1345
4958 4973 529011 ACGGTTCCTATATAAC e-e-e-d(10)-k-k-k 10 1346
Table 14
Inhibition of human STAT3 mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID
NO: 2
Human Human SEQ
Start Stop ISIS No Sequence Chemistry ID
inhibition
Site Site NO
1359 1374 529012 GTCATCCCGAAGAGTC e-e-e-d(10)-k-k-k 34
1347
1386 1401 529013 CCCGAGTCCCTTCCGA e-e-e-d(10)-k-k-k 18
1348
1390 1405 529014 GCGCCCCGAGTCCCTT e-e-e-d(10)-k-k-k 53
1349
1412 1427 529015 CGAAGAACGAAACTTC e-e-e-d(10)-k-k-k 8
1350
1418 1433 529016 TTTCTCCGAAGAACGA e-e-e-d(10)-k-k-k 31
1351
1461 1476 529017 CGAGTGCGCCCTCGCC e-e-e-d(10)-k-k-k 52
1352
1548 1563 529018 GTGACAGTCGCTCCGG e-e-e-d(10)-k-k-k 30
1353
1549 1564 529019 CGTGACAGTCGCTCCG e-e-e-d(10)-k-k-k 31
1354
1590 1605 529020 GCGCTTTCCGACCCCC e-e-e-d(10)-k-k-k 45
1355
1790 1805 529021 GTACCGGTCTGTCAAT e-e-e-d(10)-k-k-k 23
1356
e-e-e-d(10)-k-k-k
1794 1809 529022 AAGAGTACCGGTCTGT 69
1357
e-e-e-d(10)-k-k-k
1796 1811 529023 GAAAGAGTACCGGTCT 72
1358
e-e-e-d(10)-k-k-k
1906 1921 529024 CTGGCTTGACGGGTTG 64
1359
e-e-e-d(10)-k-k-k
1907 1922 529025 GCTGGCTTGACGGGTT 73
1360
e-e-e-d(10)-k-k-k
1966 1981 529026 CCGACTTTACCAGGTA 78
1361
BIOL0142WO
e-e-e-d(10)-k-k-k
1968 1983 529027 GGCCGACTTTACCAGG 92
1362
e-e-e-d(10)-k-k-k
1972 1987 529028 TTCTGGCCGACTTTAC 13
1363
e-e-e-d(10)-k-k-k
2031 2046 529029 CGTCCTATGCAATTAA 24
1364
e-e-e-d(10)-k-k-k
2039 2054 529030 GTTCATTCCGTCCTAT 41
1365
e-e-e-d(10)-k-k-k
2198 2213 529031 GACGGTTTGAATCTTG 40
1366
e-e-e-d(10)-k-k-k
2201 2216 529032 GGCGACGGTTTGAATC 37
1367
e-e-e-d(10)-k-k-k
2204 2219 529033 TTGGGCGACGGTTTGA 31
1368
e-e-e-d(10)-k-k-k
2207 2222 529034 AACTTGGGCGACGGTT 54
1369
e-e-e-d(10)-k-k-k
2253 2268 529035 CGACCTGATATGGCAC 56
1370
2255 2270 529036 AACGACCTGATATGGC e-e-e-d(10)-k-k-k 52
1371
2257 2272 529037 ACAACGACCTGATATG e-e-e-d(10)-k-k-k 24
1372
2338 2353 530406 ATACAGTAAGACCAGC k-d(10)-k-e-k-e-e 65
1373
2339 2355 530036 ACATACAGTAAGACCAG e-e-k-d(10)-k-e-k-e 58
1374
2339 2354 530356 CATACAGTAAGACCAG e-k-d(10)-k-e-k-e 65
1375
2340 2355 530104 ACATACAGTAAGACCA e-k-k-d(10)-k-k-e 67 1376
2340 2355 530151 ACATACAGTAAGACCA e-e-k-d(10)-k-k-e 64 1376
2340 2355 530201 ACATACAGTAAGACCA e-d-k-d(10)-k-k-e 42 1376
2340 2355 530251 ACATACAGTAAGACCA e-d-d-k-d(9)-k-k-e 58 1376
2340 2355 530301 ACATACAGTAAGACCA e-e-e-e-d(9)-k-k-e 56 1376
2383 2398 530407 AAAATTTACAACCCAT k-d(10)-k-e-k-e-e 9 1377
2384 2400 530037 CAAAAATTTACAACCCA e-e-k-d(10)-k-e-k-e 42 1378
2384 2399 530357 AAAAATTTACAACCCA e-k-d(10)-k-e-k-e 34 1379
2385 2400 530105 CAAAAATTTACAACCC e-k-k-d(10)-k-k-e 40 1380
2385 2400 530152 CAAAAATTTACAACCC e-e-k-d(10)-k-k-e 33 1380
2385 2400 530202 CAAAAATTTACAACCC e-d-k-d(10)-k-k-e 10 1380
2385 2400 530252 CAAAAATTTACAACCC e-d-d-k-d(9)-k-k-e 29 1380
2385 2400 530302 CAAAAATTTACAACCC e-e-e-e-d(9)-k-k-e 14 1380
2408 2423 530408 AATGCTTTATCAGCAC k-d(10)-k-e-k-e-e 36 1381
2409 2425 530038 CCAATGCTTTATCAGCA e-e-k-d(10)-k-e-k-e 71 1382
2409 2424 530358 CAATGCTTTATCAGCA e-k-d(10)-k-e-k-e 46 1383
2410 2425 530106 CCAATGCTTTATCAGC e-k-k-d(10)-k-k-e 70 1384
2410 2425 530153 CCAATGCTTTATCAGC e-e-k-d(10)-k-k-e 50 1384
2410 2425 530203 CCAATGCTTTATCAGC e-d-k-d(10)-k-k-e 43 1384
2410 2425 530253 CCAATGCTTTATCAGC e-d-d-k-d(9)-k-k-e 33 1384
2410 2425 530303 CCAATGCTTTATCAGC e-e-e-e-d(9)-k-k-e 40 1384
2669 2684 530409 ACTAAAATCAAGGCTC k-d(10)-k-e-k-e-e 42 1385
2670 2686 530039 AGACTAAAATCAAGGCT e-e-k-d(10)-k-e-k-e 73 1386
2670 2685 530359 GACTAAAATCAAGGCT e-k-d(10)-k-e-k-e 82 1387
2671 2686 530107 AGACTAAAATCAAGGC e-k-k-d(10)-k-k-e 77 1388
2671 2686 530154 AGACTAAAATCAAGGC e-e-k-d(10)-k-k-e 57 1388
2671 2686 530204 AGACTAAAATCAAGGC e-d-k-d(10)-k-k-e 28 1388
2671 2686 530254 AGACTAAAATCAAGGC e-d-d-k-d(9)-k-k-e 3 1388
2671 2686 530304 AGACTAAAATCAAGGC e-e-e-e-d(9)-k-k-e 22 1388
2703 2718 530429 AATGGTTCTTTGTGAT k-d(10)-k-e-k-e-e 60 1389
2704 2720 530065 CTAATGGTTCTTTGTGA e-e-k-d(10)-k-e-k-e 70 1390
BIOL0142WO
2704 2719 530379 TAATGGTTCTTTGTGA e-k-d(10)-k-e-k-e 54 1391
2705 2720 530127 CTAATGGTTCTTTGTG e-k-k-d(10)-k-k-e 80 411
2705 2720 530174 CTAATGGTTCTTTGTG e-e-k-d(10)-k-k-e 69 411
2705 2720 530224 CTAATGGTTCTTTGTG e-d-k-d(10)-k-k-e 32 411
2705 2720 530274 CTAATGGTTCTTTGTG e-d-d-k-d(9)-k-k-e 38 411
2705 2720 530324 CTAATGGTTCTTTGTG e-e-e-e-d(9)-k-k-e 32 411
5000 5015 530410 CTGAAATTCCTTGGTC k-d(10)-k-e-k-e-e 53 1392
5001 5017 530040 AACTGAAATTCCTTGGT e-e-k-d(10)-k-e-k-e 67 1393
5001 5016 530360 ACTGAAATTCCTTGGT e-k-d(10)-k-e-k-e 70 1394
5002 5017 530108 AACTGAAATTCCTTGG e-k-k-d(10)-k-k-e 70 1395
5002 5017 530155 AACTGAAATTCCTTGG e-e-k-d(10)-k-k-e 53 1395
5002 5017 530205 AACTGAAATTCCTTGG e-d-k-d(10)-k-k-e 44 1395
5002 5017 530255 AACTGAAATTCCTTGG e-d-d-k-d(9)-k-k-e 33 1395
5002 5017 530305 AACTGAAATTCCTTGG e-e-e-e-d(9)-k-k-e 22 1395
5699 5714 530411 ACTCTTTCAGTGGTTT k-d(10)-k-e-k-e-e 91 1396
5700 5716 530041 GTACTCTTTCAGTGGTT e-e-k-d(10)-k-e-k-e 89 1397
5700 5715 530361 TACTCTTTCAGTGGTT e-k-d(10)-k-e-k-e 88 1398
5701 5716 530109 GTACTCTTTCAGTGGT e-k-k-d(10)-k-k-e 89 1399
5701 5716 530156 GTACTCTTTCAGTGGT e-e-k-d(10)-k-k-e 91 1399
5701 5716 530206 GTACTCTTTCAGTGGT e-d-k-d(10)-k-k-e 89 1399
5701 5716 530256 GTACTCTTTCAGTGGT e-d-d-k-d(9)-k-k-e 33 1399
5701 5716 530306 GTACTCTTTCAGTGGT e-e-e-e-d(9)-k-k-e 83 1399
5883 5898 529038 CTACACTTTACGCTTA e-e-e-d(10)-k-k-k 9 1400
6474 6489 530436 AATTCATTCTTCCATA k-d(10)-k-e-k-e-e 49 1401
6475 6491 530066 GAAATTCATTCTTCCAT e-e-k-d(10)-k-e-k-e 82 1402
6475 6490 530386 AAATTCATTCTTCCAT e-k-d(10)-k-e-k-e 53 1403
6476 6491 530131 GAAATTCATTCTTCCA e-k-k-d(10)-k-k-e 97 413
6476 6491 530181 GAAATTCATTCTTCCA e-e-k-d(10)-k-k-e 82 413
6476 6491 530231 GAAATTCATTCTTCCA e-d-k-d(10)-k-k-e 75 413
6476 6491 530281 GAAATTCATTCTTCCA e-d-d-k-d(9)-k-k-e 69 413
6476 6491 530331 GAAATTCATTCTTCCA e-e-e-e-d(9)-k-k-e 53 413
6846 6861 529039 TTAAAGAGTTGCGGTA e-e-e-d(10)-k-k-k 31 1404
6847 6862 529040 ATTAAAGAGTTGCGGT e-e-e-d(10)-k-k-k 34 1405
8078 8093 530412 AGATTTACCTTCCTTA k-d(10)-k-e-k-e-e 50 1406
8079 8095 530042 GCAGATTTACCTTCCTT e-e-k-d(10)-k-e-k-e 78 1407
8079 8094 530362 CAGATTTACCTTCCTT e-k-d(10)-k-e-k-e 76 1408
8080 8095 530110 GCAGATTTACCTTCCT e-k-k-d(10)-k-k-e 84 1409
8080 8095 530157 GCAGATTTACCTTCCT e-e-k-d(10)-k-k-e 69 1409
8080 8095 530207 GCAGATTTACCTTCCT e-d-k-d(10)-k-k-e 55 1409
8080 8095 530257 GCAGATTTACCTTCCT e-d-d-k-d(9)-k-k-e 39 1409
8080 8095 530307 GCAGATTTACCTTCCT e-e-e-e-d(9)-k-k-e 77 1409
9123 9138 530413 GCCCCTATGTATAAGC k-d(10)-k-e-k-e-e 73 1410
9124 9140 530043 CTGCCCCTATGTATAAG e-e-k-d(10)-k-e-k-e 42 1411
9124 9139 530363 TGCCCCTATGTATAAG e-k-d(10)-k-e-k-e 25 1412
9125 9140 530111 CTGCCCCTATGTATAA e-k-k-d(10)-k-k-e 35 1413
BIOL0142WO
9125 9140 530158 CTGCCCCTATGTATAA e-e-k-d(10)-k-k-e 36 1413
9125 9140 530208 CTGCCCCTATGTATAA e-d-k-d(10)-k-k-e 14 1413
9125 9140 530258 CTGCCCCTATGTATAA e-d-d-k-d(9)-k-k-e 5 1413
9125 9140 530308 CTGCCCCTATGTATAA e-e-e-e-d(9)-k-k-e 25 1413
9862 9877 530414 TTCTTCCTGAGACACA k-d(10)-k-e-k-e-e 61 1414
9863 9879 530044 GCTTCTTCCTGAGACAC e-e-k-d(10)-k-e-k-e 78 1415
9863 9878 530364 CTTCTTCCTGAGACAC e-k-d(10)-k-e-k-e 59 1416
9864 9879 530112 GCTTCTTCCTGAGACA e-k-k-d(10)-k-k-e 84 1417
9864 9879 530159 GCTTCTTCCTGAGACA e-e-k-d(10)-k-k-e 69 1417
9864 9879 530209 GCTTCTTCCTGAGACA e-d-k-d(10)-k-k-e 54 1417
9864 9879 530259 GCTTCTTCCTGAGACA e-d-d-k-d(9)-k-k-e 57 1417
9864 9879 530309 GCTTCTTCCTGAGACA e-e-e-e-d(9)-k-k-e 46 1417
9864 9879 530415 GCTTCTTCCTGAGACA k-d(10)-k-e-k-e-e 51 1417
9865 9881 530045 TGGCTTCTTCCTGAGAC e-e-k-d(10)-k-e-k-e 73 1418
9865 9880 530365 GGCTTCTTCCTGAGAC e-k-d(10)-k-e-k-e 78 1419
9866 9881 530113 TGGCTTCTTCCTGAGA e-k-k-d(10)-k-k-e 60 1420
9866 9881 530160 TGGCTTCTTCCTGAGA e-e-k-d(10)-k-k-e 54 1420
9866 9881 530210 TGGCTTCTTCCTGAGA e-d-k-d(10)-k-k-e 28 1420
9866 9881 530260 TGGCTTCTTCCTGAGA e-d-d-k-d(9)-k-k-e 0 1420
9866 9881 530310 TGGCTTCTTCCTGAGA e-e-e-e-d(9)-k-k-e 26 1420
9873 9888 530416 CTCCTGTTGGCTTCTT k-d(10)-k-e-k-e-e 57 1421
9874 9890 530046 TCCTCCTGTTGGCTTCT e-e-k-d(10)-k-e-k-e 76 1422
9874 9889 530366 CCTCCTGTTGGCTTCT e-k-d(10)-k-e-k-e 75 1423
9874 9889 530417 CCTCCTGTTGGCTTCT k-d(10)-k-e-k-e-e 66 1423
9875 9891 530047 TTCCTCCTGTTGGCTTC e-e-k-d(10)-k-e-k-e 75 1424
9875 9890 530114 TCCTCCTGTTGGCTTC e-k-k-d(10)-k-k-e 80 1425
9875 9890 530161 TCCTCCTGTTGGCTTC e-e-k-d(10)-k-k-e 81 1425
9875 9890 530211 TCCTCCTGTTGGCTTC e-d-k-d(10)-k-k-e 73 1425
9875 9890 530261 TCCTCCTGTTGGCTTC e-d-d-k-d(9)-k-k-e 78 1425
9875 9890 530311 TCCTCCTGTTGGCTTC e-e-e-e-d(9)-k-k-e 82 1425
9875 9890 530367 TCCTCCTGTTGGCTTC e-k-d(10)-k-e-k-e 80 1425
9876 9891 530115 TTCCTCCTGTTGGCTT e-k-k-d(10)-k-k-e 74 1426
9876 9891 530162 TTCCTCCTGTTGGCTT e-e-k-d(10)-k-k-e 68 1426
9876 9891 530212 TTCCTCCTGTTGGCTT e-d-k-d(10)-k-k-e 58 1426
9876 9891 530262 TTCCTCCTGTTGGCTT e-d-d-k-d(9)-k-k-e 23 1426
9876 9891 530312 TTCCTCCTGTTGGCTT e-e-e-e-d(9)-k-k-e 52 1426
9876 9891 530418 TTCCTCCTGTTGGCTT k-d(10)-k-e-k-e-e 59 1426
9877 9893 530048 GGTTCCTCCTGTTGGCT e-e-k-d(10)-k-e-k-e 82 1427
9877 9892 530368 GTTCCTCCTGTTGGCT e-k-d(10)-k-e-k-e 85 1428
9878 9893 530116 GGTTCCTCCTGTTGGC e-k-k-d(10)-k-k-e 90 1429
9878 9893 530163 GGTTCCTCCTGTTGGC e-e-k-d(10)-k-k-e 79 1429
9878 9893 530213 GGTTCCTCCTGTTGGC e-d-k-d(10)-k-k-e 72 1429
9878 9893 530263 GGTTCCTCCTGTTGGC e-d-d-k-d(9)-k-k-e 73 1429
9878 9893 530313 GGTTCCTCCTGTTGGC e-e-e-e-d(9)-k-k-e 61 1429
9964 9979 529041 GTAATGTGCAGCAATC e-e-e-d(10)-k-k-k 53 1430
BIOL0142WO
9991 10006 530711 ATGTGAGGGCACATTT e-e-e-d(10)-k-k-k 25 1431
10286 10301 529042 CCAAGCCGTTTATTTC e-e-e-d(10)-k-k-k 44 1432
10291 10306 529043 GGAAGCCAAGCCGTTT e-e-e-d(10)-k-k-k 39 1433
11261 11276 530413 GCCCCTATGTATAAGC k-d(10)-k-e-k-e-e 73 1410
11262 11278 530043 CTGCCCCTATGTATAAG e-e-k-d(10)-k-e-k-e 42 1411
11262 11277 530363 TGCCCCTATGTATAAG e-k-d(10)-k-e-k-e 25 1412
11263 11278 530111 CTGCCCCTATGTATAA e-k-k-d(10)-k-k-e 35 1413
11263 11278 530158 CTGCCCCTATGTATAA e-e-k-d(10)-k-k-e 36 1413
11263 11278 530208 CTGCCCCTATGTATAA e-d-k-d(10)-k-k-e 14 1413
11263 11278 530258 CTGCCCCTATGTATAA e-d-d-k-d(9)-k-k-e 5 1413
11263 11278 530308 CTGCCCCTATGTATAA e-e-e-e-d(9)-k-k-e 25 1413
12345 12360 530414 TTCTTCCTGAGACACA k-d(10)-k-e-k-e-e 61 1414
12346 12362 530044 GCTTCTTCCTGAGACAC e-e-k-d(10)-k-e-k-e 78 1415
12346 12361 530364 CTTCTTCCTGAGACAC e-k-d(10)-k-e-k-e 59 1416
12347 12362 530112 GCTTCTTCCTGAGACA e-k-k-d(10)-k-k-e 84 1417
12347 12362 530159 GCTTCTTCCTGAGACA e-e-k-d(10)-k-k-e 69 1417
12347 12362 530209 GCTTCTTCCTGAGACA e-d-k-d(10)-k-k-e 54 1417
12347 12362 530259 GCTTCTTCCTGAGACA e-d-d-k-d(9)-k-k-e 57 1417
12347 12362 530309 GCTTCTTCCTGAGACA e-e-e-e-d(9)-k-k-e 46 1417
12347 12362 530415 GCTTCTTCCTGAGACA k-d(10)-k-e-k-e-e 51 1417
12348 12364 530045 TGGCTTCTTCCTGAGAC e-e-k-d(10)-k-e-k-e 73 1418
12348 12363 530365 GGCTTCTTCCTGAGAC e-k-d(10)-k-e-k-e 78 1419
12349 12364 530113 TGGCTTCTTCCTGAGA e-k-k-d(10)-k-k-e 60 1420
12349 12364 530160 TGGCTTCTTCCTGAGA e-e-k-d(10)-k-k-e 54 1420
12349 12364 530210 TGGCTTCTTCCTGAGA e-d-k-d(10)-k-k-e 28 1420
12349 12364 530260 TGGCTTCTTCCTGAGA e-d-d-k-d(9)-k-k-e 0 1420
12349 12364 530310 TGGCTTCTTCCTGAGA e-e-e-e-d(9)-k-k-e 26 1420
12356 12371 530416 CTCCTGTTGGCTTCTT k-d(10)-k-e-k-e-e 57 1421
12357 12373 530046 TCCTCCTGTTGGCTTCT e-e-k-d(10)-k-e-k-e 76 1422
12357 12372 530366 CCTCCTGTTGGCTTCT e-k-d(10)-k-e-k-e 75 1423
12357 12372 530417 CCTCCTGTTGGCTTCT k-d(10)-k-e-k-e-e 66 1423
12358 12374 530047 TTCCTCCTGTTGGCTTC e-e-k-d(10)-k-e-k-e 75 1424
12358 12373 530114 TCCTCCTGTTGGCTTC e-k-k-d(10)-k-k-e 80 1425
12358 12373 530161 TCCTCCTGTTGGCTTC e-e-k-d(10)-k-k-e 81 1425
12358 12373 530211 TCCTCCTGTTGGCTTC e-d-k-d(10)-k-k-e 73 1425
12358 12373 530261 TCCTCCTGTTGGCTTC e-d-d-k-d(9)-k-k-e 78 1425
12358 12373 530311 TCCTCCTGTTGGCTTC e-e-e-e-d(9)-k-k-e 82 1425
12358 12373 530367 TCCTCCTGTTGGCTTC e-k-d(10)-k-e-k-e 80 1425
12359 12374 530115 TTCCTCCTGTTGGCTT e-k-k-d(10)-k-k-e 74 1426
12359 12374 530162 TTCCTCCTGTTGGCTT e-e-k-d(10)-k-k-e 68 1426
12359 12374 530212 TTCCTCCTGTTGGCTT e-d-k-d(10)-k-k-e 58 1426
12359 12374 530262 TTCCTCCTGTTGGCTT e-d-d-k-d(9)-k-k-e 23 1426
12359 12374 530312 TTCCTCCTGTTGGCTT e-e-e-e-d(9)-k-k-e 52 1426
12359 12374 530418 TTCCTCCTGTTGGCTT k-d(10)-k-e-k-e-e 59 1426
12360 12376 530048 GGTTCCTCCTGTTGGCT e-e-k-d(10)-k-e-k-e 82 1427
BIOL0142WO
12360 12375 530368 GTTCCTCCTGTTGGCT e-k-d(10)-k-e-k-e 85 1428
12361 12376 530116 GGTTCCTCCTGTTGGC e-k-k-d(10)-k-k-e 90 1429
12361 12376 530163 GGTTCCTCCTGTTGGC e-e-k-d(10)-k-k-e 79 1429
12361 12376 530213 GGTTCCTCCTGTTGGC e-d-k-d(10)-k-k-e 72 1429
12361 12376 530263 GGTTCCTCCTGTTGGC e-d-d-k-d(9)-k-k-e 73 1429
12361 12376 530313 GGTTCCTCCTGTTGGC e-e-e-e-d(9)-k-k-e 61 1429
12586 12601 530710 TACAATTCCTGCCTGT e-e-e-d(10)-k-k-k 18 1434
15467 15482 530437 AGCTTTTCTATGAAAA k-d(10)-k-e-k-e-e 5 1435
15468 15484 530067 CAAGCTTTTCTATGAAA e-e-k-d(10)-k-e-k-e 53 1436
15468 15483 530387 AAGCTTTTCTATGAAA e-k-d(10)-k-e-k-e 24 1437
15469 15484 530132 CAAGCTTTTCTATGAA e-k-k-d(10)-k-k-e 74 423
15469 15484 530182 CAAGCTTTTCTATGAA e-e-k-d(10)-k-k-e 48 423
15469 15484 530232 CAAGCTTTTCTATGAA e-d-k-d(10)-k-k-e 21 423
15469 15484 530282 CAAGCTTTTCTATGAA e-d-d-k-d(9)-k-k-e 19 423
15469 15484 530332 CAAGCTTTTCTATGAA e-e-e-e-d(9)-k-k-e 20 423
16863 16878 530419 TAATTGTGTACTGGCA k-d(10)-k-e-k-e-e 75 1438
16864 16880 530049 TATAATTGTGTACTGGC e-e-k-d(10)-k-e-k-e 88 1439
16864 16879 530369 ATAATTGTGTACTGGC e-k-d(10)-k-e-k-e 92 1440
16865 16880 530117 TATAATTGTGTACTGG e-k-k-d(10)-k-k-e 73 1441
16865 16880 530164 TATAATTGTGTACTGG e-e-k-d(10)-k-k-e 65 1441
16865 16880 530214 TATAATTGTGTACTGG e-d-k-d(10)-k-k-e 37 1441
16865 16880 530264 TATAATTGTGTACTGG e-d-d-k-d(9)-k-k-e 48 1441
16865 16880 530314 TATAATTGTGTACTGG e-e-e-e-d(9)-k-k-e 42 1441
17385 17400 530709 TGGAGTAACAGGAACT e-e-e-d(10)-k-k-k 25 1442
21456 21471 530720 AAAGTTTCCCAATAGA e-e-e-d(10)-k-k-k 17 1443
22061 22076 529044 AGTCCTACCACGGCCC e-e-e-d(10)-k-k-k 27 1444
24514 24529 529045 TGACGATGCTTGGATA e-e-e-d(10)-k-k-k 37 1445
24515 24530 529046 CTGACGATGCTTGGAT e-e-e-d(10)-k-k-k 8 1446
24579 24594 529047 TCACTTTCCCTATACG e-e-e-d(10)-k-k-k 18 1447
25105 25120 530717 GTAGGTTGAGCAAGCA e-e-e-d(10)-k-k-k 77 1448
26061 26076 530420 ACTTTAGCCCCTTCCA k-d(10)-k-e-k-e-e 44 1449
26062 26078 530050 CAACTTTAGCCCCTTCC e-e-k-d(10)-k-e-k-e 64 1450
26062 26077 530370 AACTTTAGCCCCTTCC e-k-d(10)-k-e-k-e 55 1451
26063 26078 530118 CAACTTTAGCCCCTTC e-k-k-d(10)-k-k-e 58 1452
26063 26078 530165 CAACTTTAGCCCCTTC e-e-k-d(10)-k-k-e 38 1452
26063 26078 530215 CAACTTTAGCCCCTTC e-d-k-d(10)-k-k-e 29 1452
26063 26078 530265 CAACTTTAGCCCCTTC e-d-d-k-d(9)-k-k-e 3 1452
26063 26078 530315 CAACTTTAGCCCCTTC e-e-e-e-d(9)-k-k-e 30 1452
26767 26782 529048 AATTCATCGAGCTAAT e-e-e-d(10)-k-k-k 0 1453
37758 37773 529049 TGCCCCAATTAGGCCA e-e-e-d(10)-k-k-k 32 1454
37759 37774 529050 TTGCCCCAATTAGGCC e-e-e-d(10)-k-k-k 21 1455
41484 41499 530714 CCCTGTGGCTCCTTCC e-e-e-d(10)-k-k-k 27 1456
41760 41775 529051 TACTGTCCTCGAGACA e-e-e-d(10)-k-k-k 2 1457
42754 42769 530719 AGGAAAAGGAAGAATG e-e-e-d(10)-k-k-k 2 1458
42766 42781 529052 CGCATATGCCCTAGGA e-e-e-d(10)-k-k-k 7 1459
BIOL0142WO
e-e-e-d(10)-k-k-k
42768 42783 529053 GCCGCATATGCCCTAG 41 1460
e-e-e-d(10)-k-k-k
42769 42784 529054 GGCCGCATATGCCCTA 51 1461
e-e-e-d(10)-k-k-k
43072 43087 529055 CGGGTAAGTATACAGA 18 1462
e-e-e-d(10)-k-k-k
43074 43089 529056 CACGGGTAAGTATACA 4 1463
e-e-e-d(10)-k-k-k
43075 43090 529057 TCACGGGTAAGTATAC 5 1464
e-e-e-d(10)-k-k-k
43077 43092 529058 GCTCACGGGTAAGTAT 15 1465
e-e-e-d(10)-k-k-k
45633 45648 529059 GTATACAATGGCCTTT 59 1466
46633 46648 529060 CGACCCAATCAGATGC e-e-e-d(10)-k-k-k 34 1467
47430 47445 530708 GGATAAAATACAAAGG e-e-e-d(10)-k-k-k 14 1468
e-e-e-d(10)-k-k-k
47617 47632 529061 GTTCCGAAAAAACCTC 59 1469
e-e-e-d(10)-k-k-k
47619 47634 529062 GGGTTCCGAAAAAACC 16 1470
47752 47767 530712 TGCAAACTTTTTCTCT e-e-e-d(10)-k-k-k 21 1471
48092 48107 529063 ACCCGCTATCCACTCA e-e-e-d(10)-k-k-k 20 1472
48402 48417 530421 CACTTTCCATTCTAGT k-d(10)-k-e-k-e-e 20 1473
48403 48419 530051 CACACTTTCCATTCTAG e-e-k-d(10)-k-e-k-e 48 1474
48403 48418 530371 ACACTTTCCATTCTAG e-k-d(10)-k-e-k-e 36 1475
48404 48419 530119 CACACTTTCCATTCTA e-k-k-d(10)-k-k-e 47 1476
48404 48419 530166 CACACTTTCCATTCTA e-e-k-d(10)-k-k-e 53 1476
48404 48419 530216 CACACTTTCCATTCTA e-d-k-d(10)-k-k-e 34 1476
48404 48419 530266 CACACTTTCCATTCTA e-d-d-k-d(9)-k-k-e 31 1476
48404 48419 530316 CACACTTTCCATTCTA e-e-e-e-d(9)-k-k-e 34 1476
e-e-e-d(10)-k-k-k
48429 48444 529064 AGCCCCTATGGTTACC 32 1477
e-e-e-d(10)-k-k-k
48567 48582 529065 GTCTAGAGGCCTATCC 14 1478
e-e-e-d(10)-k-k-k
48568 48583 529066 GGTCTAGAGGCCTATC 17 1479
49762 49777 530718 AGATGTTGGATGTCTA e-e-e-d(10)-k-k-k 46 1480
50692 50707 530423 AGATTCTCTACCACTT k-d(10)-k-e-k-e-e 70 1054
50693 50709 530053 GGAGATTCTCTACCACT e-e-k-d(10)-k-e-k-e 84 1055
50693 50708 530373 GAGATTCTCTACCACT e-k-d(10)-k-e-k-e 85 1056
50694 50709 530121 GGAGATTCTCTACCAC e-k-k-d(10)-k-k-e 77 53
50694 50709 530168 GGAGATTCTCTACCAC e-e-k-d(10)-k-k-e 75 53
50694 50709 530218 GGAGATTCTCTACCAC e-d-k-d(10)-k-k-e 61 53
50694 50709 530268 GGAGATTCTCTACCAC e-d-d-k-d(9)-k-k-e 76 53
50694 50709 530318 GGAGATTCTCTACCAC e-e-e-e-d(9)-k-k-e 73 53
e-e-e-d(10)-k-k-k
50838 50853 529067 CCGCCTTAAGATCTAA 5 1481
e-e-e-d(10)-k-k-k
51714 51729 529068 CCCTTACTCTCCGCAT 15 1482
e-e-e-d(10)-k-k-k
51734 51749 529069 GGGAAGTGGTCCGACC 22 1483
e-e-e-d(10)-k-k-k
51757 51772 529070 CCGCAAGTGAGCGAGA 6 1484
e-e-e-d(10)-k-k-k
51760 51775 529071 ATCCCGCAAGTGAGCG 11 1485
e-e-e-d(10)-k-k-k
51763 51778 529072 GAAATCCCGCAAGTGA 0 1486
51905 51920 528400 CCGCCAGCTCACTCAC e-e-e-d(10)-k-k-k 57 66
51906 51921 528401 CCCGCCAGCTCACTCA e-e-e-d(10)-k-k-k 57 1059
51907 51922 528402 CCCCGCCAGCTCACTC e-e-e-d(10)-k-k-k 42 1060
51910 51925 528403 AAGCCCCGCCAGCTCA e-e-e-d(10)-k-k-k 72 1060
51911 51926 528404 AAAGCCCCGCCAGCTC e-e-e-d(10)-k-k-k 52 1062
51912 51927 528405 AAAAGCCCCGCCAGCT e-e-e-d(10)-k-k-k 27 1063
BIOL0142WO
51913 51928 528406 CAAAAGCCCCGCCAGC e-e-e-d(10)-k-k-k 29 1064
51914 51929 528407 ACAAAAGCCCCGCCAG e-e-e-d(10)-k-k-k 9 1065
51916 51931 528408 TGACAAAAGCCCCGCC e-e-e-d(10)-k-k-k 10 1066
51917 51932 528409 CTGACAAAAGCCCCGC e-e-e-d(10)-k-k-k 31 1067
51918 51933 528410 GCTGACAAAAGCCCCG e-e-e-d(10)-k-k-k 39 1068
51919 51934 528411 CGCTGACAAAAGCCCC e-e-e-d(10)-k-k-k 49
1069
51920 51935 528412 TCGCTGACAAAAGCCC e-e-e-d(10)-k-k-k 39
1070
51921 51936 528413 ATCGCTGACAAAAGCC e-e-e-d(10)-k-k-k 20
1071
51922 51937 528414 CATCGCTGACAAAAGC e-e-e-d(10)-k-k-k 10
1072
51924 51939 528415 TCCATCGCTGACAAAA e-e-e-d(10)-k-k-k 11
1073
51925 51940 528416 CTCCATCGCTGACAAA e-e-e-d(10)-k-k-k 15
1074
51926 51941 528417 ACTCCATCGCTGACAA e-e-e-d(10)-k-k-k 22
1075
51927 51942 528418 TACTCCATCGCTGACA e-e-e-d(10)-k-k-k 19
1076
51928 51943 528419 GTACTCCATCGCTGAC e-e-e-d(10)-k-k-k 37
1077
51929 51944 528420 CGTACTCCATCGCTGA e-e-e-d(10)-k-k-k 35
1078
51943 51958 528421 GAGAGTTTTCTGCACG e-e-e-d(10)-k-k-k 36
1079
51945 51960 528422 GTGAGAGTTTTCTGCA e-e-e-d(10)-k-k-k 22
1080
51964 51979 528423 GTCAGCCAGCTCCTCG e-e-e-d(10)-k-k-k 49
1081
51975 51990 528424 CGCCTCTTCCAGTCAG e-e-e-d(10)-k-k-k 42
1082
51977 51992 528425 GCCGCCTCTTCCAGTC e-e-e-d(10)-k-k-k 44
1083
51978 51993 528426 TGCCGCCTCTTCCAGT e-e-e-d(10)-k-k-k 15
1084
51983 51998 528427 TCTGTTGCCGCCTCTT e-e-e-d(10)-k-k-k 9
1085
51984 51999 528428 ATCTGTTGCCGCCTCT e-e-e-d(10)-k-k-k 30
1086
51985 52000 528429 AATCTGTTGCCGCCTC e-e-e-d(10)-k-k-k 23
1087
51986 52001 528430 CAATCTGTTGCCGCCT e-e-e-d(10)-k-k-k 12
1088
51987 52002 528431 GCAATCTGTTGCCGCC e-e-e-d(10)-k-k-k 48
1089
51988 52003 528432 GGCAATCTGTTGCCGC e-e-e-d(10)-k-k-k 18
1090
51989 52004 528433 AGGCAATCTGTTGCCG e-e-e-d(10)-k-k-k 0
1091
51990 52005 528434 CAGGCAATCTGTTGCC e-e-e-d(10)-k-k-k 8
1092
51991 52006 528435 GCAGGCAATCTGTTGC e-e-e-d(10)-k-k-k 13
1093
51995 52010 528436 CAATGCAGGCAATCTG e-e-e-d(10)-k-k-k 9
1094
51996 52011 528437 CCAATGCAGGCAATCT e-e-e-d(10)-k-k-k 26
1095
51997 52012 528438 TCCAATGCAGGCAATC e-e-e-d(10)-k-k-k 10
1096
51998 52013 528439 CTCCAATGCAGGCAAT e-e-e-d(10)-k-k-k 2
1097
51999 52014 528440 CCTCCAATGCAGGCAA e-e-e-d(10)-k-k-k 28
1098
52016 52031 528441 GGCAGATGTTGGGCGG e-e-e-d(10)-k-k-k 8
1099
52017 52032 528442 AGGCAGATGTTGGGCG e-e-e-d(10)-k-k-k 0
1100
52018 52033 528443 TAGGCAGATGTTGGGC e-e-e-d(10)-k-k-k 1 1101
52019 52034 528444 CTAGGCAGATGTTGGG e-e-e-d(10)-k-k-k 0 1102
52020 52035 528445 TCTAGGCAGATGTTGG e-e-e-d(10)-k-k-k 7 1103
52021 52036 528446 ATCTAGGCAGATGTTG e-e-e-d(10)-k-k-k 3 1104
52023 52038 528447 CGATCTAGGCAGATGT e-e-e-d(10)-k-k-k 9 72
52024 52039 528448 CCGATCTAGGCAGATG e-e-e-d(10)-k-k-k 13
1105
52026 52041 528449 AGCCGATCTAGGCAGA e-e-e-d(10)-k-k-k 4
1106
52027 52042 528450 TAGCCGATCTAGGCAG e-e-e-d(10)-k-k-k 11
1107
BIOL0142WO
52028 52043 528451 CTAGCCGATCTAGGCA e-e-e-d(10)-k-k-k 5
1108
52029 52044 528452 TCTAGCCGATCTAGGC e-e-e-d(10)-k-k-k 5
1109
52030 52045 528453 TTCTAGCCGATCTAGG e-e-e-d(10)-k-k-k 24
1110
52031 52046 528454 TTTCTAGCCGATCTAG e-e-e-d(10)-k-k-k 29
1111
52032 52047 528455 TTTTCTAGCCGATCTA e-e-e-d(10)-k-k-k 28
1112
52033 52048 528456 GTTTTCTAGCCGATCT e-e-e-d(10)-k-k-k 42
1113
52035 52050 528457 CAGTTTTCTAGCCGAT e-e-e-d(10)-k-k-k 50
1114
52036 52051 528458 CCAGTTTTCTAGCCGA e-e-e-d(10)-k-k-k 70
1115
e-e-e-d(10)-k-k-k
52083 52098 529073 TCAATCTAGCTTTCGA 33
1487
e-e-e-d(10)-k-k-k
52084 52099 529074 TTCAATCTAGCTTTCG 36
1488
e-e-e-d(10)-k-k-k
52119 52134 529075 GTACCAATTCTGTGGG 33
1489
55441 55456 528462 GATTCTGCTAATGACG e-e-e-d(10)-k-k-k 42
1119
55442 55457 528463 AGATTCTGCTAATGAC e-e-e-d(10)-k-k-k 38
1120
55446 55461 528464 GTTGAGATTCTGCTAA e-e-e-d(10)-k-k-k 30
1121
55447 55462 528465 AGTTGAGATTCTGCTA e-e-e-d(10)-k-k-k 48
1122
55454 55469 528466 GGTCTGAAGTTGAGAT e-e-e-d(10)-k-k-k 27
1123
55456 55471 528467 CGGGTCTGAAGTTGAG e-e-e-d(10)-k-k-k 44
1124
55457 55472 528468 ACGGGTCTGAAGTTGA e-e-e-d(10)-k-k-k 41
1125
55458 55473 528469 GACGGGTCTGAAGTTG e-e-e-d(10)-k-k-k 45
1126
55459 55474 528470 TGACGGGTCTGAAGTT e-e-e-d(10)-k-k-k 34
1127
55460 55475 528471 TTGACGGGTCTGAAGT e-e-e-d(10)-k-k-k 19
1128
55461 55476 528472 GTTGACGGGTCTGAAG e-e-e-d(10)-k-k-k 21 1129
55462 55477 528473 TGTTGACGGGTCTGAA e-e-e-d(10)-k-k-k 37 1130
55463 55478 528474 TTGTTGACGGGTCTGA e-e-e-d(10)-k-k-k 55 1131
55464 55479 528475 TTTGTTGACGGGTCTG e-e-e-d(10)-k-k-k 63 1132
55465 55480 528476 ATTTGTTGACGGGTCT e-e-e-d(10)-k-k-k 65 1133
56208 56223 529076 GTAACACCTCACCCTA e-e-e-d(10)-k-k-k 14 1490
58396 58411 530715 TCTGCCACCCAGGTTT e-e-e-d(10)-k-k-k 31 1491
e-e-e-d(10)-k-k-k
59836 59851 529077 TAAATTTCCGGGATCT 13
1492
e-e-e-d(10)-k-k-k
64187 64202 529078 CCGGTCCCTTGTAAAA 12
1493
e-e-e-d(10)-k-k-k
64289 64304 529079 GCCAACTCTAGGCGAG 16
1494
e-e-e-d(10)-k-k-k
64551 64566 529080 CGCAAGAGATCCCGGG 0
1495
e-e-e-d(10)-k-k-k
64552 64567 529081 TCGCAAGAGATCCCGG 16
1496
e-e-e-d(10)-k-k-k
64959 64974 529082 TGATCACCTCGACTGA 20
1497
66136 66151 530425 GCCCTTGCCAGCCATG k-d(10)-k-e-k-e-e 73 1134
66137 66153 530054 AAGCCCTTGCCAGCCAT e-e-k-d(10)-k-e-k-e 75 1135
66137 66152 530375 AGCCCTTGCCAGCCAT e-k-d(10)-k-e-k-e 77 1136
66138 66153 530123 AAGCCCTTGCCAGCCA e-k-k-d(10)-k-k-e 86 144
66138 66153 530170 AAGCCCTTGCCAGCCA e-e-k-d(10)-k-k-e 87 144
66138 66153 530220 AAGCCCTTGCCAGCCA e-d-k-d(10)-k-k-e 74 144
66138 66153 530270 AAGCCCTTGCCAGCCA e-d-d-k-d(9)-k-k-e 87 144
66138 66153 530320 AAGCCCTTGCCAGCCA e-e-e-e-d(9)-k-k-e 83 144
66183 66198 530426 TTTTTCACAAGGTCAA k-d(10)-k-e-k-e-e 55 1137
66184 66200 530059 ACTTTTTCACAAGGTCA e-e-k-d(10)-k-e-k-e 73 1138
66184 66199 530376 CTTTTTCACAAGGTCA e-k-d(10)-k-e-k-e 77 1139
BIOL0142WO
66185 66200 530124 ACTTTTTCACAAGGTC e-k-k-d(10)-k-k-e 79 153
66185 66200 530171 ACTTTTTCACAAGGTC e-e-k-d(10)-k-k-e 69 153
66185 66200 530221 ACTTTTTCACAAGGTC e-d-k-d(10)-k-k-e 64 153
66185 66200 530271 ACTTTTTCACAAGGTC e-d-d-k-d(9)-k-k-e 73 153
66185 66200 530321 ACTTTTTCACAAGGTC e-e-e-e-d(9)-k-k-e 56 153
66875 66890 529083 GCCACCCTAGTGTTGA e-e-e-d(10)-k-k-k 27 1498
67066 67081 530427 ATGATCTTATAGCCCA k-d(10)-k-e-k-e-e 43 931
67067 67083 530060 CCATGATCTTATAGCCC e-e-k-d(10)-k-e-k-e 77 1140
67067 67082 530377 CATGATCTTATAGCCC e-k-d(10)-k-e-k-e 66 932
67068 67083 530125 CCATGATCTTATAGCC e-k-k-d(10)-k-k-e 65 175
67068 67083 530172 CCATGATCTTATAGCC e-e-k-d(10)-k-k-e 59 175
67068 67083 530222 CCATGATCTTATAGCC e-d-k-d(10)-k-k-e 48 175
67068 67083 530272 CCATGATCTTATAGCC e-d-d-k-d(9)-k-k-e 63 175
67068 67083 530322 CCATGATCTTATAGCC e-e-e-e-d(9)-k-k-e 45 175
67270 67285 530716 TTTGCCTATCTATCCT e-e-e-d(10)-k-k-k 11 1499
e-e-e-d(10)-k-k-k
67346 67361 529084 CGGTCACCCCAACAAA 33 1500
e-e-e-d(10)-k-k-k
69470 69485 529085 AAGGGCGATGGTAATG 4 1501
71614 71629 530422 GTACAATTGCTTCAAC k-d(10)-k-e-k-e-e 46 1502
71615 71631 530052 CAGTACAATTGCTTCAA e-e-k-d(10)-k-e-k-e 51 1503
71615 71630 530372 AGTACAATTGCTTCAA e-k-d(10)-k-e-k-e 51 1504
71616 71631 530120 CAGTACAATTGCTTCA e-k-k-d(10)-k-k-e 78 1505
71616 71631 530167 CAGTACAATTGCTTCA e-e-k-d(10)-k-k-e 69 1505
71616 71631 530217 CAGTACAATTGCTTCA e-d-k-d(10)-k-k-e 47 1505
71616 71631 530267 CAGTACAATTGCTTCA e-d-d-k-d(9)-k-k-e 64 1505
71616 71631 530317 CAGTACAATTGCTTCA e-e-e-e-d(9)-k-k-e 60 1505
72138 72153 530713 CTCATGCCAAGATTGT e-e-e-d(10)-k-k-k 26 1506
e-e-e-d(10)-k-k-k
72299 72314 529086 AAGCCACTTACGGTGT 0 1507
e-e-e-d(10)-k-k-k
72874 72889 529087 CGTCTATTTCCAGTGT 22 1508
73648 73663 529088 ACTAGTTCAGTTGTCC e-e-e-d(10)-k-k-k 0 1509
73866 73881 530428 TAGCAGAAGTAGGAGA k-d(10)-k-e-k-e-e 49 1141
73867 73883 530061 GATAGCAGAAGTAGGAG e-e-k-d(10)-k-e-k-e 49 1142
73867 73882 530378 ATAGCAGAAGTAGGAG e-k-d(10)-k-e-k-e 48 1143
73868 73883 530126 GATAGCAGAAGTAGGA e-k-k-d(10)-k-k-e 70 223
73868 73883 530173 GATAGCAGAAGTAGGA e-e-k-d(10)-k-k-e 62 223
73868 73883 530223 GATAGCAGAAGTAGGA e-d-k-d(10)-k-k-e 44 223
73868 73883 530273 GATAGCAGAAGTAGGA e-d-d-k-d(9)-k-k-e 63 223
73868 73883 530323 GATAGCAGAAGTAGGA e-e-e-e-d(9)-k-k-e 37 223
74199 74214 530513 TTGGATGTCAGCAAGG k-d(10)-k-e-k-e-e 88 1047
74200 74215 530507 TTTGGATGTCAGCAAG e-k-d(10)-k-e-k-e 86 1144
74200 74215 530514 TTTGGATGTCAGCAAG k-d(10)-k-e-k-e-e 80 1144
74201 74216 530430 ATTTGGATGTCAGCAA k-d(10)-k-e-k-e-e 87 1145
74201 74216 530468 ATTTGGATGTCAGCAA e-k-k-d(10)-k-k-e 81 1145
74201 74216 530476 ATTTGGATGTCAGCAA e-e-k-d(10)-k-k-e 82 1145
74201 74216 530484 ATTTGGATGTCAGCAA e-d-k-d(10)-k-k-e 74 1145
74201 74216 530492 ATTTGGATGTCAGCAA e-d-d-k-d(9)-k-k-e 83 1145
BIOL0142WO
74201 74216 530500 ATTTGGATGTCAGCAA e-e-e-e-d(9)-k-k-e 56 1145
74201 74216 530508 ATTTGGATGTCAGCAA e-k-d(10)-k-e-k-e 83 1145
74202 74218 530062 CTATTTGGATGTCAGCA e-e-k-d(10)-k-e-k-e 94 1146
74202 74217 530380 TATTTGGATGTCAGCA e-k-d(10)-k-e-k-e 94 1147
74202 74217 530469 TATTTGGATGTCAGCA e-k-k-d(10)-k-k-e 91 1147
74202 74217 530477 TATTTGGATGTCAGCA e-e-k-d(10)-k-k-e 87 1147
74202 74217 530485 TATTTGGATGTCAGCA e-d-k-d(10)-k-k-e 87 1147
74202 74217 530493 TATTTGGATGTCAGCA e-d-d-k-d(9)-k-k-e 81 1147
74202 74217 530501 TATTTGGATGTCAGCA e-e-e-e-d(9)-k-k-e 74 1147
74202 74217 530515 TATTTGGATGTCAGCA k-d(10)-k-e-k-e-e 87 1147
74203 74218 481464 CTATTTGGATGTCAGC k-k-k-d(10)-k-k-k 93 245
74203 74218 518349 CTATTTGGATGTCAGC e-e-e-d(10)-k-k-k 58 245
74203 74218 519637 CTATTTGGATGTCAGC e-k-k-d(10)-k-k-e 96 245
74203 74218 530175 CTATTTGGATGTCAGC e-e-k-d(10)-k-k-e 93 245
74203 74218 530225 CTATTTGGATGTCAGC e-d-k-d(10)-k-k-e 85 245
74203 74218 530275 CTATTTGGATGTCAGC e-d-d-k-d(9)-k-k-e 91 245
74203 74218 530325 CTATTTGGATGTCAGC e-e-e-e-d(9)-k-k-e 91 245
74204 74219 530470 TCTATTTGGATGTCAG e-k-k-d(10)-k-k-e 91 1148
74204 74219 530478 TCTATTTGGATGTCAG e-e-k-d(10)-k-k-e 87 1148
74204 74219 530486 TCTATTTGGATGTCAG e-d-k-d(10)-k-k-e 84 1148
74204 74219 530494 TCTATTTGGATGTCAG e-d-d-k-d(9)-k-k-e 60 1148
74204 74219 530502 TCTATTTGGATGTCAG e-e-e-e-d(9)-k-k-e 64 1148
74204 74219 530509 TCTATTTGGATGTCAG e-k-d(10)-k-e-k-e 80 1148
74205 74220 530471 TTCTATTTGGATGTCA e-k-k-d(10)-k-k-e 83 1149
74205 74220 530479 TTCTATTTGGATGTCA e-e-k-d(10)-k-k-e 74 1149
74205 74220 530487 TTCTATTTGGATGTCA e-d-k-d(10)-k-k-e 71 1149
74205 74220 530495 TTCTATTTGGATGTCA e-d-d-k-d(9)-k-k-e 68 1149
74205 74220 530503 TTCTATTTGGATGTCA e-e-e-e-d(9)-k-k-e 53 1149
74646 74661 530431 CACCAAGGAGGCTGTT k-d(10)-k-e-k-e-e 44 1150
74647 74663 530055 AGCACCAAGGAGGCTGT e-e-k-d(10)-k-e-k-e 45 1151
74647 74662 530381 GCACCAAGGAGGCTGT e-k-d(10)-k-e-k-e 74 1152
74648 74663 530128 AGCACCAAGGAGGCTG e-k-k-d(10)-k-k-e 52 257
74648 74663 530176 AGCACCAAGGAGGCTG e-e-k-d(10)-k-k-e 66 257
74648 74663 530226 AGCACCAAGGAGGCTG e-d-k-d(10)-k-k-e 51 257
74648 74663 530276 AGCACCAAGGAGGCTG e-d-d-k-d(9)-k-k-e 70 257
74648 74663 530326 AGCACCAAGGAGGCTG e-e-e-e-d(9)-k-k-e 52 257
74714 74729 528860 GGTTTGACCTGAAGCC e-e-e-d(10)-k-k-k 58 1153
74715 74730 528861 GGGTTTGACCTGAAGC e-e-e-d(10)-k-k-k 42 1154
74716 74731 528862 AGGGTTTGACCTGAAG e-e-e-d(10)-k-k-k 57
1155
74717 74732 528863 AAGGGTTTGACCTGAA e-e-e-d(10)-k-k-k 43
1156
74718 74733 528864 TAAGGGTTTGACCTGA e-e-e-d(10)-k-k-k 50
1157
74719 74734 528865 TTAAGGGTTTGACCTG e-e-e-d(10)-k-k-k 32
1158
74734 74749 528866 GCAGCTTCAGATGTCT e-e-e-d(10)-k-k-k 60
1159
74735 74750 528867 TGCAGCTTCAGATGTC e-e-e-d(10)-k-k-k 47
1160
74770 74785 530388 CTTAAACCTTCCTATT k-d(10)-k-e-k-e-e 14
1161
BIOL0142WO
74771 74786 530338 CCTTAAACCTTCCTAT e-k-d(10)-k-e-k-e 47
1162
74772 74787 530086 TCCTTAAACCTTCCTA e-k-k-d(10)-k-k-e 58 273
74772 74787 530133 TCCTTAAACCTTCCTA e-e-k-d(10)-k-k-e 53 273
74772 74787 530183 TCCTTAAACCTTCCTA e-d-k-d(10)-k-k-e 52 273
74772 74787 530233 TCCTTAAACCTTCCTA e-d-d-k-d(9)-k-k-e 29 273
74772 74787 530283 TCCTTAAACCTTCCTA e-e-e-e-d(9)-k-k-e 32 273
74777 74792 528868 GATTCTCCTTAAACCT e-e-e-d(10)-k-k-k 45 1163
74778 74793 530389 AGATTCTCCTTAAACC k-d(10)-k-e-k-e-e 44 1164
74779 74794 530339 TAGATTCTCCTTAAAC e-k-d(10)-k-e-k-e 41 1165
74780 74795 530087 TTAGATTCTCCTTAAA e-k-k-d(10)-k-k-e 43 1166
74780 74795 530134 TTAGATTCTCCTTAAA e-e-k-d(10)-k-k-e 28 1166
74780 74795 530184 TTAGATTCTCCTTAAA e-d-k-d(10)-k-k-e 13 1166
74780 74795 530234 TTAGATTCTCCTTAAA e-d-d-k-d(9)-k-k-e 15 1166
74780 74795 530284 TTAGATTCTCCTTAAA e-e-e-e-d(9)-k-k-e 14 1166
74782 74797 530390 GCTTAGATTCTCCTTA k-d(10)-k-e-k-e-e 83 1167
74783 74798 530340 TGCTTAGATTCTCCTT e-k-d(10)-k-e-k-e 89 1168
74784 74799 528869 ATGCTTAGATTCTCCT e-e-e-d(10)-k-k-k 83 1169
74784 74799 530088 ATGCTTAGATTCTCCT e-k-k-d(10)-k-k-e 90 1169
74784 74799 530135 ATGCTTAGATTCTCCT e-e-k-d(10)-k-k-e 91 1169
74784 74799 530185 ATGCTTAGATTCTCCT e-d-k-d(10)-k-k-e 85 1169
74784 74799 530235 ATGCTTAGATTCTCCT e-d-d-k-d(9)-k-k-e 28 1169
74784 74799 530285 ATGCTTAGATTCTCCT e-e-e-e-d(9)-k-k-e 86 1169
74784 74799 530391 ATGCTTAGATTCTCCT k-d(10)-k-e-k-e-e 79 1169
74785 74801 530021 AAATGCTTAGATTCTCC e-e-k-d(10)-k-e-k-e 87 1170
74785 74800 530341 AATGCTTAGATTCTCC e-k-d(10)-k-e-k-e 88 1171
74786 74801 530089 AAATGCTTAGATTCTC e-k-k-d(10)-k-k-e 71 1172
74786 74801 530136 AAATGCTTAGATTCTC e-e-k-d(10)-k-k-e 66 1172
74786 74801 530186 AAATGCTTAGATTCTC e-d-k-d(10)-k-k-e 51 1172
74786 74801 530236 AAATGCTTAGATTCTC e-d-d-k-d(9)-k-k-e 74 1172
74786 74801 530286 AAATGCTTAGATTCTC e-e-e-e-d(9)-k-k-e 56 1172
74869 74884 528870 GTAAGCACCCTCTGCC e-e-e-d(10)-k-k-k 26 1173
74871 74886 528871 TTGTAAGCACCCTCTG e-e-e-d(10)-k-k-k 14 1174
74873 74888 528872 GGTTGTAAGCACCCTC e-e-e-d(10)-k-k-k 47 1175
74874 74889 528873 AGGTTGTAAGCACCCT e-e-e-d(10)-k-k-k 40 1176
74875 74890 528874 AAGGTTGTAAGCACCC e-e-e-d(10)-k-k-k 54 1177
74877 74892 528875 TCAAGGTTGTAAGCAC e-e-e-d(10)-k-k-k 15 1178
74878 74893 528876 GTCAAGGTTGTAAGCA e-e-e-d(10)-k-k-k 28 1179
74879 74894 528877 AGTCAAGGTTGTAAGC e-e-e-d(10)-k-k-k 28 1180
74881 74896 528878 GGAGTCAAGGTTGTAA e-e-e-d(10)-k-k-k 6 1181
74882 74897 528879 GGGAGTCAAGGTTGTA e-e-e-d(10)-k-k-k 22 1182
74901 74916 530392 GATCAAGTCCAGGGAG k-d(10)-k-e-k-e-e 47 1183
74902 74918 530022 CAGATCAAGTCCAGGGA e-e-k-d(10)-k-e-k-e 80 1184
74902 74917 530342 AGATCAAGTCCAGGGA e-k-d(10)-k-e-k-e 70 1185
74902 74917 530393 AGATCAAGTCCAGGGA k-d(10)-k-e-k-e-e 46 1185
74903 74919 530023 GCAGATCAAGTCCAGGG e-e-k-d(10)-k-e-k-e 74 1186
BIOL0142WO
74903 74918 530090 CAGATCAAGTCCAGGG e-k-k-d(10)-k-k-e 78 1187
74903 74918 530137 CAGATCAAGTCCAGGG e-e-k-d(10)-k-k-e 76 1187
74903 74918 530187 CAGATCAAGTCCAGGG e-d-k-d(10)-k-k-e 68 1187
74903 74918 530237 CAGATCAAGTCCAGGG e-d-d-k-d(9)-k-k-e 36 1187
74903 74918 530287 CAGATCAAGTCCAGGG e-e-e-e-d(9)-k-k-e 56 1187
74903 74918 530343 CAGATCAAGTCCAGGG e-k-d(10)-k-e-k-e 68 1187
74903 74918 530394 CAGATCAAGTCCAGGG k-d(10)-k-e-k-e-e 49 1187
74904 74919 518343 GCAGATCAAGTCCAGG e-e-e-d(10)-k-k-k 5 1188
74904 74920 530024 AGCAGATCAAGTCCAGG e-e-k-d(10)-k-e-k-e 79 1189
74904 74919 530091 GCAGATCAAGTCCAGG e-k-k-d(10)-k-k-e 81 1188
74904 74919 530138 GCAGATCAAGTCCAGG e-e-k-d(10)-k-k-e 81 1188
74904 74919 530188 GCAGATCAAGTCCAGG e-d-k-d(10)-k-k-e 78 1188
74904 74919 530238 GCAGATCAAGTCCAGG e-d-d-k-d(9)-k-k-e 29 1188
74904 74919 530288 GCAGATCAAGTCCAGG e-e-e-e-d(9)-k-k-e 69 1188
74904 74919 530344 GCAGATCAAGTCCAGG e-k-d(10)-k-e-k-e 85 1188
74905 74920 530092 AGCAGATCAAGTCCAG e-k-k-d(10)-k-k-e 85 1190
74905 74920 530139 AGCAGATCAAGTCCAG e-e-k-d(10)-k-k-e 79 1190
74905 74920 530189 AGCAGATCAAGTCCAG e-d-k-d(10)-k-k-e 77 1190
74905 74920 530239 AGCAGATCAAGTCCAG e-d-d-k-d(9)-k-k-e 61 1190
74905 74920 530289 AGCAGATCAAGTCCAG e-e-e-e-d(9)-k-k-e 75 1190
74907 74922 528880 ACAGCAGATCAAGTCC e-e-e-d(10)-k-k-k 65 1191
74908 74923 528881 AACAGCAGATCAAGTC e-e-e-d(10)-k-k-k 44 1192
74924 74939 528882 ACAACCTAGCCTCTGA e-e-e-d(10)-k-k-k 39 1193
74925 74940 528883 AACAACCTAGCCTCTG e-e-e-d(10)-k-k-k 46 1194
74927 74942 528884 GAAACAACCTAGCCTC e-e-e-d(10)-k-k-k 37 1195
74928 74943 528885 AGAAACAACCTAGCCT e-e-e-d(10)-k-k-k 20 1196
74929 74944 528886 CAGAAACAACCTAGCC e-e-e-d(10)-k-k-k 21 1197
74942 74957 528887 GATAAGGCACCCACAG e-e-e-d(10)-k-k-k 25 1198
74943 74958 528888 TGATAAGGCACCCACA e-e-e-d(10)-k-k-k 12 1199
74944 74959 528889 CTGATAAGGCACCCAC e-e-e-d(10)-k-k-k 25 1200
74946 74961 528890 CCCTGATAAGGCACCC e-e-e-d(10)-k-k-k 42 1201
74947 74962 528891 GCCCTGATAAGGCACC e-e-e-d(10)-k-k-k 49 1202
74952 74967 528892 TCCCAGCCCTGATAAG e-e-e-d(10)-k-k-k 0 1203
74954 74969 528893 TATCCCAGCCCTGATA e-e-e-d(10)-k-k-k 0 1204
74957 74972 528894 AAGTATCCCAGCCCTG e-e-e-d(10)-k-k-k 25 1205
74958 74973 528895 GAAGTATCCCAGCCCT e-e-e-d(10)-k-k-k 39 1206
74959 74974 528896 AGAAGTATCCCAGCCC e-e-e-d(10)-k-k-k 22 1207
74960 74975 528897 CAGAAGTATCCCAGCC e-e-e-d(10)-k-k-k 36 1208
75079 75094 528898 TGAGACCAGGATTCCT e-e-e-d(10)-k-k-k 41 1209
75083 75098 528899 GTCCTGAGACCAGGAT e-e-e-d(10)-k-k-k 19 1210
75164 75179 528900 AGCTCAACCAGACACG e-e-e-d(10)-k-k-k 54 311
75166 75181 528901 TGAGCTCAACCAGACA e-e-e-d(10)-k-k-k 40 1211
75171 75186 528902 TTCCCTGAGCTCAACC e-e-e-d(10)-k-k-k 32 1212
75179 75194 528903 GAACCATATTCCCTGA e-e-e-d(10)-k-k-k 30 313
75182 75197 528904 TAAGAACCATATTCCC e-e-e-d(10)-k-k-k 27 1213
BIOL0142WO
75209 75224 518344 GCCACTGGATATCACC e-e-e-d(10)-k-k-k 89 317
75254 75269 528905 TAAGCCTTTGCCCTGC e-e-e-d(10)-k-k-k 64 1214
75255 75270 528906 GTAAGCCTTTGCCCTG e-e-e-d(10)-k-k-k 53 1215
75256 75271 528907 AGTAAGCCTTTGCCCT e-e-e-d(10)-k-k-k 45 1216
75257 75272 528908 CAGTAAGCCTTTGCCC e-e-e-d(10)-k-k-k 40 1217
75259 75274 528909 ATCAGTAAGCCTTTGC e-e-e-d(10)-k-k-k 53
1218
75260 75275 528910 TATCAGTAAGCCTTTG e-e-e-d(10)-k-k-k 47
1219
75264 75279 528911 AGTTTATCAGTAAGCC e-e-e-d(10)-k-k-k 58
1220
75270 75285 528912 GACTCAAGTTTATCAG e-e-e-d(10)-k-k-k 37
1221
75272 75287 528913 CAGACTCAAGTTTATC e-e-e-d(10)-k-k-k 39
1222
75273 75288 528914 GCAGACTCAAGTTTAT e-e-e-d(10)-k-k-k 0
1223
75274 75289 528915 GGCAGACTCAAGTTTA e-e-e-d(10)-k-k-k 1
1224
75275 75290 528916 GGGCAGACTCAAGTTT e-e-e-d(10)-k-k-k 0
1225
75276 75291 528917 AGGGCAGACTCAAGTT e-e-e-d(10)-k-k-k 9
1226
75278 75293 528918 CGAGGGCAGACTCAAG e-e-e-d(10)-k-k-k 2
1227
75280 75295 528919 TACGAGGGCAGACTCA e-e-e-d(10)-k-k-k 20 324
75281 75296 528920 ATACGAGGGCAGACTC e-e-e-d(10)-k-k-k 14 1228
75282 75297 528921 CATACGAGGGCAGACT e-e-e-d(10)-k-k-k 0 1229
75283 75298 528922 TCATACGAGGGCAGAC e-e-e-d(10)-k-k-k 8 1230
75285 75300 528923 CCTCATACGAGGGCAG e-e-e-d(10)-k-k-k 2 1231
75286 75301 528924 CCCTCATACGAGGGCA e-e-e-d(10)-k-k-k 2 1232
75287 75302 528925 ACCCTCATACGAGGGC e-e-e-d(10)-k-k-k 0 1233
75412 75427 528926 TACGCACAGGAGAGGC e-e-e-d(10)-k-k-k 20
1233
75413 75428 528927 ATACGCACAGGAGAGG e-e-e-d(10)-k-k-k 0
1234
75414 75429 528928 CATACGCACAGGAGAG e-e-e-d(10)-k-k-k 6
1235
75415 75430 528929 CCATACGCACAGGAGA e-e-e-d(10)-k-k-k 4
1236
75416 75431 528930 CCCATACGCACAGGAG e-e-e-d(10)-k-k-k 36
1237
75417 75432 528931 TCCCATACGCACAGGA e-e-e-d(10)-k-k-k 22 1238
75418 75433 528932 TTCCCATACGCACAGG e-e-e-d(10)-k-k-k 32 1239
75419 75434 528933 GTTCCCATACGCACAG e-e-e-d(10)-k-k-k 45 1240
75420 75435 528934 TGTTCCCATACGCACA e-e-e-d(10)-k-k-k 36 1241
75421 75436 528935 GTGTTCCCATACGCAC e-e-e-d(10)-k-k-k 20 1242
75421 75436 530395 GTGTTCCCATACGCAC k-d(10)-k-e-k-e-e 71 1242
75422 75437 528936 GGTGTTCCCATACGCA e-e-e-d(10)-k-k-k 71 1243
75422 75438 530025 AGGTGTTCCCATACGCA e-e-k-d(10)-k-e-k-e 90 1244
75422 75437 530345 GGTGTTCCCATACGCA e-k-d(10)-k-e-k-e 93 1243
75422 75437 530396 GGTGTTCCCATACGCA k-d(10)-k-e-k-e-e 71 1243
75423 75438 528937 AGGTGTTCCCATACGC e-e-e-d(10)-k-k-k 73 1245
75423 75439 530026 TAGGTGTTCCCATACGC e-e-k-d(10)-k-e-k-e 87 1246
75423 75438 530093 AGGTGTTCCCATACGC e-k-k-d(10)-k-k-e 95 1245
75423 75438 530140 AGGTGTTCCCATACGC e-e-k-d(10)-k-k-e 89 1245
75423 75438 530190 AGGTGTTCCCATACGC e-d-k-d(10)-k-k-e 82 1245
75423 75438 530240 AGGTGTTCCCATACGC e-d-d-k-d(9)-k-k-e 50 1245
75423 75438 530290 AGGTGTTCCCATACGC e-e-e-e-d(9)-k-k-e 69 1245
75423 75438 530346 AGGTGTTCCCATACGC e-k-d(10)-k-e-k-e 89 1245
BIOL0142WO
75424 75439 528938 TAGGTGTTCCCATACG e-e-e-d(10)-k-k-k 72 336
75424 75439 530094 TAGGTGTTCCCATACG e-k-k-d(10)-k-k-e 88 336
75424 75439 530141 TAGGTGTTCCCATACG e-e-k-d(10)-k-k-e 80 336
75424 75439 530191 TAGGTGTTCCCATACG e-d-k-d(10)-k-k-e 74 336
75424 75439 530241 TAGGTGTTCCCATACG e-d-d-k-d(9)-k-k-e 53 336
75424 75439 530291 TAGGTGTTCCCATACG e-e-e-e-d(9)-k-k-e 68 336
75425 75440 528939 CTAGGTGTTCCCATAC e-e-e-d(10)-k-k-k 39 1247
75426 75441 528940 GCTAGGTGTTCCCATA e-e-e-d(10)-k-k-k 62 1248
75427 75442 528941 TGCTAGGTGTTCCCAT e-e-e-d(10)-k-k-k 49 1249
75429 75444 528942 CGTGCTAGGTGTTCCC e-e-e-d(10)-k-k-k 77 1250
75491 75506 528943 CAAGGTGGTTTTGAGT e-e-e-d(10)-k-k-k 25 1251
75492 75507 528944 GCAAGGTGGTTTTGAG e-e-e-d(10)-k-k-k 28 344
75507 75522 528945 CTCTGATCAGCTGAGG e-e-e-d(10)-k-k-k 74 1252
75508 75523 528946 ACTCTGATCAGCTGAG e-e-e-d(10)-k-k-k 56 1253
75549 75564 528947 GAGACCAGCTAATTTG e-e-e-d(10)-k-k-k 36 1254
75582 75597 528948 CATCTTAGAGAAGGTC e-e-e-d(10)-k-k-k 59 1255
75622 75637 528949 TCAACTGTCTCCAGGC e-e-e-d(10)-k-k-k 67 1256
75622 75637 530397 TCAACTGTCTCCAGGC k-d(10)-k-e-k-e-e 60 1256
75623 75638 528950 ATCAACTGTCTCCAGG e-e-e-d(10)-k-k-k 57 1257
75623 75639 530027 CATCAACTGTCTCCAGG e-e-k-d(10)-k-e-k-e 56 1258
75623 75638 530347 ATCAACTGTCTCCAGG e-k-d(10)-k-e-k-e 49 1257
75624 75639 530095 CATCAACTGTCTCCAG e-k-k-d(10)-k-k-e 40 354
75624 75639 530142 CATCAACTGTCTCCAG e-e-k-d(10)-k-k-e 43 354
75624 75639 530192 CATCAACTGTCTCCAG e-d-k-d(10)-k-k-e 42 354
75624 75639 530242 CATCAACTGTCTCCAG e-d-d-k-d(9)-k-k-e 0 354
75624 75639 530292 CATCAACTGTCTCCAG e-e-e-e-d(9)-k-k-e 36 354
75624 75639 530398 CATCAACTGTCTCCAG k-d(10)-k-e-k-e-e 28 354
75625 75641 530028 CACATCAACTGTCTCCA e-e-k-d(10)-k-e-k-e 57 1259
75625 75640 530348 ACATCAACTGTCTCCA e-k-d(10)-k-e-k-e 58 1260
75626 75641 530096 CACATCAACTGTCTCC e-k-k-d(10)-k-k-e 72 356
75626 75641 530143 CACATCAACTGTCTCC e-e-k-d(10)-k-k-e 74 356
75626 75641 530193 CACATCAACTGTCTCC e-d-k-d(10)-k-k-e 62 356
75626 75641 530243 CACATCAACTGTCTCC e-d-d-k-d(9)-k-k-e 34 356
75626 75641 530293 CACATCAACTGTCTCC e-e-e-e-d(9)-k-k-e 59 356
75628 75643 528951 GACACATCAACTGTCT e-e-e-d(10)-k-k-k 16 1261
75662 75677 528952 GAAGAGTGTTGCTGGA e-e-e-d(10)-k-k-k 57 1262
75664 75679 528953 CTGAAGAGTGTTGCTG e-e-e-d(10)-k-k-k 46 1263
75666 75681 528954 TACTGAAGAGTGTTGC e-e-e-d(10)-k-k-k 42 1264
75672 75687 530510 ATTATGTACTGAAGAG k-d(10)-k-e-k-e-e 53 1265
75673 75688 530504 TATTATGTACTGAAGA e-k-d(10)-k-e-k-e 25 1266
75673 75688 530511 TATTATGTACTGAAGA k-d(10)-k-e-k-e-e 31 1266
75674 75689 530432 TTATTATGTACTGAAG k-d(10)-k-e-k-e-e 15 1267
75674 75689 530463 TTATTATGTACTGAAG e-k-k-d(10)-k-k-e 20 1267
75674 75689 530472 TTATTATGTACTGAAG e-e-k-d(10)-k-k-e 17 1267
75674 75689 530480 TTATTATGTACTGAAG e-d-k-d(10)-k-k-e 4 1267
BIOL0142WO
75674 75689 530488 TTATTATGTACTGAAG e-d-d-k-d(9)-k-k-e 13 1267
75674 75689 530496 TTATTATGTACTGAAG e-e-e-e-d(9)-k-k-e 0 1267
75674 75689 530505 TTATTATGTACTGAAG e-k-d(10)-k-e-k-e 37 1267
75675 75691 530063 GCTTATTATGTACTGAA e-e-k-d(10)-k-e-k-e 74 1268
75675 75690 530382 CTTATTATGTACTGAA e-k-d(10)-k-e-k-e 17 1269
75675 75690 530465 CTTATTATGTACTGAA e-k-k-d(10)-k-k-e 63 1269
75675 75690 530473 CTTATTATGTACTGAA e-e-k-d(10)-k-k-e 45 1269
75675 75690 530481 CTTATTATGTACTGAA e-d-k-d(10)-k-k-e 14 1269
75675 75690 530489 CTTATTATGTACTGAA e-d-d-k-d(9)-k-k-e 13 1269
75675 75690 530497 CTTATTATGTACTGAA e-e-e-e-d(9)-k-k-e 7 1269
75675 75690 530512 CTTATTATGTACTGAA k-d(10)-k-e-k-e-e 21 1269
75676 75691 519638 GCTTATTATGTACTGA e-k-k-d(10)-k-k-e 86 362
75676 75691 530177 GCTTATTATGTACTGA e-e-k-d(10)-k-k-e 71 362
75676 75691 530227 GCTTATTATGTACTGA e-d-k-d(10)-k-k-e 51 362
75676 75691 530277 GCTTATTATGTACTGA e-d-d-k-d(9)-k-k-e 70 362
75676 75691 530327 GCTTATTATGTACTGA e-e-e-e-d(9)-k-k-e 61 362
75677 75692 530466 AGCTTATTATGTACTG e-k-k-d(10)-k-k-e 82 1270
75677 75692 530474 AGCTTATTATGTACTG e-e-k-d(10)-k-k-e 62 1270
75677 75692 530482 AGCTTATTATGTACTG e-d-k-d(10)-k-k-e 53 1270
75677 75692 530490 AGCTTATTATGTACTG e-d-d-k-d(9)-k-k-e 42 1270
75677 75692 530498 AGCTTATTATGTACTG e-e-e-e-d(9)-k-k-e 45 1270
75677 75692 530506 AGCTTATTATGTACTG e-k-d(10)-k-e-k-e 70 1270
75678 75693 530467 AAGCTTATTATGTACT e-k-k-d(10)-k-k-e 50 1271
75678 75693 530475 AAGCTTATTATGTACT e-e-k-d(10)-k-k-e 26 1271
75678 75693 530483 AAGCTTATTATGTACT e-d-k-d(10)-k-k-e 19 1271
75678 75693 530491 AAGCTTATTATGTACT e-d-d-k-d(9)-k-k-e 13 1271
75678 75693 530499 AAGCTTATTATGTACT e-e-e-e-d(9)-k-k-e 15 1271
75679 75694 528955 TAAGCTTATTATGTAC e-e-e-d(10)-k-k-k 0 1272
75686 75701 528956 TATCAGTTAAGCTTAT e-e-e-d(10)-k-k-k 0 1273
75689 75704 528957 GTTTATCAGTTAAGCT e-e-e-d(10)-k-k-k 31 1274
75726 75741 530433 CAATGGTAAGCCCAAG k-d(10)-k-e-k-e-e 62 1275
75727 75742 528958 CCAATGGTAAGCCCAA e-e-e-d(10)-k-k-k 66 1276
75727 75743 530056 CCCAATGGTAAGCCCAA e-e-k-d(10)-k-e-k-e 73 1277
75727 75742 530383 CCAATGGTAAGCCCAA e-k-d(10)-k-e-k-e 64 1276
75728 75743 518345 CCCAATGGTAAGCCCA e-e-e-d(10)-k-k-k 80 366
75728 75743 519636 CCCAATGGTAAGCCCA e-k-k-d(10)-k-k-e 90 366
75728 75743 530178 CCCAATGGTAAGCCCA e-e-k-d(10)-k-k-e 86 366
75728 75743 530228 CCCAATGGTAAGCCCA e-d-k-d(10)-k-k-e 77 366
75728 75743 530278 CCCAATGGTAAGCCCA e-d-d-k-d(9)-k-k-e 86 366
75728 75743 530328 CCCAATGGTAAGCCCA e-e-e-e-d(9)-k-k-e 80 366
75729 75744 528959 ACCCAATGGTAAGCCC e-e-e-d(10)-k-k-k 73 1277
75731 75746 528960 AAACCCAATGGTAAGC e-e-e-d(10)-k-k-k 43 1278
75732 75747 528961 TAAACCCAATGGTAAG e-e-e-d(10)-k-k-k 18 1279
75733 75748 528962 TTAAACCCAATGGTAA e-e-e-d(10)-k-k-k 13 1280
75734 75749 528963 TTTAAACCCAATGGTA e-e-e-d(10)-k-k-k 2 1281
BIOL0142WO
75741 75756 528964 CCTATGATTTAAACCC e-e-e-d(10)-k-k-k 17 1282
75745 75760 528965 GGTCCCTATGATTTAA e-e-e-d(10)-k-k-k 31 1283
75746 75761 528966 AGGTCCCTATGATTTA e-e-e-d(10)-k-k-k 22 1284
75802 75817 528967 CCTAAGGCCATGAACT e-e-e-d(10)-k-k-k 19 374
75803 75818 528968 ACCTAAGGCCATGAAC e-e-e-d(10)-k-k-k 25 1285
75804 75819 528969 TACCTAAGGCCATGAA e-e-e-d(10)-k-k-k 41 1286
75805 75820 528970 CTACCTAAGGCCATGA e-e-e-d(10)-k-k-k 55 1287
75806 75821 528971 GCTACCTAAGGCCATG e-e-e-d(10)-k-k-k 66 1288
75807 75822 528972 TGCTACCTAAGGCCAT e-e-e-d(10)-k-k-k 56 1289
75808 75823 528973 ATGCTACCTAAGGCCA e-e-e-d(10)-k-k-k 71 1290
75809 75824 528974 CATGCTACCTAAGGCC e-e-e-d(10)-k-k-k 58 1291
75810 75825 528975 ACATGCTACCTAAGGC e-e-e-d(10)-k-k-k 34 1292
75823 75838 528976 GTTAAGACCAGATACA e-e-e-d(10)-k-k-k 45 1293
75824 75839 528977 AGTTAAGACCAGATAC e-e-e-d(10)-k-k-k 40 1294
75825 75840 528978 GAGTTAAGACCAGATA e-e-e-d(10)-k-k-k 40 1295
75826 75841 528979 AGAGTTAAGACCAGAT e-e-e-d(10)-k-k-k 62 1296
75831 75846 530399 CAATCAGAGTTAAGAC k-d(10)-k-e-k-e-e 36 1297
75832 75848 530029 TACAATCAGAGTTAAGA e-e-k-d(10)-k-e-k-e 29 1298
75832 75847 530349 ACAATCAGAGTTAAGA e-k-d(10)-k-e-k-e 33 1299
75833 75848 528980 TACAATCAGAGTTAAG e-e-e-d(10)-k-k-k 0 378
75833 75848 530097 TACAATCAGAGTTAAG e-k-k-d(10)-k-k-e 41 378
75833 75848 530144 TACAATCAGAGTTAAG e-e-k-d(10)-k-k-e 16 378
75833 75848 530194 TACAATCAGAGTTAAG e-d-k-d(10)-k-k-e 28 378
75833 75848 530244 TACAATCAGAGTTAAG e-d-d-k-d(9)-k-k-e 0 378
75833 75848 530294 TACAATCAGAGTTAAG e-e-e-e-d(9)-k-k-e 7 378
75835 75850 528981 GCTACAATCAGAGTTA e-e-e-d(10)-k-k-k 52 1300
75836 75851 528982 TGCTACAATCAGAGTT e-e-e-d(10)-k-k-k 47 1301
75837 75852 528983 TTGCTACAATCAGAGT e-e-e-d(10)-k-k-k 44 1302
75849 75864 530400 CTCTCAGAACTTTTGC k-d(10)-k-e-k-e-e 65 1303
75850 75866 530030 TCCTCTCAGAACTTTTG e-e-k-d(10)-k-e-k-e 47 1304
75850 75865 530350 CCTCTCAGAACTTTTG e-k-d(10)-k-e-k-e 54 1305
75851 75866 530098 TCCTCTCAGAACTTTT e-k-k-d(10)-k-k-e 42 380
75851 75866 530145 TCCTCTCAGAACTTTT e-e-k-d(10)-k-k-e 38 380
75851 75866 530195 TCCTCTCAGAACTTTT e-d-k-d(10)-k-k-e 43 380
75851 75866 530245 TCCTCTCAGAACTTTT e-d-d-k-d(9)-k-k-e 28 380
75851 75866 530295 TCCTCTCAGAACTTTT e-e-e-e-d(9)-k-k-e 39 380
75957 75972 528984 CCCACGGGATTCCCTC e-e-e-d(10)-k-k-k 39 1306
75958 75973 528985 ACCCACGGGATTCCCT e-e-e-d(10)-k-k-k 36 1307
75959 75974 528986 AACCCACGGGATTCCC e-e-e-d(10)-k-k-k 47 1308
75960 75975 528987 CAACCCACGGGATTCC e-e-e-d(10)-k-k-k 39 1309
75961 75976 528988 GCAACCCACGGGATTC e-e-e-d(10)-k-k-k 48 1310
75962 75977 528989 AGCAACCCACGGGATT e-e-e-d(10)-k-k-k 40 1311
75964 75979 528990 TAAGCAACCCACGGGA e-e-e-d(10)-k-k-k 27 1312
75965 75980 528991 GTAAGCAACCCACGGG e-e-e-d(10)-k-k-k 47 1313
75966 75981 528992 GGTAAGCAACCCACGG e-e-e-d(10)-k-k-k 42 1314
BIOL0142WO
75967 75982 528993 AGGTAAGCAACCCACG e-e-e-d(10)-k-k-k 54 1315
75967 75982 530434 AGGTAAGCAACCCACG k-d(10)-k-e-k-e-e 51 1315
75968 75983 528994 TAGGTAAGCAACCCAC e-e-e-d(10)-k-k-k 53 1316
75968 75984 530064 GTAGGTAAGCAACCCAC e-e-k-d(10)-k-e-k-e 53 1317
75968 75983 530384 TAGGTAAGCAACCCAC e-k-d(10)-k-e-k-e 48 1316
75969 75984 528995 GTAGGTAAGCAACCCA e-e-e-d(10)-k-k-k 64 388
75969 75984 530129 GTAGGTAAGCAACCCA e-k-k-d(10)-k-k-e 79 388
75969 75984 530179 GTAGGTAAGCAACCCA e-e-k-d(10)-k-k-e 74 388
75969 75984 530229 GTAGGTAAGCAACCCA e-d-k-d(10)-k-k-e 64 388
75969 75984 530279 GTAGGTAAGCAACCCA e-d-d-k-d(9)-k-k-e 55 388
75969 75984 530329 GTAGGTAAGCAACCCA e-e-e-e-d(9)-k-k-e 61 388
75971 75986 528996 AGGTAGGTAAGCAACC e-e-e-d(10)-k-k-k 21 1318
75975 75990 528997 TTATAGGTAGGTAAGC e-e-e-d(10)-k-k-k 10 1319
75979 75994 528998 CACCTTATAGGTAGGT e-e-e-d(10)-k-k-k 22 1320
75981 75996 528999 ACCACCTTATAGGTAG e-e-e-d(10)-k-k-k 15 1321
75984 75999 529000 TAAACCACCTTATAGG e-e-e-d(10)-k-k-k 0 1322
75985 76000 529001 ATAAACCACCTTATAG e-e-e-d(10)-k-k-k 7 1323
75997 76012 529002 GGACAGCAGCTTATAA e-e-e-d(10)-k-k-k 12 1324
75998 76013 529003 AGGACAGCAGCTTATA e-e-e-d(10)-k-k-k 40 1325
75998 76013 530401 AGGACAGCAGCTTATA k-d(10)-k-e-k-e-e 41 1325
75999 76014 529004 CAGGACAGCAGCTTAT e-e-e-d(10)-k-k-k 38 1326
75999 76015 530031 CCAGGACAGCAGCTTAT e-e-k-d(10)-k-e-k-e 58 1327
75999 76014 530351 CAGGACAGCAGCTTAT e-k-d(10)-k-e-k-e 58 1326
75999 76014 530402 CAGGACAGCAGCTTAT k-d(10)-k-e-k-e-e 60 1326
76000 76016 530032 GCCAGGACAGCAGCTTA e-e-k-d(10)-k-e-k-e 74 1328
76000 76015 530099 CCAGGACAGCAGCTTA e-k-k-d(10)-k-k-e 73 1329
76000 76015 530146 CCAGGACAGCAGCTTA e-e-k-d(10)-k-k-e 70 1329
76000 76015 530196 CCAGGACAGCAGCTTA e-d-k-d(10)-k-k-e 67 1329
76000 76015 530246 CCAGGACAGCAGCTTA e-d-d-k-d(9)-k-k-e 39 1329
76000 76015 530296 CCAGGACAGCAGCTTA e-e-e-e-d(9)-k-k-e 67 1329
76000 76015 530352 CCAGGACAGCAGCTTA e-k-d(10)-k-e-k-e 67 1329
76001 76016 530100 GCCAGGACAGCAGCTT e-k-k-d(10)-k-k-e 77 1330
76001 76016 530147 GCCAGGACAGCAGCTT e-e-k-d(10)-k-k-e 84 1330
76001 76016 530197 GCCAGGACAGCAGCTT e-d-k-d(10)-k-k-e 71 1330
76001 76016 530247 GCCAGGACAGCAGCTT e-d-d-k-d(9)-k-k-e 53 1330
76001 76016 530297 GCCAGGACAGCAGCTT e-e-e-e-d(9)-k-k-e 75 1330
76001 76016 530403 GCCAGGACAGCAGCTT k-d(10)-k-e-k-e-e 77 1330
76002 76018 530033 TGGCCAGGACAGCAGCT e-e-k-d(10)-k-e-k-e 65 1331
76002 76017 530353 GGCCAGGACAGCAGCT e-k-d(10)-k-e-k-e 83 1332
76003 76018 530101 TGGCCAGGACAGCAGC e-k-k-d(10)-k-k-e 59 1333
76003 76018 530148 TGGCCAGGACAGCAGC e-e-k-d(10)-k-k-e 79 1333
76003 76018 530198 TGGCCAGGACAGCAGC e-d-k-d(10)-k-k-e 54 1333
76003 76018 530248 TGGCCAGGACAGCAGC e-d-d-k-d(9)-k-k-e 32 1333
76003 76018 530298 TGGCCAGGACAGCAGC e-e-e-e-d(9)-k-k-e 73 1333
76014 76029 530404 TTTGAATGCAGTGGCC k-d(10)-k-e-k-e-e 67 1334
BIOL0142WO
76015 76031 530034 AATTTGAATGCAGTGGC e-e-k-d(10)-k-e-k-e 69 1335
76015 76030 530354 ATTTGAATGCAGTGGC e-k-d(10)-k-e-k-e 85 1336
76015 76030 530405 ATTTGAATGCAGTGGC k-d(10)-k-e-k-e-e 55 1336
76016 76032 530035 GAATTTGAATGCAGTGG e-e-k-d(10)-k-e-k-e 69 1337
76016 76031 530102 AATTTGAATGCAGTGG e-k-k-d(10)-k-k-e 71 1338
76016 76031 530149 AATTTGAATGCAGTGG e-e-k-d(10)-k-k-e 70 1338
76016 76031 530199 AATTTGAATGCAGTGG e-d-k-d(10)-k-k-e 58 1338
76016 76031 530249 AATTTGAATGCAGTGG e-d-d-k-d(9)-k-k-e 47 1338
76016 76031 530299 AATTTGAATGCAGTGG e-e-e-e-d(9)-k-k-e 47 1338
76016 76031 530355 AATTTGAATGCAGTGG e-k-d(10)-k-e-k-e 72 1338
76017 76032 530103 GAATTTGAATGCAGTG e-k-k-d(10)-k-k-e 77 390
76017 76032 530150 GAATTTGAATGCAGTG e-e-k-d(10)-k-k-e 73 390
76017 76032 530200 GAATTTGAATGCAGTG e-d-k-d(10)-k-k-e 63 390
76017 76032 530250 GAATTTGAATGCAGTG e-d-d-k-d(9)-k-k-e 59 390
76017 76032 530300 GAATTTGAATGCAGTG e-e-e-e-d(9)-k-k-e 65 390
76029 76044 530435 AAGTACACATTGGAAT k-d(10)-k-e-k-e-e 62 1339
76030 76046 530057 TGAAGTACACATTGGAA e-e-k-d(10)-k-e-k-e 69 1340
76030 76045 530385 GAAGTACACATTGGAA e-k-d(10)-k-e-k-e 70 1341
76031 76046 529005 TGAAGTACACATTGGA e-e-e-d(10)-k-k-k 64 392
76031 76046 530130 TGAAGTACACATTGGA e-k-k-d(10)-k-k-e 85 392
76031 76046 530180 TGAAGTACACATTGGA e-e-k-d(10)-k-k-e 82 392
76031 76046 530230 TGAAGTACACATTGGA e-d-k-d(10)-k-k-e 65 392
76031 76046 530280 TGAAGTACACATTGGA e-d-d-k-d(9)-k-k-e 75 392
76031 76046 530330 TGAAGTACACATTGGA e-e-e-e-d(9)-k-k-e 52 392
76039 76054 529006 TTACACTATGAAGTAC e-e-e-d(10)-k-k-k 16 1342
76116 76131 529007 AGTTAAAGTAGATACA e-e-e-d(10)-k-k-k 0 1343
76121 76136 529008 CTGGAAGTTAAAGTAG e-e-e-d(10)-k-k-k 30 397
76130 76145 529009 CGTTTATTTCTGGAAG e-e-e-d(10)-k-k-k 52 1344
76144 76159 529010 CGGTTCCTATATAACG e-e-e-d(10)-k-k-k 21 1345
76145 76160 529011 ACGGTTCCTATATAAC e-e-e-d(10)-k-k-k 10 1346
Example 14: Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
Gapmers from the study described in Example 13 exhibiting significant in vitro inhibition of
STAT3 were tested at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per
well and transfected using electroporation with 39.1 nM, 156.3 nM, 625.0 nM, and 2,500.0 nM
concentrations of antisense oligonucleotide, as specified in Table 15. After a treatment period of
approximately 16 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199, described hereinabove, was used
to measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
measured by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
BIOL0142WO
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 15. As illustrated in Table 15, STAT3 mRNA levels were significantly reduced in a dose-dependent
manner in antisense oligonucleotide treated cells.
Table 15
Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
39.1 625.0 2500.0
ISIS No 156.3nM
nM nM nM
(μM)
481464 6 51 84 94 0.2
518345 0 9 56 84 0.6
518349 16 3 47 83 0.6
519636 16 41 75 89 0.2
519637 24 43 84 94 0.2
519638 6 34 70 92 0.3
528403 0 4 39 77 0.9
528458 0 15 46 81 0.7
528475 1 10 51 76 0.7
528476 0 11 42 80 0.7
528869 25 19 67 86 0.3
528880 0 3 45 76 0.8
528937 0 1 49 82 0.8
528938 0 9 50 82 0.7
528942 0 20 59 88 0.5
528959 0 4 55 79 0.7
529022 0 0 52 81 0.8
529023 0 0 53 90 0.6
529024 0 0 47 80 0.8
529025 0 11 50 90 0.6
529026 0 31 73 96 0.4
529027 0 7 36 80 0.9
530021 6 30 69 92 0.3
530025 10 33 73 92 0.3
530026 3 18 52 80 0.6
530041 0 28 72 91 0.4
530048 0 22 53 83 0.5
530049 2 16 69 92 0.4
530053 0 16 66 90 0.5
530062 4 56 85 94 0.2
530066 0 12 46 84 0.7
530088 2 39 77 93 0.3
530091 3 12 59 84 0.5
530092 7 27 65 85 0.4
530093 7 46 79 96 0.2
530094 0 17 63 89 0.5
530109 9 30 72 94 0.3
BIOL0142WO
530110 0 23 61 83 0.5
530112 0 13 42 90 0.6
530114 0 21 62 79 0.6
530116 22 40 71 92 0.2
530123 8 19 72 93 0.3
530130 0 33 64 89 0.4
530131 4 34 81 93 0.3
530135 22 38 79 94 0.2
530138 6 23 57 86 0.4
530140 4 22 62 91 0.4
530147 0 15 51 83 0.6
530156 7 41 81 96 0.2
530161 0 20 46 78 0.7
530170 0 29 67 90 0.4
530175 37 52 84 95 0.1
530178 8 24 70 86 0.4
530180 0 0 61 82 0.6
530181 0 27 52 86 0.5
530185 0 22 54 86 0.5
530190 17 17 60 87 0.4
530206 8 29 73 93 0.3
530225 0 27 67 91 0.4
530228 11 16 64 86 0.4
530261 5 25 57 91 0.4
530270 7 11 62 91 0.4
530275 14 34 73 91 0.3
530278 1 27 60 85 0.4
530285 5 20 61 82 0.5
530306 3 14 66 85 0.5
530311 6 27 59 86 0.4
530320 3 17 56 85 0.5
530325 5 35 70 92 0.3
530328 4 34 61 87 0.4
530340 8 34 74 90 0.3
530341 2 23 77 89 0.4
530344 16 20 64 89 0.4
530345 15 35 77 94 0.2
530346 5 24 66 92 0.4
530353 7 25 57 83 0.5
530354 2 24 60 81 0.5
530359 0 4 44 89 0.7
530361 13 30 59 92 0.3
530365 0 0 45 88 0.7
530367 0 15 49 88 0.5
530368 0 27 64 89 0.4
BIOL0142WO
530369 10 28 78 95 0.3
530373 13 29 64 92 0.3
530375 0 14 53 90 0.5
530380 8 40 80 94 0.2
530390 11 21 66 90 0.4
530391 20 7 49 86 0.5
530411 5 19 81 95 0.3
530430 0 8 53 91 0.6
530466 0 4 53 87 0.6
530468 4 17 65 90 0.4
530469 8 38 86 94 0.2
530470 5 39 78 91 0.3
530471 0 21 69 91 0.4
530476 7 9 32 89 0.7
530477 0 12 64 87 0.5
530478 0 14 59 90 0.5
530485 0 10 61 85 0.5
530486 0 17 64 80 0.5
530492 0 25 71 89 0.4
530493 4 23 58 88 0.4
530507 5 17 65 82 0.5
530508 0 14 56 89 0.5
530509 0 17 54 86 0.5
530513 6 24 74 91 0.3
530514 1 7 52 78 0.7
530515 0 19 73 89 0.4
Example 15: Antisense inhibition of human STAT3 in HuVEC cells
Additional antisense oligonucleotides were designed targeting a STAT3 nucleic acid and were
tested for their effects on STAT3 mRNA in vitro. Cultured HuVEC cells at a density of 20,000 cells per
well were transfected using electroporation with 1,000 nM antisense oligonucleotide. After a treatment
period of approximately 24 hours, RNA was isolated from the cells and STAT3 mRNA levels were
measured by quantitative real-time PCR. Human primer probe set RTS199, described hereinabove, was
used to measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
measured by RIBOGREEN®. Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
The chimeric antisense oligonucleotides in Table 16 are 33 deoxy, MOE and cEt gapmers or
34 deoxy, MOE and cEt gapmers. The 33 gapmers are 16 nucleosides in length, wherein the
central gap segment comprises ten 2’-deoxynucleosides and is flanked on both sides (in the 5’ and 3’
directions) by wings comprising 3 nucleosides each. The 34 gapmers are 17 nucleosides in length,
wherein the central gap segment comprises ten 2’-deoxynucleosides and is flanked on the 5’ directions by
a wing comprising 3 nucleosides and on the 3’ direction by a wing comprising 4 nucleosides. The
BIOL0142WO
internucleoside linkages throughout each gapmer are phosphorothioate (P=S) linkages. All cytosine
residues throughout each gapmer are 5’-methylcytosines. The chemistry column of Table 16 presents the
sugar motif of each gapmer, where ‘e’ indicates a 2’-MOE nucleoside, ‘k’ indicates a constrained ethyl
(cEt) nucleoside, and ‘d’ indicates a 2’- deoxynucleoside.
“Human Target start site” indicates the 5’-most nucleoside to which the gapmer is targeted in the
human gene sequence. “Human Target stop site” indicates the 3’-most nucleoside to which the gapmer is
targeted in the human gene sequence. Each gapmer listed in Table 16 is targeted to human STAT3
mRNA, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NM_139276.2). Each gapmer
listed in Table 17 is targeted to human STAT3 genomic sequence, designated herein as SEQ ID NO: 2
(the complement of GENBANK Accession No. NT_010755.14 truncated from nucleotides 4185000 to
4264000).
Table 16
Inhibition of human STAT3 mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID
NO: 1
Human Human
% SEQ
Start Stop ISIS No Sequence Chemistry
inhibition ID NO
Site Site
730 745 530011 GGAGATTCTCTACCAC k-k-k-d(10)-e-e-e 73 53
1901 1916 529974 AAGCCCTTGCCAGCCA e-e-e-d(10)-k-k-k 83 144
1901 1916 530012 AAGCCCTTGCCAGCCA k-k-k-d(10)-e-e-e 73 144
2206 2221 530015 CCATGATCTTATAGCC k-k-k-d(10)-e-e-e 38 175
3016 3031 481464 CTATTTGGATGTCAGC k-k-k-d(10)-k-k-k 94 245
3461 3476 529975 AGCACCAAGGAGGCTG e-e-e-d(10)-k-k-k 54 257
3461 3476 530013 AGCACCAAGGAGGCTG k-k-k-d(10)-e-e-e 58 257
3584 3600 530018 TCCTTAAACCTTCCTAT e-e-k-d(10)-k-e-k-e 46 1510
3585 3600 529944 TCCTTAAACCTTCCTA e-e-e-d(10)-k-k-k 44 273
3585 3600 529977 TCCTTAAACCTTCCTA k-k-k-d(10)-e-e-e 66 273
3592 3608 530019 TTAGATTCTCCTTAAAC e-e-k-d(10)-k-e-k-e 43 1511
3593 3608 529945 TTAGATTCTCCTTAAA e-e-e-d(10)-k-k-k 22 1166
3593 3608 529978 TTAGATTCTCCTTAAA k-k-k-d(10)-e-e-e 49 1166
3596 3612 530020 ATGCTTAGATTCTCCTT e-e-k-d(10)-k-e-k-e 85 1512
3597 3612 529979 ATGCTTAGATTCTCCT k-k-k-d(10)-e-e-e 86 1169
3599 3614 529946 AAATGCTTAGATTCTC e-e-e-d(10)-k-k-k 46 1172
3599 3614 529980 AAATGCTTAGATTCTC k-k-k-d(10)-e-e-e 25 1172
3716 3731 529947 CAGATCAAGTCCAGGG e-e-e-d(10)-k-k-k 68 1187
3716 3731 529981 CAGATCAAGTCCAGGG k-k-k-d(10)-e-e-e 83 1187
3718 3733 529948 AGCAGATCAAGTCCAG e-e-e-d(10)-k-k-k 75 1190
3718 3733 529982 AGCAGATCAAGTCCAG k-k-k-d(10)-e-e-e 84 1190
4236 4251 529983 AGGTGTTCCCATACGC k-k-k-d(10)-e-e-e 96 1245
4237 4252 529984 TAGGTGTTCCCATACG k-k-k-d(10)-e-e-e 91 336
4437 4452 529949 CATCAACTGTCTCCAG e-e-e-d(10)-k-k-k 48 354
4437 4452 529985 CATCAACTGTCTCCAG k-k-k-d(10)-e-e-e 37 354
4439 4454 529950 CACATCAACTGTCTCC e-e-e-d(10)-k-k-k 58 356
BIOL0142WO
4439 4454 529986 CACATCAACTGTCTCC k-k-k-d(10)-e-e-e 72 356
4646 4661 529987 TACAATCAGAGTTAAG k-k-k-d(10)-e-e-e 0 378
4664 4679 529951 TCCTCTCAGAACTTTT e-e-e-d(10)-k-k-k 38 380
4664 4679 529988 TCCTCTCAGAACTTTT k-k-k-d(10)-e-e-e 40 380
4782 4797 530016 GTAGGTAAGCAACCCA k-k-k-d(10)-e-e-e 60 388
4813 4828 529952 CCAGGACAGCAGCTTA e-e-e-d(10)-k-k-k 65 1329
4813 4828 529989 CCAGGACAGCAGCTTA k-k-k-d(10)-e-e-e 63 1329
4814 4829 529953 GCCAGGACAGCAGCTT e-e-e-d(10)-k-k-k 65 1330
4814 4829 529990 GCCAGGACAGCAGCTT k-k-k-d(10)-e-e-e 75 1330
4816 4831 529954 TGGCCAGGACAGCAGC e-e-e-d(10)-k-k-k 79 1333
4816 4831 529991 TGGCCAGGACAGCAGC k-k-k-d(10)-e-e-e 52 1333
4829 4844 529955 AATTTGAATGCAGTGG e-e-e-d(10)-k-k-k 52 1338
4829 4844 529992 AATTTGAATGCAGTGG k-k-k-d(10)-e-e-e 23 1338
4830 4845 529956 GAATTTGAATGCAGTG e-e-e-d(10)-k-k-k 60 390
4830 4845 529993 GAATTTGAATGCAGTG k-k-k-d(10)-e-e-e 51 390
4844 4859 530014 TGAAGTACACATTGGA k-k-k-d(10)-e-e-e 67 392
Table 17
Inhibition of human STAT3 mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID
NO: 2
Human Human
% SEQ ID
Start Stop ISIS No Sequence Chemistry
inhibition NO
Site Site
74203 74218 CTATTTGGATGTCAGC 481464 k-k-k-d(10)-k-k-k 94 245
74772 74787 TCCTTAAACCTTCCTA 529944 e-e-e-d(10)-k-k-k 44 273
74780 74795 TTAGATTCTCCTTAAA 529945 e-e-e-d(10)-k-k-k 22 1166
74786 74801 AAATGCTTAGATTCTC 529946 e-e-e-d(10)-k-k-k 46 1172
74903 74918 CAGATCAAGTCCAGGG 529947 e-e-e-d(10)-k-k-k 68 1187
74905 74920 AGCAGATCAAGTCCAG 529948 e-e-e-d(10)-k-k-k 75 1190
75624 75639 CATCAACTGTCTCCAG 529949 e-e-e-d(10)-k-k-k 48 354
75626 75641 CACATCAACTGTCTCC 529950 e-e-e-d(10)-k-k-k 58 356
75851 75866 TCCTCTCAGAACTTTT 529951 e-e-e-d(10)-k-k-k 38 380
76000 76015 CCAGGACAGCAGCTTA 529952 e-e-e-d(10)-k-k-k 65 1329
76001 76016 GCCAGGACAGCAGCTT 529953 e-e-e-d(10)-k-k-k 65 1330
76003 76018 TGGCCAGGACAGCAGC 529954 e-e-e-d(10)-k-k-k 79 1333
76016 76031 AATTTGAATGCAGTGG 529955 e-e-e-d(10)-k-k-k 52 1338
76017 76032 GAATTTGAATGCAGTG 529956 e-e-e-d(10)-k-k-k 60 390
2340 2355 ACATACAGTAAGACCA 529957 e-e-e-d(10)-k-k-k 21 1376
2385 2400 CAAAAATTTACAACCC 529958 e-e-e-d(10)-k-k-k 10 1380
2410 2425 CCAATGCTTTATCAGC 529959 e-e-e-d(10)-k-k-k 51 1384
2671 2686 AGACTAAAATCAAGGC 529960 e-e-e-d(10)-k-k-k 30 1388
5002 5017 AACTGAAATTCCTTGG 529961 e-e-e-d(10)-k-k-k 52 1395
5701 5716 GTACTCTTTCAGTGGT 529962 e-e-e-d(10)-k-k-k 91 1399
8080 8095 GCAGATTTACCTTCCT 529963 e-e-e-d(10)-k-k-k 55 1409
9125 9140 CTGCCCCTATGTATAA 529964 e-e-e-d(10)-k-k-k 18 1413
11263 11278 CTGCCCCTATGTATAA 529964 e-e-e-d(10)-k-k-k 18 1413
BIOL0142WO
9864 9879 GCTTCTTCCTGAGACA 529965 e-e-e-d(10)-k-k-k 52 1417
12347 12362 GCTTCTTCCTGAGACA 529965 e-e-e-d(10)-k-k-k 52 1417
9866 9881 TGGCTTCTTCCTGAGA 529966 e-e-e-d(10)-k-k-k 51 1420
12349 12364 TGGCTTCTTCCTGAGA 529966 e-e-e-d(10)-k-k-k 51 1420
9875 9890 TCCTCCTGTTGGCTTC 529967 e-e-e-d(10)-k-k-k 80 1425
12358 12373 TCCTCCTGTTGGCTTC 529967 e-e-e-d(10)-k-k-k 80 1425
9876 9891 TTCCTCCTGTTGGCTT 529968 e-e-e-d(10)-k-k-k 56 1426
12359 12374 TTCCTCCTGTTGGCTT 529968 e-e-e-d(10)-k-k-k 56 1426
9878 9893 GGTTCCTCCTGTTGGC 529969 e-e-e-d(10)-k-k-k 69 1429
12361 12376 GGTTCCTCCTGTTGGC 529969 e-e-e-d(10)-k-k-k 69 1429
16865 16880 TATAATTGTGTACTGG 529970 e-e-e-d(10)-k-k-k 41 1441
26063 26078 CAACTTTAGCCCCTTC 529971 e-e-e-d(10)-k-k-k 32 1452
48404 48419 CACACTTTCCATTCTA 529972 e-e-e-d(10)-k-k-k 30 1476
71616 71631 CAGTACAATTGCTTCA 529973 e-e-e-d(10)-k-k-k 49 1505
66138 66153 AAGCCCTTGCCAGCCA 529974 e-e-e-d(10)-k-k-k 83 144
74648 74663 AGCACCAAGGAGGCTG 529975 e-e-e-d(10)-k-k-k 54 257
2705 2720 CTAATGGTTCTTTGTG 529976 e-e-e-d(10)-k-k-k 25 411
74772 74787 TCCTTAAACCTTCCTA 529977 k-k-k-d(10)-e-e-e 66 273
74780 74795 TTAGATTCTCCTTAAA 529978 k-k-k-d(10)-e-e-e 49 1166
74784 74799 ATGCTTAGATTCTCCT 529979 k-k-k-d(10)-e-e-e 86 1169
74786 74801 AAATGCTTAGATTCTC 529980 k-k-k-d(10)-e-e-e 25 1172
74903 74918 CAGATCAAGTCCAGGG 529981 k-k-k-d(10)-e-e-e 83 1187
74905 74920 AGCAGATCAAGTCCAG 529982 k-k-k-d(10)-e-e-e 84 1190
75423 75438 AGGTGTTCCCATACGC 529983 k-k-k-d(10)-e-e-e 96 1245
75424 75439 TAGGTGTTCCCATACG 529984 k-k-k-d(10)-e-e-e 91 336
75624 75639 CATCAACTGTCTCCAG 529985 k-k-k-d(10)-e-e-e 37 354
75626 75641 CACATCAACTGTCTCC 529986 k-k-k-d(10)-e-e-e 72 356
75833 75848 TACAATCAGAGTTAAG 529987 k-k-k-d(10)-e-e-e 0 378
75851 75866 TCCTCTCAGAACTTTT 529988 k-k-k-d(10)-e-e-e 40 380
76000 76015 CCAGGACAGCAGCTTA 529989 k-k-k-d(10)-e-e-e 63 1329
76001 76016 GCCAGGACAGCAGCTT 529990 k-k-k-d(10)-e-e-e 75 1330
76003 76018 TGGCCAGGACAGCAGC 529991 k-k-k-d(10)-e-e-e 52 1333
76016 76031 AATTTGAATGCAGTGG 529992 k-k-k-d(10)-e-e-e 23 1338
76017 76032 GAATTTGAATGCAGTG 529993 k-k-k-d(10)-e-e-e 51 390
2340 2355 ACATACAGTAAGACCA 529994 k-k-k-d(10)-e-e-e 44 1376
2385 2400 CAAAAATTTACAACCC 529995 k-k-k-d(10)-e-e-e 0 1380
2410 2425 CCAATGCTTTATCAGC 529996 k-k-k-d(10)-e-e-e 65 1384
2671 2686 AGACTAAAATCAAGGC 529997 k-k-k-d(10)-e-e-e 44 1388
5002 5017 AACTGAAATTCCTTGG 529998 k-k-k-d(10)-e-e-e 35 1395
5701 5716 GTACTCTTTCAGTGGT 529999 k-k-k-d(10)-e-e-e 91 1399
8080 8095 GCAGATTTACCTTCCT 530000 k-k-k-d(10)-e-e-e 80 1409
9125 9140 CTGCCCCTATGTATAA 530001 k-k-k-d(10)-e-e-e 21 1413
11263 11278 CTGCCCCTATGTATAA 530001 k-k-k-d(10)-e-e-e 21 1413
9864 9879 GCTTCTTCCTGAGACA 530002 k-k-k-d(10)-e-e-e 74 1417
12347 12362 GCTTCTTCCTGAGACA 530002 k-k-k-d(10)-e-e-e 74 1417
BIOL0142WO
9866 9881 TGGCTTCTTCCTGAGA 530003 k-k-k-d(10)-e-e-e 67 1420
12349 12364 TGGCTTCTTCCTGAGA 530003 k-k-k-d(10)-e-e-e 67 1420
9875 9890 TCCTCCTGTTGGCTTC 530004 k-k-k-d(10)-e-e-e 83 1425
12358 12373 TCCTCCTGTTGGCTTC 530004 k-k-k-d(10)-e-e-e 83 1425
9876 9891 TTCCTCCTGTTGGCTT 530005 k-k-k-d(10)-e-e-e 77 1426
12359 12374 TTCCTCCTGTTGGCTT 530005 k-k-k-d(10)-e-e-e 77 1426
9878 9893 GGTTCCTCCTGTTGGC 530006 k-k-k-d(10)-e-e-e 89 1427
12361 12376 GGTTCCTCCTGTTGGC 530006 k-k-k-d(10)-e-e-e 89 1427
16865 16880 TATAATTGTGTACTGG 530007 k-k-k-d(10)-e-e-e 21 1441
26063 26078 CAACTTTAGCCCCTTC 530008 k-k-k-d(10)-e-e-e 58 1452
48404 48419 CACACTTTCCATTCTA 530009 k-k-k-d(10)-e-e-e 59 1476
71616 71631 CAGTACAATTGCTTCA 530010 k-k-k-d(10)-e-e-e 75 1505
50694 50709 GGAGATTCTCTACCAC 530011 k-k-k-d(10)-e-e-e 73 53
66138 66153 AAGCCCTTGCCAGCCA 530012 k-k-k-d(10)-e-e-e 73 144
74648 74663 AGCACCAAGGAGGCTG 530013 k-k-k-d(10)-e-e-e 58 257
76031 76046 TGAAGTACACATTGGA 530014 k-k-k-d(10)-e-e-e 67 392
67068 67083 CCATGATCTTATAGCC 530015 k-k-k-d(10)-e-e-e 38 175
75969 75984 GTAGGTAAGCAACCCA 530016 k-k-k-d(10)-e-e-e 60 388
2705 2720 CTAATGGTTCTTTGTG 530017 k-k-k-d(10)-e-e-e 46 411
74771 74787 TCCTTAAACCTTCCTAT 530018 e-e-k-d(10)-k-e-k-e 46 1510
74779 74795 TTAGATTCTCCTTAAAC 530019 e-e-k-d(10)-k-e-k-e 43 1511
74783 74799 ATGCTTAGATTCTCCTT 530020 e-e-k-d(10)-k-e-k-e 85 1512
Example 16: Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
Gapmers from the study described in Example 15 exhibiting significant in vitro inhibition of
STAT3 were tested at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per
well and transfected using electroporation with 39.1 nM, 156.3 nM, 625.0 nM, and 2,500.0 nM
concentrations of antisense oligonucleotide, as specified in Table 18. After a treatment period of
approximately 16 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199, described hereinabove, was used
to measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
measured by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 18. As illustrated in Table 18, STAT3 mRNA levels were significantly reduced in a dose-dependent
manner in antisense oligonucleotide treated cells.
Table 18
Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
39.1 156.3 625.0 2500.0 IC
ISIS No
nM nM nM nM (μM)
BIOL0142WO
481464 41 78 92 91 0.04
529962 30 51 86 95 0.12
529979 0 43 81 95 0.27
529982 0 0 70 90 0.56
529983 31 67 87 94 0.08
529984 17 44 83 97 0.19
529999 29 51 83 96 0.13
530006 18 38 77 94 0.22
530020 2 39 75 92 0.28
Example 17: Effect of ISIS antisense oligonucleotides targeting STAT3 in the treatment of an
MDA-MB-231 human breast cancer xenograft model
BALB/c nude mice inoculated with human breast cancer cells MDA-MB-231 were treated with
ISIS 481464 and ISIS 481549. ISIS 481549 is cross-reactive with the mouse sequence (i.e, hybridizes to
the mouse sequence). Tumor growth and tolerability of oligonucleotides in the mice was evaluated.
Treatment
The study was conducted at Pharmaron Inc (Beijing, P.R. China). The BALB/c nude mice were
obtained from Beijing HFK Bio-Technology Co., Ltd. MDA-MB-231 human breast cancer cells were
maintained in vitro as a monolayer culture in Leibovitz’s L-15 medium supplemented with 10% heat-
inactivated fetal calf serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. The
cells were maintained at 37 C in an atmosphere of 5% CO in air. The tumor cells were routinely sub-
cultured twice weekly with trypsin-EDTA treatment. Cells growing at exponential growth phase were
harvested and counted for tumor inoculation.
Three groups of eight randomly assigned 6-8 week-old female BALB/c nude mice each were
inoculated in the right flank with the MDA-MB-231 tumor fragments (3 mm x 2 mm x 2 mm, which were
generated from tumor inoculation passage) for tumor development. Antisense oligonucleotide treatment
started at day 11 after tumor inoculation when the mean tumor size reached approximately 100 mm .
Two of the groups were injected intraperitoneally twice a week for 3 weeks with 25 mg/kg of ISIS
481464 or ISIS 481549. A control group of mice was injected intraperitoneally twice a week for 3 weeks
with PBS.
All procedures related to animal handling, care, and treatment, were performed according to the
guidelines approved by the Institutional Animal Care and Use Committee (IACUC). Animals were
routinely checked for any effects of tumor growth on normal behavior, such as mobility, food
consumption, body weight changes, and any other abnormal effect.
RNA analysis
BIOL0142WO
RNA was extracted from tumor tissue for real-time PCR analysis of human STAT3 mRNA levels
using primer probe set RTS199, described hereinabove. Murine STAT3 mRNA levels were also
measured using primer probe set mSTAT3_LTS00664 (forward sequence CGACAGCTTCCCCATGGA,
designated herein as SEQ ID NO: 1513; reverse sequence ATGCCCAGTCTTGACTCTCAATC,
designated herein as SEQ ID NO: 1514; probe sequence CTGCGGCAGTTCCTGGCACCTT, designated
herein as SEQ ID NO: 1515). Results are presented as percent inhibition of STAT3, relative to PBS
control, normalized to cyclophilin. As shown in Table 19, treatment with ISIS antisense oligonucleotides
resulted in reduction of both human and murine STAT3 mRNA in comparison to the PBS control.
Table 19
Percent inhibition of STAT3 mRNA in the treatment groups relative to the PBS control in the MDA-MB-
231 xenograft model
human murine
ISIS No
STAT3 STAT3
481464 25 16
481549 22 44
Effect on tumor growth
Tumor size was measured twice weekly in two dimensions using a caliper. Tumor volumes were
calculated using the formula: V = 0.536 x a x b , where a and b are the long and short diameters of the
tumor, respectively. The tumor size was utilized for calculations of the T-C and T /C values. T-C was
calculated with T as the median time (in days) required for the tumors in the treatment groups to reach a
pre-determined size (900 mm ) , and C as the median time (in days) for the tumors in the control group to
reach the same size. The T /C value (expressed as percentage) is an indication of the anti-tumor
effectiveness of the ISIS oligonucleotides, where T and C were the mean volume of the treated and
control groups, respectively, on a given day (day 32).
The results are presented in Tables 20 and 21. The data indicates that treatment with ISIS 481464
and ISIS 481549 significantly impeded tumor growth.
Table 20
Effect of antisense inhibition of STAT3 on tumor growth in the MDA-MB-231 xenograft model
Day PBS ISIS 481464 ISIS 481549
11 103 104 104
185 142 158
18 292 200 205
22 519 305 326
745 430 436
29 1,332 643 688
32 1,741 921 984
BIOL0142WO
Table 21
Effect of antisense inhibition of STAT3 on tumor growth inhibition in the MDA-MB-231 xenograft
model
Tumor Size (mm ) T /C T-C
Treatment
at day 32 (%) at 900 mm
PBS 1,741 - -
ISIS 481464 921 53
ISIS 481549 984 57
Body weight measurements
To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body weights
were measured on a regular basis during the treatment period. The data is presented in Table 22 and
indicate that treatment with either ISIS 481464 or ISIS 481549 does not cause significant weight gain or
loss.
Table 22
Body weight measurements of mice in the MDA-MB-231 xenograft model
Day 11 Day 15 Day 18 Day 22 Day 25 Day 29 Day 32
PBS 21.8 22.2 22.5 22.5 22.9 23.4 24.0
ISIS 481464 22.3 22.8 23.0 23.2 23.8 23.9 24.9
ISIS 481549 22.2 22.5 23.0 23.3 23.7 23.7 24.6
Example 18: Effect of ISIS antisense oligonucleotides targeting STAT3 in the treatment of an A431
human epidermoid carcinoma xenograft model
BALB/c nude mice inoculated with human epidermoid cancer cells A431 were treated with ISIS
481464 and ISIS 481549. ISIS 481549 is cross-reactive with the mouse sequence (i.e, hybridizes to the
mouse sequence). The effect of the treatment on tumor growth and tolerability in the mice was evaluated.
Treatment
The study was conducted at Pharmaron Inc (Beijing, P.R. China). The BALB/c nude mice were
obtained from Beijing HFK Bio-Technology Co., Ltd. A431 human epidermoid carcinoma cells were
maintained in vitro as a monolayer culture in DMEM medium supplemented with 10% heat-inactivated
fetal calf serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. The cells were
maintained at 37 C in an atmosphere of 5% CO in air. The tumor cells were routinely sub-cultured twice
weekly with trypsin-EDTA treatment. Cells growing in an exponential growth phase were harvested and
counted for tumor inoculation.
Three groups of eight randomly assigned 6-8 week-old female BALB/c nude mice each were
inoculated subcutaneously with 5 x 10 A431 tumor cells for tumor development. Antisense
oligonucleotide treatment started at day 8 after tumor inoculation when the mean tumor size reached
BIOL0142WO
approximately 95 mm . Two of the groups were injected intraperitoneally twice a week for 4 weeks with
mg/kg of ISIS 481464 or ISIS 481549. A control group of mice was injected intraperitoneally twice a
week for 4 weeks with PBS.
All procedures related to animal handling, care, and treatment, were performed according to the
guidelines approved by the Institutional Animal Care and Use Committee (IACUC). At the time of
routine monitoring, the animals were checked for any effects of tumor growth on normal behavior, such
as mobility, food consumption, body weight changes and any other abnormal effect.
RNA analysis
RNA was extracted from tumor tissue for real-time PCR analysis of human STAT3 mRNA levels
using primer probe set RTS199, described hereinabove. Murine STAT3 mRNA levels were also
measured using primer probe set mSTAT3_LTS00664, described hereinabove. Results are presented as
percent inhibition of STAT3, relative to PBS control, normalized to cyclophilin. As shown in Table 23,
treatment with ISIS antisense oligonucleotides resulted in reduction of both human and murine STAT3
mRNA in comparison to the PBS control.
Table 23
Inhibition of STAT3 mRNA in the treatment groups relative to the PBS control in the A431 xenograft
model
human murine
ISIS No
STAT3 STAT3
481464 63 26
481549 29 38
Protein analysis
Protein was extracted from tumor lysates for western analysis of human STAT3 protein levels
with STAT3 monoclonal antibody (Cell Signaling Technology, Cat #9135). Results are presented as
percent inhibition of STAT3, relative to PBS control, normalized to the house-keeping protein, COX-II.
As shown in Table 24, treatment with ISIS antisense oligonucleotides resulted in reduction of STAT3
protein levels in comparison to the PBS control.
Table 24
Inhibition of STAT3 protein levels in the treatment groups relative to the PBS control in the A431
xenograft model
ISIS No % reduction
481464 99
481549 22
BIOL0142WO
Effect on tumor growth
Tumor size was measured twice weekly in two dimensions using a caliper, and tumor volumes
were calculated using the formula: V = 0.5 x a x b , where a and b are the long and short diameters of the
tumor, respectively. The tumor size was utilized for calculations of the T-C and T /C values. T-C was
calculated with T as the median time (in days) required for the tumors in the treatment groups to reach a
pre-determined size (800 mm ), and C as the median time (in days) for the tumors in the control group to
/C value (expressed as percentage) is an indication of the anti-tumor
reach the same size. The T
effectiveness of the ISIS oligonucleotides, where T and C were the mean volume of the treated and
control groups, respectively, on a given day (day 33).
The results are presented in Tables 25 and 26. The data indicates that treatment with either ISIS
481464 or ISIS 481549 significantly impeded tumor growth.
Table 25
Effect of antisense inhibition of STAT3 on tumor growth in the A431 xenograft model
Days PBS ISIS 481464 ISIS 481549
8 94 95 95
14 178 157 132
17 308 261 202
21 528 412 304
24 682 552 426
28 875 698 555
31 1,071 898 716
33 1,210 1,030 858
Table 26
Effect of antisense inhibition of STAT3 on tumor growth inhibition in the A431 xenograft model
Tumor Size (mm ) T /C T-C
Treatment
at day 33 (%) at 800 mm
PBS 1,210 - -
ISIS 481464 1,030 85
ISIS 481549 858 71
Body weight measurements
To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body weights
were measured on a regular basis during the treatment period. The data is presented in Table 27 and
indicate that treatment with either ISIS 481464 or ISIS 481549 does not affect the overall health of the
mice.
Table 27
Body weight measurements of mice in the A431 xenograft model
Day 8 Day 14 Day 17 Day 21 Day 24 Day 28 Day 31 Day 33
PBS 20 20 20 21 21 21 22 22
ISIS 481464 20 21 21 21 21 22 22 23
BIOL0142WO
ISIS 481549 20 20 21 21 21 22 22 22
Example 19: Effect of ISIS antisense oligonucleotides targeting STAT3 in the treatment of an NCI-
H460 human non-small cell lung cancer (NSCLC) xenograft model
BALB/c nude mice inoculated with human NCI-H460 human NSCLC were treated with ISIS
491464, which targets human STAT3, and ISIS 481549, which targets both human and murine STAT3.
The effect of the treatment on tumor growth and tolerability in the mice was evaluated.
Treatment
The study was conducted at Pharmaron Inc (Beijing, P.R. China). The BALB/c nude mice were
obtained from Beijing HFK Bio-Technology Co., Ltd. NCI-H460 human NSCLC cells were maintained
in vitro as a monolayer culture in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf
serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. The cells were
maintained at 37 C in an atmosphere of 5% CO in air. The tumor cells were routinely sub-cultured twice
weekly with trypsin-EDTA treatment. Cells growing in an exponential growth phase were harvested and
counted for tumor inoculation.
Three groups of eight randomly assigned 6-8 week-old female BALB/c nude mice each were
inoculated subcutaneously with 2 x 10 NCI-H460 tumor cells for tumor development. Antisense
oligonucleotide treatment started at day 6 after tumor inoculation when the mean tumor size reached
approximately 100 mm . Two of the groups were injected intraperitoneally twice a week for 3 weeks
with 25 mg/kg of ISIS 481464 or ISIS 481549. The third group of mice was injected intraperitoneally
twice a week for 3 weeks with PBS, and served as the control group.
All procedures related to animal handling, care, and treatment, were performed according to the
guidelines approved by the Institutional Animal Care and Use Committee (IACUC). At the time of
routine monitoring, the animals were checked for any effects of tumor growth on normal behavior, such
as mobility, food consumption, body weight changes and any other abnormal effect.
RNA analysis
RNA was extracted from tumor tissue for real-time PCR analysis of human STAT3 mRNA levels
using primer probe set RTS199, described hereinabove. Murine STAT3 mRNA levels were also
measured using primer probe set mSTAT3_LTS00664, described hereinabove. Results are presented as
percent inhibition of STAT3, relative to PBS control, normalized to cyclophilin. As shown in Table 28,
treatment with ISIS antisense oligonucleotides resulted in reduction of both human and murine STAT3
mRNA in comparison to the PBS control.
BIOL0142WO
Table 28
Inhibition of STAT3 mRNA in the treatment groups relative to the PBS control in the NCI-H460
xenograft model
human murine
ISIS No
STAT3 STAT3
481464 34 0
481549 20 35
Effect on tumor growth
Tumor size was measured twice weekly in two dimensions using a caliper, and tumor volumes
were calculated using the formula: V = 0.5 x a x b , where a and b are the long and short diameters of the
/C values. T-C was
tumor, respectively. The tumor size was utilized for calculations of the T-C and T
calculated with T as the median time (in days) required for the tumors in the treatment groups to reach a
pre-determined size (1,500 mm ), and C as the median time (in days) for the tumors in the control group
to reach the same size. The T /C value (expressed as percentage) is an indication of the anti-tumor
effectiveness of the ISIS oligonucleotides, where T and C were the mean volume of the treated and
control groups, respectively, on a given day (day 20).
The results are presented in Tables 29 and 30. The data indicates that treatment with either ISIS
481464 or ISIS 481549 significantly impeded tumor growth.
Table 29
Effect of antisense inhibition of STAT3 on tumor growth in the NCI-H460 xenograft model
Days PBS ISIS 481464 ISIS 481549
6 104 104 103
8 303 197 197
11 746 498 443
13 1,175 676 654
1,642 982 954
18 2,277 1,571 1,577
2,859 1,996 2,093
22 - 2,609 2,679
Table 30
Effect of antisense inhibition of STAT3 on tumor growth inhibition in the NCI-H460 xenograft model
Tumor Size (mm ) T /C T-C
Treatment
at day 20 (%) at 1,500 mm
PBS 1,210 - -
ISIS 481464 1,030 85
ISIS 481549 858 71
Body weight measurements
To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body weights
were measured on a regular basis during the treatment period. The data is presented in Table 31 and
BIOL0142WO
indicate that treatment with either ISIS 481464 or ISIS 481549 does not affect the overall health of the
mice.
Table 31
Body weight measurements of mice in the NCI-H460 xenograft model
Day 6 Day 8 Day 11 Day 13 Day 15 Day 18 Day 20 Day 22
PBS 20 20 20 20 20 20 21 -
ISIS 481464 20 20 20 20 19 19 20 20
ISIS 481549 20 20 20 20 20 19 20 20
Example 20: Effect of antisense inhibition of human STAT3 in a human glioblastoma orthotopic
mouse model
NU/J mice orthotopically implanted with human glioblastoma cells were treated with ISIS
455291, a 55 MOE gapmer having a sequence of CAGCAGATCAAGTCCAGGGA (SEQ ID NO:
1590). The effect of the treatment on tumor growth and tolerability in the mice was evaluated.
Treatment
Thirty NU/J mice were stereotactically implanted in the right frontal lobe with 5 x 10 U-87 MG-
luc2 cells. On day 15 after tumor cell implantation, 15 of these mice were dosed intracranially with a
bolus injection at the site of tumor implantation with 100 μg of ISIS 455291, which was dissolved in 2 μL
of PBS. The remaining 15 mice were dosed intracranially with a bolus injection at the site of tumor
implantation with 2 μL of PBS. The second group of mice served as the control group.
Analysis
On day 18 after tumor transplantation, five mice from each group were euthanized by CO
inhalation and brain samples were collected for RNA analysis. RNA was extracted from tumor tissue for
real-time PCR analysis of human STAT3 mRNA levels using primer probe set RTS199, described
hereinabove. Treatment with ISIS 455291 resulted in 27% reduction of human STAT3 mRNA in the
tumor tissue in comparison to the PBS control.
The remaining mice in each group were monitored regularly up to 2 weeks for survival analysis.
The median survival for the PBS control group was 30.5 days. The medial survival for the ISIS
oligonucleotide-treated mice was 35 days. The P value was 0.2088.
Example 21: Effect of treatment with ISIS 481549 in APC/Min mice
The effect of treatment with ISIS 481549 on STAT3 mRNA levels and intestinal adenoma
numbers in the APC/Min mouse model was evaluated. The APC/Min mice strain is predisposed to
BIOL0142WO
spontaneous intestinal adenoma formation throughout the entire intestinal tract at an early age (Moser
A.R. et al., Science 1990. 247: 322-324).
Treatment
Two groups of 4 male nine-week-old APC/Min+ mice were injected subcutaneously with 5
mg/kg or 25 mg/kg of ISIS 481549 administered five times a week (total weekly doses of 25 mg/kg and
125 mg/kg, respectively) for 4 weeks. A group of 4 male nine-week-old APC/Min+ mice were injected
subcutaneously with 50 mg/kg of control oligonucleotide, ISIS 141923, administered five times a week
(total weekly dose of 250 mg/kg) for 4 weeks. A control group of 4 male nine-week-old APC/Min+ mice
were injected subcutaneously with PBS administered five times a week for 4 weeks. Mice were
euthanized with isoflurance followed by cervical dislocation 48 hrs after the final injection.
Colons and intestines were removed, separated from each other and cleaned. Approximately 5 cm
of the upper intestinal tract was excised and homogenized in 2.5 mL RLT buffer (Qiagen) with 1% of 2-
mercaptoethanol (RLT-BMe) and placed in dry ice. The colon was cut in half and the proximal half of the
tissue was homogenized in 2.5 mL RLT-BMe and placed in dry ice. A small piece of the liver (0.2 g) was
excised and homogenized in RLT-BMe and placed in dry ice.
RNA analysis
RNA was isolated from the tissues using PureLink Total RNA Purification kit (Invitrogen;
#12173-011A), according to the manufacturer’s protocol. RT-PCR was performed using the StepOnePlus
system (Applied Biosystems), according to the manufacturer’s protocol. Murine primer probe set
mSTAT3_LTS000664 (forward primer CGACAGCTTCCCCATGGA, designated herein as SEQ ID NO:
1513; reverse primer ATGCCCAGTCTTGACTCTCAATC, designated herein as SEQ ID NO: 1514;
probe CTGCGGCAGTTCCTGGCACCTT, designated herein as SEQ ID NO: 1515) was used for
measuring STAT3 mRNA levels. The mRNA level of the housekeeping gene, Cyclophilin, was measured
with the primer probe set mcyclo_24 (forward primer TCGCCGCTTGCTGCA, designated herein as SEQ
ID NO: 1516; reverse primer ATCGGCCGTGATGTCGA, designated herein as SEQ ID NO: 1517;
probe CCATGGTCAACCCCACCGTGTTC, designated herein as SEQ ID NO: 1518) and was used to
normalize STAT3 mRNA levels.
Treatment with ISIS 481549 resulted in statistically significant reduction in STAT3 mRNA
expression in liver at 25 mg/kg/wk and 125 mg/kg/wk dosing in liver, small intestine and colon (Table
32) compared to the PBS control. Significant differences between the treatment and the control groups
were determined using the Student’s two-tailed t test (p<0.05).
Table 32
Percent inhibition of STAT3 mRNA expression levels in APC/Min+ mice
Treatment Small
Liver Colon
(mg/kg/week) intestine
ISIS 141923 (250) 0 0 0
ISIS 481549 (125) 98 73 82
ISIS 481549 (25) 79 41 32
BIOL0142WO
Adenoma number analysis
Histological analysis of the small intestine was performed to microscopically evaluate adenoma
numbers. Treatment with ISIS 481549 at 125 mg/kg/week resulted in a statistically significant decrease in
tumor number compared to the PBS control (Table 33). Significant differences between the treatment and
the control groups were determined using the Student’s two-tailed t test (p<0.05).
Table 33
Adenoma counts in APC/Min+ mice
Treatment Colon
(mg/kg/week) count
ISIS 141923 (250) 5
ISIS 481549 (125) 1
ISIS 481549 (25) 5
PBS 6
Example 22: Effect of antisense oligonucleotides targeting STAT3 in the treatment of a PC-9
NSCLC xenograft model
BALB/c nude mice (Charles River) inoculated with the human non-small cell lung cancer cell
line, PC-9, were treated with ISIS 481549 and ISIS 481464. Tumor growth and STAT3 target reduction
in the mice were evaluated.
Treatment
Six- to eight-week old female BALB/c nude mice were inoculated subcutaneously with 7 x 10
PC-9 human NSCLC cells. Mice that displayed a mean tumor volume of 150-200 mm were selected and
randomized into different treatment groups. Two groups of 7 mice were injected subcutaneously with 25
mg/kg of ISIS 481549 or ISIS 481464 administered five times a week (total weekly doses of 125 mg/kg)
for 6 weeks. A group of 7 mice were injected subcutaneously with 25 mg/kg of ISIS 347526
(TCTTATGTTTCCGAACCGTT, no known murine or human target, designated herein as SEQ ID NO:
1519) administered five times a week (total weekly doses of 125 mg/kg) for 6 weeks. A final dose of
antisense oligonucleotide was given 24 hrs before the mice were euthanized.
RNA analysis
Tumors were harvested and RNA was isolated using Qiagen RNAeasy Mini Kit (#74106),
according to the manufacturer’s protocol. STAT3 mRNA levels were measured using an ABI
StepOnePlus RT-PCR instrument with human STAT3 primer probe set RTS2033 (forward primer
GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 1520; reverse primer
TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 1521; probe
CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522). The mRNA levels of the housekeeping
gene, GAPDH, was measured with the human primer probe set (forward primer
GAAGGTGAAGGTCGGAGTC, designated herein as SEQ ID NO: 1523; reverse primer
BIOL0142WO
GAAGATGGTGATGGGATTTC, designated herein as SEQ ID NO: 1524; probe
CAAGCTTCCCGTTCTCAGCC, designated herein as SEQ ID NO: 1525) and was used to normalize
RNA levels. The results are presented in Table 34 and indicate that the antisense oligonucleotides reduced
STAT3 mRNA levels.
Table 34
Percent inhibition of STAT3 mRNA expression levels in the NSCLC xenograft model compared to the
ASO control
Treatment (mg/kg) % inhibition
ISIS 481464 (25) 40
ISIS 481549 (25) 22
Tumor growth analysis
Tumors were measured regularly throughout the study period. Tumor growth inhibition (TGI)
was calculated using the formula
TGI = [1-(X of STAT3 ASO group (final))-X of STAT3 ASO group (day1))/(X of control ASO
group (final)-X of control ASO group (day1))] x 100%, where X = mean tumor volume.
The difference of the treatment group from the control group was evaluated using the ANOVA
statistical test. The results are presented in Table 35. The data indicates that tumor growth was
significantly inhibited by ISIS 481464 with TGI of 97% by day 52. Treatment by ISIS 481549 inhibited
PC-9 tumor growth by 78%.
Table 35
Tumor growth measurements in the NSCLC xenograft model
Day 10 13 18 20 25 28 31 34 38 42 45 48 52
ISIS 481464 233 241 267 240 229 201 201 254 218 222 221 236 255
ISIS 481549 233 217 239 188 237 299 326 318 328 410 341 389 398
ISIS 347526 240 279 295 344 295 354 383 407 540 573 655 890 940
Body weight analysis
Body weights were measured regularly throughout the study period. The results are presented in
Table 36 and indicate that there were no significant changes in body weight of the treatment groups
compared to the control groups.
Table 36
Body weight measurements in the NSCLC xenograft model
Day 10 13 18 20 25 28 31 34 38 42 45 48 52
ISIS 481464 18.65 19.44 18.98 19.66 19.40 19.45 19.89 20.26 19.86 20.31 20.13 20.03 20.11
ISIS 481549 18.13 19.06 18.65 19.30 19.31 19.36 19.23 19.18 18.28 17.21 16.49 15.48 15.01
ISIS 347526 18.34 19.29 19.05 19.65 19.63 19.98 20.08 20.69 19.90 20.19 20.25 20.09 20.19
BIOL0142WO
Example 23: Effect of ISIS 481464 in the treatment of an LG-476 NSCLC xenograft model
scid tm1Wjl
NOD.Cg-Prkdc Il2rg /SzJ mice (NSG; JAX #5557), which are immunodeficient, were
inoculated with the human non-small cell lung cancer cell line, LG-476 (Jackson Laboratory) and treated
with ISIS 481464. Tumor growth and STAT3 target reduction in the mice was evaluated.
Treatment
Four- to six-week old female NSG mice were inoculated subcutaneously with LG-476 human
NSCLC cells and monitored three times weekly for clinical observations, body weights and tumor
volume. Once tumors reached 1,000 mm , the tumors were harvested and fragmented. Tumor fragments
measuring 3-5 mm were implanted subcutaneously into the right hind flank of 30 NSG mice. The mice
were monitored three times a week. When individual tumors reached a volume of 200-250 mm , the mice
were randomly assigned to 2 groups and were injected with 25 mg/kg of ISIS 481464 or PBS
administered 5 times a week (weekly doses of 125 mg/kg) for 3 weeks. Tumors were harvested 24 hrs
after the last dose.
RNA analysis
Lysates from tumors were prepared using an ABI StepOnePlus RT-PCR instrument with a
human-specific primer probe set RTS2033. The mRNA levels of the housekeeping gene, Cyclophilin,
was measured with a human-specific primer probe set (forward primer GACGGCGAGCCCTTGG,
designated herein as SEQ ID NO: 1526; reverse primer TGCTGTCTTTGGGACCTTGTC, designated
herein as SEQ ID NO: 1527; probe CCGCGTCTCCTTTGAGCTGTTTGC, designated herein as SEQ ID
NO: 1528). Significant differences between the treatment and the control groups were determined using
the Student’s two-tailed t test (p<0.05).
Treatment with ISIS 481464 resulted in 43% reduction of STAT3 mRNA levels in the tumor
mass compared to the PBS control (Figure 8), which is statistically significant.
Protein analysis
Total cell lysates were prepared by homogenizing tumor in ice-cold radio-immunoprecipitation
assay (RIPA) buffer containing protease inhibitor cocktail. The lysates were analyzed by western blotting
using STAT3 antibody (Abcam Antibodies, #ab32500). The house-keeping proteins, cytochrome oxidase
II (COXII; #ab79393) and survivin (#ab76424) were also probed. STAT3 levels were normalized to
either COXII protein or survivin protein and quantified using ImageJ software.
Treatment with ISIS 481464 resulted in 50% reduction in STAT3 protein levels in the tumor
mass compared to the PBS control, which is statistically significant.
Tumor growth analysis
Tumors were measured regularly throughout the study period. Treatment with ISIS 481464
resulted in decrease in tumor volume of approximately 39% compared to the PBS control.
Example 24: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in PC9 cells
BIOL0142WO
ISIS 481464, from the studies described above, was further tested at different doses in PC9 cells,
a non small cell lung carcinoma cell line. Cells were plated at a density of 3,000 cells per well. Cells
were incubated with 0.02μM, 0.1 μM, 0.5 μM, 2.5 μΜ, and 10.0 μM concentrations of antisense
oligonucleotide, as specified in Table 37. After approximately 24 hours, RNA was isolated from the cells
and STAT3 mRNA levels were measured by quantitative real-time PCR. Human STAT3 primer probe
set RTS2033 (forward sequence GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 1520;
reverse sequence TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 1521;
probe sequence CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522) was used to measure
mRNA levels. STAT3 mRNA levels were adjusted according to content of beta-actin, a housekeeping
gene, as measured by human primer probe set HTS5002 (forward sequence
CGGACTATGACTTAGTTGCGTTACA, designated herein as SEQ ID NO: 1529; reverse sequence
GCCATGCCAATCTCATCTTGT, designated herein as SEQ ID NO: 1530; probe sequence
CCTTTCTTGACAAAACCTAACTTGCGCAGA, designated herein as SEQ ID NO: 1531). Results are
presented as percent inhibition of STAT3, relative to untreated control cells.
) of each oligonucleotide is also presented in
The half maximal inhibitory concentration (IC
Table 37. As illustrated in Table 37, ISIS 481464 was able to penetrate the cell membrane.
Table 37
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
PC9 cells
0.02 10.0
ISIS No 0.1 μM 0.5 μM 2.5 μM IC (μM)
μM μM
481464 20 51 84 94 96 0.19
Example 25: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in C42B cells
ISIS 481464, from the studies described above, was further tested at different doses in C42B
cells, a prostate cancer cell line. Cells were plated at a density of 3,000 cells per well. Cells were
incubated with 0.02μM, 0.1 μM, 0.5 μM, 2.5 μΜ, and 10.0 μM concentrations of antisense
oligonucleotide, as specified in Table 38. After approximately 24 hours, RNA was isolated from the cells
and STAT3 mRNA levels were measured by quantitative real-time PCR. Human STAT3 primer probe
set RTS2033 (forward sequence GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 1520;
reverse sequence TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 1521;
probe sequence CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522) was used to measure
mRNA levels. STAT3 mRNA levels were adjusted according to content of beta-actin, a housekeeping
gene, as measured by human primer probe set HTS5002 (forward sequence
CGGACTATGACTTAGTTGCGTTACA, designated herein as SEQ ID NO: 1529; reverse sequence
BIOL0142WO
GCCATGCCAATCTCATCTTGT, designated herein as SEQ ID NO: 1530; probe sequence
CCTTTCTTGACAAAACCTAACTTGCGCAGA, designated herein as SEQ ID NO: 1531). Results are
presented as percent inhibition of STAT3, relative to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 38. As illustrated in Table 38, ISIS 481464 was able to penetrate the cell membrane.
Table 38
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
C42B cells
0.02 10.0
ISIS No 0.1 μM 0.5 μM 2.5 μM IC (μM)
μM μM
481464 21 38 75 87 96 0.45
Example 26: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in Colo201 cells
ISIS 481464, from the studies described above, was further tested at different doses in Colo201
cells, a colorectal cancer cell line. Cells were plated at a density of 3,000 cells per well. Cells were
incubated with 0.02μM, 0.1 μM, 0.5 μM, 2.5 μΜ, and 10.0 μM concentrations of antisense
oligonucleotide, as specified in Table 39. After approximately 24 hours, RNA was isolated from the cells
and STAT3 mRNA levels were measured by quantitative real-time PCR. Human STAT3 primer probe
set RTS2033 (forward sequence GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 1520;
reverse sequence TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 1521;
probe sequence CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522) was used to measure
mRNA levels. STAT3 mRNA levels were adjusted according to content of beta-actin, a housekeeping
gene, as measured by human primer probe set HTS5002 (forward sequence
CGGACTATGACTTAGTTGCGTTACA, designated herein as SEQ ID NO: 1529; reverse sequence
GCCATGCCAATCTCATCTTGT, designated herein as SEQ ID NO: 1530; probe sequence
CCTTTCTTGACAAAACCTAACTTGCGCAGA, designated herein as SEQ ID NO: 1531). Results are
presented as percent inhibition of STAT3, relative to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 39. As illustrated in Table 39, ISIS 481464 was able to penetrate the cell membrane.
Table 39
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
Colo201 cells
0.02 10.0
ISIS No 0.1 μM 0.5 μM 2.5 μM IC (μM)
μM μM
481464 36 53 81 93 96 0.09
BIOL0142WO
Example 27: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in BT474M1 cells
ISIS 481464, from the studies described above, was further tested at different doses in BT474M1
cells, a breast cancer cell line. Cells were plated at a density of 3,000 cells per well. Cells were incubated
with 0.02μM, 0.1 μM, 0.5 μM, 2.5 μΜ, and 10.0 μM concentrations of antisense oligonucleotide, as
specified in Table 40. After approximately 24 hours, RNA was isolated from the cells and STAT3
mRNA levels were measured by quantitative real-time PCR. Human STAT3 primer probe set RTS2033
(forward sequence GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 1520; reverse sequence
TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 1521; probe sequence
CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522) was used to measure mRNA levels.
STAT3 mRNA levels were adjusted according to content of beta-actin, a housekeeping gene, as measured
by human primer probe set HTS5002 (forward sequence CGGACTATGACTTAGTTGCGTTACA,
designated herein as SEQ ID NO: 1529; reverse sequence GCCATGCCAATCTCATCTTGT, designated
herein as SEQ ID NO: 1530; probe sequence CCTTTCTTGACAAAACCTAACTTGCGCAGA,
designated herein as SEQ ID NO: 1531). Results are presented as percent inhibition of STAT3, relative
to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 40. As illustrated in Table 40, ISIS 481464 was able to penetrate the cell membrane.
Table 40
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
BT474M1 cells
0.02 10.0
ISIS No 0.1 μM 0.5 μM 2.5 μM IC (μM)
μM μM
481464 13 25 74 94 95 0.24
Example 28: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in H929 cells
ISIS 481464, from the studies described above, was further tested at different doses in H929
cells, a multiple myeloma cell line. Cells were plated at a density of 10,000-12,000 cells per well. Cells
were incubated with 0.01 μM, 0.5 μM, 2.5 μΜ, and 10.0 μM concentrations of antisense oligonucleotide,
as specified in Table 41. After approximately 72 hours, RNA was isolated from the cells and STAT3
mRNA levels were measured by quantitative real-time PCR. Human STAT3 primer probe set RTS2033
(forward sequence GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 1520; reverse sequence
TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 1521; probe sequence
CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522) was used to measure mRNA levels.
STAT3 mRNA levels were adjusted according to content of beta-actin, a housekeeping gene, as measured
by human primer probe set HTS5002 (forward sequence CGGACTATGACTTAGTTGCGTTACA,
designated herein as SEQ ID NO: 1529; reverse sequence GCCATGCCAATCTCATCTTGT, designated
BIOL0142WO
herein as SEQ ID NO: 1530; probe sequence CCTTTCTTGACAAAACCTAACTTGCGCAGA,
designated herein as SEQ ID NO: 1531). Results are presented as percent inhibition of STAT3, relative
to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 41. As illustrated in Table 41, ISIS 481464 was able to penetrate the cell membrane.
Table 41
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
H929 cells
.0
ISIS No 0.1 μM 0.5 μM 2.5 μM IC (μM)
481464 91 95 95 95 0.04
Example 29: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in MM1R cells
ISIS 481464, from the studies described above, was further tested at different doses in MM1R
cells, a multiple myeloma cell line. Cells were plated at a density of 10,000-12,000 cells per well. Cells
were incubated with 0.01 μM, 0.5 μM, 2.5 μΜ, and 10.0 μM concentrations of antisense oligonucleotide,
as specified in Table 42. After approximately 72 hours, RNA was isolated from the cells and STAT3
mRNA levels were measured by quantitative real-time PCR. Human STAT3 primer probe set RTS2033
(forward sequence GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 1520; reverse sequence
TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 1521; probe sequence
CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522) was used to measure mRNA levels.
STAT3 mRNA levels were adjusted according to content of beta-actin, a housekeeping gene, as measured
by human primer probe set HTS5002 (forward sequence CGGACTATGACTTAGTTGCGTTACA,
designated herein as SEQ ID NO: 1529; reverse sequence GCCATGCCAATCTCATCTTGT, designated
herein as SEQ ID NO: 1530; probe sequence CCTTTCTTGACAAAACCTAACTTGCGCAGA,
designated herein as SEQ ID NO: 1531). Results are presented as percent inhibition of STAT3, relative
to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 42. As illustrated in Table 42, ISIS 481464 was able to penetrate the cell membrane.
Table 42
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
MM1R cells
.0
ISIS No 0.1 μM 0.5 μM 2.5 μM IC (μM)
481464 91 96 95 95 0.04
BIOL0142WO
Example 30: Effect of antisense oligonucleotides targeting STAT3 in the treatment of an SK-OV3
ovarian cancer xenograft model
BALB/c nude mice were inoculated with the human ovarian cancer cell line, SK-OV3 and treated
with ISIS 481464 or ISIS 481549. ISIS 481549 is cross-reactive with the mouse sequence (i.e., hybridizes
to the mouse sequence).
Study 1
Human ovarian cancer SK-OV3 cells (approximately 100mm ) were intraperitoneally injected
into nude mice. Ten days later, the mice were inoculated subcutaneously with 25 mg/kg of ISIS 481464
or ISIS 481549, administered twice a week for 11 weeks. The mice were euthanized 24 hrs after the final
dose.
RNA analysis
Lysates were prepared by using the RNA extraction kit (Invitrogen) in for RT-PCR analysis of
STAT3 mRNA levels, using human primer probe set (RTS2033) and mouse primer probe set (mSTAT3-
LTS0664). The results are presented in Table 43. The results are presented as percent inhibition of
STAT3, relative to the PBS control. The data indicates that treatment with ISIS antisense oligonucleotides
resulted in reduction of both human and murine STAT3 mRNA in comparison to the PBS control.
Table 43
Percent inhibition of STAT3 mRNA in the treatment groups relative to the PBS control in the SK-OV3
xenograft model
human murine
ISIS No
STAT3 STAT3
481464 63 0
481549 21 61
Protein analysis
Lysates were prepared with RIPA buffer for western blot analysis of STAT3 protein levels, using
an antibody against phosphorylated STAT3 (Cell Signaling). The results are presented in Figure 1. The
data indicates that treatment with ISIS 481549 resulted in reduction of phosphorylated STAT3 protein in
comparison to the PBS control.
IL-6 level analysis
Lysates were prepared by using the RNA extraction kit (Invitrogen) for RT-PCR analysis of IL-6
mRNA levels, using mouse primer probe set mIL6-LTS00629. The results are presented in Table 44. The
results are presented as percent inhibition of IL-6, relative to the PBS control. The data indicates that
treatment with ISIS 481549 resulted in significant reduction of both IL-6 mRNA in comparison to the
PBS control.
Table 44
Percent inhibition of IL-6 mRNA in the treatment groups relative to the PBS control in the SK-OV3
xenograft model
Murine
ISIS No
IL-6 (%)
BIOL0142WO
481464 8
481549 54
Tumor weight analysis
Tumors were harvested. Tumor weights were measured and the results are presented in Table 45.
The results are presented as percent of the PBS control tumor weight. The data indicates that treatment
with ISIS 481549 resulted in significant reduction of tumor weight in comparison to the PBS control.
Table 45
Percent decrease of tumor weight in the treatment groups relative to the PBS control in the SK-OV3
xenograft model
Weight
ISIS No
481464 58
481549 89
Study 2
Human ovarian cancer SK-OV3 cells (approximately 100mm ) were subcutaneously inoculated
into nude mice. Ten days later, the mice were inoculated intraperitoneally with 50 mg/kg of either ISIS
481464 or 50 mg/kg of ISIS 481464 and ISIS 481549 in combination, administered five times a week for
6 weeks. The mice were euthanized 24 hrs after the final dose.
Tumor volume analysis
Tumors were measured regularly using Vernier calipers and tumor volumes were calculated using
the formula, tumor volume = ½ (length x width ). The results are presented in Figure 2. The data indicates
that treatment of the mice with a combination of ISIS 481464 and ISIS 481549 resulted in significant
inhibition of tumor growth.
Example 31: Tolerability study of ISIS 481464 in cynomolgus monkeys
The efficacy and tolerability of ISIS 481464 in cynomolgus monkeys was evaluated.
Treatment
Male and female naïve cynomolgus monkeys were assigned to five treatment groups. Three
groups of 5 monkeys each received loading doses of 3 mg/kg, 10 mg/kg or 30 mg/kg every two days
during the first week of the study (on Days 1, 3, 5 and 7) followed by once weekly administration
thereafter (commencing on Day 14). A control group of 5 monkeys received PBS every two days during
the first week of the study (on Days 1, 3, 5 and 7) as the loading dose, followed by once weekly
administration thereafter (commencing on Day 14). These doses were administered via a one-hour
intravenous (i.v.) infusion. A fifth group of 5 monkeys received loading doses of 30 mg/kg administered
subcutaneously every two days during the first week of the study (on Days 1, 3, 5 and 7) followed by
once weekly subcutaneous (s.c.) administration thereafter (commencing on Day 14).
For the i.v. infusions, the animals were restrained, without sedation, to a chair restraint. A
catheter was placed in one of the cephalic veins and ISIS 481464 solution at the appropriate dose was
BIOL0142WO
infused at a constant rate over approximately 1 hour using a calibrated syringe pump (Stoelting Co,
USA). The dosing site was rotated between right and left arms and the dosing time was recorded. The
infusion rate was selected to deliver the calculated dose volume and the accuracy of the pumps was
monitored and recorded for each dose. At the end of infusion period, the dosing solution was switched to
PBS. In case of s.c. administration, the injections were performed in clock-wise rotation at 4 sites on the
back. Injection sites were maintained by periodic shaving and permanently numbered by tattooing.
Three monkeys from each group were sacrificed on day 44, which was approximately 48 hrs
following the last dose on day 42. The other 2 monkeys from each group are being observed for
toxicological effects. Scheduled euthanasia of the animals was conducted by exsanguination after
ketamine/xylazine-induced anesthesia and administration of sodium pentobarbital. The protocols
described in the Example were approved by the Institutional Animal Care and Use Committee (IACUC).
RNA analysis
Liver tissue was homogenized in 3 mL of RLT lysis buffer (Qiagen) supplemented with 1% of 2-
mercaptoethanol (Sigma). RNA was purified from the resulting homogenate using Qiagen RNeasy 96-
well plate for RNA purification, according to the manufacturer’s protocol. After purification, the RNA
samples were subjected to RT-PCR analysis using Perkin-Elmer ABI Prism 7700 Sequence Detection
System and STAT3 primer probe set RTS3235 (forward primer
AAGTTTATCTGTGTGACACCAACGA, designated herein as SEQ ID NO: 1532; reverse primer
CTTCACCATTATTTCCAAACTGCAT, designated herein as SEQ ID NO: 1533; probe
TGCCGATGTCCCCCCGCA, designated herein as SEQ ID NO: 1534). STAT3 mRNA levels were
normalized to monkey CyclophilinA, which was quantitated using primer probe set mk_cycloA_2
(forward primer TGCTGGACCCAACACAAATG, designated herein as SEQ ID NO: 1535; reverse
primer TGCCATCCAACCACTCAGTC, designated herein as SEQ ID NO: 1536; probe
TTCCCAGTTTTTCATCTGCACTGCCAX, designated herein as SEQ ID NO: 1537).
Treatment with ISIS 481464 at 30 mg/kg dose concentrations either via i.v. infusion or s.c.
injection resulted in statistically significant reduction in STAT3 mRNA expression in liver (Table 46)
compared to the PBS control. Significant differences between the treatment and the control groups were
determined using the Student’s t test (p<0.05).
Table 46
Percent inhibition of STAT3 mRNA levels in cynomolgus monkeys
Treatment % inhibition
3 mg i.v. 0
mg i.v. 7
mg i.v. 52
mg s.c. 51
BIOL0142WO
Protein analysis
Liver tissue was homogenized in 1 mL of ice-cold RIPA buffer (Sigma) containing inhibitor
cocktails of both proteases and phosphatases (Roche). Total lysates were separated by Bis-Tris PAGE
(Invitrogen), transferred to a PVDF membrane, and immunoblotted using primary antibodies for STAT3
(Cell Signaling, #9132) and GAPDH (Advanced Immunochemicals, #06G4-C5). Immunospecific
bands were detected with the Enhanced Chemiluminescence Plus detection kit (Amersham Biosciences)
after exposure to X-ray film. The intensity of the bands was then scanned and quantified using ImageJ
software. Significant differences between the treatment and the control groups were determined using the
Student’s t test (p<0.05).
There was a dose-dependent decrease in STAT3 protein levels, as shown in Table 47, with 33%
and 82% reduction at 3 mg/kg/week and 10 mg/kg/week respectively. STAT3 protein was undetectable at
mg/kg/week irrespective of the dosing route.
Table 47
Percent inhibition of STAT3 protein levels in cynomolgus monkeys
Treatment % inhibition
3 mg i.v. 33
mg i.v. 82
mg i.v. 100
mg s.c. 100
Liver function
To evaluate the effect of ISIS oligonucleotides on hepatic function, blood samples were collected
from all the study groups. The blood samples were collected via femoral venipuncture on day 44, 48 hrs
post-dosing. Blood samples (1mL) were collected in tubes without anticoagulant for serum separation.
The tubes were kept at room temperature for approximately 60 min and then centrifuged at 3,000 rpm for
min to obtain serum. Levels of various liver function markers were measured using a Toshiba 200FR
NEO chemistry analyzer (Toshiba Co., Japan). Plasma levels of ALT and AST were measured and the
results are presented in Table 48, expressed in IU/L. Male and female monkey data is presented
separately. The results indicate that treatment with ISIS 481464 had no effect on liver function outside the
expected range for antisense oligonucleotides.
Table 48
Effect of antisense oligonucleotide treatment on liver function markers in cynomolgus monkey plasma
Male Female Male Female
ALT ALT AST AST
(IU/L) (IU/L) (IU/L) (IU/L)
PBS 59 69 83 69
3 mg/kg i.v. 47 56 50 47
mg/kg i.v. 56 89 70 60
BIOL0142WO
mg/kg i.v. 74 75 60 73
mg/kg s.c. 62 78 61 92
Kidney function
To evaluate the effect of ISIS oligonucleotides on kidney function, blood samples were collected
from all the study groups. The blood samples were collected via femoral venipuncture on day 44, 48 hrs
post-dosing. Blood samples (1mL) were collected in tubes without anticoagulant for serum separation.
The tubes were kept at room temperature for approximately 60 min and then centrifuged at 3,000 rpm for
min to obtain serum. Levels of various kidney function markers were measured using a Toshiba
200FR NEO chemistry analyzer (Toshiba Co., Japan). Results are presented in Table 49, expressed in
mg/dL. The plasma chemistry data indicate that treatment with ISIS 481464 did not have any effect on
the kidney function outside the expected range for antisense oligonucleotides.
Table 49
Effect of antisense oligonucleotide treatment on plasma BUN and creatinine levels (mg/dL) in
cynomolgus monkeys
Male Female Male Female
BUN BUN Creatinine Creatinine
PBS 19 30 0.68 0.88
3 mg/kg i.v. 23 28 0.85 0.86
mg/kg i.v. 26 27 0.89 0.94
mg/kg i.v. 25 26 0.91 0.86
mg/kg s.c. 27 28 0.97 0.85
Body weight measurements
To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body weights
were measured and are presented in Tables 50 and 51. The results indicate that effect of treatment with
ISIS 481464 on body weights was within the expected range for antisense oligonucleotides.
Table 50
Effect of antisense oligonucleotide treatment on body weights (g) in male cynomolgus monkeys
Day 1 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42
PBS 2523 2463 2484 2471 2509 2523 2551
3 mg/kg i.v. 2604 2564 2594 2572 2589 2654 2687
mg/kg i.v. 2603 2453 2581 2561 2591 2633 2655
mg/kg i.v. 2608 2583 2613 2644 2668 2713 2776
mg/kg s.c. 2533 2441 2470 2521 2554 2609 2619
Table 51
Effect of antisense oligonucleotide treatment on body weights (g) in female cynomolgus monkeys
Day 1 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42
PBS 2266 2252 2276 2237 2362 2365 2373
3 mg/kg i.v. 2253 2242 2283 2250 2346 2350 2377
mg/kg i.v. 2293 2277 2318 2254 2358 2387 2361
mg/kg i.v. 2259 2261 2289 2268 2368 2412 2406
BIOL0142WO
mg/kg s.c. 2293 2275 2322 2281 2385 2389 2394
Example 32: Antisense inhibition of human STAT3 in HuVEC cells
Antisense oligonucleotides were designed targeting a STAT3 nucleic acid and were tested for
their effects on STAT3 mRNA in vitro. Cultured HuVEC cells at a density of 5,000 cells per well were
transfected using LipofectAMINE 2000® reagent with 30 nM antisense oligonucleotide. After a
treatment period of approximately 24 hours, RNA was isolated from the cells and STAT3 mRNA levels
were measured by quantitative real-time PCR. Human primer probe set RTS2033 (forward sequence
GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 5; reverse sequence
TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 6; probe sequence
CTGCCTAGATCGGC, designated herein as SEQ ID NO: 7) was used to measure mRNA levels.
STAT3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®.
Results are presented as percent inhibition of STAT3, relative to untreated control cells.
The chimeric antisense oligonucleotides in Tables 52 and 53 were designed as 55 MOE
gapmers. The gapmers are 20 nucleosides in length, wherein the central gap segment comprises of ten 2’-
deoxynucleosides and is flanked on both sides (in the 5’ and 3’ directions) by wings comprising five
nucleosides each. Each nucleoside in the 5’ wing segment and each nucleotide in the 3’ wing segment
has a 2’-MOE modification. The internucleoside linkages throughout each gapmer are phosphorothioate
(P=S) linkages. All cytosine residues throughout each gapmer are 5’-methylcytosines. “Human Target
start site” indicates the 5’-most nucleoside to which the gapmer is targeted in the human gene sequence.
“Human Target stop site” indicates the 3’-most nucleoside to which the gapmer is targeted human gene
sequence. Each gapmer listed in Table 52 is targeted to human STAT3 mRNA, designated herein as SEQ
ID NO: 1 (GENBANK Accession No. NM_139276.2). Each gapmer listed in Table 53 is targeted to
human STAT3 genomic sequence, designated herein as SEQ ID NO: 2 (the complement of GENBANK
Accession No. NT_010755.14 truncated from nucleotides 4185000 to 4264000).
The potency of the gapmers was compared to ISIS 337332, ISIS 337333, and ISIS 345785, which
are also 55 MOE gapmers targeting human STAT3, and which are further described in USPN
7,307,069, incorporated herein by reference.
Table 52
Inhibition of human STAT3 mRNA levels by chimeric antisense oligonucleotides having 55 MOE
wings and deoxy gap targeted to SEQ ID NO: 1
Human Human
ISIS % SEQ ID
Start Stop Sequence
NO inhibition NO
Site Site
337332 1898 1917 GAAGCCCTTGCCAGCCATGT 91
1541
337333 1903 1922 AAGGAGAAGCCCTTGCCAGC 87
1542
345785 2267 2286 TGCCTCCTCCTTGGGAATGT 82
1543
BIOL0142WO
455860 2831 2850 ACACAAGACATTTCCTTTTT 64
1544
455246 3452 3471 CAAGGAGGCTGTTAACTGAA 84
1545
455247 3454 3473 ACCAAGGAGGCTGTTAACTG 78
1546
455248 3456 3475 GCACCAAGGAGGCTGTTAAC 69
1547
455249 3458 3477 AAGCACCAAGGAGGCTGTTA 83
1548
455250 3460 3479 TAAAGCACCAAGGAGGCTGT 77
1549
455251 3462 3481 CTTAAAGCACCAAGGAGGCT 78
1550
455252 3464 3483 TGCTTAAAGCACCAAGGAGG 80
1551
455253 3466 3485 AATGCTTAAAGCACCAAGGA 75
1552
455254 3468 3487 TGAATGCTTAAAGCACCAAG 80
1553
455255 3470 3489 GCTGAATGCTTAAAGCACCA 82
1554
455256 3472 3491 AAGCTGAATGCTTAAAGCAC 67
1555
455257 3474 3493 GGAAGCTGAATGCTTAAAGC 79
1556
455258 3476 3495 AAGGAAGCTGAATGCTTAAA 79
1557
455259 3478 3497 TGAAGGAAGCTGAATGCTTA 72
1558
455260 3480 3499 CCTGAAGGAAGCTGAATGCT 75
1559
455261 3527 3546 TAAGGGTTTGACCTGAAGCC 72
1560
455262 3577 3596 TAAACCTTCCTATTTCAACA 77
1561
455263 3579 3598 CTTAAACCTTCCTATTTCAA 64
1562
455264 3581 3600 TCCTTAAACCTTCCTATTTC 73
1563
455265 3583 3602 TCTCCTTAAACCTTCCTATT 87
1564
455266 3585 3604 ATTCTCCTTAAACCTTCCTA 80
1565
455267 3587 3606 AGATTCTCCTTAAACCTTCC 87
1566
455268 3589 3608 TTAGATTCTCCTTAAACCTT 84
1567
455269 3591 3610 GCTTAGATTCTCCTTAAACC 87
1568
455270 3593 3612 ATGCTTAGATTCTCCTTAAA 87
1569
455271 3595 3614 AAATGCTTAGATTCTCCTTA 89
1570
455272 3597 3616 TAAAATGCTTAGATTCTCCT 88
1571
455273 3639 3658 ATACATTACAAAGGAAAATA 12
1572
455274 3641 3660 CAATACATTACAAAGGAAAA 28
1573
455275 3673 3692 CACCCTCTGCCCAGCCTTAC 63
1574
455276 3675 3694 AGCACCCTCTGCCCAGCCTT 79
1575
455277 3677 3696 TAAGCACCCTCTGCCCAGCC 65
1576
455278 3679 3698 TGTAAGCACCCTCTGCCCAG 62
1577
455279 3681 3700 GTTGTAAGCACCCTCTGCCC 62
1578
455280 3683 3702 AGGTTGTAAGCACCCTCTGC 75
1579
455281 3685 3704 CAAGGTTGTAAGCACCCTCT 83
1580
455282 3687 3706 GTCAAGGTTGTAAGCACCCT 86
1581
455283 3689 3708 GAGTCAAGGTTGTAAGCACC 69
1582
455284 3691 3710 GGGAGTCAAGGTTGTAAGCA 37
1583
455285 3693 3712 AAGGGAGTCAAGGTTGTAAG 56
1584
455286 3695 3714 GAAAGGGAGTCAAGGTTGTA 61
1585
455287 3697 3716 GAGAAAGGGAGTCAAGGTTG 56
1586
455288 3709 3728 ATCAAGTCCAGGGAGAAAGG 55
1587
455289 3711 3730 AGATCAAGTCCAGGGAGAAA 69
1588
BIOL0142WO
455290 3713 3732 GCAGATCAAGTCCAGGGAGA 80
1589
455291 3715 3734 CAGCAGATCAAGTCCAGGGA 90
1590
455292 3717 3736 AACAGCAGATCAAGTCCAGG 77
1591
455293 3719 3738 GAAACAGCAGATCAAGTCCA 81
1592
455294 3721 3740 CTGAAACAGCAGATCAAGTC 75
1593
455295 3723 3742 CTCTGAAACAGCAGATCAAG 76
1594
455296 3725 3744 GCCTCTGAAACAGCAGATCA 74
1595
455297 3727 3746 TAGCCTCTGAAACAGCAGAT 75
1596
455298 3729 3748 CCTAGCCTCTGAAACAGCAG 76
1597
455299 3731 3750 AACCTAGCCTCTGAAACAGC 83
1598
455300 3733 3752 ACAACCTAGCCTCTGAAACA 57
1599
455301 3735 3754 AAACAACCTAGCCTCTGAAA 72
1600
455302 3737 3756 AGAAACAACCTAGCCTCTGA 78
1601
455303 3739 3758 ACAGAAACAACCTAGCCTCT 69
1602
455304 3741 3760 CCACAGAAACAACCTAGCCT 70
1603
455305 3743 3762 ACCCACAGAAACAACCTAGC 80
1604
455306 3745 3764 GCACCCACAGAAACAACCTA 70
1605
455307 3747 3766 AGGCACCCACAGAAACAACC 75
1606
455308 3749 3768 TAAGGCACCCACAGAAACAA 70
1607
455309 3751 3770 GATAAGGCACCCACAGAAAC 65
1608
455310 3753 3772 CTGATAAGGCACCCACAGAA 66
1609
455311 3755 3774 CCCTGATAAGGCACCCACAG 81
1610
455312 3757 3776 AGCCCTGATAAGGCACCCAC 79
1611
455313 3759 3778 CCAGCCCTGATAAGGCACCC 74
1612
455314 3761 3780 TCCCAGCCCTGATAAGGCAC 74
1613
455315 3763 3782 TATCCCAGCCCTGATAAGGC 66
1614
455316 3765 3784 AGTATCCCAGCCCTGATAAG 48
1615
455317 3767 3786 GAAGTATCCCAGCCCTGATA 63
1616
455318 3769 3788 CAGAAGTATCCCAGCCCTGA 82
1617
455319 3771 3790 ATCAGAAGTATCCCAGCCCT 80
1618
455320 3879 3898 GATTCCTAAAACAAACAGGA 37
1619
455321 3881 3900 AGGATTCCTAAAACAAACAG 42
1620
455322 3883 3902 CCAGGATTCCTAAAACAAAC 72
1621
455323 3885 3904 GACCAGGATTCCTAAAACAA 71
1622
455324 3887 3906 GAGACCAGGATTCCTAAAAC 43
1623
455325 3889 3908 CTGAGACCAGGATTCCTAAA 77
1624
455326 3891 3910 TCCTGAGACCAGGATTCCTA 76
1625
455327 3893 3912 GGTCCTGAGACCAGGATTCC 69
1626
455328 3895 3914 GAGGTCCTGAGACCAGGATT 76
1627
455329 3897 3916 ATGAGGTCCTGAGACCAGGA 81
1628
455330 3899 3918 CCATGAGGTCCTGAGACCAG 84
1629
455331 3901 3920 TTCCATGAGGTCCTGAGACC 75
1630
455332 3903 3922 TCTTCCATGAGGTCCTGAGA 75
1631
455333 3905 3924 CTTCTTCCATGAGGTCCTGA 79
1632
455334 3907 3926 CTCTTCTTCCATGAGGTCCT 83
1633
BIOL0142WO
455335 3909 3928 CCCTCTTCTTCCATGAGGTC 74
1634
455336 3911 3930 CCCCCTCTTCTTCCATGAGG 72
1635
455337 3913 3932 CTCCCCCTCTTCTTCCATGA 72
1636
455338 3977 3996 CCTGAGCTCAACCAGACACG 79
1637
455339 3979 3998 TCCCTGAGCTCAACCAGACA 73
1638
455340 3981 4000 ATTCCCTGAGCTCAACCAGA 75
1639
455341 3983 4002 ATATTCCCTGAGCTCAACCA 65
1640
455342 3985 4004 CCATATTCCCTGAGCTCAAC 78
1641
455343 3987 4006 AACCATATTCCCTGAGCTCA 81
1642
455344 3989 4008 AGAACCATATTCCCTGAGCT 77
1643
455345 3991 4010 TAAGAACCATATTCCCTGAG 73
1644
455346 3993 4012 GCTAAGAACCATATTCCCTG 81
1645
455347 4067 4086 TCAGTAAGCCTTTGCCCTGC 79
1646
455348 4069 4088 TATCAGTAAGCCTTTGCCCT 72
1647
455349 4071 4090 TTTATCAGTAAGCCTTTGCC 76
1648
455350 4073 4092 AGTTTATCAGTAAGCCTTTG 84
1649
455351 4075 4094 CAAGTTTATCAGTAAGCCTT 82
1650
455352 4077 4096 CTCAAGTTTATCAGTAAGCC 82
1651
455353 4079 4098 GACTCAAGTTTATCAGTAAG 70
1652
455354 4081 4100 CAGACTCAAGTTTATCAGTA 78
1653
455355 4083 4102 GGCAGACTCAAGTTTATCAG 67
1654
455356 4085 4104 AGGGCAGACTCAAGTTTATC 51
1655
455357 4087 4106 CGAGGGCAGACTCAAGTTTA 54
1656
455358 4089 4108 TACGAGGGCAGACTCAAGTT 56
1657
455359 4091 4110 CATACGAGGGCAGACTCAAG 59
1658
455360 4093 4112 CTCATACGAGGGCAGACTCA 74
1659
455361 4095 4114 CCCTCATACGAGGGCAGACT 67
1660
455362 4122 4141 CAGCCTCAGAGGGAGGCCAG 40
1661
455363 4124 4143 ACCAGCCTCAGAGGGAGGCC 34
1662
455364 4126 4145 TCACCAGCCTCAGAGGGAGG 49
1663
455365 4128 4147 AGTCACCAGCCTCAGAGGGA 50
1664
455366 4225 4244 CCCATACGCACAGGAGAGGC 81
1665
455367 4227 4246 TTCCCATACGCACAGGAGAG 72
1666
455368 4229 4248 TGTTCCCATACGCACAGGAG 80
1667
455369 4231 4250 GGTGTTCCCATACGCACAGG 76
1668
455370 4233 4252 TAGGTGTTCCCATACGCACA 87
1669
455371 4235 4254 GCTAGGTGTTCCCATACGCA 92
1670
455372 4237 4256 GTGCTAGGTGTTCCCATACG 81
1671
455373 4304 4323 GAGGCAAGGTGGTTTTGAGT 55
1672
455374 4306 4325 CTGAGGCAAGGTGGTTTTGA 74
1673
455375 4308 4327 AGCTGAGGCAAGGTGGTTTT 79
1674
455376 4310 4329 TCAGCTGAGGCAAGGTGGTT 80
1675
455377 4312 4331 GATCAGCTGAGGCAAGGTGG 77
1676
455378 4314 4333 CTGATCAGCTGAGGCAAGGT 60
1677
455379 4316 4335 CTCTGATCAGCTGAGGCAAG 74
1678
BIOL0142WO
455380 4318 4337 AACTCTGATCAGCTGAGGCA 77
1679
455381 4320 4339 GAAACTCTGATCAGCTGAGG 78
1680
455382 4322 4341 CAGAAACTCTGATCAGCTGA 78
1681
455383 4360 4379 CAGAGACCAGCTAATTTGAT 69
1682
455384 4362 4381 TTCAGAGACCAGCTAATTTG 78
1683
455385 4364 4383 AATTCAGAGACCAGCTAATT 77
1684
455386 4366 4385 TTAATTCAGAGACCAGCTAA 83
1685
455387 4423 4442 CTCCAGGCAGGAGGACTGGG 79
1686
455388 4425 4444 GTCTCCAGGCAGGAGGACTG 65
1687
455389 4427 4446 CTGTCTCCAGGCAGGAGGAC 57
1688
455390 4429 4448 AACTGTCTCCAGGCAGGAGG 75
1689
455391 4431 4450 TCAACTGTCTCCAGGCAGGA 86
1690
455392 4433 4452 CATCAACTGTCTCCAGGCAG 80
1691
455393 4435 4454 CACATCAACTGTCTCCAGGC 86
1692
455394 4437 4456 GACACATCAACTGTCTCCAG 85
1693
455395 4471 4490 GAAGAGTGTTGCTGGAGAAG 73
1694
455396 4473 4492 CTGAAGAGTGTTGCTGGAGA 78
1695
455397 4475 4494 TACTGAAGAGTGTTGCTGGA 83
1696
455398 4477 4496 TGTACTGAAGAGTGTTGCTG 86
1697
455399 4479 4498 TATGTACTGAAGAGTGTTGC 74
1698
455400 4481 4500 ATTATGTACTGAAGAGTGTT 74
1699
455401 4483 4502 TTATTATGTACTGAAGAGTG 84
1700
455402 4485 4504 GCTTATTATGTACTGAAGAG 84
1701
455403 4487 4506 AAGCTTATTATGTACTGAAG 77
1702
455404 4489 4508 TTAAGCTTATTATGTACTGA 75
1703
455405 4491 4510 AGTTAAGCTTATTATGTACT 81
1704
455406 4493 4512 TCAGTTAAGCTTATTATGTA 58
1705
455407 4495 4514 TATCAGTTAAGCTTATTATG 65
1706
455408 4497 4516 TTTATCAGTTAAGCTTATTA 46
1707
455409 4499 4518 TGTTTATCAGTTAAGCTTAT 68
1708
455410 4501 4520 TCTGTTTATCAGTTAAGCTT 83
1709
455411 4539 4558 AACCCAATGGTAAGCCCAAG 87
1710
455412 4541 4560 TAAACCCAATGGTAAGCCCA 87
1711
455413 4543 4562 TTTAAACCCAATGGTAAGCC 78
1712
455414 4545 4564 GATTTAAACCCAATGGTAAG 31
1713
455415 4547 4566 ATGATTTAAACCCAATGGTA 71
1714
455416 4549 4568 CTATGATTTAAACCCAATGG 67
1715
455417 4551 4570 CCCTATGATTTAAACCCAAT 70
1716
455418 4553 4572 GTCCCTATGATTTAAACCCA 83
1717
455419 4555 4574 AGGTCCCTATGATTTAAACC 64
1718
455420 4589 4608 TATCTGCTCCAGAGAAGCCC 76
1719
455421 4591 4610 AATATCTGCTCCAGAGAAGC 78
1720
455422 4614 4633 CTACCTAAGGCCATGAACTT 74
1721
455423 4616 4635 TGCTACCTAAGGCCATGAAC 82
1722
455424 4618 4637 CATGCTACCTAAGGCCATGA 84
1723
BIOL0142WO
455425 4636 4655 CAGAGTTAAGACCAGATACA 84
1724
455426 4638 4657 ATCAGAGTTAAGACCAGATA 83
1725
455427 4640 4659 CAATCAGAGTTAAGACCAGA 77
1726
455428 4642 4661 TACAATCAGAGTTAAGACCA 81
1727
455429 4644 4663 GCTACAATCAGAGTTAAGAC 86
1728
455430 4646 4665 TTGCTACAATCAGAGTTAAG 85
1729
455431 4648 4667 TTTTGCTACAATCAGAGTTA 85
1730
455432 4650 4669 ACTTTTGCTACAATCAGAGT 73
1731
455433 4652 4671 GAACTTTTGCTACAATCAGA 80
1732
455434 4654 4673 CAGAACTTTTGCTACAATCA 82
1733
455435 4656 4675 CTCAGAACTTTTGCTACAAT 79
1734
455436 4658 4677 CTCTCAGAACTTTTGCTACA 76
1735
455437 4660 4679 TCCTCTCAGAACTTTTGCTA 75
1736
455438 4662 4681 GCTCCTCTCAGAACTTTTGC 85
1737
455439 4664 4683 CAGCTCCTCTCAGAACTTTT 85
1738
455440 4666 4685 CTCAGCTCCTCTCAGAACTT 80
1739
455441 4668 4687 GGCTCAGCTCCTCTCAGAAC 75
1740
455442 4770 4789 GCAACCCACGGGATTCCCTC 82
1741
455443 4772 4791 AAGCAACCCACGGGATTCCC 77
1742
455444 4774 4793 GTAAGCAACCCACGGGATTC 74
1743
455445 4776 4795 AGGTAAGCAACCCACGGGAT 76
1744
455446 4778 4797 GTAGGTAAGCAACCCACGGG 82
1745
455447 4780 4799 AGGTAGGTAAGCAACCCACG 88
1746
455448 4782 4801 ATAGGTAGGTAAGCAACCCA 83
1747
455449 4784 4803 TTATAGGTAGGTAAGCAACC 59
1748
455450 4786 4805 CCTTATAGGTAGGTAAGCAA 65
1749
455451 4788 4807 CACCTTATAGGTAGGTAAGC 62
1750
455452 4790 4809 ACCACCTTATAGGTAGGTAA 57
1751
455453 4792 4811 AAACCACCTTATAGGTAGGT 75
1752
455454 4794 4813 ATAAACCACCTTATAGGTAG 35
1753
455455 4796 4815 TTATAAACCACCTTATAGGT 39
1754
455456 4798 4817 GCTTATAAACCACCTTATAG 58
1755
455457 4800 4819 CAGCTTATAAACCACCTTAT 86
1756
455458 4802 4821 AGCAGCTTATAAACCACCTT 86
1757
455459 4804 4823 ACAGCAGCTTATAAACCACC 80
1758
455460 4806 4825 GGACAGCAGCTTATAAACCA 69
1759
455461 4808 4827 CAGGACAGCAGCTTATAAAC 72
1760
455462 4810 4829 GCCAGGACAGCAGCTTATAA 76
1761
455463 4812 4831 TGGCCAGGACAGCAGCTTAT 89
1762
455464 4814 4833 AGTGGCCAGGACAGCAGCTT 80
1763
455465 4816 4835 GCAGTGGCCAGGACAGCAGC 78
1764
455466 4818 4837 ATGCAGTGGCCAGGACAGCA 85
1765
455467 4820 4839 GAATGCAGTGGCCAGGACAG 80
1766
455468 4822 4841 TTGAATGCAGTGGCCAGGAC 83
1767
455469 4824 4843 ATTTGAATGCAGTGGCCAGG 84
1768
BIOL0142WO
455470 4826 4845 GAATTTGAATGCAGTGGCCA 81
1769
455471 4828 4847 TGGAATTTGAATGCAGTGGC 85
1770
455472 4830 4849 ATTGGAATTTGAATGCAGTG 64
1771
455473 4832 4851 ACATTGGAATTTGAATGCAG 80
1772
455474 4834 4853 ACACATTGGAATTTGAATGC 73
1773
455475 4836 4855 GTACACATTGGAATTTGAAT 80
1774
455476 4838 4857 AAGTACACATTGGAATTTGA 77
1775
455477 4840 4859 TGAAGTACACATTGGAATTT 68
1776
455478 4842 4861 TATGAAGTACACATTGGAAT 66
1777
455479 4844 4863 ACTATGAAGTACACATTGGA 83
1778
455480 4846 4865 ACACTATGAAGTACACATTG 76
1779
455481 4848 4867 TTACACTATGAAGTACACAT 78
1780
455482 4850 4869 TTTTACACTATGAAGTACAC 76
1781
455483 4852 4871 ATTTTTACACTATGAAGTAC 60
1782
455484 4854 4873 AAATTTTTACACTATGAAGT 35
1783
455485 4856 4875 ATAAATTTTTACACTATGAA 9
1784
455486 4858 4877 ATATAAATTTTTACACTATG 0
1785
455487 4860 4879 TAATATAAATTTTTACACTA 21
1786
455488 4862 4881 AATAATATAAATTTTTACAC 10
1787
455489 4864 4883 ACAATAATATAAATTTTTAC 7
1788
455490 4925 4944 AGTTAAAGTAGATACAGCAA 71
1789
455491 4927 4946 GAAGTTAAAGTAGATACAGC 63
1790
455492 4929 4948 TGGAAGTTAAAGTAGATACA 69
1791
455493 4931 4950 TCTGGAAGTTAAAGTAGATA 65
1792
455494 4933 4952 TTTCTGGAAGTTAAAGTAGA 55
1793
455495 4935 4954 TATTTCTGGAAGTTAAAGTA 57
1794
455496 4937 4956 TTTATTTCTGGAAGTTAAAG 36
1795
455497 4939 4958 CGTTTATTTCTGGAAGTTAA 77
1796
Table 53
Inhibition of human STAT3 mRNA levels by chimeric antisense oligonucleotides having 55 MOE
wings and deoxy gap targeted to SEQ ID NO: 2
Human Human
ISIS % SEQ ID
Start Stop Sequence
NO inhibition NO
Site Site
455498 917 936 CACGCCGTCATGCATAATTC 0
1797
455499 919 938 GGCACGCCGTCATGCATAAT 0
1798
455500 940 959 GCCCAGCCCCAGCCTGGCCG 35
1799
455501 962 981 ACAGCCCCTTCAGCCAATCC 15
1800
455502 964 983 TTACAGCCCCTTCAGCCAAT 14
1801
455503 966 985 AATTACAGCCCCTTCAGCCA 28
1802
455504 968 987 TGAATTACAGCCCCTTCAGC 6
1803
455505 970 989 GCTGAATTACAGCCCCTTCA 15
1804
455506 972 991 CCGCTGAATTACAGCCCCTT 4
1805
455507 974 993 AACCGCTGAATTACAGCCCC 8
1806
455508 976 995 GAAACCGCTGAATTACAGCC 16
1807
BIOL0142WO
455509 978 997 CGGAAACCGCTGAATTACAG 24
1808
455510 980 999 TCCGGAAACCGCTGAATTAC 12
1809
455511 982 1001 GCTCCGGAAACCGCTGAATT 15
1810
455512 984 1003 CAGCTCCGGAAACCGCTGAA 23
1811
455513 986 1005 CGCAGCTCCGGAAACCGCTG 4
1812
455514 988 1007 GCCGCAGCTCCGGAAACCGC 13
1813
455515 1378 1397 AGTCCCTTCCGAGGCCCGCT 81
1814
455516 1408 1427 CGAAGAACGAAACTTCCCTC 68
1815
455517 1697 1716 CAGACACACCTATTCCTGCC 82
1816
455518 1748 1767 TTATGCAATAAAGCCTACCC 70
1817
455519 1795 1814 TTAGAAAGAGTACCGGTCTG 75
1818
455520 1987 2006 AATGGCTCAATTATTTATCT 59
1819
455521 2083 2102 TTTACCCAAGATCTTGGCTC 76
1820
455522 2175 2194 ACTTCAGTGCAACCACACCC 70
1821
455523 2205 2224 CCAACTTGGGCGACGGTTTG 67
1822
455524 2281 2300 CTAACCACTGATTTTGTCAC 56
1823
455525 2316 2335 GTACACACTATACACATTTT 85
1824
455526 2346 2365 CTTTAGTTGCACATACAGTA 80
1825
455527 2383 2402 GCCAAAAATTTACAACCCAT 86
1826
455528 2413 2432 TTCAAGCCCAATGCTTTATC 76
1827
455529 2561 2580 CTGGAACATGTAATAAGGAA 71
1828
455530 2669 2688 AGAGACTAAAATCAAGGCTC 87
1829
455531 2900 2919 TAGACTCTAGACCCAATTCC 77
1830
455532 3780 3799 GAAATGACCACTGATCAAGC 74
1831
455533 3867 3886 AAGTTGGTCACCACCTCTAC 81
1832
455534 4291 4310 AACTTATTCTTCATAGCAAC 58
1833
455535 4587 4606 TATTTGGGACCCAGTTGAAA 60
1834
455536 5000 5019 AGAACTGAAATTCCTTGGTC 88
1835
455537 5030 5049 AAGTTTTAAAAGCTTCCCCT 76
1836
455538 5554 5573 TCACCCAAAGTACCAAATCA 71
1837
455539 5667 5686 CAAAAGTTATGGTGAAATTT 44
1838
455540 5699 5718 AAGTACTCTTTCAGTGGTTT 88
1839
455541 6844 6863 AATTAAAGAGTTGCGGTAAT 68
1840
455542 6926 6945 GTTTCATGAAAACGGACAAT 78
1841
455543 7050 7069 AGGATTCAGTCCCAGATCTG 18
1842
455544 7282 7301 TCAATAATGATGACTTTCTC 72
1843
455545 7528 7547 TTAAACCCAATTATTAACAG 45
1844
455546 7624 7643 GTAAAACACACATTTTATAT 62
1845
455547 7682 7701 GTAAACAGAAAGGGCTGCAA 86
1846
455548 8078 8097 GGGCAGATTTACCTTCCTTA 89
1847
455549 8126 8145 GGGTAGCAGGAAGGAAAGCC 80
1848
455550 8214 8233 AATATAAGTTCTTTGGCTGA 60
1849
455551 8244 8263 TACAATAGCAATCACCTTAG 89
1850
455552 8284 8303 CCATGAAACCCTCAAACATA 75
1851
337332 66135 66154 GAAGCCCTTGCCAGCCATGT 91
1541
BIOL0142WO
337333 66140 66159 AAGGAGAAGCCCTTGCCAGC 87
1542
345785 67129 67148 TGCCTCCTCCTTGGGAATGT 82
1543
455246 74639 74658 CAAGGAGGCTGTTAACTGAA 84
1545
455247 74641 74660 ACCAAGGAGGCTGTTAACTG 78
1546
455248 74643 74662 GCACCAAGGAGGCTGTTAAC 69
1547
455249 74645 74664 AAGCACCAAGGAGGCTGTTA 83
1548
455250 74647 74666 TAAAGCACCAAGGAGGCTGT 77
1549
455251 74649 74668 CTTAAAGCACCAAGGAGGCT 78
1550
455252 74651 74670 TGCTTAAAGCACCAAGGAGG 80
1551
455253 74653 74672 AATGCTTAAAGCACCAAGGA 75
1552
455254 74655 74674 TGAATGCTTAAAGCACCAAG 80
1553
455255 74657 74676 GCTGAATGCTTAAAGCACCA 82
1554
455256 74659 74678 AAGCTGAATGCTTAAAGCAC 67
1555
455257 74661 74680 GGAAGCTGAATGCTTAAAGC 79
1556
455258 74663 74682 AAGGAAGCTGAATGCTTAAA 79
1557
455259 74665 74684 TGAAGGAAGCTGAATGCTTA 72
1558
455260 74667 74686 CCTGAAGGAAGCTGAATGCT 75
1559
455261 74714 74733 TAAGGGTTTGACCTGAAGCC 72
1560
455262 74764 74783 TAAACCTTCCTATTTCAACA 77
1561
455263 74766 74785 CTTAAACCTTCCTATTTCAA 64
1562
455264 74768 74787 TCCTTAAACCTTCCTATTTC 73
1563
455265 74770 74789 TCTCCTTAAACCTTCCTATT 87
1564
455266 74772 74791 ATTCTCCTTAAACCTTCCTA 80
1565
455267 74774 74793 AGATTCTCCTTAAACCTTCC 87
1566
455268 74776 74795 TTAGATTCTCCTTAAACCTT 84
1567
455269 74778 74797 GCTTAGATTCTCCTTAAACC 87
1568
455270 74780 74799 ATGCTTAGATTCTCCTTAAA 87
1569
455271 74782 74801 AAATGCTTAGATTCTCCTTA 89
1570
455272 74784 74803 TAAAATGCTTAGATTCTCCT 88
1571
455273 74826 74845 ATACATTACAAAGGAAAATA 12
1572
455274 74828 74847 CAATACATTACAAAGGAAAA 28
1573
455275 74860 74879 CACCCTCTGCCCAGCCTTAC 63
1574
455276 74862 74881 AGCACCCTCTGCCCAGCCTT 79
1575
455277 74864 74883 TAAGCACCCTCTGCCCAGCC 65
1576
455278 74866 74885 TGTAAGCACCCTCTGCCCAG 62
1577
455279 74868 74887 GTTGTAAGCACCCTCTGCCC 62
1578
455280 74870 74889 AGGTTGTAAGCACCCTCTGC 75
1579
455281 74872 74891 CAAGGTTGTAAGCACCCTCT 83
1580
455282 74874 74893 GTCAAGGTTGTAAGCACCCT 86
1581
455283 74876 74895 GAGTCAAGGTTGTAAGCACC 69
1582
455284 74878 74897 GGGAGTCAAGGTTGTAAGCA 37
1583
455285 74880 74899 AAGGGAGTCAAGGTTGTAAG 56
1584
455286 74882 74901 GAAAGGGAGTCAAGGTTGTA 61
1585
455287 74884 74903 GAGAAAGGGAGTCAAGGTTG 56
1586
455288 74896 74915 ATCAAGTCCAGGGAGAAAGG 55
1587
BIOL0142WO
455289 74898 74917 AGATCAAGTCCAGGGAGAAA 69
1588
455290 74900 74919 GCAGATCAAGTCCAGGGAGA 80
1589
455291 74902 74921 CAGCAGATCAAGTCCAGGGA 90
1590
455292 74904 74923 AACAGCAGATCAAGTCCAGG 77
1591
455293 74906 74925 GAAACAGCAGATCAAGTCCA 81
1592
455294 74908 74927 CTGAAACAGCAGATCAAGTC 75
1593
455295 74910 74929 CTCTGAAACAGCAGATCAAG 76
1594
455296 74912 74931 GCCTCTGAAACAGCAGATCA 74
1595
455297 74914 74933 TAGCCTCTGAAACAGCAGAT 75
1596
455298 74916 74935 CCTAGCCTCTGAAACAGCAG 76
1597
455299 74918 74937 AACCTAGCCTCTGAAACAGC 83
1598
455300 74920 74939 ACAACCTAGCCTCTGAAACA 57
1599
455301 74922 74941 AAACAACCTAGCCTCTGAAA 72
1600
455302 74924 74943 AGAAACAACCTAGCCTCTGA 78
1601
455303 74926 74945 ACAGAAACAACCTAGCCTCT 69
1602
455304 74928 74947 CCACAGAAACAACCTAGCCT 70
1603
455305 74930 74949 ACCCACAGAAACAACCTAGC 80
1604
455306 74932 74951 GCACCCACAGAAACAACCTA 70
1605
455307 74934 74953 AGGCACCCACAGAAACAACC 75
1606
455308 74936 74955 TAAGGCACCCACAGAAACAA 70
1607
455309 74938 74957 GATAAGGCACCCACAGAAAC 65
1608
455310 74940 74959 CTGATAAGGCACCCACAGAA 66
1609
455311 74942 74961 CCCTGATAAGGCACCCACAG 81
1610
455312 74944 74963 AGCCCTGATAAGGCACCCAC 79
1611
455313 74946 74965 CCAGCCCTGATAAGGCACCC 74
1612
455314 74948 74967 TCCCAGCCCTGATAAGGCAC 74
1613
455315 74950 74969 TATCCCAGCCCTGATAAGGC 66
1614
455316 74952 74971 AGTATCCCAGCCCTGATAAG 48
1615
455317 74954 74973 GAAGTATCCCAGCCCTGATA 63
1616
455318 74956 74975 CAGAAGTATCCCAGCCCTGA 82
1617
455319 74958 74977 ATCAGAAGTATCCCAGCCCT 80
1618
455320 75066 75085 GATTCCTAAAACAAACAGGA 37
1619
455321 75068 75087 AGGATTCCTAAAACAAACAG 42
1620
455322 75070 75089 CCAGGATTCCTAAAACAAAC 72
1621
455323 75072 75091 GACCAGGATTCCTAAAACAA 71
1622
455324 75074 75093 GAGACCAGGATTCCTAAAAC 43
1623
455325 75076 75095 CTGAGACCAGGATTCCTAAA 77
1624
455326 75078 75097 TCCTGAGACCAGGATTCCTA 76
1625
455327 75080 75099 GGTCCTGAGACCAGGATTCC 69
1626
455328 75082 75101 GAGGTCCTGAGACCAGGATT 76
1627
455329 75084 75103 ATGAGGTCCTGAGACCAGGA 81
1628
455330 75086 75105 CCATGAGGTCCTGAGACCAG 84
1629
455331 75088 75107 TTCCATGAGGTCCTGAGACC 75
1630
455332 75090 75109 TCTTCCATGAGGTCCTGAGA 75
1631
455333 75092 75111 CTTCTTCCATGAGGTCCTGA 79
1632
BIOL0142WO
455334 75094 75113 CTCTTCTTCCATGAGGTCCT 83
1633
455335 75096 75115 CCCTCTTCTTCCATGAGGTC 74
1634
455336 75098 75117 CCCCCTCTTCTTCCATGAGG 72
1635
455337 75100 75119 CTCCCCCTCTTCTTCCATGA 72
1636
455338 75164 75183 CCTGAGCTCAACCAGACACG 79
1637
455339 75166 75185 TCCCTGAGCTCAACCAGACA 73
1638
455340 75168 75187 ATTCCCTGAGCTCAACCAGA 75
1639
455341 75170 75189 ATATTCCCTGAGCTCAACCA 65
1640
455342 75172 75191 CCATATTCCCTGAGCTCAAC 78
1641
455343 75174 75193 AACCATATTCCCTGAGCTCA 81
1642
455344 75176 75195 AGAACCATATTCCCTGAGCT 77
1643
455345 75178 75197 TAAGAACCATATTCCCTGAG 73
1644
455346 75180 75199 GCTAAGAACCATATTCCCTG 81
1645
455347 75254 75273 TCAGTAAGCCTTTGCCCTGC 79
1646
455348 75256 75275 TATCAGTAAGCCTTTGCCCT 72
1647
455349 75258 75277 TTTATCAGTAAGCCTTTGCC 76
1648
455350 75260 75279 AGTTTATCAGTAAGCCTTTG 84
1649
455351 75262 75281 CAAGTTTATCAGTAAGCCTT 82
1650
455352 75264 75283 CTCAAGTTTATCAGTAAGCC 82
1651
455353 75266 75285 GACTCAAGTTTATCAGTAAG 70
1652
455354 75268 75287 CAGACTCAAGTTTATCAGTA 78
1653
455355 75270 75289 GGCAGACTCAAGTTTATCAG 67
1654
455356 75272 75291 AGGGCAGACTCAAGTTTATC 51
1655
455357 75274 75293 CGAGGGCAGACTCAAGTTTA 54
1656
455358 75276 75295 TACGAGGGCAGACTCAAGTT 56
1657
455359 75278 75297 CATACGAGGGCAGACTCAAG 59
1658
455360 75280 75299 CTCATACGAGGGCAGACTCA 74
1659
455361 75282 75301 CCCTCATACGAGGGCAGACT 67
1660
455362 75309 75328 CAGCCTCAGAGGGAGGCCAG 40
1661
455363 75311 75330 ACCAGCCTCAGAGGGAGGCC 34
1662
455364 75313 75332 TCACCAGCCTCAGAGGGAGG 49
1663
455365 75315 75334 AGTCACCAGCCTCAGAGGGA 50
1664
455366 75412 75431 CCCATACGCACAGGAGAGGC 81
1665
455367 75414 75433 TTCCCATACGCACAGGAGAG 72
1666
455368 75416 75435 TGTTCCCATACGCACAGGAG 80
1667
455369 75418 75437 GGTGTTCCCATACGCACAGG 76
1668
455370 75420 75439 TAGGTGTTCCCATACGCACA 87
1669
455371 75422 75441 GCTAGGTGTTCCCATACGCA 92
1670
455372 75424 75443 GTGCTAGGTGTTCCCATACG 81
1671
455373 75491 75510 GAGGCAAGGTGGTTTTGAGT 55
1672
455374 75493 75512 CTGAGGCAAGGTGGTTTTGA 74
1673
455375 75495 75514 AGCTGAGGCAAGGTGGTTTT 79
1674
455376 75497 75516 TCAGCTGAGGCAAGGTGGTT 80
1675
455377 75499 75518 GATCAGCTGAGGCAAGGTGG 77
1676
455378 75501 75520 CTGATCAGCTGAGGCAAGGT 60
1677
BIOL0142WO
455379 75503 75522 CTCTGATCAGCTGAGGCAAG 74
1678
455380 75505 75524 AACTCTGATCAGCTGAGGCA 77
1679
455381 75507 75526 GAAACTCTGATCAGCTGAGG 78
1680
455382 75509 75528 CAGAAACTCTGATCAGCTGA 78
1681
455383 75547 75566 CAGAGACCAGCTAATTTGAT 69
1682
455384 75549 75568 TTCAGAGACCAGCTAATTTG 78
1683
455385 75551 75570 AATTCAGAGACCAGCTAATT 77
1684
455386 75553 75572 TTAATTCAGAGACCAGCTAA 83
1685
455387 75610 75629 CTCCAGGCAGGAGGACTGGG 79
1686
455388 75612 75631 GTCTCCAGGCAGGAGGACTG 65
1687
455389 75614 75633 CTGTCTCCAGGCAGGAGGAC 57
1688
455390 75616 75635 AACTGTCTCCAGGCAGGAGG 75
1689
455391 75618 75637 TCAACTGTCTCCAGGCAGGA 86
1690
455392 75620 75639 CATCAACTGTCTCCAGGCAG 80
1691
455393 75622 75641 CACATCAACTGTCTCCAGGC 86
1692
455394 75624 75643 GACACATCAACTGTCTCCAG 85
1693
455395 75658 75677 GAAGAGTGTTGCTGGAGAAG 73
1694
455396 75660 75679 CTGAAGAGTGTTGCTGGAGA 78
1695
455397 75662 75681 TACTGAAGAGTGTTGCTGGA 83
1696
455398 75664 75683 TGTACTGAAGAGTGTTGCTG 86
1697
455399 75666 75685 TATGTACTGAAGAGTGTTGC 74
1698
455400 75668 75687 ATTATGTACTGAAGAGTGTT 74
1699
455401 75670 75689 TTATTATGTACTGAAGAGTG 84
1700
455402 75672 75691 GCTTATTATGTACTGAAGAG 84
1701
455403 75674 75693 AAGCTTATTATGTACTGAAG 77
1702
455404 75676 75695 TTAAGCTTATTATGTACTGA 75
1703
455405 75678 75697 AGTTAAGCTTATTATGTACT 81
1704
455406 75680 75699 TCAGTTAAGCTTATTATGTA 58
1705
455407 75682 75701 TATCAGTTAAGCTTATTATG 65
1706
455408 75684 75703 TTTATCAGTTAAGCTTATTA 46
1707
455409 75686 75705 TGTTTATCAGTTAAGCTTAT 68
1708
455410 75688 75707 TCTGTTTATCAGTTAAGCTT 83
1709
455411 75726 75745 AACCCAATGGTAAGCCCAAG 87
1710
455412 75728 75747 TAAACCCAATGGTAAGCCCA 87
1711
455413 75730 75749 TTTAAACCCAATGGTAAGCC 78
1712
455414 75732 75751 GATTTAAACCCAATGGTAAG 31
1713
455415 75734 75753 ATGATTTAAACCCAATGGTA 71
1714
455416 75736 75755 CTATGATTTAAACCCAATGG 67
1715
455417 75738 75757 CCCTATGATTTAAACCCAAT 70
1716
455418 75740 75759 GTCCCTATGATTTAAACCCA 83
1717
455419 75742 75761 AGGTCCCTATGATTTAAACC 64
1718
455420 75776 75795 TATCTGCTCCAGAGAAGCCC 76
1719
455421 75778 75797 AATATCTGCTCCAGAGAAGC 78
1720
455422 75801 75820 CTACCTAAGGCCATGAACTT 74
1721
455423 75803 75822 TGCTACCTAAGGCCATGAAC 82
1722
BIOL0142WO
455424 75805 75824 CATGCTACCTAAGGCCATGA 84
1723
455425 75823 75842 CAGAGTTAAGACCAGATACA 84
1724
455426 75825 75844 ATCAGAGTTAAGACCAGATA 83
1725
455427 75827 75846 CAATCAGAGTTAAGACCAGA 77
1726
455428 75829 75848 TACAATCAGAGTTAAGACCA 81
1727
455429 75831 75850 GCTACAATCAGAGTTAAGAC 86
1728
455430 75833 75852 TTGCTACAATCAGAGTTAAG 85
1729
455431 75835 75854 TTTTGCTACAATCAGAGTTA 85
1730
455432 75837 75856 ACTTTTGCTACAATCAGAGT 73
1731
455433 75839 75858 GAACTTTTGCTACAATCAGA 80
1732
455434 75841 75860 CAGAACTTTTGCTACAATCA 82
1733
455435 75843 75862 CTCAGAACTTTTGCTACAAT 79
1734
455436 75845 75864 CTCTCAGAACTTTTGCTACA 76
1735
455437 75847 75866 TCCTCTCAGAACTTTTGCTA 75
1736
455438 75849 75868 GCTCCTCTCAGAACTTTTGC 85
1737
455439 75851 75870 CAGCTCCTCTCAGAACTTTT 85
1738
455440 75853 75872 CTCAGCTCCTCTCAGAACTT 80
1739
455441 75855 75874 GGCTCAGCTCCTCTCAGAAC 75
1740
455442 75957 75976 GCAACCCACGGGATTCCCTC 82
1741
455443 75959 75978 AAGCAACCCACGGGATTCCC 77
1742
455444 75961 75980 GTAAGCAACCCACGGGATTC 74
1743
455445 75963 75982 AGGTAAGCAACCCACGGGAT 76
1744
455446 75965 75984 GTAGGTAAGCAACCCACGGG 82
1745
455447 75967 75986 AGGTAGGTAAGCAACCCACG 88
1746
455448 75969 75988 ATAGGTAGGTAAGCAACCCA 83
1747
455449 75971 75990 TTATAGGTAGGTAAGCAACC 59
1748
455450 75973 75992 CCTTATAGGTAGGTAAGCAA 65
1749
455451 75975 75994 CACCTTATAGGTAGGTAAGC 62
1750
455452 75977 75996 ACCACCTTATAGGTAGGTAA 57
1751
455453 75979 75998 AAACCACCTTATAGGTAGGT 75
1752
455454 75981 76000 ATAAACCACCTTATAGGTAG 35
1753
455455 75983 76002 TTATAAACCACCTTATAGGT 39
1754
455456 75985 76004 GCTTATAAACCACCTTATAG 58
1755
455457 75987 76006 CAGCTTATAAACCACCTTAT 86
1756
455458 75989 76008 AGCAGCTTATAAACCACCTT 86
1757
455459 75991 76010 ACAGCAGCTTATAAACCACC 80
1758
455460 75993 76012 GGACAGCAGCTTATAAACCA 69
1759
455461 75995 76014 CAGGACAGCAGCTTATAAAC 72
1760
455462 75997 76016 GCCAGGACAGCAGCTTATAA 76
1761
455463 75999 76018 TGGCCAGGACAGCAGCTTAT 89
1762
455464 76001 76020 AGTGGCCAGGACAGCAGCTT 80
1763
455465 76003 76022 GCAGTGGCCAGGACAGCAGC 78
1764
455466 76005 76024 ATGCAGTGGCCAGGACAGCA 85
1765
455467 76007 76026 GAATGCAGTGGCCAGGACAG 80
1766
455468 76009 76028 TTGAATGCAGTGGCCAGGAC 83
1767
BIOL0142WO
455469 76011 76030 ATTTGAATGCAGTGGCCAGG 84
1768
455470 76013 76032 GAATTTGAATGCAGTGGCCA 81
1769
455471 76015 76034 TGGAATTTGAATGCAGTGGC 85
1770
455472 76017 76036 ATTGGAATTTGAATGCAGTG 64
1771
455473 76019 76038 ACATTGGAATTTGAATGCAG 80
1772
455474 76021 76040 ACACATTGGAATTTGAATGC 73
1773
455475 76023 76042 GTACACATTGGAATTTGAAT 80
1774
455476 76025 76044 AAGTACACATTGGAATTTGA 77
1775
455477 76027 76046 TGAAGTACACATTGGAATTT 68
1776
455478 76029 76048 TATGAAGTACACATTGGAAT 66
1777
455479 76031 76050 ACTATGAAGTACACATTGGA 83
1778
455480 76033 76052 ACACTATGAAGTACACATTG 76
1779
455481 76035 76054 TTACACTATGAAGTACACAT 78
1780
455482 76037 76056 TTTTACACTATGAAGTACAC 76
1781
455483 76039 76058 ATTTTTACACTATGAAGTAC 60
1782
455484 76041 76060 AAATTTTTACACTATGAAGT 35
1783
455485 76043 76062 ATAAATTTTTACACTATGAA 9
1784
455486 76045 76064 ATATAAATTTTTACACTATG 0
1785
455487 76047 76066 TAATATAAATTTTTACACTA 21
1786
455488 76049 76068 AATAATATAAATTTTTACAC 10
1787
455489 76051 76070 ACAATAATATAAATTTTTAC 7
1788
455490 76112 76131 AGTTAAAGTAGATACAGCAA 71
1789
455491 76114 76133 GAAGTTAAAGTAGATACAGC 63
1790
455492 76116 76135 TGGAAGTTAAAGTAGATACA 69
1791
455493 76118 76137 TCTGGAAGTTAAAGTAGATA 65
1792
455494 76120 76139 TTTCTGGAAGTTAAAGTAGA 55
1793
455495 76122 76141 TATTTCTGGAAGTTAAAGTA 57
1794
455496 76124 76143 TTTATTTCTGGAAGTTAAAG 36
1795
455497 76126 76145 CGTTTATTTCTGGAAGTTAA 77
1796
9123 9142
455553 ACCTGCCCCTATGTATAAGC 89 1852
11261 11280
455554 9484 9503 TTTGTAATATCTAACAGATA 20
1853
455555 9630 9649 TATATGACAGCCTCAATTTC 68
1854
455556 9677 9696 GGCATTTGTGTAAACAGGAA 81
1855
455557 9746 9765 TGTTAAATATTACTTAAAAT 4
1856
455558 9776 9795 AATTCCTTGGGTGGTAATCC 81
1857
455559 10071 10090 GGAAAGTTACAGGACAGGAA 77
1858
455560 10352 10371 GAAATGGCTTCTACAAAAAC 47
1859
455561 10472 10491 GGTCAGAATACCACAAACTA 80
1860
455562 10634 10653 AGTCTAATGCTTTTAGATTC 59
1861
455563 11567 11586 CATTGGAAAACTTAGGGTAA 37
1862
455564 11597 11616 ATTCTCACTGGGTATAGAGG 72
1863
455565 11700 11719 TAGCATTAATCTTTCCTAGG 92
1864
9886 9905
455566 GACTCAAAATAAGGTTCCTC 86 1865
12369 12388
BIOL0142WO
455567 12430 12449 ACAGATTTATTCATATAAGC 62
1866
455568 14060 14079 AGATCCATAGATTCTTTCTT 80
1867
455569 14129 14148 ATCTGAATCAGAATATCTGC 88
1868
455570 14190 14209 GAAGACTTTATATTCTATGG 59
1869
455571 14355 14374 TATCCTTAATATTCAGGTAC 82
1870
455572 14501 14520 TTATTAAGACATCTGAAATA 31
1871
455573 14701 14720 TTAAGTGACTACACATGGAT 76
1872
455574 14761 14780 GATAATGTAACAACCCTATC 42
1873
455575 14828 14847 CTGAAGCATGAATTCACATT 83
1874
455576 15316 15335 AAATTCCACTACTCATGAAA 62
1875
455577 15370 15389 CTTCAGAGAATATCTCATTT 83
1876
455578 15400 15419 CACATCATAGTTTTGCATGA 70
1877
455579 15525 15544 TCTGACCCATAAAGTTTAAA 70
1878
455580 16568 16587 TTGGTTAATAATAATGTATC 44
1879
455581 16832 16851 TCACACATTTGTCAAAATCC 89
1880
455582 16863 16882 TATATAATTGTGTACTGGCA 93
1881
455583 16930 16949 TGCCAGTGGTTCAGCAGAGG 77
1882
455584 17215 17234 AATGTTTATAGCAGCTTTAT 56
1883
455585 17330 17349 GTCACTTTGAATATAGTTTG 79
1884
455586 17426 17445 GGCTAAAATCCAAAACACTG 65
1885
455587 18449 18468 AACAGTATTTGAGAAAACTT 21
1886
455588 19883 19902 GGGCTACAACTCAATAACAA 63
1887
455589 20512 20531 AAGTCCTTATCATTTAGCTC 69
1888
455590 21035 21054 GATATTCCCAAAGTGACAGG 75
1889
455591 21188 21207 ATAATGAGACTTTAGCACTC 86
1890
455592 21422 21441 AATCTAAACTTCCAGCCAGG 78
1891
455593 21493 21512 ACAATAATGCATGCAAATGT 67
1892
455594 21675 21694 CACTGCTATTTCCCCAGCAA 89
1893
455595 21710 21729 CTTAAGCCCCATAAGAACAA 65
1894
455596 21823 21842 ATCTAAAACAGCAACATCTC 57
1895
455597 23917 23936 TAGTGATTGAATGTAGACTT 81
1896
455598 23980 23999 TTAGGCCACTAAGTCTGAGC 83
1897
455599 24178 24197 CAGCTGAAATCAGCCTTTGA 69
1898
455600 24345 24364 AATCTAGCTAAGTCCATAAC 43
1899
455601 24504 24523 TGCTTGGATATATAGAAGTC 80
1900
455602 24578 24597 AGGTCACTTTCCCTATACGA 81
1901
455603 24608 24627 AGAAGGAAGATTCTTTTCTC 73
1902
455604 24924 24943 CTAAGAGAGGCAACTGAAAT 60
1903
455605 25063 25082 GGCTCGAGGGCCACTGAAGG 59
1904
455606 25093 25112 AGCAAGCACATTGTCATGTC 83
1905
455607 25132 25151 GGCTGCCAAACTTTTCAAAA 76
1906
455608 25626 25645 TTTGTTCTTGCCTAAAATGC 45
1907
455609 25688 25707 TTCCTTCAAGTCAACTTATC 69
1908
455610 26031 26050 CCAGCCTACAGATGACTTTC 78
1909
455611 26061 26080 GCCAACTTTAGCCCCTTCCA 85
1910
BIOL0142WO
455612 26104 26123 AATGCAAAATCTTTACCCTT 58
1911
455613 26139 26158 CCAGCTCAAAAACACACACT 80
1912
455614 26227 26246 GTTTGAAAAATTCAAGAATG 26
1913
455615 26388 26407 ATAGTGTCTGGCTCATAATA 48
1914
455616 26597 26616 TCAGGTCCTCAAAAACACCA 84
1915
455617 26648 26667 TGGCTGGTACCAGCTGGTGG 76
1916
455618 26766 26785 ACAAATTCATCGAGCTAATG 52
1917
455619 26908 26927 AGAATAGCATGGATTTGAAT 49
1918
455620 26999 27018 CACAAACTTGATCTTGCCAC 77
1919
455626 36534 36553 GAATGTAAAGTATCTTGTTC 47
1920
455627 36578 36597 TATAAAATACACACTGGATT 57
1921
455628 36614 36633 GAAATGTGGCTGCTTCAAAC 36
1922
455629 36649 36668 TGGAGTCACTAGCCACATGT 71
1923
455630 36691 36710 GCATACAAATTTACTGAAAC 58
1924
455631 36904 36923 CAAGTTAAAATCTGCCTCAC 62
1925
455632 36975 36994 GGCATGTATTGATTGCCCTC 68
1926
455633 37026 37045 AGTAAAAGCAGTGGCTGACG 60
1927
455634 37086 37105 CACCTGCCACAGGACAAATG 28
1928
455635 37755 37774 TTGCCCCAATTAGGCCAATA 76
1929
455636 37822 37841 AAGGGCTTAAATTCCACTGG 73
1930
455637 37873 37892 GTACTTTACATGTGCAGCAC 81
1931
455638 38268 38287 AATATATCCAAAATGTTATT 8
1932
455639 38694 38713 GCAGCATCCAACAGAAATAG 62
1933
455640 39294 39313 GAGACTGAACACACGCAAAC 65
1934
455641 39324 39343 GTTCTCTGGGATAGTGAGAA 49
1935
455642 39792 39811 GAGAAACCCAGCCAGCTAAT 69
1936
455643 39937 39956 GGAAGATCTGCCTGAGATTC 46
1937
455644 40132 40151 TACAGCATCCAGCTCAGTGC 63
1938
455645 40633 40652 CCCAGTTTAGAACAATACAA 65
1939
455646 40866 40885 GTAGCCATTGCCCAACACAG 63
1940
455647 40901 40920 CACCACAAGTCCCAGTAGGG 58
1941
455648 40923 40942 TAAACCAAAGTGTGCATATG 11
1942
455649 41087 41106 AAGGACTTACCAATCTTGAC 7
1943
455650 41114 41133 ACCTAACAATTTGGAGAGTC 44
1944
455651 41239 41258 TTACAAGACCAAAGGGTGCC 68
1945
455652 41329 41348 AAATCAACCTTCAAGACATC 13
1946
455653 41397 41416 AAAAATATGTCTACCACATC 52
1947
455654 41431 41450 AAGTTCTAGCTATGACAGAA 23
1948
455655 41575 41594 AGCCTGCAGAACTATGAGCC 48
1949
455656 41629 41648 ATTGGAAGCTTGCTGAGGCC 44
1950
455657 41644 41663 CTGCCTTCCGCCATGATTGG 48
1951
455658 41747 41766 CGAGACAGTGAGTTCTTGTG 64
1952
455659 42067 42086 CTGGCCCTTCACCAAATCAG 62
1953
455660 42139 42158 GGTCAGATTTATTAGTACAA 65
1954
455661 42904 42923 ATCATACCTGAAGAAACTGC 16
1955
BIOL0142WO
455662 43059 43078 ATACAGAGCTTTGAGAAAGG 38
1956
455663 43194 43213 TGTAACAGTGAGAGTCATCT 71
1957
455664 43284 43303 TCTGAGTCTTTACACAGTAT 72
1958
455665 43724 43743 TTCATCAAGGAAAGCATTTA 31
1959
455666 43765 43784 TGGAGATGTGGACTGAACTG 19
1960
455667 43908 43927 CCTGGGCCGCAGTGGCTGCA 63
1961
455668 43926 43945 GTTTTGTCTCAGGTCTCACC 75
1962
455669 43941 43960 CCAGACCAGGGATTTGTTTT 34
1963
455670 43974 43993 CTCATTATAAAGTTGTTTGA 55
1964
455671 44507 44526 TGTACTATGAAAGTTTGTCA 80
1965
455672 44525 44544 AATGATATTGGAATAATCTG 26
1966
455673 44540 44559 CTTTGGAAAAGTTTGAATGA 26
1967
455674 44583 44602 CAGCCTCATAAAATAAGCTG 19
1968
455675 45414 45433 TACTGAGAATAGTGTTTCAC 71
1969
455676 45440 45459 AAGACATCCTTATCTTTTGC 75
1970
455677 45512 45531 TTCCAATATTTGTACCCTCA 87
1971
455678 45626 45645 TACAATGGCCTTTCTAAACC 64
1972
455679 45712 45731 AGATCTTTACTTTCATTACA 54
1973
455680 46058 46077 TATGCAAATTGCATACATTT 59
1974
455681 46091 46110 TTTCCAGATATTTTCCCATA 88
1975
455682 46241 46260 GTGTATTTCACCACAATTTT 78
1976
455683 46571 46590 TGTCTTTGAACATGATCTTC 67
1977
455684 46676 46695 GCATGACTAATTAAAACATC 58
1978
455685 46759 46778 CAGAGCAAGTGGCAGGGCTG 69
1979
455686 46791 46810 CAGAGAGAGTAAAAATTGTT 49
1980
455687 46905 46924 CAGCAGAAAGCAGTTAAATT 56
1981
455688 46941 46960 CAGTAATGGTGAGGGTGATG 28
1982
455689 46956 46975 GGTCCCCATTTCCTACAGTA 67
1983
455690 47307 47326 ACACCTGAGCATATCAGTTT 67
1984
455691 47400 47419 CAGAAAATCCTAGTGCTGCC 62
1985
455692 47424 47443 ATAAAATACAAAGGTTTTCC 23
1986
455693 47467 47486 TCCAAATTGACTTAAACCAC 74
1987
455694 47528 47547 TTGAAAACATCCTTGGGATA 44
1988
455695 47579 47598 CAGGCTGGATTTGGGCCACG 76
1989
455696 47649 47668 GCCACAGATAATGCATAAAT 39
1990
455697 47795 47814 CTGGGTTGAGGCCACAAATA 78
1991
455698 47929 47948 GTTTGTGTACTTATAATCCC 75
1992
455699 47974 47993 GACAAAATGACACACATCCT 72
1993
455700 48188 48207 TTTCACACAATTGATAACTT 57
1994
455701 48208 48227 CAGGCCAACACAGAAAGCTG 70
1995
455702 48277 48296 AGAAACCCACCTCTAATACC 31
1996
455703 48402 48421 GCCACACTTTCCATTCTAGT 90
1997
455704 48417 48436 TGGTTACCAGCTCAAGCCAC 72
1998
455705 48566 48585 CAGGTCTAGAGGCCTATCCC 73
1999
455706 48665 48684 TCTTCAAAGAACCCAGCACC 63
2000
BIOL0142WO
455707 48697 48716 AGATGGAGAGAAAGACTCTG 61
2001
455708 48728 48747 CCCACAGTGACAGTGACTCA 89
2002
455709 48768 48787 CTTAGAAGTTTTGGGAAGGT 60
2003
455710 48802 48821 ATGGTCCCTATCCAAGCCCA 81
2004
455711 48828 48847 ATGGGCAACCATTCTCTTCC 80
2005
455712 49754 49773 GTTGGATGTCTACTTAAACG 63
2006
455713 49845 49864 GACCACATGTTCAGCTAAGA 68
2007
455714 49923 49942 AAACAGAGGCAGTGGTGCTG 62
2008
455715 50053 50072 CCAAAAAGGAGGTCAATGCA 30
2009
455716 50522 50541 GTATCCCCAAGAGAAGGCTC 59
2010
455717 50571 50590 TCAAATGAAGCCAAAACCTC 63
2011
455718 50774 50793 CACTTTCTAGAGATTTTAAC 1
2012
455719 51623 51642 TCAGATCTTGCATGTCTGCG 2
2013
455720 51753 51772 CCGCAAGTGAGCGAGACACA 49
2014
455721 51827 51846 CCACATTCTTTAGTCAACTC 59
2015
455722 51856 51875 CAGAAAACATTTCCTCAGAC 3
2016
455723 52033 52052 ACCAGTTTTCTAGCCGATCT 90
2017
455724 52056 52075 AGGAAAAGCTTCTTTCATCC 34
2018
455725 52071 52090 GCTTTCGAGAAAGAAAGGAA 44
2019
455726 53203 53222 TGGATGAAGGTAAAAGTGCA 42
2020
455727 53246 53265 TCACTATAGGGCCTTGCACA 53
2021
455728 53262 53281 AGCTGGTGCAACATGCTCAC 69
2022
455729 53329 53348 GCATTCTCATGTAGAGTTGC 0
2023
455730 53344 53363 GATATGAATAGACAGGCATT 63
2024
455731 53431 53450 ATTCCCAGAACTTAAGCTTC 40
2025
455732 53571 53590 ATTCCATCATTCTTTGATGG 47
2026
455733 53900 53919 TGCACAAGGAATAAGTGAAT 51
2027
455734 54378 54397 AGAAGGGCTTGAACTACATG 15
2028
455735 54577 54596 GAGCCCAGATATGCAGAACA 58
2029
455736 54592 54611 AAATGACAAGCATCTGAGCC 16
2030
455737 54632 54651 ATTTATACCACTAGGAGGCA 52
2031
455738 55241 55260 TTCAGTGACATTAAGAAAAG 28
2032
455739 55256 55275 ATCTTAAGTTTACAGTTCAG 64
2033
455740 55277 55296 GCATGAAATTTACAATTTTT 26
2034
455741 55418 55437 TCCTGCCAATAAATTAAGAA 0
2035
455742 55657 55676 GAAGTCAGCCCGCCTCTCAC 33
2036
455743 55841 55860 GTGTCCCTCAGTAAAATCTC 53
2037
455744 55877 55896 ATGACCCTGGCCACCAACTC 63
2038
455745 55961 55980 CAGAATCAGAGAGCAAGCAG 56
2039
455746 56125 56144 CCTTAAAATCCACAGGGAAG 5
2040
455747 56151 56170 TCCCCATCACTAAGCCTTAC 31
2041
455748 56203 56222 TAACACCTCACCCTACAGGC 56
2042
455749 56287 56306 ACACCATACTAAGTTTCTGA 68
2043
455750 57995 58014 CTTGTCAATGCACACTTTAA 80
2044
455751 58074 58093 TCTAGTTCAAATGATGTCTG 66
2045
BIOL0142WO
455752 58089 58108 AATAAAGACAGAGTCTCTAG 30
2046
455753 58106 58125 CAAAATGAAGATCTCTGAAT 23
2047
455754 58173 58192 AGCTTTGTGGCTTTGTTCAG 60
2048
455755 58259 58278 TGAATGACATGTACAAGTAA 52
2049
455756 58377 58396 TGTGTAAGGACTATATACTC 64
2050
455757 58471 58490 TTCAGCACAGTAACATACTG 41
2051
455758 58496 58515 AGATGTGTTACAATTGCCTA 76
2052
455759 58696 58715 TTTACATCCTGAAAGGTATT 51
2053
455760 59471 59490 ATATGTACTTATTAAACCTA 18
2054
455761 59748 59767 ACAAAAGGAAGCCTCTAGGC 0
2055
455762 59913 59932 CCAAGTGTTTGAATTCTGCA 83
2056
455763 60155 60174 CAGGTTGATGTTTCTAATTC 60
2057
455764 60170 60189 CTACAGCTGAAAGAACAGGT 76
2058
455765 60249 60268 ATGTTCCAAGCCAGAGAGCT 54
2059
455766 60323 60342 GGTGTGGAGAACAACTCAGC 72
2060
455767 60373 60392 GGGAATTTGGAAAGCCCCAG 0
2061
455768 60392 60411 CAGCCGCAGGAGCTGGATGG 42
2062
455769 60407 60426 GGAGCCAAGCAGGGTCAGCC 73
2063
455770 60433 60452 GGAGAGAAAAACAGGGCACT 69
2064
455771 60448 60467 TATCCCACCTCAGTGGGAGA 1
2065
455772 60602 60621 TCTGAATCAATGAAAAGCAG 79
2066
455773 60703 60722 CATCACAATTTTTAAAAATG 0
2067
455774 61216 61235 GTATTTTTAAAACACATATA 0
2068
455775 61251 61270 CTTAATATACATATGAATAC 14
2069
455786 61340 61359 CAAATATCACAGAGACAGTC 88
2070
455787 61758 61777 GTACAGCAACCTTATTTTAA 5
2071
455788 61853 61872 TTAAATCCTGGGAATGGCAC 83
2072
455789 61959 61978 CTAATGTTGATGGGTATTTA 60
2073
455790 62043 62062 CATGGTTATGTGTATCTGCA 89
2074
455791 62067 62086 TTCACTTGATGTGAAATGAA 18
2075
455792 62500 62519 TGCCAGGGACACAACTTGCT 82
2076
455793 62595 62614 ATGGCATTCAGTACTAACAG 59
2077
455794 62610 62629 TTTTCCTCAGAGAGAATGGC 67
2078
455795 63284 63303 AGTCACAATCAGGGAAGCCT 77
2079
455796 63449 63468 AGTAATCATTCCACCTTCTC 70
2080
455797 63464 63483 CAGTGTTAAGCAAACAGTAA 41
2081
455798 63554 63573 ATACACACATCTTCTAAGCA 48
2082
455799 63576 63595 TCAAGTTTGCTGAAAGCTGA 48
2083
455800 63591 63610 ATAGAGATTTTCATATCAAG 41
2084
455801 64070 64089 ACAGGGAGGTCTCAGGAATC 77
2085
455802 64122 64141 TTTAAGACCTTGGAGGCATT 36
2086
455803 64586 64605 AGGGATGGTGCTCATTGTCT 20
2087
455804 64810 64829 GCCGGATCCCTTTTCTGGGC 64
2088
455805 64955 64974 TGATCACCTCGACTGAAAAC 65
2089
455806 65058 65077 GTGCCACCTTCCAACACACA 74
2090
BIOL0142WO
455807 65530 65549 CAGACAGGTGTATTTGGTGG 65
2091
455808 65895 65914 ACTTTGCAAAATTTAGCCCA 77
2092
455809 65928 65947 TCCCATTCCCACGAGAATTT 76
2093
455810 65972 65991 GCCTTCAAGCCAGAGCCCTC 76
2094
455811 65987 66006 GACCAAGAGTTCAGGGCCTT 59
2095
455812 66099 66118 GTAATGGGAAAGCCAAGTCT 51
2096
455813 66128 66147 TTGCCAGCCATGTTTTCCTG 67
2097
455814 66283 66302 AGGGCATCCATCCCCTGCCA 7
2098
455815 66664 66683 TCACTGGAGCAAGCAAAACA 64
2099
455816 66775 66794 GGTCATAGAAAATAAACTTG 62
2100
455817 66863 66882 AGTGTTGAGACCCTGAACAC 53
2101
455818 66918 66937 AGAGAAAACTGCCCATTTTT 71
2102
455819 66948 66967 AGATCATGGAACCTACAGCT 18
2103
455820 66963 66982 GGACATGGGAAGGAAAGATC 27
2104
455821 67191 67210 CAACAACTACCTGGGTCAGC 51
2105
455822 67271 67290 AGGCATTTGCCTATCTATCC 58
2106
455823 67334 67353 CCAACAAAAGCACTCACTAC 56
2107
455824 67773 67792 TGAAATCTGGGCCTCAAACC 78
2108
455825 67843 67862 GAAACCCTTTCTTCAGACCA 79
2109
455826 68621 68640 TCAAAACAGCAAGTGCTGAA 60
2110
455827 69053 69072 AACCCTAAAGGATCACATTA 43
2111
455828 69357 69376 CAAAGAGCCGTGTGGCAGGG 65
2112
455829 69395 69414 GACCAGCCGTGGGACCCCAA 84
2113
455830 69473 69492 CCACAGGAAGGGCGATGGTA 58
2114
455831 69498 69517 GCAGGAAAGGACCTGGCCTC 45
2115
455832 70567 70586 TTAGGGAGCTGACACCCTAG 56
2116
455833 70645 70664 CAATTCAGTGCAGAATTCAA 80
2117
455834 70675 70694 TCTGAGTTTACTTTGGGCCA 75
2118
455835 70725 70744 CATGATGACCATGTGAAAGA 82
2119
455836 70890 70909 CTGAATGCTTACACCAAGAG 83
2120
455837 70973 70992 CCAATTTTCTATGAGCTTTG 85
2121
455838 71013 71032 CTTTTATGTATAAAATAAGA 6
2122
455839 71573 71592 CCAGGTACATCTTCAATAGC 75
2123
455840 71610 71629 GTACAATTGCTTCAACTAGA 87
2124
455841 71698 71717 ACATTTTTGGATGAGGGCAT 81
2125
455842 71750 71769 AAAGCCAAAGGTTATATCTC 77
2126
455843 71765 71784 AATGCTTGTGGTTCCAAAGC 79
2127
455844 71929 71948 TGTAAAAGTTTAACAGCCTC 70
2128
455845 71992 72011 CATAACCTTTTCCCACCTGA 79
2129
455846 72036 72055 CAGTTCTTTGCACAAAGCTG 76
2130
455847 72127 72146 CAAGATTGTCTGGAAAGCTC 76
2131
455848 72202 72221 TCGCATTCAGTAAGCAGAGC 47
2132
455849 72229 72248 AAACCAGTTTTCTTACTGAC 17
2133
455850 72285 72304 CGGTGTCACACAGATAAACT 73
2134
455851 72367 72386 TTAACTCTCACCCAGTGTCC 61
2135
BIOL0142WO
455852 72406 72425 GTACTAAACATAGCCCAGGG 78
2136
455853 72687 72706 AAATACTCACCAAACTGCCC 4
2137
455854 72768 72787 GTGACCAGCTCTCGGTGTGT 10
2138
455855 73340 73359 GATTTGGTTTGTCCAAACTG 49
2139
455856 73530 73549 GTCAGAAAAGCCAGATTTAC 46
2140
455857 73621 73640 GCAACTGGCAGGCCACGCCC 39
2141
455858 73636 73655 AGTTGTCCACCCTCTGCAAC 0
2142
455859 73683 73702 TGTCAAAGGTGAGGGACTCT 57
2143
455860 74018 74037 ACACAAGACATTTCCTTTTT 64 1544
Example 33: Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
Gapmers from the study described in Example 32 exhibiting significant in vitro inhibition of
STAT3 were tested at various doses in HuVEC cells. Cells were plated at a density of 5,000 cells per
well and transfected using LipofectAMINE2000® reagent with 1.1 nM, 3.3 nM, 10.0 nM, and 30.0 nM
concentrations of antisense oligonucleotide, as specified in Table 54. After a treatment period of
approximately 16 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199 (forward sequence
ACATGCCACTTTGGTGTTTCATAA, designated herein as SEQ ID NO: 6; reverse sequence
TCTTCGTAGATTGTGCTGATAGAGAAC, designated herein as SEQ ID NO: 7; probe sequence
CAGTATAGCCGCTTCCTGCAAGAGTCGAA, designated herein as SEQ ID NO: 8) was used to
measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as measured
by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated control
cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 54 and was calculated by plotting the concentrations of oligonucleotides used versus the percent
inhibition of STAT3 mRNA expression achieved at each concentration, and noting the concentration of
oligonucleotide at which 50% inhibition of STAT3 mRNA expression was achieved compared to the
control. As illustrated in Table 54, STAT3 mRNA levels were significantly reduced in a dose-dependent
manner in antisense oligonucleotide treated cells.
Table 54
Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
.0 30.0 IC
ISIS No 1.1 nM 3.3 nM
nM nM (nM)
337332 7 19 46 80 10.4
345785 8 22 46 74 11.3
455265 20 43 64 85 5.0
455267 16 30 62 79 6.7
455269 23 49 72 84 4.0
455270 3 28 60 79 8.1
455271 16 40 71 86 4.9
BIOL0142WO
455272 28 30 57 86 5.7
455282 18 28 55 80 7.4
455291 21 45 75 85 4.1
455370 6 23 53 78 9.0
455371 15 46 73 90 4.5
455391 10 30 54 75 8.5
455393 6 33 62 81 7.0
455394 5 33 63 85 6.7
455398 7 25 56 76 8.8
455411 10 21 58 82 7.9
455412 15 27 50 79 8.4
455429 17 43 67 81 5.2
455438 20 43 66 83 5.0
455439 10 41 67 84 5.7
455447 7 23 53 87 7.7
455457 9 24 52 79 8.8
455458 8 34 62 83 6.7
455463 6 37 63 85 6.3
455471 11 42 67 78 5.9
455525 0 9 42 72 13.4
455527 0 21 60 87 7.8
455530 11 26 62 83 7.1
455536 5 21 62 85 7.6
455540 8 28 65 87 6.5
455547 6 19 45 67 13.4
455548 0 41 68 90 5.8
455551 0 3 33 72 15.9
455553 0 29 64 87 7.2
455565 0 19 54 86 8.8
455566 13 28 45 76 9.6
455569 0 16 47 76 11.1
455581 0 19 62 85 8.6
455582 0 26 70 89 6.9
455591 7 17 47 68 12.8
455594 0 16 48 76 10.9
455611 14 43 68 81 5.4
455637 10 22 56 76 8.9
455677 0 18 46 72 11.9
455681 16 19 42 69 13.0
455703 9 40 72 92 5.1
455708 11 15 45 77 10.7
455723 3 9 33 68 17.0
455762 0 9 42 70 14.1
455786 21 32 50 79 7.4
455790 13 19 56 84 7.8
BIOL0142WO
455840 17 30 52 77 7.9
Example 34: Antisense inhibition of human STAT3 in HuVEC cells by oligonucleotides designed by
microwalk
Additional gapmers were designed based on the gapmers presented in Example 1 that
demonstrated an inhibition of at least 50%. These gapmers were designed by creating gapmers shifted
slightly upstream and downstream (i.e., “microwalk”) of the original gapmers. These gapmers were
tested in vitro. ISIS 337332 was also included in the assay as a comparator. Cultured HuVEC cells at a
density of 5,000 cells per well were transfected using LipofectAMINE 2000® reagent with 30 nM
antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from
the cells and STAT3 mRNA levels were measured by quantitative real-time PCR. The human primer
probe set RTS199, described hereinabove, was used to measure STAT3 mRNA levels. STAT3 mRNA
levels were adjusted according to total RNA content, as measured by RIBOGREEN . Results are
presented as percent inhibition of STAT3, relative to untreated control cells. The results are presented in
Table 55.
The chimeric antisense oligonucleotides in Table 55 were designed as 55 MOE gapmers.
The gapmers designated with an asterisk (*) in Table 55 are the original gapmers from which gapmers,
ISIS 465226-466744, were designed via microwalk. The 55 gapmers are 20 nucleosides in length,
wherein the central gap segment is comprised of ten 2’-deoxynucleosides and is flanked on both sides (in
the 5’ and 3’ directions) by wings comprising five nucleosides each. Each nucleoside in the 5’ wing
segment and each nucleoside in the 3’ wing segment has a 2’-MOE modification. The internucleoside
linkages throughout each gapmer are phosphorothioate (P=S) linkages. All cytosine residues throughout
each gapmer are 5’-methylcytosines. “Target start site” indicates the 5’-most nucleoside to which the
gapmer is targeted. “Target stop site” indicates the 3’-most nucleoside to which the gapmer is targeted.
Each gapmer listed in Table 55 is targeted to the target region spanning nucleobases 2313-76017 of SEQ
ID NO: 2 (the complement of GENBANK Accession No. NT_010755.14 truncated from nucleotides
4185000 to 4264000).
Table 55
Inhibition of human STAT3 mRNA levels by chimeric antisense oligonucleotides targeted to SEQ ID
NO: 2
Start Stop % SEQ ID
ISIS No Sequence
Site Site inhibition NO
466646 2313 2332 CACACTATACACATTTTTAA 3
2144
466647 2314 2333 ACACACTATACACATTTTTA 11
2145
466648 2315 2334 TACACACTATACACATTTTT 8
2146
455525* 2316 2335 GTACACACTATACACATTTT 47 1824
466649 2317 2336 GGTACACACTATACACATTT 46
2147
466650 2318 2337 AGGTACACACTATACACATT 46
2148
466651 2319 2338 CAGGTACACACTATACACAT 54
2149
466652 2320 2339 GCAGGTACACACTATACACA 68
2150
BIOL0142WO
466653 2321 2340 AGCAGGTACACACTATACAC 43
2151
466654 2322 2341 CAGCAGGTACACACTATACA 56
2152
466655 2323 2342 CCAGCAGGTACACACTATAC 72
2153
466656 2324 2343 ACCAGCAGGTACACACTATA 52
2154
466657 2325 2344 GACCAGCAGGTACACACTAT 69
2155
466658 2326 2345 AGACCAGCAGGTACACACTA 15
2156
466659 2327 2346 AAGACCAGCAGGTACACACT 49
2157
466660 2328 2347 TAAGACCAGCAGGTACACAC 59
2158
466661 2329 2348 GTAAGACCAGCAGGTACACA 73
2159
466662 2330 2349 AGTAAGACCAGCAGGTACAC 65
2160
466663 2331 2350 CAGTAAGACCAGCAGGTACA 64
2161
466664 2332 2351 ACAGTAAGACCAGCAGGTAC 53
2162
466665 2333 2352 TACAGTAAGACCAGCAGGTA 67
2163
466666 2334 2353 ATACAGTAAGACCAGCAGGT 75
2164
466667 2335 2354 CATACAGTAAGACCAGCAGG 66
2165
466668 2336 2355 ACATACAGTAAGACCAGCAG 55
2166
466669 2337 2356 CACATACAGTAAGACCAGCA 71
2167
466670 2338 2357 GCACATACAGTAAGACCAGC 83
2168
466671 2339 2358 TGCACATACAGTAAGACCAG 28
2169
466672 2340 2359 TTGCACATACAGTAAGACCA 70
2170
466673 2341 2360 GTTGCACATACAGTAAGACC 39
2171
466674 2342 2361 AGTTGCACATACAGTAAGAC 53
2172
466675 2343 2362 TAGTTGCACATACAGTAAGA 43
2173
455527* 2383 2402 GCCAAAAATTTACAACCCAT 48 1826
465806 2384 2403 AGCCAAAAATTTACAACCCA 29
2174
465807 2385 2404 CAGCCAAAAATTTACAACCC 7
2175
465808 2386 2405 CCAGCCAAAAATTTACAACC 35
2176
465809 2387 2406 GCCAGCCAAAAATTTACAAC 10
2177
465810 2388 2407 AGCCAGCCAAAAATTTACAA 37
2178
465811 2389 2408 CAGCCAGCCAAAAATTTACA 29
2179
465812 2390 2409 ACAGCCAGCCAAAAATTTAC 3
2180
465813 2391 2410 CACAGCCAGCCAAAAATTTA 6
2181
465814 2392 2411 GCACAGCCAGCCAAAAATTT 35
2182
465815 2393 2412 AGCACAGCCAGCCAAAAATT 22
2183
465816 2394 2413 CAGCACAGCCAGCCAAAAAT 23
2184
465817 2395 2414 TCAGCACAGCCAGCCAAAAA 33
2185
465818 2396 2415 ATCAGCACAGCCAGCCAAAA 32
2186
465819 2397 2416 TATCAGCACAGCCAGCCAAA 48
2187
465820 2398 2417 TTATCAGCACAGCCAGCCAA 32
2188
465821 2399 2418 TTTATCAGCACAGCCAGCCA 0
2189
465822 2400 2419 CTTTATCAGCACAGCCAGCC 49
2190
465823 2401 2420 GCTTTATCAGCACAGCCAGC 69
2191
465824 2402 2421 TGCTTTATCAGCACAGCCAG 48
2192
465825 2403 2422 ATGCTTTATCAGCACAGCCA 74
2193
465826 2404 2423 AATGCTTTATCAGCACAGCC 62
2194
BIOL0142WO
465827 2405 2424 CAATGCTTTATCAGCACAGC 67
2195
465828 2406 2425 CCAATGCTTTATCAGCACAG 71
2196
465829 2407 2426 CCCAATGCTTTATCAGCACA 47
2197
465830 2408 2427 GCCCAATGCTTTATCAGCAC 81
2198
465831 2409 2428 AGCCCAATGCTTTATCAGCA 75
2199
465832 2410 2429 AAGCCCAATGCTTTATCAGC 57
2200
465349 2655 2674 AGGCTCCAACCTCTAAAACA 41
2201
465350 2656 2675 AAGGCTCCAACCTCTAAAAC 34
2202
465351 2657 2676 CAAGGCTCCAACCTCTAAAA 43
2203
465352 2658 2677 TCAAGGCTCCAACCTCTAAA 51
2204
465353 2659 2678 ATCAAGGCTCCAACCTCTAA 38
2205
465354 2660 2679 AATCAAGGCTCCAACCTCTA 29
2206
465355 2661 2680 AAATCAAGGCTCCAACCTCT 56
2207
465356 2662 2681 AAAATCAAGGCTCCAACCTC 24
2208
465357 2663 2682 TAAAATCAAGGCTCCAACCT 46
2209
465358 2664 2683 CTAAAATCAAGGCTCCAACC 45
2210
465359 2665 2684 ACTAAAATCAAGGCTCCAAC 50
2211
465366 2666 2685 GACTAAAATCAAGGCTCCAA 51
2212
465367 2667 2686 AGACTAAAATCAAGGCTCCA 64
2213
465368 2668 2687 GAGACTAAAATCAAGGCTCC 76
2214
455530* 2669 2688 AGAGACTAAAATCAAGGCTC 74 1829
455536* 5000 5019 AGAACTGAAATTCCTTGGTC 52 1835
465833 5001 5020 CAGAACTGAAATTCCTTGGT 81
2215
465834 5002 5021 ACAGAACTGAAATTCCTTGG 81
2216
465835 5003 5022 AACAGAACTGAAATTCCTTG 48
2217
465836 5004 5023 GAACAGAACTGAAATTCCTT 46
2218
465837 5005 5024 AGAACAGAACTGAAATTCCT 39
2219
465838 5006 5025 AAGAACAGAACTGAAATTCC 22
2220
465839 5007 5026 AAAGAACAGAACTGAAATTC 3
2221
465840 5008 5027 AAAAGAACAGAACTGAAATT 0
2222
465841 5009 5028 CAAAAGAACAGAACTGAAAT 0
2223
465842 5010 5029 ACAAAAGAACAGAACTGAAA 0
2224
465843 5011 5030 TACAAAAGAACAGAACTGAA 3
2225
465844 5012 5031 CTACAAAAGAACAGAACTGA 0
2226
465845 5013 5032 CCTACAAAAGAACAGAACTG 13
2227
465846 5014 5033 CCCTACAAAAGAACAGAACT 0
2228
465847 5015 5034 CCCCTACAAAAGAACAGAAC 7
2229
465848 5016 5035 TCCCCTACAAAAGAACAGAA 33
2230
465849 5017 5036 TTCCCCTACAAAAGAACAGA 18
2231
465850 5018 5037 CTTCCCCTACAAAAGAACAG 0
2232
465851 5019 5038 GCTTCCCCTACAAAAGAACA 43
2233
465852 5020 5039 AGCTTCCCCTACAAAAGAAC 32
2234
465853 5021 5040 AAGCTTCCCCTACAAAAGAA 0
2235
465854 5022 5041 AAAGCTTCCCCTACAAAAGA 15
2236
465855 5023 5042 AAAAGCTTCCCCTACAAAAG 14
2237
BIOL0142WO
465856 5024 5043 TAAAAGCTTCCCCTACAAAA 4
2238
465857 5025 5044 TTAAAAGCTTCCCCTACAAA 0
2239
465858 5026 5045 TTTAAAAGCTTCCCCTACAA 11
2240
465859 5027 5046 TTTTAAAAGCTTCCCCTACA 11
2241
465860 5688 5707 CAGTGGTTTTTATAAATGAC 29
2242
465861 5689 5708 TCAGTGGTTTTTATAAATGA 19
2243
465862 5690 5709 TTCAGTGGTTTTTATAAATG 4
2244
465863 5691 5710 TTTCAGTGGTTTTTATAAAT 0
2245
465864 5692 5711 CTTTCAGTGGTTTTTATAAA 0
2246
465865 5693 5712 TCTTTCAGTGGTTTTTATAA 0
2247
465866 5694 5713 CTCTTTCAGTGGTTTTTATA 35
2248
465867 5695 5714 ACTCTTTCAGTGGTTTTTAT 67
2249
465868 5696 5715 TACTCTTTCAGTGGTTTTTA 60
2250
465886 5697 5716 GTACTCTTTCAGTGGTTTTT 85
2251
465887 5698 5717 AGTACTCTTTCAGTGGTTTT 62
2252
455540* 5699 5718 AAGTACTCTTTCAGTGGTTT 76 1839
465888 5700 5719 CAAGTACTCTTTCAGTGGTT 80
2253
465906 5701 5720 TCAAGTACTCTTTCAGTGGT 74
2254
465926 5702 5721 CTCAAGTACTCTTTCAGTGG 80
2255
465927 5703 5722 CCTCAAGTACTCTTTCAGTG 71
2256
465928 5704 5723 CCCTCAAGTACTCTTTCAGT 54
2257
465929 5705 5724 TCCCTCAAGTACTCTTTCAG 33
2258
465930 5706 5725 GTCCCTCAAGTACTCTTTCA 56
2259
465931 5707 5726 TGTCCCTCAAGTACTCTTTC 43
2260
465932 5708 5727 ATGTCCCTCAAGTACTCTTT 33
2261
465486 7674 7693 AAAGGGCTGCAAAAAATCTG 39
2262
465487 7675 7694 GAAAGGGCTGCAAAAAATCT 11
2263
465488 7676 7695 AGAAAGGGCTGCAAAAAATC 28
2264
465489 7677 7696 CAGAAAGGGCTGCAAAAAAT 39
2265
465490 7678 7697 ACAGAAAGGGCTGCAAAAAA 29
2266
465506 7679 7698 AACAGAAAGGGCTGCAAAAA 36
2267
465507 7680 7699 AAACAGAAAGGGCTGCAAAA 35
2268
465508 7681 7700 TAAACAGAAAGGGCTGCAAA 47
2269
455547* 7682 7701 GTAAACAGAAAGGGCTGCAA 72 1846
465509 7683 7702 GGTAAACAGAAAGGGCTGCA 70
2270
465510 7684 7703 TGGTAAACAGAAAGGGCTGC 63
2271
465511 7685 7704 CTGGTAAACAGAAAGGGCTG 60
2272
465526 7686 7705 CCTGGTAAACAGAAAGGGCT 65
2273
465527 7687 7706 ACCTGGTAAACAGAAAGGGC 26
2274
465528 7688 7707 AACCTGGTAAACAGAAAGGG 53
2275
465529 7689 7708 TAACCTGGTAAACAGAAAGG 35
2276
465530 7690 7709 ATAACCTGGTAAACAGAAAG 3
2277
465531 7691 7710 GATAACCTGGTAAACAGAAA 17
2278
465532 7692 7711 AGATAACCTGGTAAACAGAA 14
2279
465533 7693 7712 AAGATAACCTGGTAAACAGA 26
2280
BIOL0142WO
455548* 8078 8097 GGGCAGATTTACCTTCCTTA 77 1847
466722 8241 8260 AATAGCAATCACCTTAGGAA 53
2281
466723 8242 8261 CAATAGCAATCACCTTAGGA 62
2282
466724 8243 8262 ACAATAGCAATCACCTTAGG 48
2283
455551* 8244 8263 TACAATAGCAATCACCTTAG 65 1850
466725 8245 8264 CTACAATAGCAATCACCTTA 15
2284
466726 8246 8265 ACTACAATAGCAATCACCTT 45
2285
466727 8247 8266 AACTACAATAGCAATCACCT 42
2286
466728 8248 8267 AAACTACAATAGCAATCACC 26
2287
466729 8249 8268 AAAACTACAATAGCAATCAC 14
2288
466730 8250 8269 CAAAACTACAATAGCAATCA 0
2289
466731 8251 8270 TCAAAACTACAATAGCAATC 29
2290
466732 8252 8271 TTCAAAACTACAATAGCAAT 20
2291
466733 8253 8272 TTTCAAAACTACAATAGCAA 14
2292
466734 8254 8273 GTTTCAAAACTACAATAGCA 58
2293
466735 8255 8274 TGTTTCAAAACTACAATAGC 28
2294
466736 8256 8275 GTGTTTCAAAACTACAATAG 42
2295
466737 8257 8276 AGTGTTTCAAAACTACAATA 13
2296
466738 8258 8277 AAGTGTTTCAAAACTACAAT 18
2297
466739 8259 8278 CAAGTGTTTCAAAACTACAA 30
2298
466740 8260 8279 CCAAGTGTTTCAAAACTACA 49
2299
466741 8261 8280 ACCAAGTGTTTCAAAACTAC 46
2300
466742 8262 8281 AACCAAGTGTTTCAAAACTA 41
2301
466743 8263 8282 CAACCAAGTGTTTCAAAACT 13
2302
9123 9142
455553* ACCTGCCCCTATGTATAAGC 75 1852
11261 11280
9124 9143
466744 CACCTGCCCCTATGTATAAG 67 2303
11262 11281
9125 9144
466745 CCACCTGCCCCTATGTATAA 69 2304
11263 11282
9126 9145
466746 TCCACCTGCCCCTATGTATA 68 2305
11264 11283
9127 9146
466747 TTCCACCTGCCCCTATGTAT 69 2306
11265 11284
9128 9147
466748 ATTCCACCTGCCCCTATGTA 58 2307
11266 11285
9129 9148
466749 TATTCCACCTGCCCCTATGT 38 2308
11267 11286
9130 9149
466750 TTATTCCACCTGCCCCTATG 47 309
11268 11287
466751 9131 9150 TTTATTCCACCTGCCCCTAT 54
2310
466752 9132 9151 TTTTATTCCACCTGCCCCTA 50
2311
466753 9133 9152 GTTTTATTCCACCTGCCCCT 58
2312
466754 9134 9153 TGTTTTATTCCACCTGCCCC 53
2313
466755 9135 9154 ATGTTTTATTCCACCTGCCC 69
2314
BIOL0142WO
466756 9136 9155 TATGTTTTATTCCACCTGCC 3
2315
466757 9137 9156 TTATGTTTTATTCCACCTGC 48
2316
466758 9138 9157 ATTATGTTTTATTCCACCTG 53
2317
466759 9139 9158 AATTATGTTTTATTCCACCT 24
2318
466760 9140 9159 TAATTATGTTTTATTCCACC 10
2319
466761 9141 9160 CTAATTATGTTTTATTCCAC 13
2320
466762 9142 9161 CCTAATTATGTTTTATTCCA 23
2321
466763 9143 9162 TCCTAATTATGTTTTATTCC 27
2322
466764 9144 9163 CTCCTAATTATGTTTTATTC 21
2323
466765 9145 9164 CCTCCTAATTATGTTTTATT 30
2324
9862 9881
465740 TGGCTTCTTCCTGAGACACA 81 2325
12345 12364
9863 9882
465741 TTGGCTTCTTCCTGAGACAC 68 2326
12346 12365
9864 9883
465742 GTTGGCTTCTTCCTGAGACA 81 2327
12347 12366
9865 9884
465743 TGTTGGCTTCTTCCTGAGAC 68 2328
12348 12367
9866 9885
465744 CTGTTGGCTTCTTCCTGAGA 44 2329
12349 12368
9867 9886
465745 CCTGTTGGCTTCTTCCTGAG 73 2330
12350 12369
9868 9887
465746 TCCTGTTGGCTTCTTCCTGA 61 2331
12351 12370
9869 9888
465747 CTCCTGTTGGCTTCTTCCTG 53 2332
12352 12371
9870 9889
465748 CCTCCTGTTGGCTTCTTCCT 78 2333
12353 12372
9871 9890
465749 TCCTCCTGTTGGCTTCTTCC 73 2334
12354 12373
9872 9891
465750 TTCCTCCTGTTGGCTTCTTC 70 2335
12355 12374
9873 9892
465751 GTTCCTCCTGTTGGCTTCTT 89 2336
12356 12375
9874 9893
465752 GGTTCCTCCTGTTGGCTTCT 86 2337
12357 12376
9875 9894
465753 AGGTTCCTCCTGTTGGCTTC 73 2338
12358 12377
9876 9895
465754 AAGGTTCCTCCTGTTGGCTT 85 2339
12359 12378
9877 9896
465755 TAAGGTTCCTCCTGTTGGCT 82 2340
12360 12379
9878 9897
465756 ATAAGGTTCCTCCTGTTGGC 72 2341
12361 12380
465757 9879 9898 AATAAGGTTCCTCCTGTTGG 61 2342
BIOL0142WO
12362 12381
9880 9899
465758 AAATAAGGTTCCTCCTGTTG 40 2343
12363 12382
9881 9900
465759 AAAATAAGGTTCCTCCTGTT 41 2344
12364 12383
9882 9901
465760 CAAAATAAGGTTCCTCCTGT 20 2345
12365 12384
9883 9902
465761 TCAAAATAAGGTTCCTCCTG 57 2346
12366 12385
9884 9903
465762 CTCAAAATAAGGTTCCTCCT 48 2347
12367 12386
9885 9904
465763 ACTCAAAATAAGGTTCCTCC 52 2348
12368 12387
9886 9905
455566* GACTCAAAATAAGGTTCCTC 59 1855
12369 12388
9887 9906
465764 TGACTCAAAATAAGGTTCCT 54 2349
12370 12389
9888 9907
465765 CTGACTCAAAATAAGGTTCC 47 2350
12371 12390
9889 9908
465766 CCTGACTCAAAATAAGGTTC 55 2351
12372 12391
9890 9909
465767 ACCTGACTCAAAATAAGGTT 48 2352
12373 12382
9123 9142
455553* ACCTGCCCCTATGTATAAGC 75 1852
11261 11280
9124 9143
466744 CACCTGCCCCTATGTATAAG 67 2303
11262 11281
9125 9144
466745 CCACCTGCCCCTATGTATAA 69 2304
11263 11282
9126 9145
466746 TCCACCTGCCCCTATGTATA 68 2305
11264 11283
9127 9146
466747 TTCCACCTGCCCCTATGTAT 69 2306
11265 11284
9128 9147
466748 ATTCCACCTGCCCCTATGTA 58 2307
11266 11285
9129 9148
466749 TATTCCACCTGCCCCTATGT 38 2308
11267 11286
9130 9149
466750 TTATTCCACCTGCCCCTATG 47 2309
11268 11287
465726 11695 11714 TTAATCTTTCCTAGGCAAAG 19
2353
465727 11696 11715 ATTAATCTTTCCTAGGCAAA 22
2354
465728 11697 11716 CATTAATCTTTCCTAGGCAA 43
2355
465729 11698 11717 GCATTAATCTTTCCTAGGCA 68
2356
465730 11699 11718 AGCATTAATCTTTCCTAGGC 80
2357
455565* 11700 11719 TAGCATTAATCTTTCCTAGG 74 1864
BIOL0142WO
465731 11701 11720 TTAGCATTAATCTTTCCTAG 42
2358
465732 11702 11721 ATTAGCATTAATCTTTCCTA 22
2359
465733 11703 11722 GATTAGCATTAATCTTTCCT 40
2360
465734 11704 11723 AGATTAGCATTAATCTTTCC 0
2361
465735 11705 11724 AAGATTAGCATTAATCTTTC 10
2362
465736 11706 11725 TAAGATTAGCATTAATCTTT 3
2363
465737 12342 12361 CTTCTTCCTGAGACACAGCC 71
2364
465738 12343 12362 GCTTCTTCCTGAGACACAGC 74
2365
465739 12344 12363 GGCTTCTTCCTGAGACACAG 83
2366
9862 9881
465740 TGGCTTCTTCCTGAGACACA 81 2325
12345 12364
9863 9882
465741 TTGGCTTCTTCCTGAGACAC 68 2326
12346 12365
9864 9883
465742 GTTGGCTTCTTCCTGAGACA 81 2327
12347 12366
9865 9884
465743 TGTTGGCTTCTTCCTGAGAC 68 2328
12348 12367
9866 9885
465744 CTGTTGGCTTCTTCCTGAGA 44 2329
12349 12368
9867 9886
465745 CCTGTTGGCTTCTTCCTGAG 73 2330
12350 12369
9868 9887
465746 TCCTGTTGGCTTCTTCCTGA 61 2331
12351 12370
9869 9888
465747 CTCCTGTTGGCTTCTTCCTG 53 2332
12352 12371
9870 9889
465748 CCTCCTGTTGGCTTCTTCCT 78 2333
12353 12372
9871 9890
465749 TCCTCCTGTTGGCTTCTTCC 73 2334
12354 12373
9872 9891
465750 TTCCTCCTGTTGGCTTCTTC 70 2335
12355 12374
9873 9892
465751 GTTCCTCCTGTTGGCTTCTT 89 2336
12356 12375
9874 9893
465752 GGTTCCTCCTGTTGGCTTCT 86 2337
12357 12376
9875 9894
465753 AGGTTCCTCCTGTTGGCTTC 73 2338
12358 12377
9876 9895
465754 AAGGTTCCTCCTGTTGGCTT 85 2339
12359 12378
9877 9896
465755 TAAGGTTCCTCCTGTTGGCT 82 2340
12360 12379
9878 9897
465756 ATAAGGTTCCTCCTGTTGGC 72 2341
12361 12380
9879 9898
465757 AATAAGGTTCCTCCTGTTGG 61 2342
12362 12381
BIOL0142WO
9880 9899
465758 AAATAAGGTTCCTCCTGTTG 40 2343
12363 12382
9881 9900
465759 AAAATAAGGTTCCTCCTGTT 41 2344
12364 12383
9882 9901
465760 CAAAATAAGGTTCCTCCTGT 20 2345
12365 12384
9883 9902
465761 TCAAAATAAGGTTCCTCCTG 57 2346
12366 12385
9884 9903
465762 CTCAAAATAAGGTTCCTCCT 48 2347
12367 12386
9885 9904
465763 ACTCAAAATAAGGTTCCTCC 52 2348
12368 12387
9886 9905
455566* GACTCAAAATAAGGTTCCTC 59 1865
12369 12388
9887 9906
465764 TGACTCAAAATAAGGTTCCT 54 2349
12370 12389
9888 9907
465765 CTGACTCAAAATAAGGTTCC 47 2350
12371 12390
9889 9908
465766 CCTGACTCAAAATAAGGTTC 55 2351
12372 12391
9890 9909
465767 ACCTGACTCAAAATAAGGTT 48 2352
12373 12392
465369 14101 14120 TGAGGATGACCCCAGATAAA 64
2367
465370 14102 14121 GTGAGGATGACCCCAGATAA 60
2368
465371 14103 14122 TGTGAGGATGACCCCAGATA 47
2369
465372 14104 14123 CTGTGAGGATGACCCCAGAT 68
2370
465373 14105 14124 CCTGTGAGGATGACCCCAGA 67
2371
465374 14106 14125 GCCTGTGAGGATGACCCCAG 70
2372
465375 14107 14126 TGCCTGTGAGGATGACCCCA 75
2373
465376 14108 14127 ATGCCTGTGAGGATGACCCC 72
2374
465377 14109 14128 TATGCCTGTGAGGATGACCC 58
2375
465378 14110 14129 CTATGCCTGTGAGGATGACC 56
2376
465379 14111 14130 GCTATGCCTGTGAGGATGAC 65
2377
465380 14112 14131 TGCTATGCCTGTGAGGATGA 23
2378
465386 14113 14132 CTGCTATGCCTGTGAGGATG 64
2379
465387 14114 14133 TCTGCTATGCCTGTGAGGAT 66
2380
465388 14115 14134 ATCTGCTATGCCTGTGAGGA 69
2381
465389 14116 14135 TATCTGCTATGCCTGTGAGG 59
2382
465390 14117 14136 ATATCTGCTATGCCTGTGAG 51
2383
465391 14118 14137 AATATCTGCTATGCCTGTGA 57
2384
465392 14119 14138 GAATATCTGCTATGCCTGTG 60
2385
465393 14120 14139 AGAATATCTGCTATGCCTGT 53
2386
465394 14121 14140 CAGAATATCTGCTATGCCTG 55
2387
465395 14122 14141 TCAGAATATCTGCTATGCCT 64
2388
465396 14123 14142 ATCAGAATATCTGCTATGCC 43
2389
BIOL0142WO
465397 14124 14143 AATCAGAATATCTGCTATGC 37
2390
465398 14125 14144 GAATCAGAATATCTGCTATG 22
2391
465399 14126 14145 TGAATCAGAATATCTGCTAT 33
2392
465400 14127 14146 CTGAATCAGAATATCTGCTA 58
2393
465401 14128 14147 TCTGAATCAGAATATCTGCT 77
2394
455569* 14129 14148 ATCTGAATCAGAATATCTGC 67 1868
465406 14130 14149 CATCTGAATCAGAATATCTG 45
2395
465407 14131 14150 CCATCTGAATCAGAATATCT 47
2396
465408 14132 14151 ACCATCTGAATCAGAATATC 55
2397
465409 14133 14152 GACCATCTGAATCAGAATAT 72
2398
465410 14134 14153 GGACCATCTGAATCAGAATA 70
2399
465411 14135 14154 AGGACCATCTGAATCAGAAT 67
2400
465426 14136 14155 AAGGACCATCTGAATCAGAA 71
2401
465427 14137 14156 CAAGGACCATCTGAATCAGA 73
2402
465428 14138 14157 CCAAGGACCATCTGAATCAG 64
2403
465429 14139 14158 ACCAAGGACCATCTGAATCA 54
2404
465446 14140 14159 GACCAAGGACCATCTGAATC 65
2405
465447 14141 14160 GGACCAAGGACCATCTGAAT 72
2406
465448 14142 14161 AGGACCAAGGACCATCTGAA 68
2407
465449 14143 14162 AAGGACCAAGGACCATCTGA 78
2408
465450 14144 14163 TAAGGACCAAGGACCATCTG 37
2409
465451 14145 14164 CTAAGGACCAAGGACCATCT 73
2410
465452 14146 14165 ACTAAGGACCAAGGACCATC 65
2411
465453 14147 14166 AACTAAGGACCAAGGACCAT 54
2412
465454 14148 14167 AAACTAAGGACCAAGGACCA 49
2413
465455 14149 14168 CAAACTAAGGACCAAGGACC 61
2414
465456 14150 14169 TCAAACTAAGGACCAAGGAC 53
2415
465457 14151 14170 CTCAAACTAAGGACCAAGGA 59
2416
465534 16802 16821 CAACAGAGTGAAATGTAATG 16
2417
465535 16803 16822 TCAACAGAGTGAAATGTAAT 12
2418
465536 16804 16823 CTCAACAGAGTGAAATGTAA 52
2419
465537 16805 16824 GCTCAACAGAGTGAAATGTA 74
2420
465538 16806 16825 TGCTCAACAGAGTGAAATGT 17
2421
465539 16807 16826 ATGCTCAACAGAGTGAAATG 37
2422
465540 16808 16827 AATGCTCAACAGAGTGAAAT 14
2423
465541 16809 16828 GAATGCTCAACAGAGTGAAA 30
2424
465542 16810 16829 AGAATGCTCAACAGAGTGAA 23
2425
465543 16811 16830 TAGAATGCTCAACAGAGTGA 43
2426
465544 16812 16831 ATAGAATGCTCAACAGAGTG 38
2427
465545 16813 16832 CATAGAATGCTCAACAGAGT 38
2428
465546 16814 16833 CCATAGAATGCTCAACAGAG 56
2429
465547 16815 16834 TCCATAGAATGCTCAACAGA 37
2430
465548 16816 16835 ATCCATAGAATGCTCAACAG 48
2431
465549 16817 16836 AATCCATAGAATGCTCAACA 24
2432
465550 16818 16837 AAATCCATAGAATGCTCAAC 34
2433
BIOL0142WO
465551 16819 16838 AAAATCCATAGAATGCTCAA 30
2434
465552 16820 16839 CAAAATCCATAGAATGCTCA 32
2435
465553 16821 16840 TCAAAATCCATAGAATGCTC 46
2436
465554 16822 16841 GTCAAAATCCATAGAATGCT 57
2437
465555 16823 16842 TGTCAAAATCCATAGAATGC 32
2438
465556 16824 16843 TTGTCAAAATCCATAGAATG 5
2439
465557 16825 16844 TTTGTCAAAATCCATAGAAT 2
2440
465558 16826 16845 ATTTGTCAAAATCCATAGAA 17
2441
465559 16827 16846 CATTTGTCAAAATCCATAGA 17
2442
465560 16828 16847 ACATTTGTCAAAATCCATAG 31
2443
465561 16829 16848 CACATTTGTCAAAATCCATA 43
2444
465562 16830 16849 ACACATTTGTCAAAATCCAT 42
2445
465563 16831 16850 CACACATTTGTCAAAATCCA 56
2446
455581* 16832 16851 TCACACATTTGTCAAAATCC 55 1880
465564 16833 16852 ATCACACATTTGTCAAAATC 34 2447
465565 16834 16853 CATCACACATTTGTCAAAAT 40
2448
465566 16835 16854 TCATCACACATTTGTCAAAA 41
2449
465567 16836 16855 ATCATCACACATTTGTCAAA 37
2450
465568 16837 16856 CATCATCACACATTTGTCAA 44
2451
465569 16838 16857 ACATCATCACACATTTGTCA 60
2452
465570 16839 16858 TACATCATCACACATTTGTC 9
2453
465571 16840 16859 ATACATCATCACACATTTGT 48
2454
465572 16841 16860 TATACATCATCACACATTTG 46
2455
465573 16842 16861 ATATACATCATCACACATTT 28
2456
455582* 16863 16882 TATATAATTGTGTACTGGCA 79 1881
465458 16864 16883 TTATATAATTGTGTACTGGC 83
2457
465459 16865 16884 TTTATATAATTGTGTACTGG 22
2458
465460 16866 16885 TTTTATATAATTGTGTACTG 8
2459
465461 16867 16886 ATTTTATATAATTGTGTACT 0
2460
465462 16868 16887 TATTTTATATAATTGTGTAC 1
2461
465463 16869 16888 CTATTTTATATAATTGTGTA 9
2462
465464 16870 16889 ACTATTTTATATAATTGTGT 0
2463
465465 16871 16890 AACTATTTTATATAATTGTG 7
2464
465466 16872 16891 AAACTATTTTATATAATTGT 13
2465
465606 21187 21206 TAATGAGACTTTAGCACTCT 67
2466
455591* 21188 21207 ATAATGAGACTTTAGCACTC 62 1890
465607 21189 21208 AATAATGAGACTTTAGCACT 41
2467
465608 21190 21209 CAATAATGAGACTTTAGCAC 54
2468
465609 21191 21210 GCAATAATGAGACTTTAGCA 6
2469
465610 21193 21212 CTGCAATAATGAGACTTTAG 77
2470
465611 21194 21213 ACTGCAATAATGAGACTTTA 53
2471
465612 21195 21214 AACTGCAATAATGAGACTTT 39
2472
465266 21638 21657 ATTTGAATAAATGAATGAAA 0
2473
465267 21639 21658 TATTTGAATAAATGAATGAA 0
2474
465268 21640 21659 ATATTTGAATAAATGAATGA 0
2475
BIOL0142WO
465269 21641 21660 AATATTTGAATAAATGAATG 0
2476
465270 21642 21661 AAATATTTGAATAAATGAAT 0
2477
465271 21643 21662 CAAATATTTGAATAAATGAA 0
2478
465272 21644 21663 TCAAATATTTGAATAAATGA 0
2479
465273 21645 21664 CTCAAATATTTGAATAAATG 0
2480
465274 21646 21665 GCTCAAATATTTGAATAAAT 0
2481
465275 21647 21666 TGCTCAAATATTTGAATAAA 6
2482
465276 21648 21667 ATGCTCAAATATTTGAATAA 0
2483
465277 21649 21668 AATGCTCAAATATTTGAATA 0
2484
465278 21650 21669 GAATGCTCAAATATTTGAAT 19
2485
465279 21651 21670 AGAATGCTCAAATATTTGAA 0
2486
465280 21652 21671 CAGAATGCTCAAATATTTGA 5
2487
465281 21653 21672 ACAGAATGCTCAAATATTTG 9
2488
465282 21654 21673 TACAGAATGCTCAAATATTT 1
2489
465283 21655 21674 CTACAGAATGCTCAAATATT 0
2490
465284 21656 21675 ACTACAGAATGCTCAAATAT 0
2491
465285 21657 21676 AACTACAGAATGCTCAAATA 2
2492
465286 21658 21677 CAACTACAGAATGCTCAAAT 12
2493
465287 21659 21678 GCAACTACAGAATGCTCAAA 26
2494
465288 21660 21679 AGCAACTACAGAATGCTCAA 39
2495
465289 21661 21680 CAGCAACTACAGAATGCTCA 53
2496
465290 21662 21681 CCAGCAACTACAGAATGCTC 26
2497
465291 21663 21682 CCCAGCAACTACAGAATGCT 42
2498
465292 21664 21683 CCCCAGCAACTACAGAATGC 40
2499
465293 21665 21684 TCCCCAGCAACTACAGAATG 13
2500
465294 21666 21685 TTCCCCAGCAACTACAGAAT 30
2501
465295 21667 21686 TTTCCCCAGCAACTACAGAA 16
2502
465296 21668 21687 ATTTCCCCAGCAACTACAGA 5
2503
465297 21669 21688 TATTTCCCCAGCAACTACAG 7
2504
465298 21670 21689 CTATTTCCCCAGCAACTACA 20
2505
465299 21671 21690 GCTATTTCCCCAGCAACTAC 7
2506
465300 21672 21691 TGCTATTTCCCCAGCAACTA 25
2507
465301 21673 21692 CTGCTATTTCCCCAGCAACT 31
2508
465302 21674 21693 ACTGCTATTTCCCCAGCAAC 14
2509
455594* 21675 21694 CACTGCTATTTCCCCAGCAA 43 1893
465303 21676 21695 TCACTGCTATTTCCCCAGCA 23
2510
465304 21677 21696 TTCACTGCTATTTCCCCAGC 45
2511
465305 21678 21697 GTTCACTGCTATTTCCCCAG 11
2512
465306 21679 21698 AGTTCACTGCTATTTCCCCA 62
2513
465307 21680 21699 CAGTTCACTGCTATTTCCCC 52
2514
465308 21681 21700 TCAGTTCACTGCTATTTCCC 40
2515
465309 21682 21701 TTCAGTTCACTGCTATTTCC 29
2516
465310 21683 21702 CTTCAGTTCACTGCTATTTC 40
2517
465311 21684 21703 TCTTCAGTTCACTGCTATTT 25
2518
465312 21685 21704 TTCTTCAGTTCACTGCTATT 18
2519
BIOL0142WO
465313 21686 21705 ATTCTTCAGTTCACTGCTAT 7
2520
465314 21687 21706 CATTCTTCAGTTCACTGCTA 33
2521
465315 21688 21707 ACATTCTTCAGTTCACTGCT 39
2522
465316 21689 21708 GACATTCTTCAGTTCACTGC 49
2523
465317 21690 21709 AGACATTCTTCAGTTCACTG 50
2524
465318 21691 21710 AAGACATTCTTCAGTTCACT 37
2525
465319 21692 21711 AAAGACATTCTTCAGTTCAC 26
2526
465320 21693 21712 CAAAGACATTCTTCAGTTCA 13
2527
465321 21694 21713 ACAAAGACATTCTTCAGTTC 0
2528
465322 21695 21714 AACAAAGACATTCTTCAGTT 11
2529
465323 21696 21715 GAACAAAGACATTCTTCAGT 10
2530
465324 21697 21716 AGAACAAAGACATTCTTCAG 14
2531
465325 21698 21717 AAGAACAAAGACATTCTTCA 7
2532
465326 21699 21718 TAAGAACAAAGACATTCTTC 13
2533
465327 21700 21719 ATAAGAACAAAGACATTCTT 1
2534
465328 21701 21720 CATAAGAACAAAGACATTCT 16
2535
465329 21702 21721 CCATAAGAACAAAGACATTC 38
2536
465330 21703 21722 CCCATAAGAACAAAGACATT 11
2537
465331 21704 21723 CCCCATAAGAACAAAGACAT 0
2538
465332 21705 21724 GCCCCATAAGAACAAAGACA 30
2539
465333 21706 21725 AGCCCCATAAGAACAAAGAC 22
2540
465334 21707 21726 AAGCCCCATAAGAACAAAGA 21
2541
465613 26034 26053 TCTCCAGCCTACAGATGACT 32
2542
465614 26035 26054 CTCTCCAGCCTACAGATGAC 31
2543
465615 26036 26055 TCTCTCCAGCCTACAGATGA 29
2544
465616 26037 26056 CTCTCTCCAGCCTACAGATG 22
2545
465617 26038 26057 CCTCTCTCCAGCCTACAGAT 44
2546
465618 26039 26058 TCCTCTCTCCAGCCTACAGA 41
2547
465619 26040 26059 TTCCTCTCTCCAGCCTACAG 32
2548
465620 26041 26060 GTTCCTCTCTCCAGCCTACA 0
2549
465621 26042 26061 AGTTCCTCTCTCCAGCCTAC 44
2550
465622 26043 26062 CAGTTCCTCTCTCCAGCCTA 39
2551
465623 26044 26063 CCAGTTCCTCTCTCCAGCCT 47
2552
465624 26045 26064 TCCAGTTCCTCTCTCCAGCC 49
2553
465625 26046 26065 TTCCAGTTCCTCTCTCCAGC 46
2554
465626 26047 26066 CTTCCAGTTCCTCTCTCCAG 47
2555
465627 26048 26067 CCTTCCAGTTCCTCTCTCCA 28
2556
465628 26049 26068 CCCTTCCAGTTCCTCTCTCC 28
2557
465629 26050 26069 CCCCTTCCAGTTCCTCTCTC 21
2558
465630 26051 26070 GCCCCTTCCAGTTCCTCTCT 65
2559
465631 26052 26071 AGCCCCTTCCAGTTCCTCTC 60
2560
465632 26053 26072 TAGCCCCTTCCAGTTCCTCT 56
2561
465633 26054 26073 TTAGCCCCTTCCAGTTCCTC 52
2562
465634 26055 26074 TTTAGCCCCTTCCAGTTCCT 53
2563
465635 26056 26075 CTTTAGCCCCTTCCAGTTCC 39
2564
BIOL0142WO
465636 26057 26076 ACTTTAGCCCCTTCCAGTTC 31
2565
465637 26058 26077 AACTTTAGCCCCTTCCAGTT 46
2566
465638 26059 26078 CAACTTTAGCCCCTTCCAGT 37
2567
465639 26060 26079 CCAACTTTAGCCCCTTCCAG 48
2568
455611* 26061 26080 GCCAACTTTAGCCCCTTCCA 62 1870
465640 26062 26081 AGCCAACTTTAGCCCCTTCC 71 2569
465641 26063 26082 CAGCCAACTTTAGCCCCTTC 70
2570
465642 26064 26083 TCAGCCAACTTTAGCCCCTT 66
2571
465643 26065 26084 CTCAGCCAACTTTAGCCCCT 35
2572
465644 26066 26085 ACTCAGCCAACTTTAGCCCC 49
2573
465645 26067 26086 TACTCAGCCAACTTTAGCCC 33
2574
465646 26068 26087 CTACTCAGCCAACTTTAGCC 28
2575
465647 26069 26088 ACTACTCAGCCAACTTTAGC 12
2576
465648 26070 26089 AACTACTCAGCCAACTTTAG 34
2577
465649 26071 26090 TAACTACTCAGCCAACTTTA 26
2578
455637* 37873 37892 GTACTTTACATGTGCAGCAC 78 1931
465650 37874 37893 TGTACTTTACATGTGCAGCA 71
2579
465651 37875 37894 GTGTACTTTACATGTGCAGC 75
2580
465652 37876 37895 TGTGTACTTTACATGTGCAG 65
2581
465653 37877 37896 CTGTGTACTTTACATGTGCA 65
2582
465654 37878 37897 CCTGTGTACTTTACATGTGC 60
2583
465655 37879 37898 TCCTGTGTACTTTACATGTG 51
2584
465656 37880 37899 CTCCTGTGTACTTTACATGT 48
2585
465657 37881 37900 TCTCCTGTGTACTTTACATG 25
2586
465658 37882 37901 ATCTCCTGTGTACTTTACAT 33
2587
465659 37883 37902 AATCTCCTGTGTACTTTACA 23
2588
465660 37884 37903 AAATCTCCTGTGTACTTTAC 24
2589
465661 37885 37904 TAAATCTCCTGTGTACTTTA 26
2590
465666 37886 37905 CTAAATCTCCTGTGTACTTT 16
2591
465667 37887 37906 TCTAAATCTCCTGTGTACTT 27
2592
465668 37888 37907 TTCTAAATCTCCTGTGTACT 30
2593
465669 37889 37908 TTTCTAAATCTCCTGTGTAC 30
2594
465670 37890 37909 TTTTCTAAATCTCCTGTGTA 11
2595
465671 37891 37910 GTTTTCTAAATCTCCTGTGT 37
2596
465672 37892 37911 AGTTTTCTAAATCTCCTGTG 49
2597
465686 37893 37912 AAGTTTTCTAAATCTCCTGT 19
2598
465687 37894 37913 GAAGTTTTCTAAATCTCCTG 46
2599
465688 37895 37914 CGAAGTTTTCTAAATCTCCT 53
2600
465689 37896 37915 ACGAAGTTTTCTAAATCTCC 45
2601
465690 37897 37916 TACGAAGTTTTCTAAATCTC 9
2602
465706 37898 37917 CTACGAAGTTTTCTAAATCT 14
2603
465707 37899 37918 GCTACGAAGTTTTCTAAATC 32
2604
455677* 45512 45531 TTCCAATATTTGTACCCTCA 49 1971
465574 45513 45532 TTTCCAATATTTGTACCCTC 43
2605
465575 45514 45533 CTTTCCAATATTTGTACCCT 50
2606
BIOL0142WO
465576 45515 45534 GCTTTCCAATATTTGTACCC 58
2607
465577 45516 45535 TGCTTTCCAATATTTGTACC 35
2608
465578 45517 45536 TTGCTTTCCAATATTTGTAC 31
2609
465579 45518 45537 CTTGCTTTCCAATATTTGTA 29
2610
465580 45519 45538 CCTTGCTTTCCAATATTTGT 35
2611
465581 45520 45539 CCCTTGCTTTCCAATATTTG 26
2612
465582 45521 45540 TCCCTTGCTTTCCAATATTT 34
2613
465583 45522 45541 GTCCCTTGCTTTCCAATATT 39
2614
465584 45523 45542 TGTCCCTTGCTTTCCAATAT 44
2615
465585 45524 45543 CTGTCCCTTGCTTTCCAATA 60
2616
465586 45525 45544 TCTGTCCCTTGCTTTCCAAT 59
2617
465587 45526 45545 TTCTGTCCCTTGCTTTCCAA 47
2618
455681* 46091 46110 TTTCCAGATATTTTCCCATA 48 1975
465335 46092 46111 GTTTCCAGATATTTTCCCAT 71
2619
465336 46093 46112 TGTTTCCAGATATTTTCCCA 53
2620
466676 48396 48415 CTTTCCATTCTAGTTTTACC 1
2621
466677 48397 48416 ACTTTCCATTCTAGTTTTAC 19
2622
466678 48398 48417 CACTTTCCATTCTAGTTTTA 23
2623
466679 48399 48418 ACACTTTCCATTCTAGTTTT 9
2624
466680 48400 48419 CACACTTTCCATTCTAGTTT 31
2625
466681 48401 48420 CCACACTTTCCATTCTAGTT 64
2626
455703* 48402 48421 GCCACACTTTCCATTCTAGT 75 1997
466682 48403 48422 AGCCACACTTTCCATTCTAG 56
2627
466683 48404 48423 AAGCCACACTTTCCATTCTA 40
2628
466684 48405 48424 CAAGCCACACTTTCCATTCT 24
2629
466685 48406 48425 TCAAGCCACACTTTCCATTC 39
2630
466686 48407 48426 CTCAAGCCACACTTTCCATT 38
2631
466687 48408 48427 GCTCAAGCCACACTTTCCAT 53
2632
466688 48409 48428 AGCTCAAGCCACACTTTCCA 59
2633
466689 48410 48429 CAGCTCAAGCCACACTTTCC 51
2634
466690 48411 48430 CCAGCTCAAGCCACACTTTC 43
2635
466691 48412 48431 ACCAGCTCAAGCCACACTTT 30
2636
466692 48413 48432 TACCAGCTCAAGCCACACTT 35
2637
466693 48414 48433 TTACCAGCTCAAGCCACACT 32
2638
466694 48415 48434 GTTACCAGCTCAAGCCACAC 53
2639
466695 48416 48435 GGTTACCAGCTCAAGCCACA 54
2640
455704* 48417 48436 TGGTTACCAGCTCAAGCCAC 61 1998
455708* 48728 48747 CCCACAGTGACAGTGACTCA 58 2002
465708 48729 48748 TCCCACAGTGACAGTGACTC 61
2641
465709 48730 48749 TTCCCACAGTGACAGTGACT 60
2642
465710 48731 48750 CTTCCCACAGTGACAGTGAC 55
2643
455723* 52033 52052 ACCAGTTTTCTAGCCGATCT 24 2017
466696 52034 52053 TACCAGTTTTCTAGCCGATC 54
2644
466697 52035 52054 TTACCAGTTTTCTAGCCGAT 41
2645
466698 52036 52055 TTTACCAGTTTTCTAGCCGA 37
2646
BIOL0142WO
466699 52037 52056 CTTTACCAGTTTTCTAGCCG 17
2647
466700 52038 52057 CCTTTACCAGTTTTCTAGCC 11
2648
466701 52039 52058 TCCTTTACCAGTTTTCTAGC 24
2649
466702 52040 52059 ATCCTTTACCAGTTTTCTAG 1
2650
466703 52041 52060 CATCCTTTACCAGTTTTCTA 7
2651
466704 52042 52061 TCATCCTTTACCAGTTTTCT 0
2652
466705 52043 52062 TTCATCCTTTACCAGTTTTC 15
2653
466706 52044 52063 TTTCATCCTTTACCAGTTTT 0
2654
466707 52045 52064 CTTTCATCCTTTACCAGTTT 9
2655
466708 52046 52065 TCTTTCATCCTTTACCAGTT 0
2656
466709 52047 52066 TTCTTTCATCCTTTACCAGT 8
2657
466710 52048 52067 CTTCTTTCATCCTTTACCAG 11
2658
466711 52049 52068 GCTTCTTTCATCCTTTACCA 8
2659
466712 52050 52069 AGCTTCTTTCATCCTTTACC 6
2660
466713 52051 52070 AAGCTTCTTTCATCCTTTAC 0
2661
466714 52052 52071 AAAGCTTCTTTCATCCTTTA 18
2662
466715 52053 52072 AAAAGCTTCTTTCATCCTTT 2
2663
466716 52054 52073 GAAAAGCTTCTTTCATCCTT 9
2664
466717 52055 52074 GGAAAAGCTTCTTTCATCCT 1
2665
455724* 52056 52075 AGGAAAAGCTTCTTTCATCC 0 2018
455762* 59913 59932 CCAAGTGTTTGAATTCTGCA 36 2056
466766 59914 59933 ACCAAGTGTTTGAATTCTGC 58
2666
466767 59915 59934 TACCAAGTGTTTGAATTCTG 32
2667
466768 59916 59935 ATACCAAGTGTTTGAATTCT 21
2668
466769 59917 59936 CATACCAAGTGTTTGAATTC 9
2669
466770 59918 59937 ACATACCAAGTGTTTGAATT 14
2670
466771 59919 59938 CACATACCAAGTGTTTGAAT 26
2671
466772 59920 59939 CCACATACCAAGTGTTTGAA 8
2672
466773 59921 59940 CCCACATACCAAGTGTTTGA 19
2673
466774 59922 59941 TCCCACATACCAAGTGTTTG 5
2674
466775 59923 59942 CTCCCACATACCAAGTGTTT 25
2675
466776 59924 59943 CCTCCCACATACCAAGTGTT 32
2676
466777 59925 59944 TCCTCCCACATACCAAGTGT 12
2677
466778 59926 59945 CTCCTCCCACATACCAAGTG 10
2678
466779 59927 59946 GCTCCTCCCACATACCAAGT 15
2679
466780 59928 59947 AGCTCCTCCCACATACCAAG 5
2680
466781 59929 59948 GAGCTCCTCCCACATACCAA 23
2681
465768 61325 61344 CAGTCTAGAATAGCCATGGA 71
2682
465769 61326 61345 ACAGTCTAGAATAGCCATGG 72
2683
465770 61327 61346 GACAGTCTAGAATAGCCATG 78
2684
465771 61328 61347 AGACAGTCTAGAATAGCCAT 74
2685
465772 61329 61348 GAGACAGTCTAGAATAGCCA 70
2686
465773 61330 61349 AGAGACAGTCTAGAATAGCC 70
2687
465774 61331 61350 CAGAGACAGTCTAGAATAGC 63
2688
465775 61332 61351 ACAGAGACAGTCTAGAATAG 55
2689
BIOL0142WO
465776 61333 61352 CACAGAGACAGTCTAGAATA 64
2690
465777 61334 61353 TCACAGAGACAGTCTAGAAT 71
2691
465778 61335 61354 ATCACAGAGACAGTCTAGAA 79
2692
465779 61336 61355 TATCACAGAGACAGTCTAGA 66
2693
465780 61337 61356 ATATCACAGAGACAGTCTAG 64
2694
465781 61338 61357 AATATCACAGAGACAGTCTA 48
2695
465782 61339 61358 AAATATCACAGAGACAGTCT 65
2696
455786* 61340 61359 CAAATATCACAGAGACAGTC 63 2070
465783 61341 61360 GCAAATATCACAGAGACAGT 69
2697
465786 61342 61361 TGCAAATATCACAGAGACAG 78
2698
465787 61343 61362 ATGCAAATATCACAGAGACA 72
2699
465788 61344 61363 AATGCAAATATCACAGAGAC 59
2700
465789 61345 61364 AAATGCAAATATCACAGAGA 23
2701
465790 61346 61365 AAAATGCAAATATCACAGAG 28
2702
465791 61347 61366 TAAAATGCAAATATCACAGA 0
2703
465792 61348 61367 TTAAAATGCAAATATCACAG 12
2704
465793 61349 61368 TTTAAAATGCAAATATCACA 3
2705
465794 61350 61369 GTTTAAAATGCAAATATCAC 2
2706
465795 61351 61370 AGTTTAAAATGCAAATATCA 0
2707
465796 61352 61371 CAGTTTAAAATGCAAATATC 13
2708
465797 61353 61372 TCAGTTTAAAATGCAAATAT 0
2709
465798 61354 61373 TTCAGTTTAAAATGCAAATA 0
2710
465799 61355 61374 ATTCAGTTTAAAATGCAAAT 1
2711
465800 61356 61375 TATTCAGTTTAAAATGCAAA 0
2712
465801 61357 61376 ATATTCAGTTTAAAATGCAA 0
2713
455790* 62043 62062 CATGGTTATGTGTATCTGCA 69 2074
465337 62044 62063 ACATGGTTATGTGTATCTGC 69
2714
465338 62045 62064 CACATGGTTATGTGTATCTG 40
2715
465339 62046 62065 CCACATGGTTATGTGTATCT 32
2716
337332 66135 66154 GAAGCCCTTGCCAGCCATGT 79 1541
455840* 71610 71629 GTACAATTGCTTCAACTAGA 81 2124
466782 71611 71630 AGTACAATTGCTTCAACTAG 54
2717
466783 71612 71631 CAGTACAATTGCTTCAACTA 68
2718
466784 71613 71632 GCAGTACAATTGCTTCAACT 72
2719
465588 71614 71633 GGCAGTACAATTGCTTCAAC 69
2720
455264* 74768 74787 TCCTTAAACCTTCCTATTTC 26 1563
465226 74769 74788 CTCCTTAAACCTTCCTATTT 45 2721
455265* 74770 74789 TCTCCTTAAACCTTCCTATT 57 1564
465227 74771 74790 TTCTCCTTAAACCTTCCTAT 54 2722
455266* 74772 74791 ATTCTCCTTAAACCTTCCTA 52 1565
465228 74773 74792 GATTCTCCTTAAACCTTCCT 64 2723
455267* 74774 74793 AGATTCTCCTTAAACCTTCC 60 1566
465229 74775 74794 TAGATTCTCCTTAAACCTTC 22 2724
455268* 74776 74795 TTAGATTCTCCTTAAACCTT 55 1567
465230 74777 74796 CTTAGATTCTCCTTAAACCT 69 2725
BIOL0142WO
455269* 74778 74797 GCTTAGATTCTCCTTAAACC 84 1568
465231 74779 74798 TGCTTAGATTCTCCTTAAAC 64 2726
455270* 74780 74799 ATGCTTAGATTCTCCTTAAA 50 1569
465232 74781 74800 AATGCTTAGATTCTCCTTAA 71 2727
455271* 74782 74801 AAATGCTTAGATTCTCCTTA 69 1570
465233 74783 74802 AAAATGCTTAGATTCTCCTT 69 2728
455272* 74784 74803 TAAAATGCTTAGATTCTCCT 56 1571
455281* 74872 74891 CAAGGTTGTAAGCACCCTCT 63 1580
465234 74873 74892 TCAAGGTTGTAAGCACCCTC 54 2729
455282* 74874 74893 GTCAAGGTTGTAAGCACCCT 8 1581
465235 74875 74894 AGTCAAGGTTGTAAGCACCC 65 2730
455283* 74876 74895 GAGTCAAGGTTGTAAGCACC 48 1582
455290* 74900 74919 GCAGATCAAGTCCAGGGAGA 77 1589
465236 74901 74920 AGCAGATCAAGTCCAGGGAG 80 2731
455291* 74902 74921 CAGCAGATCAAGTCCAGGGA 82 1590
465237 74903 74922 ACAGCAGATCAAGTCCAGGG 82 2732
455292* 74904 74923 AACAGCAGATCAAGTCCAGG 69 1591
455369* 75418 75437 GGTGTTCCCATACGCACAGG 75 1668
465238 75419 75438 AGGTGTTCCCATACGCACAG 68 2733
455370* 75420 75439 TAGGTGTTCCCATACGCACA 67 1669
465239 75421 75440 CTAGGTGTTCCCATACGCAC 82 2734
455371* 75422 75441 GCTAGGTGTTCCCATACGCA 85 1670
465240 75423 75442 TGCTAGGTGTTCCCATACGC 77 2735
455372* 75424 75443 GTGCTAGGTGTTCCCATACG 72 1671
455390* 75616 75635 AACTGTCTCCAGGCAGGAGG 65 1689
465241 75617 75636 CAACTGTCTCCAGGCAGGAG 51 2736
455391* 75618 75637 TCAACTGTCTCCAGGCAGGA 52 1690
465242 75619 75638 ATCAACTGTCTCCAGGCAGG 76 2737
455392* 75620 75639 CATCAACTGTCTCCAGGCAG 63 1691
465243 75621 75640 ACATCAACTGTCTCCAGGCA 70 2738
455393* 75622 75641 CACATCAACTGTCTCCAGGC 75 1692
465244 75623 75642 ACACATCAACTGTCTCCAGG 61 2739
455394* 75624 75643 GACACATCAACTGTCTCCAG 69 1693
455397* 75662 75681 TACTGAAGAGTGTTGCTGGA 77 1696
465245 75663 75682 GTACTGAAGAGTGTTGCTGG 84 2740
455398* 75664 75683 TGTACTGAAGAGTGTTGCTG 76 1697
465246 75665 75684 ATGTACTGAAGAGTGTTGCT 72 2741
455399* 75666 75685 TATGTACTGAAGAGTGTTGC 70 1698
455411* 75726 75745 AACCCAATGGTAAGCCCAAG 77 1710
465247 75727 75746 AAACCCAATGGTAAGCCCAA 61 2742
455412* 75728 75747 TAAACCCAATGGTAAGCCCA 72 1711
465248 75729 75748 TTAAACCCAATGGTAAGCCC 69 2743
455413* 75730 75749 TTTAAACCCAATGGTAAGCC 38 1712
455428* 75829 75848 TACAATCAGAGTTAAGACCA 58 1727
465249 75830 75849 CTACAATCAGAGTTAAGACC 58 2744
BIOL0142WO
455429* 75831 75850 GCTACAATCAGAGTTAAGAC 71 1728
465250 75832 75851 TGCTACAATCAGAGTTAAGA 59 2745
455430* 75833 75852 TTGCTACAATCAGAGTTAAG 47 1729
455437* 75847 75866 TCCTCTCAGAACTTTTGCTA 36 1736
465251 75848 75867 CTCCTCTCAGAACTTTTGCT 47 2746
455438* 75849 75868 GCTCCTCTCAGAACTTTTGC 75 1737
465252 75850 75869 AGCTCCTCTCAGAACTTTTG 71 2747
455439* 75851 75870 CAGCTCCTCTCAGAACTTTT 68 1738
465253 75852 75871 TCAGCTCCTCTCAGAACTTT 62 2748
455440* 75853 75872 CTCAGCTCCTCTCAGAACTT 58 1739
455446* 75965 75984 GTAGGTAAGCAACCCACGGG 69 1745
465254 75966 75985 GGTAGGTAAGCAACCCACGG 79 2749
455447* 75967 75986 AGGTAGGTAAGCAACCCACG 80 1476
465255 75968 75987 TAGGTAGGTAAGCAACCCAC 84 2750
455448* 75969 75988 ATAGGTAGGTAAGCAACCCA 71 1474
455456* 75985 76004 GCTTATAAACCACCTTATAG 37 1755
465256 75986 76005 AGCTTATAAACCACCTTATA 43 2751
455457* 75987 76006 CAGCTTATAAACCACCTTAT 57 1756
465257 75988 76007 GCAGCTTATAAACCACCTTA 73 2752
455458* 75989 76008 AGCAGCTTATAAACCACCTT 75 1757
465258 75990 76009 CAGCAGCTTATAAACCACCT 65 2753
455459* 75991 76010 ACAGCAGCTTATAAACCACC 46 1758
455462* 75997 76016 GCCAGGACAGCAGCTTATAA 70 1761
466718 75998 76017 GGCCAGGACAGCAGCTTATA 87 2754
455463* 75999 76018 TGGCCAGGACAGCAGCTTAT 83 1762
466719 76000 76019 GTGGCCAGGACAGCAGCTTA 76 2755
455464* 76001 76020 AGTGGCCAGGACAGCAGCTT 82 1763
455470* 76013 76032 GAATTTGAATGCAGTGGCCA 75 1769
466720 76014 76033 GGAATTTGAATGCAGTGGCC 87 2756
455471* 76015 76034 TGGAATTTGAATGCAGTGGC 75 1770
466721 76016 76035 TTGGAATTTGAATGCAGTGG 72 2757
455472* 76017 76036 ATTGGAATTTGAATGCAGTG 60 1771
Example 35: Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
Gapmers from the study described in Example 3 exhibiting significant in vitro inhibition of
STAT3 were tested at various doses in HuVEC cells. Cells were plated at a density of 5,000 cells per
well and transfected using LipofectAMINE2000® reagent with 8.8 nM, 17.5 nM, 35.0 nM, and 70.0 nM
concentrations of antisense oligonucleotide, as specified in Table 56. After a treatment period of
approximately 16 hours, RNA was isolated from the cells and STAT3 mRNA levels were measured by
quantitative real-time PCR. Human STAT3 primer probe set RTS199, described hereinabove, was used
to measure mRNA levels. STAT3 mRNA levels were adjusted according to total RNA content, as
BIOL0142WO
measured by RIBOGREEN . Results are presented as percent inhibition of STAT3, relative to untreated
control cells.
As illustrated in Table 56, STAT3 mRNA levels were reduced in a dose-dependent manner in
antisense oligonucleotide treated cells.
Table 56
Dose-dependent antisense inhibition of human STAT3 in HuVEC cells using LipofectAMINE 2000®
reagent
ISIS No 8.8 nM 17.5 nM 35.0 nM 70.0 nM
337332 50 71 81 88
455269 62 69 79 82
455291 72 81 87 88
455371 71 83 88 90
455447 53 70 81 79
455463 68 79 84 87
455464 69 78 84 86
455471 62 82 88 90
455547 43 64 75 87
455565 41 73 83 92
455582 50 67 81 87
455637 50 65 79 85
455703 45 65 81 85
455840 58 70 80 85
465236 62 76 81 85
465237 67 81 86 90
465239 64 77 85 92
465240 50 66 76 83
465245 70 81 87 87
465254 54 75 81 86
465255 63 74 84 85
465335 46 62 74 80
465449 49 71 84 84
465458 54 73 84 88
465509 66 80 86 83
465510 48 66 76 82
465511 56 68 75 79
465526 53 68 76 76
465537 41 60 77 85
465588 52 73 76 79
465610 35 57 71 79
465730 51 75 85 87
465739 72 81 88 90
465740 70 81 86 89
465742 63 76 87 88
465748 48 62 67 74
BIOL0142WO
465751 70 81 87 87
465752 76 82 88 89
465754 70 83 86 87
465755 70 81 85 89
465770 52 69 77 77
465771 40 55 64 75
465778 40 69 75 77
465786 56 71 76 83
465830 66 77 83 82
465833 50 67 79 86
465834 42 67 77 81
465886 58 73 83 87
465888 49 68 82 12
465926 43 64 76 82
466661 47 63 80 84
466666 39 66 80 86
466670 73 83 89 90
466718 73 78 84 85
466719 63 73 83 83
466720 80 87 86 86
Example 36: Dose-dependent antisense inhibition of human STAT3 in HuVEC cells
Gapmers from the study described in Example 3 were further tested at various doses in HuVEC
cells. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with
187.5 nM, 375.0 nM, 750.0 nM, 1,500.0 nM, 3,000.0 nM, and 6,000.0 nM concentrations of antisense
oligonucleotide, as specified in Table 57. After a treatment period of approximately 16 hours, RNA was
isolated from the cells and STAT3 mRNA levels were measured by quantitative real-time PCR. Human
STAT3 primer probe set RTS199, described hereinabove, was used to measure mRNA levels. STAT3
mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN . Results are
presented as percent inhibition of STAT3, relative to untreated control cells.
As illustrated in Table 57, STAT3 mRNA levels were significantly reduced in a dose-dependent
manner in antisense oligonucleotide treated cells.
Table 57
Dose-dependent antisense inhibition of human STAT3 in HuVEC cells using electroporation
187.5 375.0 750.0 1500.0 3000.0 6000.0
ISIS No
nM nM nM nM nM nM
(μM)
337332 35 51 73 84 97 98 0.3
455269 64 76 87 89 92 90 <0.2
455291 63 79 88 90 90 93 <0.2
455371 50 81 90 94 96 95 <0.2
455447 37 49 61 91 94 96 0.3
BIOL0142WO
455463 57 78 89 93 95 94 <0.2
455464 57 67 78 80 79 87 <0.2
455471 50 73 81 86 91 92 <0.2
455547 19 49 63 82 92 94 0.5
455582 42 62 82 92 97 97 0.2
455637 44 60 63 87 91 92 0.2
455840 39 58 75 81 88 89 0.2
465236 56 67 71 83 91 92 <0.2
465237 56 75 87 92 94 93 <0.2
465239 60 78 88 95 99 99 <0.2
465240 49 67 80 85 94 95 0.1
465245 54 67 81 86 90 90 <0.2
465254 28 50 63 76 91 92 0.4
465255 46 55 78 89 92 94 0.2
465335 25 52 65 89 95 95 0.4
465449 28 56 78 72 96 96 0.3
465458 19 68 84 91 96 97 0.3
465509 42 68 77 84 88 88 0.1
465510 15 43 60 73 85 88 0.6
465511 19 39 47 68 79 86 0.8
465526 15 39 54 64 82 84 0.8
465537 44 65 82 90 95 90 0.1
465565 12 45 62 80 93 97 0.6
465588 44 66 82 85 85 87 0.1
465610 33 56 72 89 96 97 0.3
465730 48 51 72 91 94 91 0.2
465739 42 78 85 93 96 92 0.9
465740 54 69 80 96 98 98 <0.2
465742 67 55 91 93 87 93 <0.2
465748 49 67 88 96 98 99 0.1
465751 56 63 82 91 98 98 0.1
465752 62 79 84 93 96 90 <0.2
465754 41 69 84 63 94 93 <0.2
465755 47 56 67 83 93 97 0.2
465770 52 54 70 85 88 83 0.2
465771 38 62 76 83 84 86 0.2
465778 40 58 79 84 96 96 0.2
465786 41 68 88 94 95 93 0.1
465830 50 73 89 93 88 92 <0.2
465833 27 44 76 89 88 97 0.4
465834 8 27 57 80 93 97 0.7
465886 58 79 90 97 98 96 <0.2
465888 39 60 65 90 94 97 0.3
465926 23 50 41 85 93 94 0.5
466661 31 58 76 90 95 96 0.3
BIOL0142WO
466666 44 55 79 92 96 97 0.2
466670 50 54 82 96 96 96 0.2
466718 55 79 90 93 95 96 <0.2
466719 44 52 73 65 87 91 0.3
466720 48 78 90 90 90 90 <0.2
Example 37: Tolerability of antisense oligonucleotides targeting human STAT3 in CD1 mice
Thirty-nine antisense oligonucleotides exhibiting a high level of potency were further tested for in
vivo tolerability.
Groups of eight male CD1 mice were injected subcutaneously twice a week for 6 weeks with 50
mg/kg of ISIS antisense oligonucleotides. One group of eight male CD1 mice was injected
subcutaneously twice a week for 6 weeks with PBS. This group served as the control group. Three days
after the last dose mice were euthanized and organs and plasma were harvested for further analysis.
Liver, spleen, and kidney weights were measured at the end of the study and were compared to PBS
treated mice.
To evaluate the effect of ISIS oligonucleotides on hepatic function, plasma concentrations of
transaminases were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e,
Melville, NY). Plasma concentrations of ALT (alanine transaminase) and AST (aspartate transaminase)
were measured.
To evaluate the effect of ISIS oligonucleotides on kidney function, plasma concentrations of
blood urea nitrogen (BUN) were measured using an automated clinical chemistry analyzer (Hitachi
Olympus AU400e, Melville, NY).
Blood obtained from all mice groups were sent to Antech Diagnostics for hematocrit (HCT),
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular
hemoglobin concentration (MCHC) measurements and analyses, as well as measurements of the
differential blood cell counts, such as that of WBC, RBC, and total hemoglobin content.
Among the 39 antisense oligonucleotides tested, certain antisense oligonucleotides, including
ISIS 455265, ISIS 455269, ISIS 455271, ISIS 455272, ISIS 455291, ISIS 455371, ISIS 455394, ISIS
455703, ISIS 455429, ISIS 455471, ISIS 455527, ISIS 455530, ISIS 455536, ISIS 455548, ISIS 455611,
ISIS 465236, ISIS 465237, ISIS 465588, ISIS 465740, ISIS 465754, ISIS 465830, ISIS 466670, and ISIS
466720 met tolerability thresholds for organ weight, ALT, AST, BUN, and hematological parameters.
Example 38: Measurement of half-life of antisense oligonucleotide in CD1 mouse liver
CD1 mice were treated with ISIS antisense oligonucleotides described and the oligonucleotide
half-life in the liver was evaluated.
Treatment
BIOL0142WO
Groups of twelve CD1 mice each were injected subcutaneously twice per week for 2 weeks with
50 mg/kg of ISIS 455265, ISIS 455269, ISIS 455271, ISIS 455272, ISIS 455291, ISIS 455371, ISIS
455393, ISIS 455553, ISIS 455582, ISIS 455703, ISIS 455394, ISIS 455429, ISIS 455438, ISIS 455471,
ISIS 455527, ISIS 455530, ISIS 455536, ISIS 455540, ISIS 455548, ISIS 455611, ISIS 455429, ISIS
455463, ISIS 455464, ISIS 455471, ISIS 455527, ISIS 455611, ISIS 465236, ISIS 465237, ISIS 465239,
ISIS 465588, ISIS 465740, ISIS 465742, ISIS 465751, ISIS 465752, ISIS 465754, ISIS 465830, ISIS
466670, ISIS 466718, and ISIS 466720. Four mice from each group were sacrificed 3 days, 28 days, and
56 days following the final dose. Livers were harvested for analysis.
Measurement of oligonucleotide concentration
The concentration of the full-length oligonucleotide as well as the total oligonucleotide
concentration (including the degraded form) was measured. The method used is a modification of
previously published methods (Leeds et al., 1996; Geary et al., 1999), which includes a phenol-
chloroform (liquid-liquid) extraction followed by a solid phase extraction. An internal standard (ISIS
355868, a 27-mer 2’-O-methoxyethyl modified phosphorothioate oligonucleotide,
GCGTTTGCTCTTCTTCTTGCGTTTTTT, designated herein as SEQ ID NO: 2758) was added prior to
extraction. Tissue sample concentrations were calculated using calibration curves, with a lower limit of
quantitation (LLOQ) of approximately 1.14 µg/g. Half-lives were then calculated using WinNonlin
software (PHARSIGHT).
The half-life of each oligonucleotide is presented in Table 58. Antisense oligonucleotides with
half-lives within 11-34 days were chosen for further studies.
Table 58
Half-life of ISIS oligonucleotides in the liver of CD1 mice
ISIS No Half-life (days)
455265 12
455269 48
455271 16
455272 16
455291 19
455371 28
455394 17
455703 27
455429 15
455471 15
455527 13
455530 12
455536 20
BIOL0142WO
455548 13
455611 37
465236 22
465237 17
465588 14
465740 15
465754 23
465830 23
466670 11
466720 17
Example 39: Tolerability of antisense oligonucleotides targeting human STAT3 in Sprague-Dawley
rats
Twenty-three antisense oligonucleotides exhibiting a high level of potency were further tested for
in vivo tolerability.
Groups of four Sprague-Dawley rats were injected subcutaneously twice a week for 6 weeks with
50 mg/kg of ISIS antisense oligonucleotides. One group of rats was injected subcutaneously twice a
week for 6 weeks with PBS. This group served as the control group. Three days after the last dose rats
were euthanized and organs and plasma were harvested for further analysis. Liver, spleen, and kidney
weights were measured at the end of the study and were compared to PBS treated rats
To evaluate the effect of ISIS oligonucleotides on hepatic function, plasma concentrations of
transaminases were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e,
Melville, NY). Plasma concentrations of AST (aspartate transaminase) and total bilirubin were
measured.
To evaluate the effect of ISIS oligonucleotides on kidney function, BUN, total urine protein, and
creatinine were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e,
Melville, NY).
Among the 23 antisense oligonucleotides tested, certain antisense oligonucleotides, including
ISIS 455269, ISIS 455291, ISIS 455371, ISIS 455703, ISIS 455429, ISIS 465236, ISIS 465237, ISIS
465754, ISIS 465830, and ISIS 466670 met tolerability thresholds for organ weight, AST, bilirubin,
BUN, total urine protein, and creatinine.
Example 40: Measurement of half-life of antisense oligonucleotide in Sprague-Dawley rat liver and
kidney
Sprague Dawley rats were treated with ISIS antisense oligonucleotides and the oligonucleotide
half-life as well as the elapsed time for oligonucleotide degradation and elimination from the liver and
kidney was evaluated.
BIOL0142WO
Treatment
Groups of four Sprague Dawley rats each were injected subcutaneously twice a week for 2 weeks
with 20 mg/kg of ISIS 455265, ISIS 455269, ISIS 455271, ISIS 455272, ISIS 455291, ISIS 455371, ISIS
455394, ISIS 455703, ISIS 455429, ISIS 455471, ISIS 455527, ISIS 455530, ISIS 455536, ISIS 455548,
ISIS 455611, ISIS 465236, ISIS 465237, ISIS 465588, ISIS 465740, ISIS 465754, ISIS 465830, ISIS
466670, and ISIS 466720. Three days after the last dose, the rats were sacrificed and livers and kidneys
were collected for analysis.
Measurement of oligonucleotide concentration
The concentration of the full-length oligonucleotide as well as the total oligonucleotide
concentration (including the degraded form) was measured. The method used is a modification of
previously published methods (Leeds et al., 1996; Geary et al., 1999), which includes a phenol-
chloroform (liquid-liquid) extraction followed by a solid phase extraction. An internal standard (ISIS
355868, a 27-mer 2’-O-methoxyethyl modified phosphorothioate oligonucleotide,
GCGTTTGCTCTTCTTCTTGCGTTTTTT, designated herein as SEQ ID NO: 2758) was added prior to
extraction. Tissue sample concentrations were calculated using calibration curves, with a lower limit of
quantitation (LLOQ) of approximately 1.14 µg/g. The kidney to liver ratio of the full-length
oligonucleotide concentration, as well as that for the total oligonucleotide concentration were calculated.
The results are presented in Table 59.
Table 59
Kidney to liver ratio of full-length and total oligonucleotide concentrations in Sprague-Dawley rats
Full
ISIS No Total
length
455265 3.6 3.8
455269 2.1 2.4
455271 3.1 3.0
455272 2.9 3.1
455291 2.7 3.3
455371 2.2 2.4
455394 1.8 2.2
455703 2.3 2.8
455429 3.8 3.9
455471 2.7 2.9
455527 5.0 3.9
455530 3.9 2.9
455536 3.5 3.6
455548 2.5 2.9
455611 2.3 2.3
465236 2.3 3.3
465237 2.4 2.7
BIOL0142WO
465588 2.8 2.6
465740 2.4 2.6
465754 1.6 1.8
465830 5.1 2.6
466670 3.1 4.4
466720 2.3 2.6
Example 41: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in SK-BR-3 cells
Gapmers from the rodent tolerability studies described in Examples 6-9 were tested at various
doses in SK-BR-3 cells. Cells were plated at a density of 4,000 cells per well. Cells were incubated
without any transfection reagent with 0.02 μM, 0.10 μM, 0.50 μM, 1.00 μΜ. 2.50 μΜ, and 10.00 μM
concentrations of antisense oligonucleotide, as specified in Table 60. After approximately 24 hours, RNA
was isolated from the cells and STAT3 mRNA levels were measured by quantitative real-time PCR.
Human STAT3 primer probe set RTS199, as described hereinabove, was used to measure mRNA levels.
STAT3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN .
Results are presented as percent inhibition of STAT3, relative to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 60.
Table 60
Dose-dependent antisense inhibition of human STAT3 by free-uptake of ISIS oligonucleotide by SK-BR-
3 cells
ISIS No
0.02 μM 0.1 μM 0.5 μM 1 μM 2.5 μM 10 μM IC (μM)
455265 22 14 25 19 30 37 >10.0
455269 17 17 21 45 64 67 1.3
455271 0 0 0 11 16 53 9.0
455272 0 0 0 5 12 51 9.6
455291 9 15 31 45 58 76 1.2
455371 16 20 34 37 54 70 1.7
455394 0 2 14 6 30 55 8.3
455429 0 0 0 12 29 57 7.9
455471 0 16 28 24 42 58 2.9
455527 5 15 14 21 35 45 >10.0
455530 0 14 12 14 28 36 >10.0
455536 0 0 0 1 8 26 >10.0
455548 16 14 17 17 20 44 >10.0
455611 19 1 3 21 35 38 >10.0
455703 0 0 0 0 3 33 >10.0
465236 0 7 15 19 37 60 3.8
465237 2 13 22 29 50 67 2.3
465588 5 3 21 18 42 44 >10.0
BIOL0142WO
465740 1 14 0 19 14 39 >10.0
465754 0 0 4 15 39 55 7.7
465830 6 18 23 17 42 67 3.0
466670 21 19 33 35 58 71 1.6
466720 0 0 11 13 27 53 8.7
Example 42: Measurement of viscosity of ISIS antisense oligonucleotides targeting human STAT3
The viscosity of antisense oligonucleotides selected from the studies described in Examples 6-10
was measured with the aim of screening out antisense oligonucleotides which have a viscosity more than
40 cP. Oligonucleotides having a viscosity greater than 40 cP would be too viscous to be administered to
any subject.
ISIS oligonucleotides (32-35 mg) were weighed into a glass vial, 120 μL of water was added and
the antisense oligonucleotide was dissolved into solution by heating the vial at 50 C. Part of (75 μL) the
pre-heated sample was pipetted to a micro-viscometer (Cambridge). The temperature of the micro-
viscometter was set to 25 C and the viscosity of the sample was measured. Another part (20 μL) of the
pre-heated sample was pipetted into 10 mL of water for UV reading at 260 nM at 85 C (Cary UV
instrument). The results are presented in Table 61 and indicate that all the antisense oligonucleotides
solutions are optimal in their viscosity under the criterion stated above.
Table 61
Viscosity of ISIS antisense oligonucleotides targeting human STAT3
ISIS No Viscosity
455269 6.1
455291 13.6
466371 7.2
455703 17.6
455429 9.3
465237 26.2
465754 19.7
465830 8.1
466670 15.9
Example 43: Effect of ISIS antisense oligonucleotides targeting human STAT3 in cynomolgus
monkeys
Nine antisense oligonucleotides exhibiting a high level of potency were further tested for in
cynomolgus monkeys. Antisense oligonucleotide tolerability and pharmacokinetic profile in the liver and
kidney was evaluated.
The study was conducted at the Korea Institute of Toxicology, Republic of Korea. Prior to the
study, the monkeys were kept in quarantine for a 30-day time period, during which standard panels of
BIOL0142WO
serum chemistry and hematology, examination of fecal samples for ova and parasites, and a tuberculosis
test, were conducted to screen out abnormal or ailing monkeys. Nine groups of four randomly assigned
male cynomolgus monkeys each were injected subcutaneously thrice per week for the first week, and
subsequently twice a week for the next 7 weeks, with 25 mg/kg of ISIS antisense oligonucleotides. A
control group of 4 cynomolgus monkeys was injected with PBS subcutaneously thrice per week for the
first week, and subsequently twice a week for the next 7 weeks. Terminal sacrifices of all groups were
conducted on day 55, which was 48 hours after the last dose.
During the study period, the monkeys were observed daily for signs of illness or distress. Any
animal showing adverse effects to the treatment was removed and referred to the veterinarian and Study
Director.
To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, spleen heart,
kidney, liver, and gall bladder weights were measured at day 55. Organ weights were measured and
treatment group weights were compared to the corresponding PBS control weights
To evaluate the effect of ISIS oligonucleotides on hepatic and kidney function, blood samples
were collected from all the study groups. The monkeys were fasted overnight prior to blood collection.
Approximately, 1 mL each of blood samples was collected in tubes without any anticoagulant for serum
separation. The tubes were kept at room temperature for 90 min and then centrifuged (3000 rpm for 10
min at room temperature) to obtain serum. Concentrations of transaminases were measured using a
Toshiba 200FR NEO chemistry analyzer (Toshiba Co., Japan). Plasma concentrations of ALT (alanine
transaminase), AST (aspartate transaminase), and BUN were measured on day 55. C-reactive protein
(CRP), which is synthesized in the liver and which serves as a marker of inflammation, was also similarly
measured on day 55.
To evaluate the effect of ISIS oligonucleotides on factors involved in inflammation, blood was
collected on day 55 from all animals for analyses of complement C3 levels, MIP-1β cytokine levels, and
platelet number.
For complement C3 analysis, approximately 0.5 mL each of blood sample was collected in tubes
without anticoagulant for serum separation. For cytokine level analyses, approximately 2 mL each of
blood sample was collected in tubes without anticoagulant for serum separation. The tubes were kept at
room temperature for 90 min and then centrifuged (3000 rpm for 10 min at room temperature) to obtain
serum. Complement C3 was measured using an automatic analyzer (Toshiba 200 FR NEO chemistry
analyzer, Toshiba co., Japan). Serum was utilized for cytokine analysis using a nine-panel Searchlight
Multiplex Array.
For platelet count, approximately 0.5 mL each of blood samples was collected in tubes containing
potassium salt of EDTA. Samples were analyzed for platelet count using an ADVIA120 hematology
analyzer (Bayer, USA).
BIOL0142WO
The concentration of oligonucleotide was measured in the liver and kidney on day 55. The
method used is a modification of previously published methods (Leeds et al., 1996; Geary et al., 1999),
which includes a phenol-chloroform (liquid-liquid) extraction followed by a solid phase extraction. An
internal standard (ISIS 355868, a 27-mer 2’-O-methoxyethyl modified phosphorothioate oligonucleotide,
GCGTTTGCTCTTCTTCTTGCGTTTTTT, designated herein as SEQ ID NO: 2758) was added prior to
extraction. Tissue sample concentrations were calculated using calibration curves, with a lower limit of
quantitation (LLOQ) of approximately 1.14 µg/g.
Among the 9 antisense oligonucleotides tested, certain antisense oligonucleotides, including ISIS
455269, ISIS 455371, ISIS 455429, and ISIS 455670 met tolerability thresholds for organ weight, ALT,
AST, BUN, and hematological parameters.
Example 44: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in MDA-MB-231 cells
ISIS oligonucleotides from the study described in Example 12 were further tested at different
doses in MDA-MB-231 cells. Cells were plated at a density of 4,000 cells per well. Cells were incubated
without any transfection reagent with 0.02 μM, 0.20 μM, 1.00 μM, 5.00 μΜ, and 10.00 μM
concentrations of antisense oligonucleotide, as specified in Table 62. After approximately 24 hours, RNA
was isolated from the cells and STAT3 mRNA levels were measured by quantitative real-time PCR.
Human STAT3 primer probe set RTS199, as described hereinabove, was used to measure mRNA levels.
STAT3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN .
Results are presented as percent inhibition of STAT3, relative to untreated control cells. The half
maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in Table 62.
Table 62
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
MDA-MB-231 cells
0.02 0.20 1.00 5.00 10.00 IC
ISIS No
μM μM μM μM μM (μM)
455269 0 3 30 47 59 6.4
455291 1 3 13 41 47 8.3
455371 5 0 10 34 43 >10.0
455429 0 0 22 31 43 >10.0
455703 0 5 13 28 39 >10.0
465237 0 0 22 39 41 >10.0
465754 5 1 22 30 46 >10.0
465830 0 0 17 43 52 7.5
466670 4 7 18 49 56 6.5
Example 45: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in U251-MG cells
BIOL0142WO
ISIS oligonucleotides from the study described in Example 12 were further tested at different
doses in U251-MG cells. Cells were plated at a density of 4,000 cells per well. Cells were incubated
without any transfection reagent with 0.1 μM, 1.0 μM, 5.0 μM, 10.0 μΜ, and 20.0 μM concentrations of
antisense oligonucleotide, as specified in Table 63. After approximately 24 hours, RNA was isolated
from the cells and STAT3 mRNA levels were measured by quantitative real-time PCR. Human STAT3
primer probe set RTS199, as described hereinabove, was used to measure mRNA levels. STAT3 mRNA
levels were adjusted according to total RNA content, as measured by RIBOGREEN . Results are
presented as percent inhibition of STAT3, relative to untreated control cells. The half maximal inhibitory
concentration (IC ) of each oligonucleotide is also presented in Table 63.
Table 63
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
U251-MG cells
.0 20.0 IC
ISIS No
0.1 μM 1.0 μM 5.0 μM μM μM (μM)
455269 3 16 31 47 56 11.9
455291 0 11 29 42 51 14.1
455371 3 0 25 33 39 >20.0
455429 6 0 25 33 39 >20.0
455703 5 2 13 33 36 >20.0
465237 2 0 7 2 6 >20.0
465754 0 0 8 16 4 >20.0
465830 0 0 18 2 10 >20.0
466670 0 0 18 25 37 >20.0
Example 46: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in A431 cells
ISIS oligonucleotides from the study described in Example 12 were further tested at different
doses in A431 cells. Cells were plated at a density of 4,000 cells per well. Cells were incubated without
any transfection reagent with 0.02 μM, 0.2 μM, 1.0 μM, 5.0 μΜ, and 10.0 μM concentrations of antisense
oligonucleotide, as specified in Table 64. After approximately 24 hours, RNA was isolated from the cells
and STAT3 mRNA levels were measured by quantitative real-time PCR. Human STAT3 primer probe
set RTS199, as described hereinabove, was used to measure mRNA levels. STAT3 mRNA levels were
adjusted according to total RNA content, as measured by RIBOGREEN . Results are presented as
percent inhibition of STAT3, relative to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 64. As illustrated in Table 64, the ISIS oligonucleotides were able to penetrate the cell membrane
and significantly reduce STAT3 mRNA levels in a dose-dependent manner.
Table 64
BIOL0142WO
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
A431 cells
ISIS No 0.02 μM 0.2 μM 1.0 μM 5.0 μM 10.0 μM IC (μM)
41 64 86 86 89 0.15
455269
61 83 85 86 0.17
455291
65 82 88 92 0.15
455371
73 84 87 88 0.19
455429
12 55 72 82 82 0.13
455703
23 72 82 86 87 0.13
465237
0 67 73 79 83 0.15
465754
0 50 67 71 78 0.21
465830
36 79 88 93 94 0.03
466670
Example 47: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in H460 cells
ISIS oligonucleotides from the study described in Example 12 were further tested at different
doses in H460 cells. Cells were plated at a density of 4,000 cells per well. Cells were incubated without
any transfection reagent with 0.02 μM, 0.20 μM, 1.00 μM, 5.00 μΜ, and 10.00 μM concentrations of
antisense oligonucleotide, as specified in Table 65. After approximately 24 hours, RNA was isolated
from the cells and STAT3 mRNA levels were measured by quantitative real-time PCR. Human STAT3
primer probe set RTS199, as described hereinabove, was used to measure mRNA levels. STAT3 mRNA
levels were adjusted according to total RNA content, as measured by RIBOGREEN . Results are
presented as percent inhibition of STAT3, relative to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 65. As illustrated in Table 65, the ISIS oligonucleotides were able to penetrate the cell membrane
and significantly reduce STAT3 mRNA levels in a dose-dependent manner.
Table 65
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
H460 cells
0.02 0.20 1.00 5.00 10.00 IC
ISIS No
μM μM μM μM μM (μM)
455269 3 69 81 92 94 0.1
455291 0 29 79 88 92 0.3
455371 0 20 63 85 89 0.8
455429 3 37 75 87 88 0.6
455703 4 24 69 87 92 0.3
465237 0 20 72 87 89 0.6
465754 10 45 80 91 92 0.2
465830 10 28 65 82 89 0.7
BIOL0142WO
466670 15 32 71 90 93 0.3
Example 48: Effect of ISIS oligonucleotides targeting STAT3 in the treatment of U251 human
glioma cancer xenograft model
BALB/c nude mice inoculated with human U251 glioma tumor cells were treated with ISIS
oligonucleotides from the study described in Example 12. The effect of the treatment on tumor growth in
the mice was evaluated.
Treatment
BALB/c nude mice were subcutaneously implanted with 1 x 10 tumor cells. On day 4 of the
implantation, groups of 4 mice each were administered 50 mg/kg injected intraperitoneally five times a
week for 3 and a half weeks of ISIS 455269, ISIS 455291, ISIS 455371, ISIS 455703, ISIS 455429, ISIS
465237, ISIS 465754, ISIS 465830, or ISIS 466670. One group of mice was administered 50 mg/kg
injected intraperitoneally five times a week for 3 and a half weeks of the control oligonucleotide, ISIS
141923. One group of mice was administered PBS injected intraperitoneally five times a week for 3 and
a half weeks.
Effect on tumor growth
Tumor size was measured twice weekly in two dimensions using a caliper, and tumor volumes
were calculated using the formula: V = 0.5 x a x b , where a and b are the long and short diameters of the
tumor, respectively. The results are presented in Table 66. The data indicates that treatment with ISIS
oligonucleotides significantly impeded tumor growth. ‘n/a’ indicates that the data points for that time
point are not available.
Table 66
Effect of antisense inhibition of STAT3 on tumor growth in the U251 xenograft model
Day 10 Day 14 Day 17 Day 21 Day 23 Day 29 Day 32 Day 35
PBS 205 216 285 381 519 771 937 1,141
ISIS 141923 175 178 296 404 544 719 923 1,027
ISIS 455269 157 151 227 307 349 418 486 542
ISIS 455291 149 169 193 238 297 429 635 610
ISIS 455371 141 169 253 379 375 598 838 912
ISIS 455429 180 160 251 337 427 546 807 897
ISIS 455703 156 161 246 342 414 615 872 991
ISIS 465237 149 166 245 326 350 551 703 744
ISIS 465830 173 205 287 346 383 696 844 825
ISIS 466670 112 172 208 254 274 492 462 669
BIOL0142WO
Example 49: Effect of ISIS 455291 targeting STAT3 in the treatment of an MDA-MB-231 human
breast cancer xenograft model
BALB/c nude mice inoculated with human breast cancer cells MDA-MB-231 were treated with
ISIS 455291. The effect of the treatment on tumor growth and tolerability in the mice was evaluated.
Treatment
The study was conducted at Pharmaron Inc (Beijing, P.R. China). The BALB/c nude mice were
obtained from Beijing HFK Bio-Technology Co., Ltd. MDA-MB-231 human breast cancer cells were
maintained in vitro as a monolayer culture in Leibovitz’s L-15 medium supplemented with 10% heat-
inactivated fetal calf serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. The
cells were maintained at 37 C in an atmosphere of 5% CO in air. The tumor cells were routinely sub-
cultured twice weekly with trypsin-EDTA treatment. Cells growing an exponential growth phase were
harvested and counted for tumor inoculation.
Two groups of eight randomly assigned 6-8 week-old female BALB/c nude mice each were
inoculated at the right flank with the MDA-MB-231 tumor fragments (3 mm x 2 mm x 2 mm, which were
generated from tumor inoculation passage) for tumor development. Antisense oligonucleotide treatment
started at day 11 after tumor inoculation when the mean tumor size reached approximately 100 mm . One
of the groups was injected intraperitoneally twice a week for 3 weeks with 50 mg/kg of ISIS 455291. The
other group of mice was injected intraperitoneally twice a week for 3 weeks with PBS, and served as the
control group.
All procedures related to animal handling, care, and treatment, were performed according to the
guidelines approved by the Institutional Animal Care and Use Committee (IACUC). At the time of
routine monitoring, the animals were checked for any effects of tumor growth on normal behavior, such
as mobility, food consumption, body weight changes and any other abnormal effect.
RNA analysis
RNA was extracted from tumor tissue for real-time PCR analysis of human STAT3 mRNA levels
using primer probe set RTS199, described hereinabove. Murine STAT3 mRNA levels were also
measured using primer probe set mSTAT3_LTS00664 (forward sequence CGACAGCTTCCCCATGGA,
designated herein as SEQ ID NO: 1513; reverse sequence ATGCCCAGTCTTGACTCTCAATC,
designated herein as SEQ ID NO: 1514; probe sequence CTGCGGCAGTTCCTGGCACCTT, designated
herein as SEQ ID NO: 1515). Results are presented as percent inhibition of STAT3, relative to PBS
control, normalized to cyclophilin. As shown in Table 67, treatment with ISIS 455291 resulted in
reduction of both human and murine STAT3 mRNA in comparison to the PBS control.
Table 67
Inhibition of STAT3 mRNA in the treatment groups relative to the PBS control in the MDA-MB-231
xenograft model
BIOL0142WO
% inhibition
Human STAT3 91
Murine STAT3 94
Effect on tumor growth
Tumor size was measured twice weekly in two dimensions using a caliper, and tumor volumes
were calculated using the formula: V = 0.536 x a x b , where a and b are the long and short diameters of
/C values. T-C
the tumor, respectively. The tumor size was utilized for calculations of the T-C and T
was calculated with T as the median time (in days) required for the tumors in the treatment groups to
reach a pre-determined size (900 mm ), and C as the median time (in days) for the tumors in the control
/C value (expressed as percentage) is an indication of the anti-
group to reach the same size. The T
tumor effectiveness of the ISIS oligonucleotides, where T and C were the mean volume of the treated
and control groups, respectively, on a given day (day 32).
The results are presented in Tables 68 and 69. The data indicates that inhibition of STAT3
mRNA significantly impeded tumor growth.
Table 68
Effect of antisense inhibition of STAT3 on tumor growth in the MDA-MB-231 xenograft model
Days PBS ISIS 455291
11 103 103
185 156
18 292 205
22 519 320
745 437
29 1,332 792
32 1,741 1,075
Table 69
Effect of antisense inhibition of STAT3 on tumor growth inhibition in the MDA-MB-231 xenograft
model
Tumor Size (mm ) T /C T-C
Treatment
at day 32 (%) at 900 mm
PBS 1,741
ISIS 455291 1,075 62
Body weight measurements
To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body weights
were measured on a regular basis during the treatment period. The data is presented in Table 70 and
indicate that treatment with ISIS 455291 does not affect the overall body weight of the mice.
Table 70
Body weight measurements of mice in the MDA-MB-231 xenograft model
Day 11 Day 15 Day 18 Day 22 Day 25 Day 29 Day 32
BIOL0142WO
PBS 22 22 23 23 23 23 24
ISIS 455291 22 22 23 23 24 24 25
Example 50: Effect of ISIS 455291 targeting STAT3 in the treatment of an A431 human
epidermoid carcinoma xenograft model
BALB/c nude mice inoculated with human epidermoid cancer cells A431 were treated with ISIS
455291. The effect of the treatment on tumor growth and tolerability in the mice was evaluated.
Treatment
The study was conducted at Pharmaron Inc (Beijing, P.R. China). The BALB/c nude mice were
obtained from Beijing HFK Bio-Technology Co., Ltd. A431 human epidermoid carcinoma cells were
maintained in vitro as a monolayer culture in DMEM medium supplemented with 10% heat-inactivated
fetal calf serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. The cells were
maintained at 37 C in an atmosphere of 5% CO in air. The tumor cells were routinely sub-cultured twice
weekly with trypsin-EDTA treatment. Cells growing in an exponential growth phase were harvested and
counted for tumor inoculation.
Two groups of eight randomly assigned 6-8 week-old female BALB/c nude mice each were
inoculated subcutaneously with 5 x 10 A431 tumor cells for tumor development. Antisense
oligonucleotide treatment started at day 8 after tumor inoculation when the mean tumor size reached
approximately 95 mm . One of the groups was injected intraperitoneally twice a week for 4 weeks with
50 mg/kg of ISIS 455291. The other group of mice was injected intraperitoneally twice a week for 3
weeks with PBS, and served as the control group.
All procedures related to animal handling, care, and treatment, were performed according to the
guidelines approved by the Institutional Animal Care and Use Committee (IACUC). At the time of
routine monitoring, the animals were checked for any effects of tumor growth on normal behavior, such
as mobility, food consumption, body weight changes and any other abnormal effect.
RNA analysis
RNA was extracted from tumor tissue for real-time PCR analysis of human STAT3 mRNA levels
using primer probe set RTS199, described hereinabove. Murine STAT3 mRNA levels were also
measured using primer probe set mSTAT3_LTS00664. Results are presented as percent inhibition of
STAT3, relative to PBS control, normalized to cyclophilin. As shown in Table 71, treatment with ISIS
455291 resulted in reduction of both human and murine STAT3 mRNA in comparison to the PBS control.
Table 71
Inhibition of STAT3 mRNA in the treatment groups relative to the PBS control in the A431 xenograft
model
% inhibition
Human STAT3 67
BIOL0142WO
Murine STAT3 92
Effect on tumor growth
Tumor size was measured twice weekly in two dimensions using a caliper, and tumor volumes
were calculated using the formula: V = 0.5 x a x b , where a and b are the long and short diameters of the
tumor, respectively. The tumor size was utilized for calculations of the T-C and T /C values. T-C was
calculated with T as the median time (in days) required for the tumors in the treatment groups to reach a
pre-determined size (800 mm ), and C as the median time (in days) for the tumors in the control group to
reach the same size. The T /C value (expressed as percentage) is an indication of the anti-tumor
effectiveness of the ISIS oligonucleotides, where T and C were the mean volume of the treated and
control groups, respectively, on a given day (day 33).
The results are presented in Tables 72 and 73. The data indicates that inhibition of STAT3
mRNA impeded tumor growth.
Table 72
Effect of antisense inhibition of STAT3 on tumor growth in the A431 xenograft model
Days PBS ISIS 455291
8 94 95
14 178 173
17 308 242
21 528 393
24 682 572
28 875 759
31 1,071 984
33 1,210 1,112
Table 73
Effect of antisense inhibition of STAT3 on tumor growth inhibition in the A431 xenograft model
Tumor Size (mm ) T /C T-C
Treatment
at day 33 (%) at 800 mm
PBS 1,210 - -
ISIS 455291 1,112 92
Body weight measurements
To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body weights
were measured on a regular basis during the treatment period. The data is presented in Table 74 and
indicate that treatment with ISIS 455291 does not affect the overall body weight of the mice.
Table 74
Body weight measurements of mice in the A431 xenograft model
Day 8 Day 14 Day 17 Day 21 Day 24 Day 28 Day 31 Day 33
PBS 20 20 20 21 21 21 22 22
ISIS 455291 20 21 21 22 22 22 23 23
BIOL0142WO
Example 51: Effect of ISIS 455291 targeting STAT3 in the treatment of an NCI-H460 human non-
small cell lung cancer (NSCLC) xenograft model
BALB/c nude mice inoculated with human NCI-H460 human NSCLC were treated with ISIS
455291. The effect of the treatment on tumor growth and tolerability in the mice was evaluated.
Treatment
The study was conducted at Pharmaron Inc (Beijing, P.R. China). The BALB/c nude mice were
obtained from Beijing HFK Bio-Technology Co., Ltd. NCI-H460 human NSCLC cells were maintained
in vitro as a monolayer culture in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf
serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. The cells were
maintained at 37 C in an atmosphere of 5% CO in air. The tumor cells were routinely sub-cultured twice
weekly with trypsin-EDTA treatment. Cells growing in an exponential growth phase were harvested and
counted for tumor inoculation.
Two groups of eight randomly assigned 6-8 week-old female BALB/c nude mice each were
NCI-H460 tumor cells for tumor development. Antisense
inoculated subcutaneously with 2 x 10
oligonucleotide treatment started at day 6 after tumor inoculation when the mean tumor size reached
approximately 100 mm . One of the groups was injected intraperitoneally twice a week for 3 weeks with
50 mg/kg of ISIS 455291. The other group of mice was injected intraperitoneally twice a week for 3
weeks with PBS, and served as the control group.
All procedures related to animal handling, care, and treatment, were performed according to the
guidelines approved by the Institutional Animal Care and Use Committee (IACUC). At the time of
routine monitoring, the animals were checked for any effects of tumor growth on normal behavior, such
as mobility, food consumption, body weight changes and any other abnormal effect.
Effect on tumor growth
Tumor size was measured twice weekly in two dimensions using a caliper, and tumor volumes
were calculated using the formula: V = 0.5 x a x b , where a and b are the long and short diameters of the
tumor, respectively. The tumor size was utilized for calculations of the T-C and T /C values. T-C was
calculated with T as the median time (in days) required for the tumors in the treatment groups to reach a
pre-determined size (1,500 mm ), and C as the median time (in days) for the tumors in the control group
to reach the same size. The T /C value (expressed as percentage) is an indication of the anti-tumor
effectiveness of the ISIS oligonucleotides, where T and C were the mean volume of the treated and
control groups, respectively, on a given day (day 20).
The results are presented in Tables 75 and 76. The data indicates that inhibition of STAT3
significantly impeded tumor growth.
BIOL0142WO
Table 75
Effect of antisense inhibition of STAT3 on tumor growth in the NCI-H460 xenograft model
Days PBS ISIS 455291
6 104 104
8 303 180
11 746 408
13 1,175 620
1,642 819
18 2,277 1,320
2,859 1,812
22 - 2,330
Table 76
Effect of antisense inhibition of STAT3 on tumor growth inhibition in the NCI-H460 xenograft model
Tumor Size (mm ) T /C T-C
Treatment
at day 20 (%) at 800 mm
PBS 1,210
ISIS 455291 1,812 63
Body weight measurements
To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body weights
were measured on a regular basis during the treatment period. The data is presented in Table 77 and
indicate that treatment with ISIS 455291 does not affect the overall body weight of the mice.
Table 77
Body weight measurements of mice in the NCI-H460 xenograft model
Day 6 Day 8 Day 11 Day 13 Day 15 Day 18 Day 20 Day 22
PBS 20 20 20 20 20 20 21 -
ISIS 455291 20 20 20 20 20 19 20 20
Example 52: Effect of antisense inhibition of human STAT3 in a human glioblastoma
orthotopic mouse model
NU/J mice orthotopically implanted with human glioblastoma cells were treated with
ISIS 455291, a 55 MOE gapmer having a sequence of CAGCAGATCAAGTCCAGGGA
(SEQ ID NO: 1590. The effect of the treatment on tumor growth and tolerability in the mice was
evaluated.
Treatment
Thirty NU/J mice were stereotactically implanted in the right frontal lobe with 5 x 10 U-
87 MG-luc2 cells. On day 15 after tumor cell implantation, 15 of these mice were dosed
intracranially with a bolus injection at the site of tumor implantation with 100 μg of ISIS
BIOL0142WO
455291, which was dissolved in 2 μL of PBS. The remaining 15 mice were dosed intracranially
with a bolus injection at the site of tumor implantation with 2 μL of PBS. The second group of
mice served as the control group.
Analysis
On day 18 after tumor transplantation, five mice from each group were euthanized by
CO inhalation and brain samples were collected for RNA analysis. RNA was extracted from
tumor tissue for real-time PCR analysis of human STAT3 mRNA levels using primer probe set
RTS199, described hereinabove. Treatment with ISIS 455291 resulted in 27% reduction of
human STAT3 mRNA in the tumor tissue in comparison to the PBS control.
The remaining mice in each group were monitored regularly up to 2 weeks for survival
analysis. The median survival for the PBS control group was 30.5 days. The medial survival for
the ISIS oligonucleotide-treated mice was 35 days. The P value was 0.2088.
Example 53: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in PC9 cells
ISIS 455703 and ISIS 455291, from the studies described above, were further tested at different
doses in PC9 cells, a non small cell lung carcinoma cell line. Cells were plated at a density of 3,000 cells
per well. Cells were incubated with 0.02μM, 0.1 μM, 0.5 μM, 2.5 μΜ, and 10.0 μM concentrations of
antisense oligonucleotide, as specified in Table 78. After approximately 24 hours, RNA was isolated
from the cells and STAT3 mRNA levels were measured by quantitative real-time PCR. Human STAT3
primer probe set RTS2033 (forward sequence GAGGCCCGCCCAACA, designated herein as SEQ ID
NO: 1520; reverse sequence TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID
NO: 1521; probe sequence CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522) was used to
measure mRNA levels. STAT3 mRNA levels were adjusted according to content of beta-actin, a
housekeeping gene, as measured by human primer probe set HTS5002 (forward sequence
CGGACTATGACTTAGTTGCGTTACA, designated herein as SEQ ID NO: 1529; reverse sequence
GCCATGCCAATCTCATCTTGT, designated herein as SEQ ID NO: 1530; probe sequence
CCTTTCTTGACAAAACCTAACTTGCGCAGA, designated herein as SEQ ID NO: 1531). Results are
presented as percent inhibition of STAT3, relative to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 78. As illustrated in Table 78, ISIS 455703 and ISIS 455291were able to penetrate the cell
membrane.
BIOL0142WO
Table 78
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
PC9 cells
0.02 10.0 IC
ISIS No 0.1 μM 0.5 μM 2.5 μM
μM μM (μM)
455703 6 5 17 50 49 9.0
455291
0 0 42 67 75 1.2
Example 54: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in C42B cells
ISIS 455291, from the studies described above, was further tested at different doses in C42B
cells, a prostate cancer cell line. Cells were plated at a density of 3,000 cells per well. Cells were
incubated with 0.02μM, 0.1 μM, 0.5 μM, 2.5 μΜ, and 10.0 μM concentrations of antisense
oligonucleotide, as specified in Table 79. After approximately 24 hours, RNA was isolated from the cells
and STAT3 mRNA levels were measured by quantitative real-time PCR. Human STAT3 primer probe
set RTS2033 (forward sequence GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 1520;
reverse sequence TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 1521;
probe sequence CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522) was used to measure
mRNA levels. STAT3 mRNA levels were adjusted according to content of beta-actin, a housekeeping
gene, as measured by human primer probe set HTS5002 (forward sequence
CGGACTATGACTTAGTTGCGTTACA, designated herein as SEQ ID NO: 1529; reverse sequence
GCCATGCCAATCTCATCTTGT, designated herein as SEQ ID NO: 1530; probe sequence
CCTTTCTTGACAAAACCTAACTTGCGCAGA, designated herein as SEQ ID NO: 1531). Results are
presented as percent inhibition of STAT3, relative to untreated control cells.
As illustrated in Table 79, ISIS 455291 was able to penetrate the cell membrane.
Table 79
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
C42B cells
0.02 10.0
ISIS No 0.1 μM 0.5 μM 2.5 μM
μM μM
455291 0 0 17 10 41
Example 55: Dose-dependent antisense inhibition of STAT3 following free uptake of antisense
oligonucleotide in Colo201 cells
ISIS 455291, from the studies described above, was further tested at different doses in Colo201
cells, a colorectal cancer cell line. Cells were plated at a density of 3,000 cells per well. Cells were
BIOL0142WO
incubated with 0.02μM, 0.1 μM, 0.5 μM, 2.5 μΜ, and 10.0 μM concentrations of antisense
oligonucleotide, as specified in Table 80. After approximately 24 hours, RNA was isolated from the cells
and STAT3 mRNA levels were measured by quantitative real-time PCR. Human STAT3 primer probe
set RTS2033 (forward sequence GAGGCCCGCCCAACA, designated herein as SEQ ID NO: 1520;
reverse sequence TTCTGCTAATGACGTTATCCAGTTTT, designated herein as SEQ ID NO: 1521;
probe sequence CTGCCTAGATCGGC, designated herein as SEQ ID NO: 1522) was used to measure
mRNA levels. STAT3 mRNA levels were adjusted according to content of beta-actin, a housekeeping
gene, as measured by human primer probe set HTS5002 (forward sequence
CGGACTATGACTTAGTTGCGTTACA, designated herein as SEQ ID NO: 1529; reverse sequence
GCCATGCCAATCTCATCTTGT, designated herein as SEQ ID NO: 1530; probe sequence
CCTTTCTTGACAAAACCTAACTTGCGCAGA, designated herein as SEQ ID NO: 1531). Results are
presented as percent inhibition of STAT3, relative to untreated control cells.
The half maximal inhibitory concentration (IC ) of each oligonucleotide is also presented in
Table 80. As illustrated in Table 29, ISIS 455291 was able to penetrate the cell membrane.
Table 80
Dose-dependent antisense inhibition of STAT3 mRNA levels by free-uptake of ISIS oligonucleotide by
Colo201 cells
0.02 10.0 IC
ISIS No 0.1 μM 0.5 μM 2.5 μM
μM μM (μM)
455291 21 18 34 52 81 1.2
BIOL0142WO
Claims (1)
- CLAIMS 5 1. A single stranded modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 12 contiguous nucleobases complementary to an equal length portion of nucleobases 3008 to 3033 of SEQ ID NO: 1, wherein the nucleobase sequence is complementary to SEQ ID NO: 1. 10 2. The single stranded modified oligonucleotide of claim 1, wherein the nucleobase sequence of the modified oligonucleotide comprises the sequence of SEQ ID NO: 245 or SEQ ID NO: 1045. 3. The single stranded modified oligonucleotide of claim 1 or 2, wherein the nucleobase sequence of the modified oligonucleotide consists of the sequence of SEQ ID NO: 245. 4. The single stranded modified oligonucleotide of any of claims1-3, wherein at least one internucleoside linkage is a modified internucleoside linkage. 5. The single stranded modified oligonucleotide of any of the preceding claims, wherein each 20 internucleoside linkage is a phosphorothioate internucleoside linkage. 6. The single stranded modified oligonucleotide of any of the preceding claims, wherein at least one nucleoside comprises a modified sugar. 25 7. The single stranded modified oligonucleotide of claim 6, wherein at least one modified sugar is a bicyclic sugar. 8. The single stranded modified oligonucleotide of claim 7, wherein the bicyclic sugar comprises a 4’- CH -O-2’ bridge or a 4’-CH(CH )-O-2’ bridge. 9. The single stranded modified oligonucleotide of claim 6, wherein the modified sugar comprises a 2’-O(CH ) -OCH group or a 2’-O-CH group. 2 2 3 3 10. The single stranded modified oligonucleotide of any of the preceding claims, wherein at least 35 one nucleoside comprises a modified nucleobase. BIOL0142WO 11. The single stranded modified oligonucleotide of claim 10, wherein the modified nucleobase is a 5’-methylcytosine. 12. The single stranded modified oligonucleotide of any of the preceding claims, wherein the 5 modified oligonucleotide comprises: a 5’-wing consisting of 1 to 5 linked nucleosides; a 3’-wing consisting of 1 to 5 linked nucleosides; a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides; and wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside or one 10 2’-substituted nucleoside. 13. The single stranded modified oligonucleotide of any of the preceding claims, wherein the modified oligonucleotide comprises: a 5’-wing consisting of 1 to 5 linked nucleosides; 15 a 3’-wing consisting of 1 to 5 linked nucleosides; a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides; and wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside and at least one 2’-substituted nucleoside. 20 14. The single stranded modified oligonucleotide of any of the preceding claims, wherein the modified oligonucleotide comprises: a 5’-wing consisting of 3 linked nucleosides; a 3’-wing consisting of 3 linked nucleosides; a gap between the 5’-wing and the 3’-wing consisting of 10 linked 2’-deoxynucleosides; 25 wherein each nucleoside of each of the 5’-wing and the 3’-wing comprises a constrained ethyl nucleoside; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5’-methylcytosine. 30 15. A single-stranded modified oligonucleotide consisting of 12 to 22 linked nucleosides, wherein the modified oligonucleotide comprises: a 5’-wing consisting of 1 to 5 linked nucleosides; a 3’-wing consisting of 1 to 5 linked nucleosides; a gap between the 5’-wing and the 3’-wing consisting of 8 to 12 linked 2’-deoxynucleosides; 35 wherein at least one of the 5’-wing and the 3’-wing comprises at least one bicyclic nucleoside or a 2’- substituted nucleoside; BIOL0142WO wherein the nucleobase sequence of the modified oligonucleotide is complementary to an equal length portion of nucleobases 3016 to 3031 of the nucleobase sequence of SEQ ID NO: 1; and wherein the compound inhibits expression of STAT3 mRNA expression. 5 16. The single stranded modified oligonucleotide of any of claims 12 - 15, wherein at least one of the 5’-wing and the 3’-wing comprises at least one 2’-deoxynucleoside. 17. The single stranded modified oligonucleotide of any of claims 12 - 16, comprising at least one bicyclic nucleoside. 18. The single stranded modified oligonucleotide of claim 17, wherein at least one bicyclic nucleoside comprises a 4’-CH(CH )-O-2’ bridge or a 4’- CH -O-2’ bridge. 19. The single stranded modified oligonucleotide of claim 18, wherein each bicyclic nucleoside 15 comprises a 4’-CH(CH )-O-2’ bridge or a 4’- CH -O-2’ bridge. 20. The single stranded modified oligonucleotide of any of claims 12 - 19, wherein at least one internucleoside linkage is a modified internucleoside linkage. 20 21. The single stranded modified oligonucleotide of claim 20, wherein each modified internucleoside linkage is a phosphorothioate linkage. 22. The single stranded modified oligonucleotide of any of claims 12 - 21, wherein at least one nucleoside comprises a modified nucleobase. 23. The single stranded modified oligonucleotide of claim 22, wherein the modified nucleobase is a 5’-methylcytosine. 24. A single-stranded modified oligonucleotide consisting of 12 to 30 linked nucleosides and 30 having a nucleobase sequence comprising at least 12 contiguous nucleobases of the nucleobase sequence of SEQ ID NO: 245 or SEQ ID NO: 1045. 25. A single stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 245, or a pharmaceutically acceptable 35 salt thereof, wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleotides; a 5’-wing segment consisting of three linked nucleosides; and a 3’-wing segment consisting of three linked nucleosides; wherein the gap BIOL0142WO segment is positioned between the 5’-wing segment and the 3’-wing segment; wherein each nucleotide of each wing segment comprises a constrained ethyl nucleoside; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine of the modified oligonucleotide is a 5’-methylcytosine. 26. A pharmaceutical composition comprising the single stranded modified oligonucleotide of any of the preceding claims, and a pharmaceutically acceptable diluent or carrier. 27. Use of the single stranded modified oligonucleotide or composition of any one of claims 1 to 10 25 in the manufacture of a medicament for treating cancer. 28. The single stranded oligonucleotide of any one of claims 1 to 25 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161471001P | 2011-04-01 | 2011-04-01 | |
US201161471015P | 2011-04-01 | 2011-04-01 | |
US201161471045P | 2011-04-01 | 2011-04-01 | |
US201161471035P | 2011-04-01 | 2011-04-01 | |
US61/471,035 | 2011-04-01 | ||
US61/471,001 | 2011-04-01 | ||
US61/471,015 | 2011-04-01 | ||
US61/471,045 | 2011-04-01 | ||
US201161558316P | 2011-11-10 | 2011-11-10 | |
US201161558308P | 2011-11-10 | 2011-11-10 | |
US61/558,316 | 2011-11-10 | ||
US61/558,308 | 2011-11-10 | ||
PCT/US2012/031642 WO2012135736A2 (en) | 2011-04-01 | 2012-03-30 | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ616036A NZ616036A (en) | 2015-09-25 |
NZ616036B2 true NZ616036B2 (en) | 2016-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10479993B2 (en) | Modulation of signal transducer and activator of transcription 3 (STAT3) expression | |
AU2013331434B2 (en) | Compositions for modulating C90RF72 expression | |
EP2906696B2 (en) | Methods for modulating c9orf72 expression | |
EP2794880B1 (en) | Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression | |
WO2016167780A1 (en) | Compositions for modulating expression of c9orf72 antisense transcript | |
WO2016112132A1 (en) | Compositions for modulating expression of c9orf72 antisense transcript | |
WO2016168592A2 (en) | Compositions for modulating c9orf72 expression | |
WO2013120003A1 (en) | Modulation of rna by repeat targeting | |
EP3058068A1 (en) | Compositions for modulating expression of c9orf72 antisense transcript | |
EP2640853A2 (en) | Modulation of alpha synuclein expression | |
WO2016141145A1 (en) | Methods for modulating mecp2 expression | |
WO2011123394A1 (en) | Modulation of matrix metalloproteinase 13 (mmp-13) expression | |
NZ616036B2 (en) | Modulation of signal transducer and activator of transcription 3 (stat3) expression |